{"PMC7112947": [["IntroductionThe lysosomal cysteine proteases (cathepsins) were believed to be responsible for the terminal protein degradation in the lysosomes [1].", [["lysosomal", "ANATOMY", 16, 25], ["lysosomes", "ANATOMY", 134, 143], ["cysteine", "CHEMICAL", 26, 34], ["cathepsins", "GENE_OR_GENE_PRODUCT", 46, 56], ["lysosomes", "CELLULAR_COMPONENT", 134, 143], ["lysosomal cysteine proteases", "PROTEIN", 16, 44], ["cathepsins", "PROTEIN", 46, 56], ["terminal protein", "PROTEIN", 98, 114], ["The lysosomal cysteine proteases (cathepsins", "TREATMENT", 12, 56], ["the terminal protein degradation", "PROBLEM", 94, 126], ["lysosomal cysteine", "OBSERVATION", 16, 34], ["terminal", "OBSERVATION_MODIFIER", 98, 106], ["protein degradation", "OBSERVATION", 107, 126]]], ["Similar to other proteases, cathepsins are regulated by their endogenous protein inhibitors called cystatins at every level of their biosynthesis [2].", [["cathepsins", "GENE_OR_GENE_PRODUCT", 28, 38], ["cystatins", "GENE_OR_GENE_PRODUCT", 99, 108], ["proteases", "PROTEIN", 17, 26], ["cathepsins", "PROTEIN", 28, 38], ["cystatins", "PROTEIN", 99, 108], ["cathepsins", "TREATMENT", 28, 38], ["their endogenous protein inhibitors", "TREATMENT", 56, 91], ["cystatins", "TREATMENT", 99, 108]]], ["Cystatins comprise a super-family (type I\u2013III) of evolutionary related proteins: Type I cystatins are cytosolic proteins, lacking disulphide bridges; Type II cystatins are found both inside and outside of cells, comprising at least 14 members; Type III cystatins are large multifunctional plasma proteins, containing three type II cystatin-like domains [3].IntroductionBelonging to the member of family II of the cystatin super-family, cystatin C is a potent inhibitor of cysteine proteases [4].", [["cytosolic", "ANATOMY", 102, 111], ["cells", "ANATOMY", 205, 210], ["plasma", "ANATOMY", 289, 295], ["Cystatins", "CHEMICAL", 0, 9], ["disulphide", "CHEMICAL", 130, 140], ["cysteine", "CHEMICAL", 472, 480], ["Cystatins", "GENE_OR_GENE_PRODUCT", 0, 9], ["Type I cystatins", "GENE_OR_GENE_PRODUCT", 81, 97], ["Type II cystatins", "GENE_OR_GENE_PRODUCT", 150, 167], ["cells", "CELL", 205, 210], ["Type III cystatins", "GENE_OR_GENE_PRODUCT", 244, 262], ["plasma", "ORGANISM_SUBSTANCE", 289, 295], ["type II cystatin-like domains", "GENE_OR_GENE_PRODUCT", 323, 352], ["cystatin", "GENE_OR_GENE_PRODUCT", 413, 421], ["cystatin C", "GENE_OR_GENE_PRODUCT", 436, 446], ["cysteine", "AMINO_ACID", 472, 480], ["Cystatins", "PROTEIN", 0, 9], ["super-family", "PROTEIN", 21, 33], ["Type I cystatins", "PROTEIN", 81, 97], ["cytosolic proteins", "PROTEIN", 102, 120], ["disulphide bridges", "PROTEIN", 130, 148], ["Type II cystatins", "PROTEIN", 150, 167], ["Type III cystatins", "PROTEIN", 244, 262], ["multifunctional plasma proteins", "PROTEIN", 273, 304], ["type II cystatin-like domains", "PROTEIN", 323, 352], ["family II", "PROTEIN", 396, 405], ["cystatin super-family", "PROTEIN", 413, 434], ["cystatin C", "PROTEIN", 436, 446], ["cysteine proteases", "PROTEIN", 472, 490], ["Type I cystatins", "PROBLEM", 81, 97], ["cytosolic proteins", "PROBLEM", 102, 120], ["lacking disulphide bridges", "PROBLEM", 122, 148], ["Type II cystatins", "PROBLEM", 150, 167], ["Type III cystatins", "PROBLEM", 244, 262], ["large multifunctional plasma proteins", "PROBLEM", 267, 304], ["three type II cystatin-like domains", "PROBLEM", 317, 352], ["the cystatin super", "TREATMENT", 409, 427], ["cystatin C", "TREATMENT", 436, 446], ["a potent inhibitor of cysteine proteases", "TREATMENT", 450, 490], ["cytosolic proteins", "OBSERVATION", 102, 120], ["disulphide bridges", "OBSERVATION", 130, 148], ["large", "OBSERVATION_MODIFIER", 267, 272], ["multifunctional plasma proteins", "OBSERVATION", 273, 304]]], ["It is an alkaline secreted protein, with a molecular mass of 13.343 Da, which could strongly inhibit the activities of papain-like cysteine proteases and legumain [5].", [["cysteine", "CHEMICAL", 131, 139], ["papain-like cysteine proteases", "GENE_OR_GENE_PRODUCT", 119, 149], ["legumain", "SIMPLE_CHEMICAL", 154, 162], ["alkaline secreted protein", "PROTEIN", 9, 34], ["papain", "PROTEIN", 119, 125], ["cysteine proteases", "PROTEIN", 131, 149], ["an alkaline secreted protein", "PROBLEM", 6, 34], ["a molecular mass", "PROBLEM", 41, 57], ["papain", "TREATMENT", 119, 125], ["cysteine proteases", "TREATMENT", 131, 149], ["alkaline secreted", "OBSERVATION_MODIFIER", 9, 26], ["mass", "OBSERVATION", 53, 57]]], ["Cystatin C encoding gene was once believed to be the house-keeping gene found in all of the nucleated cells without tissue specificity.", [["cells", "ANATOMY", 102, 107], ["tissue", "ANATOMY", 116, 122], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 0, 10], ["cells", "CELL", 102, 107], ["tissue", "TISSUE", 116, 122], ["Cystatin C encoding gene", "DNA", 0, 24], ["house-keeping gene", "DNA", 53, 71], ["nucleated cells", "CELL_TYPE", 92, 107], ["Cystatin C encoding gene", "PROBLEM", 0, 24], ["nucleated cells", "OBSERVATION", 92, 107]]], ["Produced at a constant speed in the body, cystatin C is secreted abundantly into various biological fluids including urine, blood, seminal fluid, saliva and cerebrospinal fluid [6].IntroductionIn the early 1960s, Fossum and Whitaker isolated from chicken egg white a substance that can inhibit the vigor of papain, ficin and dipeptidase [7].", [["body", "ANATOMY", 36, 40], ["fluids", "ANATOMY", 100, 106], ["urine", "ANATOMY", 117, 122], ["blood", "ANATOMY", 124, 129], ["seminal fluid", "ANATOMY", 131, 144], ["saliva", "ANATOMY", 146, 152], ["cerebrospinal fluid", "ANATOMY", 157, 176], ["ficin", "CHEMICAL", 315, 320], ["body", "ORGANISM_SUBDIVISION", 36, 40], ["cystatin C", "GENE_OR_GENE_PRODUCT", 42, 52], ["urine", "ORGANISM_SUBSTANCE", 117, 122], ["blood", "ORGANISM_SUBSTANCE", 124, 129], ["seminal fluid", "ORGANISM_SUBSTANCE", 131, 144], ["saliva", "ORGANISM_SUBSTANCE", 146, 152], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 157, 176], ["chicken", "ORGANISM", 247, 254], ["egg", "ORGANISM_SUBDIVISION", 255, 258], ["papain", "GENE_OR_GENE_PRODUCT", 307, 313], ["ficin", "GENE_OR_GENE_PRODUCT", 315, 320], ["cystatin C", "PROTEIN", 42, 52], ["papain", "PROTEIN", 307, 313], ["ficin", "PROTEIN", 315, 320], ["chicken", "SPECIES", 247, 254], ["chicken", "SPECIES", 247, 254], ["cystatin C", "TREATMENT", 42, 52], ["urine, blood, seminal fluid, saliva and cerebrospinal fluid", "TEST", 117, 176], ["papain", "TREATMENT", 307, 313], ["body", "ANATOMY", 36, 40], ["blood", "ANATOMY", 124, 129], ["seminal", "ANATOMY", 131, 138], ["fluid", "OBSERVATION", 139, 144], ["cerebrospinal", "ANATOMY", 157, 170], ["fluid", "OBSERVATION", 171, 176]]], ["However, it was not named cystatin C until early 80s, when Anastasi adopted the affinity chromatography method for the first time in the isolation, and since then, cystatin C was successively purified in different species [8].", [["cystatin C", "GENE_OR_GENE_PRODUCT", 26, 36], ["cystatin C", "GENE_OR_GENE_PRODUCT", 164, 174], ["cystatin C", "PROTEIN", 26, 36], ["cystatin C", "PROTEIN", 164, 174], ["cystatin C", "TREATMENT", 26, 36], ["the affinity chromatography method", "TREATMENT", 76, 110], ["cystatin C", "PROBLEM", 164, 174]]], ["Cystatin C can combine closely but reversibly with cysteine protease molecules.", [["cysteine", "CHEMICAL", 51, 59], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 0, 10], ["Cystatin C", "PROTEIN", 0, 10], ["cysteine protease molecules", "PROTEIN", 51, 78], ["Cystatin C", "PROBLEM", 0, 10], ["cysteine protease molecules", "PROBLEM", 51, 78]]], ["Amino acid sequence analysis revealed that cystatin C has three highly conservative domains: 1) N-terminal region, including glycine-11 (sequence of cystatin C) highly conservative sequence; 2) The first hairpin loop, including highly conservative QVVAG sequence (glutamine-55-glycine-59); 3) The second hairpin loop, including proline-105 and tryptophan-106 [9].", [["Amino acid", "CHEMICAL", 0, 10], ["glycine", "CHEMICAL", 125, 132], ["glutamine-55-glycine", "CHEMICAL", 264, 284], ["proline-105 and tryptophan-106", "CHEMICAL", 328, 358], ["Amino acid", "CHEMICAL", 0, 10], ["glycine", "CHEMICAL", 125, 132], ["glutamine-55-glycine-59", "CHEMICAL", 264, 287], ["proline", "CHEMICAL", 328, 335], ["tryptophan", "CHEMICAL", 344, 354], ["Amino acid", "AMINO_ACID", 0, 10], ["cystatin C", "GENE_OR_GENE_PRODUCT", 43, 53], ["glycine", "AMINO_ACID", 125, 132], ["cystatin C", "GENE_OR_GENE_PRODUCT", 149, 159], ["glutamine", "AMINO_ACID", 264, 273], ["proline-105", "SIMPLE_CHEMICAL", 328, 339], ["tryptophan", "SIMPLE_CHEMICAL", 344, 354], ["cystatin C", "PROTEIN", 43, 53], ["N-terminal region", "PROTEIN", 96, 113], ["glycine-11", "PROTEIN", 125, 135], ["cystatin C", "PROTEIN", 149, 159], ["QVVAG sequence", "PROTEIN", 248, 262], ["Amino acid sequence analysis", "TEST", 0, 28], ["cystatin C", "PROBLEM", 43, 53], ["N-terminal region", "PROBLEM", 96, 113], ["glycine", "TEST", 125, 132], ["cystatin C) highly conservative sequence", "TREATMENT", 149, 189], ["The first hairpin loop", "TREATMENT", 194, 216], ["highly conservative QVVAG sequence", "TREATMENT", 228, 262], ["glutamine", "TEST", 264, 273], ["The second hairpin loop", "TREATMENT", 293, 316], ["proline", "TEST", 328, 335], ["tryptophan", "TEST", 344, 354]]], ["X-ray scattering techniques were used to analyze the three dimensional structure of chicken cystatin C, and showed that the molecular center has a long alpha helix around five anti-parallel beta folded lamellar structure.", [["chicken", "ORGANISM", 84, 91], ["cystatin C", "GENE_OR_GENE_PRODUCT", 92, 102], ["chicken cystatin C", "PROTEIN", 84, 102], ["long alpha helix", "PROTEIN", 147, 163], ["anti-parallel beta folded lamellar structure", "PROTEIN", 176, 220], ["chicken", "SPECIES", 84, 91], ["chicken", "SPECIES", 84, 91], ["X-ray scattering techniques", "TREATMENT", 0, 27], ["chicken cystatin C", "TEST", 84, 102], ["a long alpha helix", "PROBLEM", 145, 163], ["anti-parallel beta", "OBSERVATION", 176, 194], ["folded lamellar structure", "OBSERVATION", 195, 220]]], ["At the end of the beta patches is exposed the first beta hairpin loop, the N-terminal region and second hairpin loop are located in both sides.", [["N", "CHEMICAL", 75, 76], ["N-terminal region", "DNA", 75, 92], ["the beta patches", "TREATMENT", 14, 30], ["the first beta hairpin loop", "TREATMENT", 42, 69], ["the N-terminal region and second hairpin loop", "TREATMENT", 71, 116], ["hairpin loop", "OBSERVATION", 57, 69], ["terminal", "ANATOMY_MODIFIER", 77, 85], ["region", "ANATOMY_MODIFIER", 86, 92], ["second", "OBSERVATION_MODIFIER", 97, 103], ["hairpin loop", "OBSERVATION", 104, 116], ["both", "ANATOMY_MODIFIER", 132, 136], ["sides", "ANATOMY_MODIFIER", 137, 142]]], ["These three structure domains constitute a wedge structure that complementary to the target enzyme's active site to play inhibition roles effectively [10].IntroductionThe functions of cystatin C are closely related to that of its target enzymes.", [["cystatin C", "GENE_OR_GENE_PRODUCT", 184, 194], ["cystatin C", "PROTEIN", 184, 194], ["target enzymes", "PROTEIN", 230, 244], ["a wedge structure", "PROBLEM", 41, 58], ["cystatin C", "TREATMENT", 184, 194], ["its target enzymes", "TEST", 226, 244], ["wedge structure", "OBSERVATION", 43, 58]]], ["With activities both inside and outside the cell, the cysteine proteases play fundamental roles in multiple biological processes, such as protein turnover, regulation of innate immune cells phagocytosis, activation of precursor proteins (e.g. enzymes and pro-hormone), major histocompatibility complex-II (MHC-II) mediated antigen presentation, as well as apoptosis [11,12].", [["cell", "ANATOMY", 44, 48], ["immune cells", "ANATOMY", 177, 189], ["cysteine", "CHEMICAL", 54, 62], ["cell", "CELL", 44, 48], ["immune cells", "CELL", 177, 189], ["major histocompatibility complex-II", "GENE_OR_GENE_PRODUCT", 269, 304], ["MHC-II", "GENE_OR_GENE_PRODUCT", 306, 312], ["cysteine proteases", "PROTEIN", 54, 72], ["innate immune cells", "CELL_TYPE", 170, 189], ["precursor proteins", "PROTEIN", 218, 236], ["enzymes", "PROTEIN", 243, 250], ["pro-hormone", "PROTEIN", 255, 266], ["major histocompatibility complex-II (MHC-II", "PROTEIN", 269, 312], ["the cysteine proteases", "TREATMENT", 50, 72], ["protein turnover", "TREATMENT", 138, 154], ["innate immune cells phagocytosis", "TREATMENT", 170, 202], ["precursor proteins", "PROBLEM", 218, 236], ["enzymes", "TEST", 243, 250], ["pro-hormone", "TEST", 255, 266]]], ["Therefore, the activities of these multifunctional enzymes need to be tightly controlled by their endogenous inhibitors, like cystatin C.IntroductionClinically, cystatin C is mostly used as a biomarker of kidney functions for its relatively lower molecular weight and easier detection to measure glomerular filtration rate (GFR) than chemical compounds, radioisotopes or radiocontrast agents [13].", [["kidney", "ANATOMY", 205, 211], ["glomerular", "ANATOMY", 296, 306], ["cystatin", "GENE_OR_GENE_PRODUCT", 126, 134], ["cystatin C", "GENE_OR_GENE_PRODUCT", 161, 171], ["kidney", "ORGAN", 205, 211], ["glomerular", "TISSUE", 296, 306], ["radiocontrast agents", "SIMPLE_CHEMICAL", 371, 391], ["multifunctional enzymes", "PROTEIN", 35, 58], ["cystatin C", "PROTEIN", 161, 171], ["these multifunctional enzymes", "TEST", 29, 58], ["their endogenous inhibitors", "TREATMENT", 92, 119], ["cystatin C.Introduction", "TREATMENT", 126, 149], ["cystatin C", "TREATMENT", 161, 171], ["easier detection", "TEST", 268, 284], ["glomerular filtration rate", "TEST", 296, 322], ["chemical compounds", "TREATMENT", 334, 352], ["radiocontrast agents", "TREATMENT", 371, 391], ["kidney", "ANATOMY", 205, 211]]], ["Since cystatin C is removed from the blood stream by glomerular filtration, whose decline as a result of failed kidney functions will lead to increased serum cystatin C concentration, the main determinant of blood cystatin C levels was believed to be the rate at which it is filtered at the glomerulus [14].", [["blood stream", "ANATOMY", 37, 49], ["glomerular", "ANATOMY", 53, 63], ["kidney", "ANATOMY", 112, 118], ["serum", "ANATOMY", 152, 157], ["blood", "ANATOMY", 208, 213], ["glomerulus", "ANATOMY", 291, 301], ["cystatin C", "GENE_OR_GENE_PRODUCT", 6, 16], ["blood", "ORGANISM_SUBSTANCE", 37, 42], ["stream", "ORGANISM_SUBSTANCE", 43, 49], ["glomerular", "TISSUE", 53, 63], ["kidney", "ORGAN", 112, 118], ["serum", "ORGANISM_SUBSTANCE", 152, 157], ["cystatin C", "GENE_OR_GENE_PRODUCT", 158, 168], ["blood", "ORGANISM_SUBSTANCE", 208, 213], ["cystatin C", "GENE_OR_GENE_PRODUCT", 214, 224], ["cystatin C", "PROTEIN", 6, 16], ["serum cystatin C", "PROTEIN", 152, 168], ["blood cystatin C", "PROTEIN", 208, 224], ["cystatin C", "TREATMENT", 6, 16], ["the blood stream", "TEST", 33, 49], ["glomerular filtration", "TREATMENT", 53, 74], ["whose decline", "PROBLEM", 76, 89], ["failed kidney functions", "PROBLEM", 105, 128], ["increased serum cystatin C concentration", "PROBLEM", 142, 182], ["blood cystatin C levels", "TEST", 208, 231], ["glomerular", "ANATOMY", 53, 63], ["filtration", "OBSERVATION", 64, 74], ["kidney", "ANATOMY", 112, 118], ["main", "OBSERVATION_MODIFIER", 188, 192], ["glomerulus", "ANATOMY", 291, 301]]], ["However, recent studies increasingly reported direct involvement of cystatin C in many immunological disorders other than renal diseases, and cystatin C encoding gene can be subject to the regulation of cytokines under inflammatory or infectious conditions [15,16].", [["renal", "ANATOMY", 122, 127], ["immunological disorders", "DISEASE", 87, 110], ["renal diseases", "DISEASE", 122, 136], ["cystatin C", "GENE_OR_GENE_PRODUCT", 68, 78], ["renal", "ORGAN", 122, 127], ["cystatin C", "GENE_OR_GENE_PRODUCT", 142, 152], ["cystatin C", "PROTEIN", 68, 78], ["cystatin C encoding gene", "DNA", 142, 166], ["cytokines", "PROTEIN", 203, 212], ["recent studies", "TEST", 9, 23], ["cystatin C", "PROBLEM", 68, 78], ["many immunological disorders", "PROBLEM", 82, 110], ["renal diseases", "PROBLEM", 122, 136], ["cystatin C encoding gene", "TREATMENT", 142, 166], ["cytokines under inflammatory or infectious conditions", "PROBLEM", 203, 256], ["renal", "ANATOMY", 122, 127], ["diseases", "OBSERVATION", 128, 136], ["inflammatory", "OBSERVATION_MODIFIER", 219, 231]]], ["Therefore, the oscillation of blood cystatin C levels measured by its activity could actually reflect the change of cystatin C production, consumption, inactivation or even fibrillation rather than its filtration in the kidney, and the readout of plasma cystatin C concentration might have important clinical implications.", [["blood", "ANATOMY", 30, 35], ["kidney", "ANATOMY", 220, 226], ["plasma", "ANATOMY", 247, 253], ["fibrillation", "DISEASE", 173, 185], ["blood", "ORGANISM_SUBSTANCE", 30, 35], ["cystatin C", "GENE_OR_GENE_PRODUCT", 36, 46], ["cystatin C", "GENE_OR_GENE_PRODUCT", 116, 126], ["kidney", "ORGAN", 220, 226], ["plasma", "ORGANISM_SUBSTANCE", 247, 253], ["cystatin C", "GENE_OR_GENE_PRODUCT", 254, 264], ["blood cystatin C", "PROTEIN", 30, 46], ["cystatin C", "PROTEIN", 116, 126], ["plasma cystatin C", "PROTEIN", 247, 264], ["blood cystatin C levels", "TEST", 30, 53], ["cystatin C production", "PROBLEM", 116, 137], ["even fibrillation", "PROBLEM", 168, 185], ["its filtration in the kidney", "PROBLEM", 198, 226], ["plasma cystatin C concentration", "TREATMENT", 247, 278], ["fibrillation", "OBSERVATION", 173, 185], ["kidney", "ANATOMY", 220, 226]]], ["Here, we summarize the latest development of studies on the involvement of cystatin C in immune responses under inflammatory and autoimmune conditions at various levels from diseases, cells, down to the molecules.", [["cells", "ANATOMY", 184, 189], ["cystatin C", "GENE_OR_GENE_PRODUCT", 75, 85], ["cells", "CELL", 184, 189], ["cystatin C", "PROTEIN", 75, 85], ["cystatin C", "PROBLEM", 75, 85], ["immune responses", "PROBLEM", 89, 105], ["inflammatory and autoimmune conditions", "PROBLEM", 112, 150], ["diseases", "PROBLEM", 174, 182], ["inflammatory", "OBSERVATION_MODIFIER", 112, 124]]], ["The diverse functions and clinical relevance of cystatin C foretell the involvement of this protease inhibitor in multiple pathophysiological processes, which could be strategically utilized for translational applications.Pathogen invasion ::: Cystatin C affects immunityOne of the important roles of cystatin C is to protect the host against invading microorganisms and parasites that use cysteine proteases to enter the body [2].", [["body", "ANATOMY", 422, 426], ["cysteine", "CHEMICAL", 390, 398], ["cystatin C", "GENE_OR_GENE_PRODUCT", 48, 58], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 244, 254], ["cystatin C", "GENE_OR_GENE_PRODUCT", 301, 311], ["cystatin C", "PROTEIN", 48, 58], ["Cystatin C", "PROTEIN", 244, 254], ["cystatin C", "PROTEIN", 301, 311], ["cysteine proteases", "PROTEIN", 390, 408], ["cystatin C", "TREATMENT", 48, 58], ["this protease inhibitor", "TREATMENT", 87, 110], ["translational applications", "TREATMENT", 195, 221], ["Cystatin C affects", "PROBLEM", 244, 262], ["cystatin C", "TREATMENT", 301, 311], ["invading microorganisms", "PROBLEM", 343, 366], ["parasites", "PROBLEM", 371, 380], ["cysteine proteases", "TREATMENT", 390, 408], ["invasion", "OBSERVATION", 231, 239]]], ["Cystatins have been found in epithelial cells [19], neutrophils from the liver [20], DCs of lymphoid tissue [21] and thymic medullary cells [22].", [["epithelial cells", "ANATOMY", 29, 45], ["neutrophils", "ANATOMY", 52, 63], ["liver", "ANATOMY", 73, 78], ["DCs", "ANATOMY", 85, 88], ["lymphoid tissue", "ANATOMY", 92, 107], ["thymic medullary cells", "ANATOMY", 117, 139], ["Cystatins", "CHEMICAL", 0, 9], ["Cystatins", "CHEMICAL", 0, 9], ["Cystatins", "GENE_OR_GENE_PRODUCT", 0, 9], ["epithelial cells", "CELL", 29, 45], ["neutrophils", "CELL", 52, 63], ["liver", "ORGAN", 73, 78], ["DCs", "CELL", 85, 88], ["lymphoid tissue [21]", "CELL", 92, 112], ["thymic medullary cells", "CELL", 117, 139], ["Cystatins", "PROTEIN", 0, 9], ["epithelial cells", "CELL_TYPE", 29, 45], ["neutrophils", "CELL_TYPE", 52, 63], ["DCs", "CELL_TYPE", 85, 88], ["thymic medullary cells", "CELL_TYPE", 117, 139], ["Cystatins", "TEST", 0, 9], ["epithelial cells", "TEST", 29, 45], ["neutrophils from the liver", "TEST", 52, 78], ["lymphoid tissue", "TEST", 92, 107], ["thymic medullary cells", "PROBLEM", 117, 139], ["epithelial cells", "OBSERVATION", 29, 45], ["liver", "ANATOMY", 73, 78], ["lymphoid tissue", "OBSERVATION", 92, 107], ["thymic", "ANATOMY", 117, 123], ["medullary cells", "OBSERVATION", 124, 139]]], ["The selective expression of the inhibitor in these cells correlates with the tissues participating in the first-line of defense against pathogens.", [["cells", "ANATOMY", 51, 56], ["tissues", "ANATOMY", 77, 84], ["cells", "CELL", 51, 56], ["tissues", "TISSUE", 77, 84], ["the inhibitor", "TREATMENT", 28, 41], ["pathogens", "PROBLEM", 136, 145], ["selective", "OBSERVATION_MODIFIER", 4, 13], ["expression", "OBSERVATION", 14, 24]]], ["For instance, analysis of proteins uniquely involved in the development of the skin demonstrated strong expression of cystatin in neonatal mouse skin, which decreases with aging, suggesting an important role of this protease inhibitor in the development of the epidermis [23].", [["skin", "ANATOMY", 79, 83], ["skin", "ANATOMY", 145, 149], ["epidermis", "ANATOMY", 261, 270], ["skin", "ORGAN", 79, 83], ["cystatin", "GENE_OR_GENE_PRODUCT", 118, 126], ["mouse", "ORGANISM", 139, 144], ["skin", "ORGAN", 145, 149], ["cystatin", "PROTEIN", 118, 126], ["mouse", "SPECIES", 139, 144], ["mouse", "SPECIES", 139, 144], ["analysis of proteins", "TEST", 14, 34], ["cystatin in neonatal mouse skin", "PROBLEM", 118, 149], ["this protease inhibitor", "TREATMENT", 211, 234], ["skin", "ANATOMY", 79, 83], ["skin", "ANATOMY", 145, 149]]], ["Furthermore, in vivo mouse models have also revealed that cystatins are key molecules in a biochemical pathway that control skin barrier formation [24,25].", [["skin barrier", "ANATOMY", 124, 136], ["mouse", "ORGANISM", 21, 26], ["cystatins", "GENE_OR_GENE_PRODUCT", 58, 67], ["skin barrier", "TISSUE", 124, 136], ["cystatins", "PROTEIN", 58, 67], ["mouse", "SPECIES", 21, 26], ["mouse", "SPECIES", 21, 26], ["cystatins", "TREATMENT", 58, 67], ["a biochemical pathway", "TREATMENT", 89, 110], ["skin", "ANATOMY", 124, 128]]], ["The involvement of cystatins in these tissues suggests that they may have a role in the host defense mechanism against pathogenic agents, like virus for example.", [["tissues", "ANATOMY", 38, 45], ["cystatins", "GENE_OR_GENE_PRODUCT", 19, 28], ["tissues", "TISSUE", 38, 45], ["cystatins", "PROTEIN", 19, 28], ["cystatins in these tissues", "PROBLEM", 19, 45], ["pathogenic agents", "TREATMENT", 119, 136], ["cystatins", "OBSERVATION", 19, 28]]], ["Along this line, cystatin has been found to interfere with coronavirus replication in human lung cells [26], partially block poliovirus replication in infected human cells [27], suppress the infectivity of adenovirus in human respiratory passage or conjunctiva [28] and herpes simplex virus in human submandibular-sublingual and parotid [29].Pathogen invasion ::: Cystatin C affects immunityApart from virus, the initiation of inflammation could also come from an invasion of parasites, whose secretion of cysteine proteases was believed to play key roles in parasite-host interactions including the establishment of infection [30].", [["lung cells", "ANATOMY", 92, 102], ["cells", "ANATOMY", 166, 171], ["respiratory", "ANATOMY", 226, 237], ["conjunctiva", "ANATOMY", 249, 260], ["submandibular-sublingual", "ANATOMY", 300, 324], ["parotid", "ANATOMY", 329, 336], ["herpes simplex virus", "DISEASE", 270, 290], ["inflammation", "DISEASE", 427, 439], ["infection", "DISEASE", 617, 626], ["cysteine", "CHEMICAL", 506, 514], ["cystatin", "GENE_OR_GENE_PRODUCT", 17, 25], ["coronavirus", "ORGANISM", 59, 70], ["human", "ORGANISM", 86, 91], ["lung cells", "CELL", 92, 102], ["poliovirus", "ORGANISM", 125, 135], ["human", "ORGANISM", 160, 165], ["cells", "CELL", 166, 171], ["adenovirus", "ORGANISM", 206, 216], ["human", "ORGANISM", 220, 225], ["conjunctiva", "ORGAN", 249, 260], ["herpes simplex virus", "ORGANISM", 270, 290], ["human", "ORGANISM", 294, 299], ["submandibular", "ORGAN", 300, 313], ["sublingual", "ORGAN", 314, 324], ["parotid", "ORGAN", 329, 336], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 364, 374], ["cysteine", "AMINO_ACID", 506, 514], ["cystatin", "PROTEIN", 17, 25], ["human lung cells", "CELL_TYPE", 86, 102], ["infected human cells", "CELL_TYPE", 151, 171], ["Cystatin C", "PROTEIN", 364, 374], ["cysteine proteases", "PROTEIN", 506, 524], ["coronavirus", "SPECIES", 59, 70], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 160, 165], ["human", "SPECIES", 220, 225], ["herpes simplex virus", "SPECIES", 270, 290], ["human", "SPECIES", 294, 299], ["coronavirus", "SPECIES", 59, 70], ["human", "SPECIES", 86, 91], ["poliovirus", "SPECIES", 125, 135], ["human", "SPECIES", 160, 165], ["adenovirus", "SPECIES", 206, 216], ["human", "SPECIES", 220, 225], ["herpes simplex virus", "SPECIES", 270, 290], ["human", "SPECIES", 294, 299], ["cystatin", "TREATMENT", 17, 25], ["coronavirus replication in human lung cells", "PROBLEM", 59, 102], ["partially block poliovirus replication", "PROBLEM", 109, 147], ["infected human cells", "PROBLEM", 151, 171], ["the infectivity of adenovirus in human respiratory passage", "PROBLEM", 187, 245], ["conjunctiva", "TEST", 249, 260], ["herpes simplex virus", "PROBLEM", 270, 290], ["Cystatin C affects", "PROBLEM", 364, 382], ["virus", "PROBLEM", 402, 407], ["inflammation", "PROBLEM", 427, 439], ["an invasion of parasites", "PROBLEM", 461, 485], ["cysteine proteases", "TREATMENT", 506, 524], ["infection", "PROBLEM", 617, 626], ["lung", "ANATOMY", 92, 96], ["poliovirus replication", "OBSERVATION", 125, 147], ["infected human cells", "OBSERVATION", 151, 171], ["respiratory passage", "OBSERVATION", 226, 245], ["conjunctiva", "ANATOMY", 249, 260], ["submandibular", "ANATOMY", 300, 313], ["sublingual", "ANATOMY", 314, 324], ["parotid", "ANATOMY", 329, 336], ["invasion", "OBSERVATION", 351, 359], ["virus", "OBSERVATION", 402, 407], ["inflammation", "OBSERVATION", 427, 439], ["invasion", "OBSERVATION", 464, 472], ["parasites", "OBSERVATION", 476, 485], ["infection", "OBSERVATION", 617, 626]]], ["Furthermore, the parasite cysteine proteases can not only digest the host extracellular matrix (ECM) to facilitate their invasion, but also help to ensure a T helper 2 (Th2)-like response in favor their proliferation [31].", [["extracellular matrix", "ANATOMY", 74, 94], ["ECM", "ANATOMY", 96, 99], ["cysteine", "CHEMICAL", 26, 34], ["extracellular matrix", "CELLULAR_COMPONENT", 74, 94], ["ECM", "CELLULAR_COMPONENT", 96, 99], ["T helper 2", "GENE_OR_GENE_PRODUCT", 157, 167], ["Th2", "GENE_OR_GENE_PRODUCT", 169, 172], ["parasite cysteine proteases", "PROTEIN", 17, 44], ["the parasite cysteine proteases", "TREATMENT", 13, 44], ["their invasion", "PROBLEM", 115, 129], ["invasion", "OBSERVATION", 121, 129]]], ["In agreement with this notion, one study has demonstrated that BALB/c mice with fatal visceral leishmaniasis can be clinically cured of the disease by chicken cystatin in synergy with interferon-\u03b3 (IFN-\u03b3) treatment [32].", [["visceral leishmaniasis", "ANATOMY", 86, 108], ["visceral leishmaniasis", "DISEASE", 86, 108], ["interferon-\u03b3 (IFN-\u03b3", "CHEMICAL", 184, 203], ["BALB/c mice", "ORGANISM", 63, 74], ["chicken", "ORGANISM", 151, 158], ["cystatin", "GENE_OR_GENE_PRODUCT", 159, 167], ["interferon-\u03b3", "GENE_OR_GENE_PRODUCT", 184, 196], ["IFN-\u03b3", "SIMPLE_CHEMICAL", 198, 203], ["chicken cystatin", "PROTEIN", 151, 167], ["interferon", "PROTEIN", 184, 194], ["IFN", "PROTEIN", 198, 201], ["mice", "SPECIES", 70, 74], ["chicken", "SPECIES", 151, 158], ["mice", "SPECIES", 70, 74], ["chicken", "SPECIES", 151, 158], ["one study", "TEST", 31, 40], ["BALB/c mice", "TREATMENT", 63, 74], ["fatal visceral leishmaniasis", "PROBLEM", 80, 108], ["the disease", "PROBLEM", 136, 147], ["chicken cystatin in synergy", "TREATMENT", 151, 178], ["interferon-\u03b3 (IFN-\u03b3) treatment", "TREATMENT", 184, 214], ["visceral", "ANATOMY", 86, 94], ["leishmaniasis", "OBSERVATION", 95, 108]]], ["Later on, it was revealed that the successful therapy of lethal murine visceral leishmaniasis with cystatin C in combination with IFN-\u03b3 correlated with up-regulation of cystatin C and nitric oxide (NO) generation, successful Th2 to Th1 conversion at molecular and cellular levels, leading to the reduced parasite numbers and abrogation of parasite infection [33].Pathogen invasion ::: Cystatin C affects immunityNot only cystatin protein itself, but also its mimetics were found to have anti-effects on pathogenic microorganisms.", [["visceral", "ANATOMY", 71, 79], ["cellular", "ANATOMY", 264, 272], ["visceral leishmaniasis", "DISEASE", 71, 93], ["cystatin C", "CHEMICAL", 99, 109], ["IFN-\u03b3", "CHEMICAL", 130, 135], ["nitric oxide", "CHEMICAL", 184, 196], ["NO", "CHEMICAL", 198, 200], ["parasite infection", "DISEASE", 339, 357], ["nitric oxide", "CHEMICAL", 184, 196], ["NO", "CHEMICAL", 198, 200], ["murine", "ORGANISM", 64, 70], ["visceral", "ORGANISM_SUBDIVISION", 71, 79], ["cystatin C", "GENE_OR_GENE_PRODUCT", 99, 109], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 130, 135], ["cystatin C", "GENE_OR_GENE_PRODUCT", 169, 179], ["nitric oxide", "SIMPLE_CHEMICAL", 184, 196], ["NO", "SIMPLE_CHEMICAL", 198, 200], ["Th2", "GENE_OR_GENE_PRODUCT", 225, 228], ["Th1", "GENE_OR_GENE_PRODUCT", 232, 235], ["cellular", "CELL", 264, 272], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 385, 395], ["cystatin", "GENE_OR_GENE_PRODUCT", 421, 429], ["cystatin C", "PROTEIN", 99, 109], ["IFN", "PROTEIN", 130, 133], ["cystatin C", "PROTEIN", 169, 179], ["Cystatin C", "PROTEIN", 385, 395], ["cystatin protein", "PROTEIN", 421, 437], ["murine", "SPECIES", 64, 70], ["lethal murine visceral leishmaniasis", "TREATMENT", 57, 93], ["cystatin C", "TREATMENT", 99, 109], ["IFN", "TREATMENT", 130, 133], ["cystatin C", "TREATMENT", 169, 179], ["nitric oxide", "TREATMENT", 184, 196], ["successful Th2 to Th1 conversion", "TREATMENT", 214, 246], ["the reduced parasite numbers", "PROBLEM", 292, 320], ["parasite infection", "PROBLEM", 339, 357], ["Cystatin C affects", "PROBLEM", 385, 403], ["cystatin protein itself", "PROBLEM", 421, 444], ["pathogenic microorganisms", "PROBLEM", 503, 528], ["visceral", "ANATOMY", 71, 79], ["leishmaniasis", "OBSERVATION", 80, 93], ["reduced", "OBSERVATION_MODIFIER", 296, 303], ["parasite", "OBSERVATION", 304, 312], ["parasite", "OBSERVATION_MODIFIER", 339, 347], ["infection", "OBSERVATION", 348, 357], ["invasion", "OBSERVATION", 372, 380]]], ["One study demonstrated that a small peptide derivative that mimics part of the proteinase-binding center of human cystatin C could inhibit a cysteine protease specific for the growth of streptococci, thus blocking the propagation of these bacteria both in vivo and in vitro [34].", [["cysteine", "CHEMICAL", 141, 149], ["human", "ORGANISM", 108, 113], ["cystatin C", "GENE_OR_GENE_PRODUCT", 114, 124], ["proteinase", "PROTEIN", 79, 89], ["human cystatin C", "PROTEIN", 108, 124], ["cysteine protease", "PROTEIN", 141, 158], ["human", "SPECIES", 108, 113], ["human", "SPECIES", 108, 113], ["One study", "TEST", 0, 9], ["a small peptide derivative", "TREATMENT", 28, 54], ["human cystatin C", "TREATMENT", 108, 124], ["a cysteine protease", "TREATMENT", 139, 158], ["streptococci", "PROBLEM", 186, 198], ["these bacteria", "PROBLEM", 233, 247], ["small", "OBSERVATION_MODIFIER", 30, 35], ["streptococci", "OBSERVATION", 186, 198], ["bacteria", "OBSERVATION", 239, 247]]], ["Similarly, recombinant human cystatin C was also proven to inhibit the growth of herpes simplex virus and human coronaviruses [35].", [["herpes simplex virus", "DISEASE", 81, 101], ["human", "ORGANISM", 23, 28], ["cystatin C", "GENE_OR_GENE_PRODUCT", 29, 39], ["herpes simplex virus", "ORGANISM", 81, 101], ["human", "ORGANISM", 106, 111], ["recombinant human cystatin C", "PROTEIN", 11, 39], ["human", "SPECIES", 23, 28], ["herpes simplex virus", "SPECIES", 81, 101], ["human", "SPECIES", 106, 111], ["human", "SPECIES", 23, 28], ["herpes simplex virus", "SPECIES", 81, 101], ["human coronaviruses", "SPECIES", 106, 125], ["recombinant human cystatin C", "TREATMENT", 11, 39], ["herpes simplex virus", "PROBLEM", 81, 101], ["human coronaviruses", "PROBLEM", 106, 125]]], ["Recently, nematode homologs of cystatin were reported to have anti-inflammatory functions and investigated for their therapeutic potentials [36,37].Antigen presentation ::: Cystatin C affects immunityOnce entering the body, the pathogens will be captured to alert host immune system by the antigen presenting cells (APCs) including DCs, where foreign proteins will be digested, processed and loaded onto an important molecule, MHC-II, to be presented for T cell recognition.", [["body", "ANATOMY", 218, 222], ["immune system", "ANATOMY", 269, 282], ["antigen presenting cells", "ANATOMY", 290, 314], ["APCs", "ANATOMY", 316, 320], ["DCs", "ANATOMY", 332, 335], ["T cell", "ANATOMY", 455, 461], ["cystatin", "GENE_OR_GENE_PRODUCT", 31, 39], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 173, 183], ["body", "ORGANISM_SUBDIVISION", 218, 222], ["immune system", "ANATOMICAL_SYSTEM", 269, 282], ["antigen presenting cells", "CELL", 290, 314], ["APCs", "CELL", 316, 320], ["DCs", "CELL", 332, 335], ["MHC-II", "GENE_OR_GENE_PRODUCT", 427, 433], ["T cell", "CELL", 455, 461], ["cystatin", "PROTEIN", 31, 39], ["Cystatin C", "PROTEIN", 173, 183], ["antigen presenting cells", "CELL_TYPE", 290, 314], ["APCs", "CELL_TYPE", 316, 320], ["DCs", "CELL_TYPE", 332, 335], ["foreign proteins", "PROTEIN", 343, 359], ["MHC-II", "PROTEIN", 427, 433], ["cystatin", "TREATMENT", 31, 39], ["Cystatin C affects", "PROBLEM", 173, 191], ["the pathogens", "PROBLEM", 224, 237], ["DCs", "PROBLEM", 332, 335], ["foreign proteins", "PROBLEM", 343, 359], ["body", "ANATOMY", 218, 222]]], ["The development of MHC-II needs cysteine proteinase cathepsin S to assist.", [["cysteine", "CHEMICAL", 32, 40], ["MHC-II", "GENE_OR_GENE_PRODUCT", 19, 25], ["cysteine proteinase cathepsin S", "GENE_OR_GENE_PRODUCT", 32, 63], ["MHC-II", "PROTEIN", 19, 25], ["cysteine proteinase cathepsin S", "PROTEIN", 32, 63], ["cysteine proteinase cathepsin S", "TREATMENT", 32, 63]]], ["Therefore, it is possible for cystatin C, as a endogenous inhibitor of the cathepsin S, to play a regulatory role in the antigen presentation by inhibiting cathepsin S during the removal of the invariant chain (Ii) to generate effective MHC-antigenic peptide complex [38].Antigen presentation ::: Cystatin C affects immunityHowever, the hypothesis that cystatin C control MHC-II expression by regulating cathepsin S activity has been challenged by several other studies: For example, cathepsin S-deficient DC express normal levels of MHC-II on the plasma membrane [39,40], and DCs can control MHC-II surface expression in the absence of the Ii [41].", [["DC", "ANATOMY", 506, 508], ["plasma membrane", "ANATOMY", 548, 563], ["DCs", "ANATOMY", 577, 580], ["surface", "ANATOMY", 600, 607], ["cystatin C", "GENE_OR_GENE_PRODUCT", 30, 40], ["cathepsin S", "GENE_OR_GENE_PRODUCT", 75, 86], ["cathepsin S", "GENE_OR_GENE_PRODUCT", 156, 167], ["Ii", "GENE_OR_GENE_PRODUCT", 211, 213], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 297, 307], ["cystatin C", "GENE_OR_GENE_PRODUCT", 353, 363], ["MHC-II", "GENE_OR_GENE_PRODUCT", 372, 378], ["cathepsin S", "GENE_OR_GENE_PRODUCT", 404, 415], ["cathepsin S-", "GENE_OR_GENE_PRODUCT", 484, 496], ["MHC-II", "GENE_OR_GENE_PRODUCT", 534, 540], ["plasma membrane", "CELLULAR_COMPONENT", 548, 563], ["DCs", "CELL", 577, 580], ["MHC-II", "GENE_OR_GENE_PRODUCT", 593, 599], ["cystatin C", "PROTEIN", 30, 40], ["cathepsin S", "PROTEIN", 75, 86], ["cathepsin S", "PROTEIN", 156, 167], ["invariant chain", "PROTEIN", 194, 209], ["Ii", "PROTEIN", 211, 213], ["MHC", "PROTEIN", 237, 240], ["Cystatin C", "PROTEIN", 297, 307], ["cystatin C", "PROTEIN", 353, 363], ["MHC", "PROTEIN", 372, 375], ["cathepsin S", "PROTEIN", 404, 415], ["cathepsin S-deficient DC", "CELL_LINE", 484, 508], ["MHC-II", "PROTEIN", 534, 540], ["DCs", "CELL_TYPE", 577, 580], ["MHC", "PROTEIN", 593, 596], ["cystatin C", "TREATMENT", 30, 40], ["a endogenous inhibitor", "TREATMENT", 45, 67], ["the cathepsin S", "TREATMENT", 71, 86], ["cathepsin S", "TREATMENT", 156, 167], ["the removal of the invariant chain (Ii)", "TREATMENT", 175, 214], ["Cystatin C affects immunity", "PROBLEM", 297, 324], ["cystatin C control MHC", "TREATMENT", 353, 375], ["the plasma membrane", "TEST", 544, 563]]], ["Furthermore, El-Sukkari showed in a separate study using mouse primary DCs isolated from cystatin C-deficient mice that cystatin C is neither necessary nor sufficient to control MHC-II expression and antigen presentation in DCs [42].", [["DCs", "ANATOMY", 71, 74], ["DCs", "ANATOMY", 224, 227], ["mouse", "ORGANISM", 57, 62], ["DCs", "CELL", 71, 74], ["cystatin C", "GENE_OR_GENE_PRODUCT", 89, 99], ["mice", "ORGANISM", 110, 114], ["cystatin C", "GENE_OR_GENE_PRODUCT", 120, 130], ["MHC-II", "GENE_OR_GENE_PRODUCT", 178, 184], ["DCs", "CELL", 224, 227], ["El-Sukkari", "PROTEIN", 13, 23], ["mouse primary DCs", "CELL_TYPE", 57, 74], ["cystatin C", "PROTEIN", 89, 99], ["cystatin C", "PROTEIN", 120, 130], ["MHC", "PROTEIN", 178, 181], ["DCs", "CELL_TYPE", 224, 227], ["mouse", "SPECIES", 57, 62], ["mice", "SPECIES", 110, 114], ["mouse", "SPECIES", 57, 62], ["a separate study", "TEST", 34, 50], ["mouse primary DCs", "TREATMENT", 57, 74], ["cystatin C-deficient mice", "TREATMENT", 89, 114], ["cystatin C", "TREATMENT", 120, 130]]], ["These discrepant findings obtained from different laboratories could be caused by difference among DC subsets or maturation of the DCs investigated, like bone-marrow derived DCs versus primary splenic DC, immature or steady DCs versus mature or activated DCs etc. Indeed, cystatin C was found to be differentially expressed among closely related DC subsets [42], and therefore it is not impossible that other cysteine protease inhibitors play compensatory roles in the DC subsets that lack or have limited expression of cystatin C either constitutively or following maturation or activation.", [["DC", "ANATOMY", 99, 101], ["DCs", "ANATOMY", 131, 134], ["bone-marrow", "ANATOMY", 154, 165], ["DCs", "ANATOMY", 174, 177], ["splenic DC", "ANATOMY", 193, 203], ["DCs", "ANATOMY", 224, 227], ["DCs", "ANATOMY", 255, 258], ["DC", "ANATOMY", 346, 348], ["DC", "ANATOMY", 469, 471], ["cysteine", "CHEMICAL", 409, 417], ["DCs", "CELL", 131, 134], ["bone-marrow derived DCs", "CELL", 154, 177], ["splenic DC", "CELL", 193, 203], ["DCs", "CELL", 224, 227], ["DCs", "CELL", 255, 258], ["cystatin C", "GENE_OR_GENE_PRODUCT", 272, 282], ["DC", "CELL", 346, 348], ["cystatin C", "GENE_OR_GENE_PRODUCT", 520, 530], ["DC subsets", "CELL_TYPE", 99, 109], ["DCs", "CELL_TYPE", 131, 134], ["bone-marrow derived DCs", "CELL_TYPE", 154, 177], ["primary splenic DC", "CELL_TYPE", 185, 203], ["immature or steady DCs", "CELL_TYPE", 205, 227], ["DCs", "CELL_TYPE", 255, 258], ["cystatin C", "PROTEIN", 272, 282], ["DC subsets", "CELL_TYPE", 346, 356], ["DC subsets", "CELL_TYPE", 469, 479], ["cystatin C", "PROTEIN", 520, 530], ["the DCs", "TEST", 127, 134], ["bone-marrow derived DCs", "PROBLEM", 154, 177], ["primary splenic DC", "PROBLEM", 185, 203], ["cystatin C", "PROBLEM", 272, 282], ["other cysteine protease inhibitors", "TREATMENT", 403, 437], ["cystatin C", "PROBLEM", 520, 530], ["bone", "ANATOMY", 154, 158], ["splenic", "ANATOMY", 193, 200]]], ["In supporting this possibility, experiments using bone marrow-derived DCs indicated that interleukin (IL)-6 mediated signal transducer and activator of transcription 3 (STAT3) activation decreased cystatin C expression [36].", [["bone marrow", "ANATOMY", 50, 61], ["DCs", "ANATOMY", 70, 73], ["bone marrow-derived DCs", "CELL", 50, 73], ["interleukin (IL)-6", "GENE_OR_GENE_PRODUCT", 89, 107], ["signal transducer and activator of transcription 3", "GENE_OR_GENE_PRODUCT", 117, 167], ["STAT3", "GENE_OR_GENE_PRODUCT", 169, 174], ["cystatin C", "GENE_OR_GENE_PRODUCT", 197, 207], ["DCs", "CELL_TYPE", 70, 73], ["interleukin (IL)-6", "PROTEIN", 89, 107], ["STAT3", "PROTEIN", 169, 174], ["cystatin C", "PROTEIN", 197, 207], ["bone marrow", "TEST", 50, 61], ["interleukin (IL)", "TREATMENT", 89, 105], ["activator of transcription", "TREATMENT", 139, 165], ["STAT3) activation decreased cystatin C expression", "TREATMENT", 169, 218]]], ["Consistently, we found that IL-10 can down-regulate cystatin C expression in splenic primary DCs through interferon regulatory factor 8 (IRF8) during systemic inflammation [43].Antigen presentation ::: Cystatin C affects immunityWhile the role of cystatin C in antigen presentation is open to debate, a cystatin homolog, the Bm-CPI-2, produced by the filarial nematode parasites as one of the most abundant transcripts [44], was found to inhibit multiple cysteine protease activities in human B cells, and suppress substantially the presentation of selected T cell epitopes by living APCs [45].", [["splenic primary DCs", "ANATOMY", 77, 96], ["B cells", "ANATOMY", 493, 500], ["T cell", "ANATOMY", 558, 564], ["APCs", "ANATOMY", 584, 588], ["inflammation", "DISEASE", 159, 171], ["cysteine", "CHEMICAL", 455, 463], ["IL-10", "GENE_OR_GENE_PRODUCT", 28, 33], ["cystatin C", "GENE_OR_GENE_PRODUCT", 52, 62], ["splenic primary DCs", "CELL", 77, 96], ["interferon regulatory factor 8", "GENE_OR_GENE_PRODUCT", 105, 135], ["IRF8", "GENE_OR_GENE_PRODUCT", 137, 141], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 202, 212], ["cystatin C", "GENE_OR_GENE_PRODUCT", 247, 257], ["antigen", "GENE_OR_GENE_PRODUCT", 261, 268], ["cystatin", "GENE_OR_GENE_PRODUCT", 303, 311], ["Bm-CPI-2", "GENE_OR_GENE_PRODUCT", 325, 333], ["filarial nematode parasites", "ORGANISM", 351, 378], ["human", "ORGANISM", 487, 492], ["B cells", "CELL", 493, 500], ["T cell", "CELL", 558, 564], ["IL", "PROTEIN", 28, 30], ["cystatin C", "PROTEIN", 52, 62], ["splenic primary DCs", "CELL_TYPE", 77, 96], ["interferon regulatory factor 8", "PROTEIN", 105, 135], ["IRF8", "PROTEIN", 137, 141], ["Cystatin C", "PROTEIN", 202, 212], ["cystatin C", "PROTEIN", 247, 257], ["cystatin homolog", "PROTEIN", 303, 319], ["Bm-CPI-2", "DNA", 325, 333], ["cysteine protease", "PROTEIN", 455, 472], ["human B cells", "CELL_TYPE", 487, 500], ["T cell epitopes", "PROTEIN", 558, 573], ["APCs", "CELL_TYPE", 584, 588], ["human", "SPECIES", 487, 492], ["human", "SPECIES", 487, 492], ["IL", "TEST", 28, 30], ["cystatin C expression", "TREATMENT", 52, 73], ["splenic primary DCs", "TREATMENT", 77, 96], ["interferon regulatory factor", "TREATMENT", 105, 133], ["systemic inflammation", "PROBLEM", 150, 171], ["Cystatin C affects", "PROBLEM", 202, 220], ["cystatin C in antigen presentation", "PROBLEM", 247, 281], ["a cystatin homolog", "TREATMENT", 301, 319], ["CPI", "TEST", 328, 331], ["the filarial nematode parasites", "PROBLEM", 347, 378], ["multiple cysteine protease activities", "TREATMENT", 446, 483], ["human B cells", "TREATMENT", 487, 500], ["selected T cell epitopes", "TREATMENT", 549, 573], ["splenic", "ANATOMY", 77, 84], ["primary DCs", "OBSERVATION", 85, 96], ["inflammation", "OBSERVATION", 159, 171], ["Bm", "ANATOMY", 325, 327], ["filarial", "ANATOMY", 351, 359]]], ["Since filarial worms can invade the host by lymphatic vessels afferent to the lymph nodes to initiate specific immune response, it is easier for CPI-2 to contact DCs and other APCs in lymphoid tissue, leading to the impairment or ablation of antigen presentation during anti-parasite immune responses.Inflammatory skin diseases ::: Immune disorders ::: Cystatin C affects immunityAtopic dermatitis and psoriasis are two common chronic inflammatory skin diseases, in which cell proliferative machinery and the formation of the epidermal barrier are altered.Inflammatory skin diseases ::: Immune disorders ::: Cystatin C affects immunityCystatin is involved in cellular proliferation and could be a useful target for diseases of abnormal proliferative conditions.", [["worms", "ANATOMY", 15, 20], ["lymphatic vessels", "ANATOMY", 44, 61], ["lymph nodes", "ANATOMY", 78, 89], ["DCs", "ANATOMY", 162, 165], ["APCs", "ANATOMY", 176, 180], ["lymphoid tissue", "ANATOMY", 184, 199], ["skin", "ANATOMY", 314, 318], ["skin", "ANATOMY", 448, 452], ["cell", "ANATOMY", 472, 476], ["epidermal barrier", "ANATOMY", 526, 543], ["skin", "ANATOMY", 569, 573], ["cellular", "ANATOMY", 659, 667], ["skin diseases", "DISEASE", 314, 327], ["Immune disorders", "DISEASE", 332, 348], ["Atopic dermatitis", "DISEASE", 380, 397], ["psoriasis", "DISEASE", 402, 411], ["skin diseases", "DISEASE", 448, 461], ["skin diseases", "DISEASE", 569, 582], ["Immune disorders", "DISEASE", 587, 603], ["filarial worms", "ORGANISM", 6, 20], ["lymphatic vessels", "MULTI-TISSUE_STRUCTURE", 44, 61], ["afferent", "MULTI-TISSUE_STRUCTURE", 62, 70], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 78, 89], ["CPI-2", "GENE_OR_GENE_PRODUCT", 145, 150], ["DCs", "CELL", 162, 165], ["APCs", "CELL", 176, 180], ["lymphoid tissue", "TISSUE", 184, 199], ["antigen", "GENE_OR_GENE_PRODUCT", 242, 249], ["skin", "ORGAN", 314, 318], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 353, 363], ["skin", "ORGAN", 448, 452], ["cell", "CELL", 472, 476], ["epidermal barrier", "TISSUE", 526, 543], ["skin", "ORGAN", 569, 573], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 608, 618], ["Cystatin", "GENE_OR_GENE_PRODUCT", 635, 643], ["cellular", "CELL", 659, 667], ["DCs", "CELL_TYPE", 162, 165], ["APCs", "CELL_TYPE", 176, 180], ["Cystatin C", "PROTEIN", 353, 363], ["Cystatin C", "PROTEIN", 608, 618], ["Cystatin", "PROTEIN", 635, 643], ["worms", "SPECIES", 15, 20], ["filarial worms", "PROBLEM", 6, 20], ["CPI", "TEST", 145, 148], ["lymphoid tissue", "PROBLEM", 184, 199], ["the impairment", "PROBLEM", 212, 226], ["antigen presentation", "PROBLEM", 242, 262], ["Inflammatory skin diseases", "PROBLEM", 301, 327], ["Immune disorders", "PROBLEM", 332, 348], ["Cystatin C affects", "PROBLEM", 353, 371], ["Atopic dermatitis", "PROBLEM", 380, 397], ["psoriasis", "PROBLEM", 402, 411], ["two common chronic inflammatory skin diseases", "PROBLEM", 416, 461], ["cell proliferative machinery", "TREATMENT", 472, 500], ["the epidermal barrier", "PROBLEM", 522, 543], ["Inflammatory skin diseases", "PROBLEM", 556, 582], ["Immune disorders", "PROBLEM", 587, 603], ["Cystatin C affects immunityCystatin", "PROBLEM", 608, 643], ["cellular proliferation", "PROBLEM", 659, 681], ["diseases", "PROBLEM", 715, 723], ["abnormal proliferative conditions", "PROBLEM", 727, 760], ["lymphatic vessels", "ANATOMY", 44, 61], ["lymph nodes", "OBSERVATION", 78, 89], ["lymphoid tissue", "OBSERVATION", 184, 199], ["skin", "ANATOMY", 314, 318], ["diseases", "OBSERVATION", 319, 327], ["dermatitis", "OBSERVATION", 387, 397], ["psoriasis", "OBSERVATION", 402, 411], ["common", "OBSERVATION_MODIFIER", 420, 426], ["chronic", "OBSERVATION_MODIFIER", 427, 434], ["inflammatory", "OBSERVATION_MODIFIER", 435, 447], ["skin", "ANATOMY", 448, 452], ["diseases", "OBSERVATION", 453, 461], ["cell proliferative machinery", "OBSERVATION", 472, 500], ["epidermal barrier", "OBSERVATION", 526, 543], ["altered", "OBSERVATION_MODIFIER", 548, 555], ["skin", "ANATOMY", 569, 573], ["diseases", "OBSERVATION", 574, 582], ["cellular proliferation", "OBSERVATION", 659, 681], ["abnormal", "OBSERVATION_MODIFIER", 727, 735], ["proliferative conditions", "OBSERVATION", 736, 760]]], ["The mRNA levels of cystatin were found to be increased in psoriatic plaques of the psoriasis vulgaris, a common inflammatory disease of the skin, characterized by hyper-proliferation of skin cells that ultimately leads to red, scaly plaques [46].", [["psoriatic plaques", "ANATOMY", 58, 75], ["skin", "ANATOMY", 140, 144], ["skin cells", "ANATOMY", 186, 196], ["scaly plaques", "ANATOMY", 227, 240], ["psoriatic plaques", "DISEASE", 58, 75], ["psoriasis vulgaris", "DISEASE", 83, 101], ["inflammatory disease of the skin", "DISEASE", 112, 144], ["plaques", "DISEASE", 233, 240], ["cystatin", "GENE_OR_GENE_PRODUCT", 19, 27], ["skin", "ORGAN", 140, 144], ["skin cells", "CELL", 186, 196], ["cystatin", "PROTEIN", 19, 27], ["skin cells", "CELL_TYPE", 186, 196], ["psoriasis vulgaris", "SPECIES", 83, 101], ["The mRNA levels", "TEST", 0, 15], ["cystatin", "TEST", 19, 27], ["psoriatic plaques", "PROBLEM", 58, 75], ["the psoriasis vulgaris", "PROBLEM", 79, 101], ["a common inflammatory disease of the skin", "PROBLEM", 103, 144], ["hyper-proliferation of skin cells", "PROBLEM", 163, 196], ["red, scaly plaques", "PROBLEM", 222, 240], ["increased", "OBSERVATION_MODIFIER", 45, 54], ["psoriatic", "OBSERVATION_MODIFIER", 58, 67], ["plaques", "OBSERVATION", 68, 75], ["psoriasis vulgaris", "ANATOMY", 83, 101], ["common", "OBSERVATION_MODIFIER", 105, 111], ["inflammatory", "OBSERVATION_MODIFIER", 112, 124], ["skin", "ANATOMY", 140, 144], ["hyper", "OBSERVATION_MODIFIER", 163, 168], ["proliferation", "OBSERVATION_MODIFIER", 169, 182], ["skin cells", "OBSERVATION", 186, 196], ["scaly", "OBSERVATION_MODIFIER", 227, 232], ["plaques", "OBSERVATION", 233, 240]]], ["In addition, polymorphism in the genes for cystatin C has been associated with atopic dermatitis, a chronic inflammatory skin disease often associated with a defective epidermal barrier [47,48].", [["skin", "ANATOMY", 121, 125], ["epidermal barrier", "ANATOMY", 168, 185], ["atopic dermatitis", "DISEASE", 79, 96], ["skin disease", "DISEASE", 121, 133], ["cystatin C", "GENE_OR_GENE_PRODUCT", 43, 53], ["skin", "ORGAN", 121, 125], ["cystatin C", "PROTEIN", 43, 53], ["polymorphism", "PROBLEM", 13, 25], ["cystatin C", "PROBLEM", 43, 53], ["atopic dermatitis", "PROBLEM", 79, 96], ["a chronic inflammatory skin disease", "PROBLEM", 98, 133], ["a defective epidermal barrier", "PROBLEM", 156, 185], ["associated with", "UNCERTAINTY", 63, 78], ["atopic dermatitis", "OBSERVATION", 79, 96], ["chronic", "OBSERVATION_MODIFIER", 100, 107], ["inflammatory", "OBSERVATION_MODIFIER", 108, 120], ["skin", "ANATOMY", 121, 125], ["disease", "OBSERVATION", 126, 133], ["defective", "OBSERVATION_MODIFIER", 158, 167], ["epidermal", "OBSERVATION_MODIFIER", 168, 177]]], ["Cystatin was found to protect skin barrier from allergic reactions, including atopic dermatitis, and inhibition of proteolytic activity of major mite allergens by cystatin blocked the up-regulation of IL-8 and granulocyte-macrophage colony stimulating factor (GM-CSF) release from keratinocytes stimulated with the allergens [49,50].", [["skin barrier", "ANATOMY", 30, 42], ["keratinocytes", "ANATOMY", 281, 294], ["allergic reactions", "DISEASE", 48, 66], ["atopic dermatitis", "DISEASE", 78, 95], ["Cystatin", "GENE_OR_GENE_PRODUCT", 0, 8], ["skin barrier", "TISSUE", 30, 42], ["cystatin", "GENE_OR_GENE_PRODUCT", 163, 171], ["IL-8", "GENE_OR_GENE_PRODUCT", 201, 205], ["granulocyte-macrophage colony stimulating factor", "GENE_OR_GENE_PRODUCT", 210, 258], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 260, 266], ["keratinocytes", "CELL", 281, 294], ["Cystatin", "PROTEIN", 0, 8], ["cystatin", "PROTEIN", 163, 171], ["IL-8", "PROTEIN", 201, 205], ["granulocyte-macrophage colony stimulating factor", "PROTEIN", 210, 258], ["CSF", "PROTEIN", 263, 266], ["keratinocytes", "CELL_TYPE", 281, 294], ["Cystatin", "TREATMENT", 0, 8], ["skin barrier", "TREATMENT", 30, 42], ["allergic reactions", "PROBLEM", 48, 66], ["atopic dermatitis", "PROBLEM", 78, 95], ["proteolytic activity", "TREATMENT", 115, 135], ["major mite allergens", "PROBLEM", 139, 159], ["cystatin", "TEST", 163, 171], ["IL", "TEST", 201, 203], ["granulocyte", "TEST", 210, 221], ["skin", "ANATOMY", 30, 34], ["allergic reactions", "OBSERVATION", 48, 66], ["atopic dermatitis", "OBSERVATION", 78, 95], ["granulocyte", "ANATOMY", 210, 221]]], ["Moreover, loss-of-function mutations in the gene for cystatins have been identified as the underlying genetic cause of another skin disease, exfoliative ichthyosis [51].", [["skin", "ANATOMY", 127, 131], ["skin disease", "DISEASE", 127, 139], ["exfoliative ichthyosis", "DISEASE", 141, 163], ["cystatins", "GENE_OR_GENE_PRODUCT", 53, 62], ["skin", "ORGAN", 127, 131], ["cystatins", "PROTEIN", 53, 62], ["loss-of-function mutations", "PROBLEM", 10, 36], ["cystatins", "TREATMENT", 53, 62], ["another skin disease", "PROBLEM", 119, 139], ["exfoliative ichthyosis", "PROBLEM", 141, 163], ["skin", "ANATOMY", 127, 131], ["disease", "OBSERVATION", 132, 139]]], ["Consistently, it has been demonstrated that disturbance of the cystatin-cathepsin pathway could contribute to dys-regulated skin barrier function in vivo as was observed in the inflammatory dermatoses [47].Inflammatory skin diseases ::: Immune disorders ::: Cystatin C affects immunityRecently, genetic studies have also revealed that abnormalities in epithelium-expressed genes were important etiological factors [52,53].", [["skin barrier", "ANATOMY", 124, 136], ["skin", "ANATOMY", 219, 223], ["epithelium", "ANATOMY", 352, 362], ["dermatoses", "DISEASE", 190, 200], ["skin diseases", "DISEASE", 219, 232], ["Immune disorders", "DISEASE", 237, 253], ["cystatin", "GENE_OR_GENE_PRODUCT", 63, 71], ["cathepsin", "GENE_OR_GENE_PRODUCT", 72, 81], ["skin barrier", "TISSUE", 124, 136], ["skin", "ORGAN", 219, 223], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 258, 268], ["epithelium", "TISSUE", 352, 362], ["cystatin", "PROTEIN", 63, 71], ["cathepsin", "PROTEIN", 72, 81], ["Cystatin C", "PROTEIN", 258, 268], ["the cystatin-cathepsin pathway", "TREATMENT", 59, 89], ["dys-regulated skin barrier function", "PROBLEM", 110, 145], ["the inflammatory dermatoses", "PROBLEM", 173, 200], ["Inflammatory skin diseases", "PROBLEM", 206, 232], ["Immune disorders", "PROBLEM", 237, 253], ["Cystatin C affects", "TEST", 258, 276], ["genetic studies", "TEST", 295, 310], ["abnormalities in epithelium", "PROBLEM", 335, 362], ["inflammatory", "OBSERVATION_MODIFIER", 177, 189], ["dermatoses", "OBSERVATION", 190, 200], ["skin", "ANATOMY", 219, 223], ["diseases", "OBSERVATION", 224, 232]]], ["Furthermore, decreased mRNA and protein expression levels of cystatin were observed in the inflamed skin during atopic dermatitis and psoriasis, supporting protective roles of cystatin for the skin inflammation [54].Rheumatoid arthritis ::: Immune disorders ::: Cystatin C affects immunityAs a systemic autoimmune disease that mainly affects the arthrosis, rheumatoid arthritis (RA) is a chronic inflammatory lesion of multiple joints that take on the symmetry and peripheral with progressive destruction of articular cartilages and bones [55].", [["skin", "ANATOMY", 100, 104], ["skin", "ANATOMY", 193, 197], ["joints", "ANATOMY", 428, 434], ["articular cartilages", "ANATOMY", 508, 528], ["bones", "ANATOMY", 533, 538], ["atopic dermatitis", "DISEASE", 112, 129], ["psoriasis", "DISEASE", 134, 143], ["skin inflammation", "DISEASE", 193, 210], ["Rheumatoid arthritis", "DISEASE", 216, 236], ["Immune disorders", "DISEASE", 241, 257], ["autoimmune disease", "DISEASE", 303, 321], ["arthrosis", "DISEASE", 346, 355], ["rheumatoid arthritis", "DISEASE", 357, 377], ["RA", "DISEASE", 379, 381], ["cystatin", "GENE_OR_GENE_PRODUCT", 61, 69], ["skin", "ORGAN", 100, 104], ["cystatin", "GENE_OR_GENE_PRODUCT", 176, 184], ["skin", "ORGAN", 193, 197], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 262, 272], ["joints", "MULTI-TISSUE_STRUCTURE", 428, 434], ["articular cartilages", "TISSUE", 508, 528], ["bones", "TISSUE", 533, 538], ["cystatin", "PROTEIN", 61, 69], ["cystatin", "PROTEIN", 176, 184], ["Cystatin C", "PROTEIN", 262, 272], ["decreased mRNA and protein expression levels of cystatin", "PROBLEM", 13, 69], ["the inflamed skin", "PROBLEM", 87, 104], ["atopic dermatitis", "PROBLEM", 112, 129], ["psoriasis", "PROBLEM", 134, 143], ["cystatin", "TREATMENT", 176, 184], ["the skin inflammation", "PROBLEM", 189, 210], ["Rheumatoid arthritis", "PROBLEM", 216, 236], ["Immune disorders", "PROBLEM", 241, 257], ["Cystatin C affects", "PROBLEM", 262, 280], ["a systemic autoimmune disease", "PROBLEM", 292, 321], ["the arthrosis", "PROBLEM", 342, 355], ["rheumatoid arthritis", "PROBLEM", 357, 377], ["a chronic inflammatory lesion of multiple joints", "PROBLEM", 386, 434], ["progressive destruction of articular cartilages and bones", "PROBLEM", 481, 538], ["decreased mRNA", "OBSERVATION", 13, 27], ["inflamed", "OBSERVATION_MODIFIER", 91, 99], ["skin", "ANATOMY", 100, 104], ["atopic dermatitis", "OBSERVATION", 112, 129], ["psoriasis", "OBSERVATION", 134, 143], ["skin", "ANATOMY", 193, 197], ["inflammation", "OBSERVATION", 198, 210], ["arthritis", "OBSERVATION", 227, 236], ["systemic", "OBSERVATION_MODIFIER", 294, 302], ["autoimmune", "OBSERVATION", 303, 313], ["arthrosis", "OBSERVATION", 346, 355], ["rheumatoid", "OBSERVATION_MODIFIER", 357, 367], ["arthritis", "OBSERVATION", 368, 377], ["RA", "ANATOMY", 379, 381], ["chronic", "OBSERVATION_MODIFIER", 388, 395], ["inflammatory", "OBSERVATION_MODIFIER", 396, 408], ["lesion", "OBSERVATION", 409, 415], ["multiple", "OBSERVATION_MODIFIER", 419, 427], ["joints", "ANATOMY", 428, 434], ["peripheral", "ANATOMY_MODIFIER", 465, 475], ["progressive", "OBSERVATION_MODIFIER", 481, 492], ["destruction", "OBSERVATION", 493, 504], ["articular cartilages", "ANATOMY", 508, 528], ["bones", "ANATOMY", 533, 538]]], ["Interestingly, it is believed that in the inflamed joints the cystatin targeted enzymes, especially cathepsin B, H, L, S and K play significant roles in tissue destruction [56], and were highlighted as potential drug targets to treat tissue degenerative and inflammatory processes [57].", [["tissue", "ANATOMY", 153, 159], ["tissue", "ANATOMY", 234, 240], ["joints", "MULTI-TISSUE_STRUCTURE", 51, 57], ["cystatin", "GENE_OR_GENE_PRODUCT", 62, 70], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 100, 111], ["H, L, S", "GENE_OR_GENE_PRODUCT", 113, 120], ["K", "GENE_OR_GENE_PRODUCT", 125, 126], ["tissue", "TISSUE", 153, 159], ["tissue", "TISSUE", 234, 240], ["cystatin targeted enzymes", "PROTEIN", 62, 87], ["cathepsin B", "PROTEIN", 100, 111], ["H, L, S and K", "PROTEIN", 113, 126], ["the cystatin targeted enzymes", "TEST", 58, 87], ["cathepsin", "TEST", 100, 109], ["tissue destruction", "PROBLEM", 153, 171], ["tissue degenerative and inflammatory processes", "PROBLEM", 234, 280], ["inflamed joints", "ANATOMY", 42, 57], ["significant", "OBSERVATION_MODIFIER", 132, 143], ["tissue", "ANATOMY", 153, 159], ["destruction", "OBSERVATION", 160, 171], ["degenerative", "OBSERVATION", 241, 253], ["inflammatory", "OBSERVATION_MODIFIER", 258, 270]]], ["In particular, cathepsin B and L, the substrate enzymes of cystatin C, were found to degrade the components of cartilage, like proteoglycans, collagen II, IX and XI [58], as well as the bone matrix proteins osteocalcin and osteonectin [59,60], indicating the involvement of cystatin C in the development of the autoimmune disease, which is supported by the data from both mouse and human studies described below.Rheumatoid arthritis ::: Immune disorders ::: Cystatin C affects immunityCollagen-induced arthritis (CIA) is a mouse model for human RA.", [["cartilage", "ANATOMY", 111, 120], ["bone matrix", "ANATOMY", 186, 197], ["autoimmune disease", "DISEASE", 311, 329], ["Rheumatoid arthritis", "DISEASE", 412, 432], ["Immune disorders", "DISEASE", 437, 453], ["arthritis", "DISEASE", 502, 511], ["CIA", "DISEASE", 513, 516], ["RA", "DISEASE", 545, 547], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 15, 26], ["L", "GENE_OR_GENE_PRODUCT", 31, 32], ["cystatin C", "GENE_OR_GENE_PRODUCT", 59, 69], ["cartilage", "TISSUE", 111, 120], ["proteoglycans", "GENE_OR_GENE_PRODUCT", 127, 140], ["collagen II", "GENE_OR_GENE_PRODUCT", 142, 153], ["IX", "GENE_OR_GENE_PRODUCT", 155, 157], ["XI [58]", "GENE_OR_GENE_PRODUCT", 162, 169], ["bone", "TISSUE", 186, 190], ["osteocalcin", "GENE_OR_GENE_PRODUCT", 207, 218], ["osteonectin", "GENE_OR_GENE_PRODUCT", 223, 234], ["cystatin C", "GENE_OR_GENE_PRODUCT", 274, 284], ["mouse", "ORGANISM", 372, 377], ["human", "ORGANISM", 382, 387], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 458, 468], ["Collagen", "GENE_OR_GENE_PRODUCT", 485, 493], ["mouse", "ORGANISM", 523, 528], ["human", "ORGANISM", 539, 544], ["cathepsin B", "PROTEIN", 15, 26], ["L", "PROTEIN", 31, 32], ["substrate enzymes", "PROTEIN", 38, 55], ["cystatin C", "PROTEIN", 59, 69], ["collagen II", "PROTEIN", 142, 153], ["IX", "PROTEIN", 155, 157], ["XI", "PROTEIN", 162, 164], ["bone matrix proteins", "PROTEIN", 186, 206], ["osteocalcin", "PROTEIN", 207, 218], ["osteonectin", "PROTEIN", 223, 234], ["cystatin C", "PROTEIN", 274, 284], ["Cystatin C", "PROTEIN", 458, 468], ["mouse", "SPECIES", 372, 377], ["human", "SPECIES", 382, 387], ["mouse", "SPECIES", 523, 528], ["human", "SPECIES", 539, 544], ["mouse", "SPECIES", 372, 377], ["human", "SPECIES", 382, 387], ["mouse", "SPECIES", 523, 528], ["human", "SPECIES", 539, 544], ["the substrate enzymes", "TEST", 34, 55], ["cystatin C", "TEST", 59, 69], ["the bone matrix proteins osteocalcin", "TEST", 182, 218], ["osteonectin", "TEST", 223, 234], ["cystatin C", "PROBLEM", 274, 284], ["the autoimmune disease", "PROBLEM", 307, 329], ["human studies", "TEST", 382, 395], ["Rheumatoid arthritis", "PROBLEM", 412, 432], ["Immune disorders", "PROBLEM", 437, 453], ["Cystatin C affects", "PROBLEM", 458, 476], ["immunityCollagen", "TREATMENT", 477, 493], ["arthritis", "PROBLEM", 502, 511], ["human RA", "TREATMENT", 539, 547], ["cartilage", "ANATOMY", 111, 120], ["bone", "ANATOMY", 186, 190], ["autoimmune disease", "OBSERVATION", 311, 329], ["arthritis", "OBSERVATION", 423, 432], ["immunityCollagen", "OBSERVATION_MODIFIER", 477, 493], ["arthritis", "OBSERVATION", 502, 511], ["RA", "ANATOMY", 545, 547]]], ["Both the priming and inflammatory phases of the CIA have been suggested to rely on proteases, of which, the cysteine proteases have been proposed to be detrimental to the arthritic and even immunomodulatory process [61].", [["CIA", "DISEASE", 48, 51], ["cysteine", "CHEMICAL", 108, 116], ["CIA", "GENE_OR_GENE_PRODUCT", 48, 51], ["proteases", "PROTEIN", 83, 92], ["cysteine proteases", "PROTEIN", 108, 126], ["the cysteine proteases", "TREATMENT", 104, 126], ["inflammatory", "OBSERVATION_MODIFIER", 21, 33], ["CIA", "ANATOMY", 48, 51], ["arthritic", "OBSERVATION", 171, 180]]], ["Therefore, it is not surprising to think that cystatin C was associated with the development of the inflammatory joint disease.", [["joint", "ANATOMY", 113, 118], ["inflammatory joint disease", "DISEASE", 100, 126], ["cystatin C", "GENE_OR_GENE_PRODUCT", 46, 56], ["joint", "ORGAN", 113, 118], ["cystatin C", "PROTEIN", 46, 56], ["cystatin C", "PROBLEM", 46, 56], ["the inflammatory joint disease", "PROBLEM", 96, 126], ["inflammatory joint disease", "OBSERVATION", 100, 126]]], ["Along this line, the lack of cystatin C was found to enhance CIA onset and primarily affected the in vivo priming of the immune system [61].", [["cystatin C", "GENE_OR_GENE_PRODUCT", 29, 39], ["cystatin C", "PROTEIN", 29, 39], ["this line", "TREATMENT", 6, 15], ["cystatin C", "PROBLEM", 29, 39], ["CIA onset", "PROBLEM", 61, 70]]], ["To further dissect the cellular mechanism behind the observed phenomenon, evidences of a more activated APC compartment was observed to explain the elevated autoimmune response towards type II collagen, which resulted in an enhanced development of chronic arthritis [61].Rheumatoid arthritis ::: Immune disorders ::: Cystatin C affects immunityIn human RA, cathepsin B is expressed in synovial fibroblasts and synovial cells attached to cartilages and bones at sites of erosion [55].", [["cellular", "ANATOMY", 23, 31], ["APC compartment", "ANATOMY", 104, 119], ["synovial fibroblasts", "ANATOMY", 385, 405], ["synovial cells", "ANATOMY", 410, 424], ["cartilages", "ANATOMY", 437, 447], ["bones", "ANATOMY", 452, 457], ["sites", "ANATOMY", 461, 466], ["chronic arthritis", "DISEASE", 248, 265], ["Rheumatoid arthritis", "DISEASE", 271, 291], ["Immune disorders", "DISEASE", 296, 312], ["cellular", "CELL", 23, 31], ["APC", "GENE_OR_GENE_PRODUCT", 104, 107], ["type II collagen", "GENE_OR_GENE_PRODUCT", 185, 201], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 317, 327], ["human", "ORGANISM", 347, 352], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 357, 368], ["synovial fibroblasts", "CELL", 385, 405], ["synovial cells", "CELL", 410, 424], ["cartilages", "TISSUE", 437, 447], ["bones", "ORGAN", 452, 457], ["type II collagen", "PROTEIN", 185, 201], ["Cystatin C", "PROTEIN", 317, 327], ["cathepsin B", "PROTEIN", 357, 368], ["synovial fibroblasts", "CELL_TYPE", 385, 405], ["synovial cells", "CELL_TYPE", 410, 424], ["human", "SPECIES", 347, 352], ["human", "SPECIES", 347, 352], ["the observed phenomenon", "PROBLEM", 49, 72], ["a more activated APC compartment", "PROBLEM", 87, 119], ["the elevated autoimmune response", "PROBLEM", 144, 176], ["type II collagen", "PROBLEM", 185, 201], ["chronic arthritis", "PROBLEM", 248, 265], ["Rheumatoid arthritis", "PROBLEM", 271, 291], ["Immune disorders", "PROBLEM", 296, 312], ["Cystatin C affects", "PROBLEM", 317, 335], ["immunityIn human RA", "TREATMENT", 336, 355], ["cathepsin B", "TREATMENT", 357, 368], ["synovial fibroblasts", "PROBLEM", 385, 405], ["synovial cells", "PROBLEM", 410, 424], ["cartilages and bones", "PROBLEM", 437, 457], ["erosion", "PROBLEM", 470, 477], ["elevated", "OBSERVATION_MODIFIER", 148, 156], ["autoimmune", "OBSERVATION", 157, 167], ["chronic", "OBSERVATION_MODIFIER", 248, 255], ["arthritis", "OBSERVATION", 256, 265], ["arthritis", "OBSERVATION", 282, 291], ["RA", "ANATOMY", 353, 355], ["synovial fibroblasts", "OBSERVATION", 385, 405], ["synovial cells", "OBSERVATION", 410, 424], ["cartilages", "ANATOMY", 437, 447], ["bones", "ANATOMY", 452, 457], ["erosion", "OBSERVATION", 470, 477]]], ["In agreement with the mouse data, cystatin C was also found to be the most prominent cystatin in synovial fluid of RA patients who have significantly reduced levels of cystatin C in circulation [62].", [["synovial fluid", "ANATOMY", 97, 111], ["mouse", "ORGANISM", 22, 27], ["cystatin C", "GENE_OR_GENE_PRODUCT", 34, 44], ["cystatin", "GENE_OR_GENE_PRODUCT", 85, 93], ["synovial fluid", "ORGANISM_SUBSTANCE", 97, 111], ["patients", "ORGANISM", 118, 126], ["cystatin C", "GENE_OR_GENE_PRODUCT", 168, 178], ["cystatin C", "PROTEIN", 34, 44], ["cystatin", "PROTEIN", 85, 93], ["cystatin C", "PROTEIN", 168, 178], ["mouse", "SPECIES", 22, 27], ["patients", "SPECIES", 118, 126], ["mouse", "SPECIES", 22, 27], ["cystatin C", "TREATMENT", 34, 44], ["cystatin C in circulation", "PROBLEM", 168, 193], ["synovial", "ANATOMY", 97, 105], ["fluid", "OBSERVATION", 106, 111], ["RA", "ANATOMY", 115, 117]]], ["In order to compare the expression of cathepsin B and cystatin C in RA synovial membrane, a group of ten RA patients and healthy controls was chosen to examine the quantities of cathepsin B and cystatin C expression in synovium using immunohistochemical method and investigate the cellular sources that produce these two bioactive proteins [63].", [["RA synovial membrane", "ANATOMY", 68, 88], ["synovium", "ANATOMY", 219, 227], ["cellular", "ANATOMY", 281, 289], ["RA", "DISEASE", 105, 107], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 38, 49], ["cystatin C", "GENE_OR_GENE_PRODUCT", 54, 64], ["synovial membrane", "MULTI-TISSUE_STRUCTURE", 71, 88], ["patients", "ORGANISM", 108, 116], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 178, 189], ["cystatin C", "GENE_OR_GENE_PRODUCT", 194, 204], ["synovium", "TISSUE", 219, 227], ["cellular", "CELL", 281, 289], ["cathepsin B", "PROTEIN", 38, 49], ["cystatin C", "PROTEIN", 54, 64], ["cathepsin B", "PROTEIN", 178, 189], ["cystatin C", "PROTEIN", 194, 204], ["patients", "SPECIES", 108, 116], ["cathepsin B", "TREATMENT", 38, 49], ["cystatin C in RA synovial membrane", "TREATMENT", 54, 88], ["cathepsin B", "TREATMENT", 178, 189], ["cystatin C expression in synovium", "TREATMENT", 194, 227], ["immunohistochemical method", "TEST", 234, 260], ["the cellular sources", "PROBLEM", 277, 297], ["RA", "ANATOMY", 68, 70], ["synovial membrane", "ANATOMY", 71, 88], ["synovium", "ANATOMY", 219, 227]]], ["The results showed that cathepsin B and cystatin C were highly expressed in RA synovial tissues, in which fibroblast-like and macrophage-like cells from fibro-proliferative tissue at the site of cartilage and bone destruction were positive for cystatin C and cathepsin B, whereas only limited expression of these molecules was exhibited in normal synovial tissue [63].", [["RA synovial tissues", "ANATOMY", 76, 95], ["fibroblast-like", "ANATOMY", 106, 121], ["macrophage-like cells", "ANATOMY", 126, 147], ["fibro-proliferative tissue", "ANATOMY", 153, 179], ["site", "ANATOMY", 187, 191], ["cartilage", "ANATOMY", 195, 204], ["bone", "ANATOMY", 209, 213], ["synovial tissue", "ANATOMY", 347, 362], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 24, 35], ["cystatin C", "GENE_OR_GENE_PRODUCT", 40, 50], ["RA synovial tissues", "TISSUE", 76, 95], ["fibroblast-like", "CELL", 106, 121], ["macrophage-like cells", "CELL", 126, 147], ["fibro-proliferative tissue", "TISSUE", 153, 179], ["cartilage", "TISSUE", 195, 204], ["bone", "TISSUE", 209, 213], ["cystatin C", "GENE_OR_GENE_PRODUCT", 244, 254], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 259, 270], ["synovial tissue", "TISSUE", 347, 362], ["cathepsin B", "PROTEIN", 24, 35], ["cystatin C", "PROTEIN", 40, 50], ["fibroblast-like and macrophage-like cells", "CELL_TYPE", 106, 147], ["cystatin C", "PROTEIN", 244, 254], ["cathepsin B", "PROTEIN", 259, 270], ["cathepsin B and cystatin C", "TREATMENT", 24, 50], ["fibroblast", "TEST", 106, 116], ["macrophage-like cells", "PROBLEM", 126, 147], ["fibro-proliferative tissue", "PROBLEM", 153, 179], ["bone destruction", "PROBLEM", 209, 225], ["cystatin C and cathepsin B", "PROBLEM", 244, 270], ["these molecules", "PROBLEM", 307, 322], ["RA", "ANATOMY", 76, 78], ["synovial tissues", "ANATOMY", 79, 95], ["macrophage", "OBSERVATION_MODIFIER", 126, 136], ["proliferative tissue", "OBSERVATION", 159, 179], ["cartilage", "ANATOMY", 195, 204], ["bone", "ANATOMY", 209, 213], ["destruction", "OBSERVATION", 214, 225], ["synovial tissue", "OBSERVATION", 347, 362]]], ["Osteoclasts also revealed positive staining for cystatin C, but not for cathepsin B, which means that cystatin C is the product of both macrophage-like and fibroblast-like synoviocytes.", [["Osteoclasts", "ANATOMY", 0, 11], ["macrophage", "ANATOMY", 136, 146], ["fibroblast-like synoviocytes", "ANATOMY", 156, 184], ["Osteoclasts", "CELL", 0, 11], ["cystatin C", "GENE_OR_GENE_PRODUCT", 48, 58], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 72, 83], ["cystatin C", "GENE_OR_GENE_PRODUCT", 102, 112], ["macrophage", "CELL", 136, 146], ["fibroblast-like synoviocytes", "CELL", 156, 184], ["Osteoclasts", "CELL_TYPE", 0, 11], ["cystatin C", "PROTEIN", 48, 58], ["cathepsin B", "PROTEIN", 72, 83], ["cystatin C", "PROTEIN", 102, 112], ["macrophage-like and fibroblast-like synoviocytes", "CELL_TYPE", 136, 184], ["Osteoclasts", "PROBLEM", 0, 11], ["positive staining", "PROBLEM", 26, 43], ["cystatin C", "PROBLEM", 48, 58], ["cathepsin B", "PROBLEM", 72, 83], ["cystatin C", "PROBLEM", 102, 112], ["fibroblast-like synoviocytes", "PROBLEM", 156, 184], ["positive", "OBSERVATION_MODIFIER", 26, 34], ["staining", "OBSERVATION", 35, 43], ["both macrophage", "OBSERVATION", 131, 146], ["synoviocytes", "ANATOMY", 172, 184]]], ["The strong expression of the cystatin C in the diseased rheumatoid synovium suggests that cystatin C is either correlated with the disease development, or important but insufficient to prevent matrix degradation by cathepsin B. Although the exact roles that cystatin C plays in the inflammatory lesions remain to be discovered, it could currently serve as diagnostic biomarker or therapeutic target for the treatment of the autoimmune disease.Cystatin C and DCs ::: Cystatin C regulates immunity at cellular levelsDCs have strong ability to initiate T cell activation and bridge connection between innate and adaptive immunity in the case of an acute infection [66], but to maintain immune tolerance to self-tissues and organs at steady state [67].", [["rheumatoid synovium", "ANATOMY", 56, 75], ["matrix", "ANATOMY", 193, 199], ["inflammatory lesions", "ANATOMY", 282, 302], ["DCs", "ANATOMY", 458, 461], ["cellular levelsDCs", "ANATOMY", 499, 517], ["T cell", "ANATOMY", 550, 556], ["tissues", "ANATOMY", 708, 715], ["organs", "ANATOMY", 720, 726], ["autoimmune disease", "DISEASE", 424, 442], ["infection", "DISEASE", 651, 660], ["cystatin C", "GENE_OR_GENE_PRODUCT", 29, 39], ["rheumatoid synovium", "TISSUE", 56, 75], ["cystatin C", "GENE_OR_GENE_PRODUCT", 90, 100], ["matrix", "CELLULAR_COMPONENT", 193, 199], ["cathepsin B.", "GENE_OR_GENE_PRODUCT", 215, 227], ["cystatin C", "GENE_OR_GENE_PRODUCT", 258, 268], ["lesions", "PATHOLOGICAL_FORMATION", 295, 302], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 443, 453], ["DCs", "CELL", 458, 461], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 466, 476], ["cellular levelsDCs", "CELL", 499, 517], ["T cell", "CELL", 550, 556], ["tissues", "TISSUE", 708, 715], ["organs", "ORGAN", 720, 726], ["cystatin C", "PROTEIN", 29, 39], ["cystatin C", "PROTEIN", 90, 100], ["cathepsin B.", "PROTEIN", 215, 227], ["cystatin C", "PROTEIN", 258, 268], ["Cystatin C", "PROTEIN", 443, 453], ["DCs", "CELL_TYPE", 458, 461], ["Cystatin C", "PROTEIN", 466, 476], ["the cystatin C in the diseased rheumatoid synovium", "PROBLEM", 25, 75], ["cystatin C", "PROBLEM", 90, 100], ["the disease development", "PROBLEM", 127, 150], ["matrix degradation", "PROBLEM", 193, 211], ["cystatin C plays", "PROBLEM", 258, 274], ["the inflammatory lesions", "PROBLEM", 278, 302], ["diagnostic biomarker", "TEST", 356, 376], ["the treatment", "TREATMENT", 403, 416], ["the autoimmune disease", "PROBLEM", 420, 442], ["Cystatin C regulates immunity at cellular levelsDCs", "PROBLEM", 466, 517], ["T cell activation", "TREATMENT", 550, 567], ["bridge connection between innate and adaptive immunity", "TREATMENT", 572, 626], ["an acute infection", "PROBLEM", 642, 660], ["strong", "OBSERVATION_MODIFIER", 4, 10], ["diseased", "OBSERVATION_MODIFIER", 47, 55], ["rheumatoid synovium", "OBSERVATION", 56, 75], ["disease", "OBSERVATION", 131, 138], ["inflammatory", "OBSERVATION_MODIFIER", 282, 294], ["lesions", "OBSERVATION", 295, 302], ["autoimmune", "OBSERVATION", 424, 434], ["acute", "OBSERVATION_MODIFIER", 645, 650], ["infection", "OBSERVATION", 651, 660]]], ["Literature has reported that the expression of cystatin C varies widely among hematopoietic cell types, with cells of the monocyte/macrophage and DC lineages expressing it at much higher levels than B or T cells, indicating possible roles of cystatin C in DCs [42].Cystatin C and DCs ::: Cystatin C regulates immunity at cellular levelsExternal stimuli can transform DCs from immature status to mature status by increasing many DC surface molecules such as antigen presenting molecules MHC-I and MHC-II; co-stimulatory molecules CD80 and CD86, adherence molecules CD40, CD54 and integrin, which are essential for the immunological functions of DCs [68].", [["hematopoietic cell", "ANATOMY", 78, 96], ["cells", "ANATOMY", 109, 114], ["monocyte", "ANATOMY", 122, 130], ["macrophage", "ANATOMY", 131, 141], ["DC", "ANATOMY", 146, 148], ["B", "ANATOMY", 199, 200], ["T cells", "ANATOMY", 204, 211], ["DCs", "ANATOMY", 256, 259], ["DCs", "ANATOMY", 280, 283], ["cellular", "ANATOMY", 321, 329], ["DCs", "ANATOMY", 367, 370], ["DC surface", "ANATOMY", 428, 438], ["DCs", "ANATOMY", 644, 647], ["cystatin C", "GENE_OR_GENE_PRODUCT", 47, 57], ["hematopoietic cell", "CELL", 78, 96], ["cells", "CELL", 109, 114], ["monocyte", "CELL", 122, 130], ["macrophage", "CELL", 131, 141], ["DC lineages", "CELL", 146, 157], ["B", "CELL", 199, 200], ["T cells", "CELL", 204, 211], ["cystatin C", "GENE_OR_GENE_PRODUCT", 242, 252], ["DCs", "CELL", 256, 259], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 265, 275], ["DCs", "CELL", 280, 283], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 288, 298], ["cellular", "CELL", 321, 329], ["DCs", "CELL", 367, 370], ["antigen presenting molecules MHC-I", "GENE_OR_GENE_PRODUCT", 457, 491], ["MHC-II", "GENE_OR_GENE_PRODUCT", 496, 502], ["CD80", "GENE_OR_GENE_PRODUCT", 529, 533], ["CD86", "GENE_OR_GENE_PRODUCT", 538, 542], ["CD40", "GENE_OR_GENE_PRODUCT", 564, 568], ["CD54", "GENE_OR_GENE_PRODUCT", 570, 574], ["integrin", "GENE_OR_GENE_PRODUCT", 579, 587], ["DCs", "CELL", 644, 647], ["cystatin C", "PROTEIN", 47, 57], ["hematopoietic cell types", "CELL_TYPE", 78, 102], ["monocyte/macrophage and DC lineages", "CELL_TYPE", 122, 157], ["B or T cells", "CELL_TYPE", 199, 211], ["cystatin C", "PROTEIN", 242, 252], ["DCs", "CELL_TYPE", 256, 259], ["Cystatin C", "PROTEIN", 265, 275], ["DCs", "CELL_TYPE", 280, 283], ["Cystatin C", "PROTEIN", 288, 298], ["DCs", "CELL_TYPE", 367, 370], ["DC surface molecules", "PROTEIN", 428, 448], ["antigen presenting molecules", "PROTEIN", 457, 485], ["MHC-I and MHC-II", "PROTEIN", 486, 502], ["co-stimulatory molecules", "PROTEIN", 504, 528], ["CD80", "PROTEIN", 529, 533], ["CD86", "PROTEIN", 538, 542], ["adherence molecules", "PROTEIN", 544, 563], ["CD40", "PROTEIN", 564, 568], ["CD54", "PROTEIN", 570, 574], ["integrin", "PROTEIN", 579, 587], ["DCs", "CELL_TYPE", 644, 647], ["cystatin C varies", "PROBLEM", 47, 64], ["hematopoietic cell types", "PROBLEM", 78, 102], ["the monocyte/macrophage", "TREATMENT", 118, 141], ["DC lineages", "TREATMENT", 146, 157], ["cystatin C in DCs", "TREATMENT", 242, 259], ["Cystatin C regulates immunity at cellular levels", "PROBLEM", 288, 336], ["External stimuli", "TREATMENT", 336, 352], ["increasing many DC surface molecules", "PROBLEM", 412, 448], ["CD80", "TEST", 529, 533], ["CD86", "TEST", 538, 542], ["CD40", "TEST", 564, 568], ["CD54", "TEST", 570, 574], ["integrin", "TREATMENT", 579, 587], ["hematopoietic cell types", "OBSERVATION", 78, 102], ["monocyte", "ANATOMY", 122, 130], ["macrophage", "ANATOMY", 131, 141]]], ["We and others have demonstrated that higher concentrations of cystatin C were measured in immature DC, but gradually decreased with DC maturation, which lead to the elevated activity of cathepsin L and S, indicating an essential role of cystatin C in controlling the degradation of intracellular antigens and T cell stimulatory capacity of DCs [43,69].Cystatin C and DCs ::: Cystatin C regulates immunity at cellular levelsCystatin C affects DC functions not only by its quantity but also by its quality, as it is one of the few amyloid proteins.", [["DC", "ANATOMY", 99, 101], ["DC", "ANATOMY", 132, 134], ["intracellular", "ANATOMY", 282, 295], ["T cell", "ANATOMY", 309, 315], ["DCs", "ANATOMY", 340, 343], ["DCs", "ANATOMY", 367, 370], ["cellular", "ANATOMY", 408, 416], ["DC", "ANATOMY", 442, 444], ["cystatin C", "GENE_OR_GENE_PRODUCT", 62, 72], ["DC", "CELL", 99, 101], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 186, 197], ["cystatin C", "GENE_OR_GENE_PRODUCT", 237, 247], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 282, 295], ["T cell", "CELL", 309, 315], ["DCs", "CELL", 340, 343], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 352, 362], ["DCs", "CELL", 367, 370], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 375, 385], ["cellular", "CELL", 408, 416], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 423, 433], ["DC", "CELL", 442, 444], ["amyloid", "GENE_OR_GENE_PRODUCT", 529, 536], ["cystatin C", "PROTEIN", 62, 72], ["immature DC", "CELL_TYPE", 90, 101], ["DC", "CELL_TYPE", 132, 134], ["cathepsin L and S", "PROTEIN", 186, 203], ["cystatin C", "PROTEIN", 237, 247], ["intracellular antigens", "PROTEIN", 282, 304], ["DCs", "CELL_TYPE", 340, 343], ["Cystatin C", "PROTEIN", 352, 362], ["DCs", "CELL_TYPE", 367, 370], ["Cystatin C", "PROTEIN", 375, 385], ["Cystatin C", "PROTEIN", 423, 433], ["DC", "CELL_TYPE", 442, 444], ["amyloid proteins", "PROTEIN", 529, 545], ["cystatin C", "PROBLEM", 62, 72], ["the elevated activity of cathepsin L and S", "PROBLEM", 161, 203], ["cystatin C", "TREATMENT", 237, 247], ["intracellular antigens", "TREATMENT", 282, 304], ["Cystatin C regulates immunity at cellular levels", "PROBLEM", 375, 423], ["Cystatin C affects", "PROBLEM", 423, 441], ["the few amyloid proteins", "PROBLEM", 521, 545], ["few", "OBSERVATION_MODIFIER", 525, 528], ["amyloid", "OBSERVATION", 529, 536]]], ["Cystatin C amyloidogenesis starts with cystatin C dimerization by a process known as \u201cthree dimentional domain swapping\u201d, in which two parts of the cystatin structure become separated from each other and next exchanged between two molecules [70].", [["Cystatin C", "GENE_OR_GENE_PRODUCT", 0, 10], ["cystatin C", "GENE_OR_GENE_PRODUCT", 39, 49], ["cystatin", "GENE_OR_GENE_PRODUCT", 148, 156], ["Cystatin C", "PROTEIN", 0, 10], ["cystatin C", "PROTEIN", 39, 49], ["dimentional domain", "PROTEIN", 92, 110], ["cystatin structure", "PROTEIN", 148, 166], ["Cystatin C amyloidogenesis", "PROBLEM", 0, 26], ["cystatin C dimerization", "PROBLEM", 39, 62], ["three dimentional domain swapping", "PROBLEM", 86, 119], ["the cystatin structure", "PROBLEM", 144, 166], ["cystatin", "OBSERVATION", 148, 156]]], ["Interestingly, with their inhibitory region hidden within the dimer interface, cystatin C dimers cannot inhibit cysteine proteases to regulate the immunological functions of DCs [71].", [["DCs", "ANATOMY", 174, 177], ["cysteine", "CHEMICAL", 112, 120], ["cystatin C", "GENE_OR_GENE_PRODUCT", 79, 89], ["DCs", "CELL", 174, 177], ["cystatin C dimers", "PROTEIN", 79, 96], ["cysteine proteases", "PROTEIN", 112, 130], ["DCs", "CELL_TYPE", 174, 177], ["cystatin C dimers", "TREATMENT", 79, 96], ["cysteine proteases", "TREATMENT", 112, 130]]], ["To identify the mechanistic factors leading to cystatin C dimerization either as post-translational regulation of its activity, or as amyloid precursor protein, we compared the intracellular accumulation of reactive oxygen species (ROS) in the immature and mature states, and found strong correlation between ROS levels and cystatin C dimer not only in same cell type (DCs) at different developmental stages, but also in different cell types (DCs and macrophage) at the same developmental stages [43].", [["intracellular", "ANATOMY", 177, 190], ["cell type", "ANATOMY", 358, 367], ["DCs", "ANATOMY", 369, 372], ["cell", "ANATOMY", 431, 435], ["DCs", "ANATOMY", 443, 446], ["macrophage", "ANATOMY", 451, 461], ["oxygen", "CHEMICAL", 216, 222], ["ROS", "CHEMICAL", 232, 235], ["oxygen", "CHEMICAL", 216, 222], ["cystatin C", "GENE_OR_GENE_PRODUCT", 47, 57], ["amyloid precursor protein", "GENE_OR_GENE_PRODUCT", 134, 159], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 177, 190], ["reactive oxygen species", "SIMPLE_CHEMICAL", 207, 230], ["ROS", "SIMPLE_CHEMICAL", 232, 235], ["ROS", "SIMPLE_CHEMICAL", 309, 312], ["cystatin C", "GENE_OR_GENE_PRODUCT", 324, 334], ["cell type", "CELL", 358, 367], ["DCs", "CELL", 369, 372], ["cell", "CELL", 431, 435], ["DCs", "CELL", 443, 446], ["macrophage", "CELL", 451, 461], ["cystatin C", "PROTEIN", 47, 57], ["amyloid precursor protein", "PROTEIN", 134, 159], ["cystatin C dimer", "PROTEIN", 324, 340], ["DCs", "CELL_TYPE", 369, 372], ["DCs", "CELL_TYPE", 443, 446], ["macrophage", "CELL_TYPE", 451, 461], ["the mechanistic factors", "PROBLEM", 12, 35], ["cystatin C dimerization", "TREATMENT", 47, 70], ["amyloid precursor protein", "TEST", 134, 159], ["reactive oxygen species", "PROBLEM", 207, 230], ["ROS levels", "TEST", 309, 319], ["cystatin C dimer", "PROBLEM", 324, 340], ["reactive", "OBSERVATION_MODIFIER", 207, 215], ["oxygen species", "OBSERVATION", 216, 230], ["immature", "OBSERVATION_MODIFIER", 244, 252], ["developmental stages", "OBSERVATION_MODIFIER", 387, 407], ["different cell types", "OBSERVATION", 421, 441]]], ["Furthermore, artificially enhancing the intracellular oxidative status resulted in a time-dependent cystatin C dimer enrichment, which could be prevented by inhibiting mitochondria activity, indicating the ROSs released from mitochondria are responsible for the observed constitutive cystatin C dimer formation and lose of its inhibitor\u2019s activity [43].", [["intracellular", "ANATOMY", 40, 53], ["mitochondria", "ANATOMY", 168, 180], ["mitochondria", "ANATOMY", 225, 237], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 40, 53], ["cystatin C", "GENE_OR_GENE_PRODUCT", 100, 110], ["mitochondria", "CELLULAR_COMPONENT", 168, 180], ["ROSs", "GENE_OR_GENE_PRODUCT", 206, 210], ["mitochondria", "CELLULAR_COMPONENT", 225, 237], ["cystatin C dimer", "GENE_OR_GENE_PRODUCT", 284, 300], ["cystatin C", "PROTEIN", 100, 110], ["ROSs", "PROTEIN", 206, 210], ["cystatin C", "PROTEIN", 284, 294], ["artificially enhancing the intracellular oxidative status", "PROBLEM", 13, 70], ["a time-dependent cystatin C dimer enrichment", "PROBLEM", 83, 127], ["the observed constitutive cystatin C dimer formation", "PROBLEM", 258, 310], ["oxidative status", "OBSERVATION", 54, 70]]], ["Therefore, the importance of cystatin C in DCs is manifested by its multiple controls at different levels affected by both intrinsic and extrinsic factors.Cystatin C and DCs ::: Cystatin C regulates immunity at cellular levelsThe predominant expression of cystatin C in DCs is not evenly presented among different DC subsets.", [["DCs", "ANATOMY", 43, 46], ["DCs", "ANATOMY", 170, 173], ["cellular", "ANATOMY", 211, 219], ["DCs", "ANATOMY", 270, 273], ["DC", "ANATOMY", 314, 316], ["cystatin C", "GENE_OR_GENE_PRODUCT", 29, 39], ["DCs", "CELL", 43, 46], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 155, 165], ["DCs", "CELL", 170, 173], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 178, 188], ["cellular", "CELL", 211, 219], ["cystatin C", "GENE_OR_GENE_PRODUCT", 256, 266], ["DCs", "CELL", 270, 273], ["DC", "CELL", 314, 316], ["cystatin C", "PROTEIN", 29, 39], ["DCs", "CELL_TYPE", 43, 46], ["Cystatin C", "PROTEIN", 155, 165], ["DCs", "CELL_TYPE", 170, 173], ["Cystatin C", "PROTEIN", 178, 188], ["cystatin C", "PROTEIN", 256, 266], ["DCs", "CELL_TYPE", 270, 273], ["DC subsets", "CELL_TYPE", 314, 324], ["cystatin C in DCs", "TREATMENT", 29, 46], ["Cystatin C regulates immunity at cellular levels", "PROBLEM", 178, 226], ["cystatin C in DCs", "PROBLEM", 256, 273], ["multiple", "OBSERVATION_MODIFIER", 68, 76], ["extrinsic factors", "OBSERVATION", 137, 154], ["predominant", "OBSERVATION_MODIFIER", 230, 241], ["expression", "OBSERVATION_MODIFIER", 242, 252]]], ["Further analysis of the DC subsets directly isolated from the spleen demonstrated that the CD8+ DC were the major producer of cystatin C, with little or no expression in the closely related CD8\u2212 DC [43,72].", [["DC", "ANATOMY", 24, 26], ["spleen", "ANATOMY", 62, 68], ["CD8+ DC", "ANATOMY", 91, 98], ["CD8\u2212", "ANATOMY", 190, 194], ["DC", "ANATOMY", 195, 197], ["DC", "CELL", 24, 26], ["spleen", "ORGAN", 62, 68], ["CD8", "GENE_OR_GENE_PRODUCT", 91, 94], ["cystatin C", "GENE_OR_GENE_PRODUCT", 126, 136], ["CD8", "GENE_OR_GENE_PRODUCT", 190, 193], ["DC subsets", "CELL_TYPE", 24, 34], ["CD8", "PROTEIN", 91, 94], ["DC", "CELL_TYPE", 96, 98], ["cystatin C", "PROTEIN", 126, 136], ["CD8", "PROTEIN", 190, 193], ["DC", "CELL_TYPE", 195, 197], ["Further analysis", "TEST", 0, 16], ["the DC subsets", "TEST", 20, 34], ["the CD8", "TEST", 87, 94], ["cystatin C", "PROBLEM", 126, 136], ["spleen", "ANATOMY", 62, 68]]], ["This differential expression pattern of cystatin C among cells of common lineages suggests that its gene could be subjected to the regulation by cell-specific transcription factors.", [["cells", "ANATOMY", 57, 62], ["cell", "ANATOMY", 145, 149], ["cystatin C", "GENE_OR_GENE_PRODUCT", 40, 50], ["cells", "CELL", 57, 62], ["cell", "CELL", 145, 149], ["cystatin C", "PROTEIN", 40, 50], ["transcription factors", "PROTEIN", 159, 180], ["cystatin C among cells of common lineages", "PROBLEM", 40, 81]]], ["In addition, mature DC can secrete a large number of immune-stimulatory cytokines and chemokines to induce the pro-inflammatory Th cells differentiation and memory T cells activation [73], of which IL-6 signaling in vivo was found to decrease cystatin C expression in DCs [36].", [["DC", "ANATOMY", 20, 22], ["Th cells", "ANATOMY", 128, 136], ["memory T cells", "ANATOMY", 157, 171], ["DCs", "ANATOMY", 268, 271], ["DC", "CELL", 20, 22], ["Th cells", "CELL", 128, 136], ["memory T cells", "CELL", 157, 171], ["IL-6", "GENE_OR_GENE_PRODUCT", 198, 202], ["cystatin C", "GENE_OR_GENE_PRODUCT", 243, 253], ["DCs", "CELL", 268, 271], ["mature DC", "CELL_TYPE", 13, 22], ["immune-stimulatory cytokines", "PROTEIN", 53, 81], ["chemokines", "PROTEIN", 86, 96], ["pro-inflammatory Th cells", "CELL_TYPE", 111, 136], ["memory T cells", "CELL_TYPE", 157, 171], ["IL-6", "PROTEIN", 198, 202], ["cystatin C", "PROTEIN", 243, 253], ["DCs", "CELL_TYPE", 268, 271], ["immune-stimulatory cytokines", "TREATMENT", 53, 81], ["chemokines", "TREATMENT", 86, 96], ["IL", "TEST", 198, 200], ["cystatin C expression", "TREATMENT", 243, 264]]], ["Along the same line, we found that in an inflammatory mouse model created by intravenous injection of CpG oligodeoxynucleotides, mimics of bacterial and viral DNA responsible for immune stimulation, the synthesis of cystatin C in DCs as well as the circulating pools of cystatin C in blood were greatly reduced [74].", [["intravenous", "ANATOMY", 77, 88], ["DCs", "ANATOMY", 230, 233], ["blood", "ANATOMY", 284, 289], ["CpG", "CHEMICAL", 102, 105], ["mouse", "ORGANISM", 54, 59], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 77, 88], ["DNA", "CELLULAR_COMPONENT", 159, 162], ["cystatin C", "GENE_OR_GENE_PRODUCT", 216, 226], ["DCs", "CELL", 230, 233], ["cystatin C", "GENE_OR_GENE_PRODUCT", 270, 280], ["blood", "ORGANISM_SUBSTANCE", 284, 289], ["bacterial and viral DNA", "DNA", 139, 162], ["cystatin C", "PROTEIN", 216, 226], ["DCs", "CELL_TYPE", 230, 233], ["cystatin C", "PROTEIN", 270, 280], ["mouse", "SPECIES", 54, 59], ["mouse", "SPECIES", 54, 59], ["an inflammatory mouse model", "TREATMENT", 38, 65], ["intravenous injection of CpG oligodeoxynucleotides", "TREATMENT", 77, 127], ["bacterial", "PROBLEM", 139, 148], ["viral DNA", "PROBLEM", 153, 162], ["immune stimulation", "TREATMENT", 179, 197], ["cystatin C in DCs", "TREATMENT", 216, 233], ["cystatin C in blood", "TEST", 270, 289], ["inflammatory", "OBSERVATION", 41, 53], ["viral DNA", "OBSERVATION", 153, 162]]], ["Collectively, these data suggest that cystatin C can affect the functions of DCs, which in turn secrete inflammatory cytokines to regulate cystatin C expression for further immune regulation.Cystatin C and mononuclear phagocytic cells ::: Cystatin C regulates immunity at cellular levelsMononuclear phagocytic cells consist of the phagocytic cells located in reticular connective tissue, primarily monocytes and macrophages.", [["DCs", "ANATOMY", 77, 80], ["mononuclear phagocytic cells", "ANATOMY", 206, 234], ["cellular", "ANATOMY", 272, 280], ["Mononuclear phagocytic cells", "ANATOMY", 287, 315], ["phagocytic cells", "ANATOMY", 331, 347], ["reticular connective tissue", "ANATOMY", 359, 386], ["monocytes", "ANATOMY", 398, 407], ["macrophages", "ANATOMY", 412, 423], ["cystatin C", "GENE_OR_GENE_PRODUCT", 38, 48], ["DCs", "CELL", 77, 80], ["cystatin C", "GENE_OR_GENE_PRODUCT", 139, 149], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 191, 201], ["mononuclear phagocytic cells", "CELL", 206, 234], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 239, 249], ["cellular", "CELL", 272, 280], ["Mononuclear phagocytic cells", "CELL", 287, 315], ["phagocytic cells", "CELL", 331, 347], ["reticular connective tissue", "TISSUE", 359, 386], ["monocytes", "CELL", 398, 407], ["macrophages", "CELL", 412, 423], ["cystatin C", "PROTEIN", 38, 48], ["DCs", "CELL_TYPE", 77, 80], ["inflammatory cytokines", "PROTEIN", 104, 126], ["cystatin C", "PROTEIN", 139, 149], ["Cystatin C", "PROTEIN", 191, 201], ["mononuclear phagocytic cells", "CELL_TYPE", 206, 234], ["Cystatin C", "PROTEIN", 239, 249], ["Mononuclear phagocytic cells", "CELL_TYPE", 287, 315], ["phagocytic cells", "CELL_TYPE", 331, 347], ["monocytes", "CELL_TYPE", 398, 407], ["macrophages", "CELL_TYPE", 412, 423], ["cystatin C", "PROBLEM", 38, 48], ["DCs", "PROBLEM", 77, 80], ["secrete inflammatory cytokines", "PROBLEM", 96, 126], ["cystatin C expression", "TREATMENT", 139, 160], ["further immune regulation", "TREATMENT", 165, 190], ["Cystatin C", "TEST", 191, 201], ["mononuclear phagocytic cells", "TEST", 206, 234], ["Cystatin C regulates", "TEST", 239, 259], ["cellular levels", "TEST", 272, 287], ["Mononuclear phagocytic cells", "TEST", 287, 315], ["the phagocytic cells", "TEST", 327, 347], ["inflammatory", "OBSERVATION_MODIFIER", 104, 116], ["mononuclear phagocytic cells", "OBSERVATION", 206, 234], ["Mononuclear phagocytic cells", "OBSERVATION", 287, 315], ["phagocytic cells", "OBSERVATION", 331, 347], ["reticular", "ANATOMY_MODIFIER", 359, 368], ["connective tissue", "ANATOMY", 369, 386], ["primarily monocytes", "OBSERVATION", 388, 407], ["macrophages", "OBSERVATION", 412, 423]]], ["Research shows that cystatin C can regulate host immune response via these cells.Cystatin C was found to inhibit phagocytosis of granulocyte and macrophage, and increase the synthesis of NO in mice peritoneal macrophages [32].", [["cells", "ANATOMY", 75, 80], ["granulocyte", "ANATOMY", 129, 140], ["macrophage", "ANATOMY", 145, 155], ["peritoneal macrophages", "ANATOMY", 198, 220], ["NO", "CHEMICAL", 187, 189], ["NO", "CHEMICAL", 187, 189], ["cystatin C", "GENE_OR_GENE_PRODUCT", 20, 30], ["cells", "CELL", 75, 80], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 81, 91], ["granulocyte", "CELL", 129, 140], ["macrophage", "CELL", 145, 155], ["NO", "SIMPLE_CHEMICAL", 187, 189], ["mice", "ORGANISM", 193, 197], ["peritoneal macrophages", "CELL", 198, 220], ["cystatin C", "PROTEIN", 20, 30], ["Cystatin C", "PROTEIN", 81, 91], ["granulocyte", "CELL_TYPE", 129, 140], ["macrophage", "CELL_TYPE", 145, 155], ["peritoneal macrophages", "CELL_TYPE", 198, 220], ["mice", "SPECIES", 193, 197], ["mice", "SPECIES", 193, 197], ["cystatin C", "PROBLEM", 20, 30], ["Cystatin C", "PROBLEM", 81, 91], ["phagocytosis", "TEST", 113, 125], ["granulocyte", "TEST", 129, 140], ["macrophage", "TEST", 145, 155], ["granulocyte", "OBSERVATION", 129, 140], ["macrophage", "OBSERVATION_MODIFIER", 145, 155], ["peritoneal", "ANATOMY", 198, 208], ["macrophages", "OBSERVATION", 209, 220]]], ["Along this line, further studies revealed that the interaction between cystatin C and cysteine protease can release a bioactive peptide that inhibits the phagocytosis and oxidative burst in eosinophil and monocyte [75].", [["eosinophil", "ANATOMY", 190, 200], ["monocyte", "ANATOMY", 205, 213], ["cysteine", "CHEMICAL", 86, 94], ["cystatin C", "GENE_OR_GENE_PRODUCT", 71, 81], ["cysteine protease", "GENE_OR_GENE_PRODUCT", 86, 103], ["eosinophil", "CELL", 190, 200], ["monocyte", "CELL", 205, 213], ["cystatin C", "PROTEIN", 71, 81], ["cysteine protease", "PROTEIN", 86, 103], ["eosinophil", "CELL_TYPE", 190, 200], ["further studies", "TEST", 17, 32], ["cystatin C and cysteine protease", "TREATMENT", 71, 103], ["a bioactive peptide", "TREATMENT", 116, 135], ["the phagocytosis", "TEST", 150, 166], ["oxidative burst in eosinophil", "PROBLEM", 171, 200], ["monocyte", "TEST", 205, 213], ["oxidative burst", "OBSERVATION", 171, 186]]], ["Microglia, also called the macrophages in the brain, is the major cell type that expresses cystatin C in the brain [76].", [["Microglia", "ANATOMY", 0, 9], ["macrophages", "ANATOMY", 27, 38], ["brain", "ANATOMY", 46, 51], ["cell", "ANATOMY", 66, 70], ["brain", "ANATOMY", 109, 114], ["Microglia", "CELL", 0, 9], ["macrophages", "CELL", 27, 38], ["brain", "ORGAN", 46, 51], ["cell type", "CELL", 66, 75], ["cystatin C", "GENE_OR_GENE_PRODUCT", 91, 101], ["brain", "ORGAN", 109, 114], ["Microglia", "CELL_TYPE", 0, 9], ["macrophages", "CELL_TYPE", 27, 38], ["cystatin C", "PROTEIN", 91, 101], ["Microglia", "PROBLEM", 0, 9], ["cystatin C in the brain", "PROBLEM", 91, 114], ["macrophages", "OBSERVATION", 27, 38], ["brain", "ANATOMY", 46, 51], ["brain", "ANATOMY", 109, 114]]], ["However, deposition of cystatin C fibrils in these cells produces angiopathy [77], compromising their immune surveilling capacity in the central nervous systems.Cystatin C and mononuclear phagocytic cells ::: Cystatin C regulates immunity at cellular levelsGiven the strong influence of cystatin C on these myeloid innate immune cells, many factors impact on host immunity by regulating the synthesis and production of this protease inhibitor.", [["cells", "ANATOMY", 51, 56], ["central nervous systems", "ANATOMY", 137, 160], ["mononuclear phagocytic cells", "ANATOMY", 176, 204], ["cellular", "ANATOMY", 242, 250], ["myeloid", "ANATOMY", 307, 314], ["immune cells", "ANATOMY", 322, 334], ["angiopathy", "DISEASE", 66, 76], ["cystatin C fibrils", "GENE_OR_GENE_PRODUCT", 23, 41], ["cells", "CELL", 51, 56], ["central nervous systems", "ANATOMICAL_SYSTEM", 137, 160], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 161, 171], ["mononuclear phagocytic cells", "CELL", 176, 204], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 209, 219], ["cellular", "CELL", 242, 250], ["cystatin C", "GENE_OR_GENE_PRODUCT", 287, 297], ["myeloid", "CELL", 307, 314], ["innate immune cells", "CELL", 315, 334], ["cystatin C fibrils", "PROTEIN", 23, 41], ["Cystatin C", "PROTEIN", 161, 171], ["mononuclear phagocytic cells", "CELL_TYPE", 176, 204], ["Cystatin C", "PROTEIN", 209, 219], ["cystatin C", "PROTEIN", 287, 297], ["myeloid innate immune cells", "CELL_TYPE", 307, 334], ["cystatin C fibrils", "TREATMENT", 23, 41], ["angiopathy", "PROBLEM", 66, 76], ["their immune surveilling capacity", "PROBLEM", 96, 129], ["Cystatin C", "TEST", 161, 171], ["mononuclear phagocytic cells", "TEST", 176, 204], ["Cystatin C regulates immunity at cellular levels", "PROBLEM", 209, 257], ["cystatin C", "TREATMENT", 287, 297], ["these myeloid innate immune cells", "TREATMENT", 301, 334], ["host immunity", "TREATMENT", 359, 372], ["the synthesis", "TREATMENT", 387, 400], ["this protease inhibitor", "TREATMENT", 419, 442], ["angiopathy", "OBSERVATION", 66, 76], ["immune surveilling capacity", "OBSERVATION", 102, 129], ["central", "ANATOMY_MODIFIER", 137, 144], ["nervous systems", "ANATOMY", 145, 160], ["mononuclear phagocytic cells", "OBSERVATION", 176, 204]]], ["Treatment of resident mouse peritoneal macrophages in vitro with the bacterial compound lipopolysaccharide (LPS) or pro-inflammatory IFN-\u03b3 could down-regulate cystatin C secretion [65].", [["peritoneal macrophages", "ANATOMY", 28, 50], ["lipopolysaccharide", "CHEMICAL", 88, 106], ["LPS", "CHEMICAL", 108, 111], ["mouse", "ORGANISM", 22, 27], ["peritoneal macrophages", "CELL", 28, 50], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 88, 106], ["LPS", "SIMPLE_CHEMICAL", 108, 111], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 133, 138], ["cystatin C", "GENE_OR_GENE_PRODUCT", 159, 169], ["resident mouse peritoneal macrophages", "CELL_TYPE", 13, 50], ["pro-inflammatory IFN-\u03b3", "PROTEIN", 116, 138], ["cystatin C", "PROTEIN", 159, 169], ["mouse", "SPECIES", 22, 27], ["mouse", "SPECIES", 22, 27], ["resident mouse peritoneal macrophages", "TREATMENT", 13, 50], ["the bacterial compound lipopolysaccharide", "TEST", 65, 106], ["pro-inflammatory IFN", "TEST", 116, 136], ["cystatin C secretion", "PROBLEM", 159, 179], ["peritoneal", "ANATOMY", 28, 38], ["macrophages", "OBSERVATION", 39, 50]]], ["Consistently, during inflammation, reduced cystatin C secretion was accompanied by increased activities of cysteine proteases in macrophage microenvironment [78].", [["macrophage", "ANATOMY", 129, 139], ["inflammation", "DISEASE", 21, 33], ["cysteine", "CHEMICAL", 107, 115], ["cystatin C", "GENE_OR_GENE_PRODUCT", 43, 53], ["macrophage", "CELL", 129, 139], ["cystatin C", "PROTEIN", 43, 53], ["cysteine proteases", "PROTEIN", 107, 125], ["inflammation", "PROBLEM", 21, 33], ["reduced cystatin C secretion", "PROBLEM", 35, 63], ["cysteine proteases", "TREATMENT", 107, 125], ["inflammation", "OBSERVATION", 21, 33]]], ["The variation of cystatin C production in these conditions, can in turn affect immune system by regulating cytokine secretion from these cells.", [["immune system", "ANATOMY", 79, 92], ["cells", "ANATOMY", 137, 142], ["cystatin C", "GENE_OR_GENE_PRODUCT", 17, 27], ["immune system", "ANATOMICAL_SYSTEM", 79, 92], ["cells", "CELL", 137, 142], ["cystatin C", "PROTEIN", 17, 27], ["cytokine", "PROTEIN", 107, 115], ["cystatin C production", "PROBLEM", 17, 38], ["immune system", "PROBLEM", 79, 92], ["cytokine secretion from these cells", "PROBLEM", 107, 142]]], ["For example, in early phase of parasite infection, cystatin C can induce human peripheral blood mononuclear cells to secrete tumor necrosis factor-\u03b1 (TNF-\u03b1), reduce IL-12 but increase IL-10 generation.", [["peripheral blood mononuclear cells", "ANATOMY", 79, 113], ["infection", "DISEASE", 40, 49], ["cystatin C", "CHEMICAL", 51, 61], ["tumor", "DISEASE", 125, 130], ["parasite", "CELL", 31, 39], ["cystatin C", "GENE_OR_GENE_PRODUCT", 51, 61], ["human", "ORGANISM", 73, 78], ["peripheral blood mononuclear cells", "CELL", 79, 113], ["tumor necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 125, 148], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 150, 155], ["IL-12", "GENE_OR_GENE_PRODUCT", 165, 170], ["IL-10", "GENE_OR_GENE_PRODUCT", 184, 189], ["cystatin C", "PROTEIN", 51, 61], ["human peripheral blood mononuclear cells", "CELL_TYPE", 73, 113], ["tumor necrosis factor-\u03b1", "PROTEIN", 125, 148], ["TNF", "PROTEIN", 150, 153], ["IL-12", "PROTEIN", 165, 170], ["IL", "PROTEIN", 184, 186], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 73, 78], ["parasite infection", "PROBLEM", 31, 49], ["cystatin C", "PROBLEM", 51, 61], ["human peripheral blood mononuclear cells", "PROBLEM", 73, 113], ["secrete tumor necrosis factor", "PROBLEM", 117, 146], ["TNF", "TEST", 150, 153], ["IL", "TEST", 165, 167], ["early phase", "OBSERVATION_MODIFIER", 16, 27], ["parasite", "OBSERVATION_MODIFIER", 31, 39], ["infection", "OBSERVATION", 40, 49], ["peripheral", "ANATOMY_MODIFIER", 79, 89], ["blood", "ANATOMY", 90, 95], ["mononuclear cells", "OBSERVATION", 96, 113], ["tumor necrosis", "OBSERVATION", 125, 139]]], ["Since IL-10 is a known inhibitory cytokine to inhibit Th1 cell differentiation and T cell proliferative responses to antigen stimulation, the cystatin C induced IL-10 generation may participate in host T cell conversion from Th1 into Th2, skewing the host immune system to favor parasite propagation [79].Cystatin C and mononuclear phagocytic cells ::: Cystatin C regulates immunity at cellular levelsIn addition to its effect on cytokine release, cystatin C also influences the phenotype of mononuclear phagocytic cells.", [["Th1 cell", "ANATOMY", 54, 62], ["T cell", "ANATOMY", 83, 89], ["T cell", "ANATOMY", 202, 208], ["immune system", "ANATOMY", 256, 269], ["mononuclear phagocytic cells", "ANATOMY", 320, 348], ["cellular", "ANATOMY", 386, 394], ["mononuclear phagocytic cells", "ANATOMY", 492, 520], ["IL-10", "GENE_OR_GENE_PRODUCT", 6, 11], ["Th1 cell", "CELL", 54, 62], ["T cell", "CELL", 83, 89], ["cystatin C", "GENE_OR_GENE_PRODUCT", 142, 152], ["IL-10", "GENE_OR_GENE_PRODUCT", 161, 166], ["host T cell", "CELL", 197, 208], ["Th2", "GENE_OR_GENE_PRODUCT", 234, 237], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 305, 315], ["mononuclear phagocytic cells", "CELL", 320, 348], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 353, 363], ["cellular", "CELL", 386, 394], ["cystatin C", "GENE_OR_GENE_PRODUCT", 448, 458], ["mononuclear phagocytic cells", "CELL", 492, 520], ["IL-10", "PROTEIN", 6, 11], ["inhibitory cytokine", "PROTEIN", 23, 42], ["cystatin C", "PROTEIN", 142, 152], ["Th1", "CELL_TYPE", 225, 228], ["Th2", "CELL_TYPE", 234, 237], ["Cystatin C", "PROTEIN", 305, 315], ["mononuclear phagocytic cells", "CELL_TYPE", 320, 348], ["Cystatin C", "PROTEIN", 353, 363], ["cytokine", "PROTEIN", 430, 438], ["cystatin C", "PROTEIN", 448, 458], ["mononuclear phagocytic cells", "CELL_TYPE", 492, 520], ["a known inhibitory cytokine", "TREATMENT", 15, 42], ["Th1 cell differentiation", "PROBLEM", 54, 78], ["T cell proliferative responses", "PROBLEM", 83, 113], ["antigen stimulation", "TREATMENT", 117, 136], ["the cystatin C induced IL", "TREATMENT", 138, 163], ["host T cell conversion", "TREATMENT", 197, 219], ["parasite propagation", "PROBLEM", 279, 299], ["Cystatin C", "TEST", 305, 315], ["mononuclear phagocytic cells", "TEST", 320, 348], ["Cystatin C regulates immunity at cellular levels", "PROBLEM", 353, 401], ["cytokine release", "TREATMENT", 430, 446], ["cystatin C", "TEST", 448, 458], ["mononuclear phagocytic cells", "PROBLEM", 492, 520], ["Th1 cell differentiation", "OBSERVATION", 54, 78], ["cell proliferative", "OBSERVATION", 85, 103], ["mononuclear phagocytic cells", "OBSERVATION", 320, 348], ["mononuclear phagocytic cells", "OBSERVATION", 492, 520]]], ["This is in line with a recent study showing that cystatin C induced early and transient expression of activation markers on macrophages demonstrated by the up-regulated of MHC-II, CD40, CD80 and CD86 in response to cystatin C [80].", [["macrophages", "ANATOMY", 124, 135], ["cystatin C", "GENE_OR_GENE_PRODUCT", 49, 59], ["macrophages", "CELL", 124, 135], ["MHC-II", "GENE_OR_GENE_PRODUCT", 172, 178], ["CD40", "GENE_OR_GENE_PRODUCT", 180, 184], ["CD80", "GENE_OR_GENE_PRODUCT", 186, 190], ["CD86", "GENE_OR_GENE_PRODUCT", 195, 199], ["cystatin C", "GENE_OR_GENE_PRODUCT", 215, 225], ["cystatin C", "PROTEIN", 49, 59], ["activation markers", "PROTEIN", 102, 120], ["macrophages", "CELL_TYPE", 124, 135], ["MHC-II", "PROTEIN", 172, 178], ["CD40", "PROTEIN", 180, 184], ["CD80", "PROTEIN", 186, 190], ["CD86", "PROTEIN", 195, 199], ["a recent study", "TEST", 21, 35], ["cystatin C", "PROBLEM", 49, 59], ["activation markers on macrophages", "PROBLEM", 102, 135], ["CD80", "TEST", 186, 190], ["CD86", "TEST", 195, 199], ["cystatin C", "TEST", 215, 225]]], ["Moreover, molecular events following the treatment of cystatin C were investigated and found that cystatin C was internalized by monocytes via an active endocytic process, leading to decreased phosphorylation and activation of the mitogen-activated protein kinase extracellular signal-regulated kinase-1/2 (MAPK-ERK1/2) signaling pathway [81,82].", [["monocytes", "ANATOMY", 129, 138], ["cystatin C", "GENE_OR_GENE_PRODUCT", 54, 64], ["cystatin C", "GENE_OR_GENE_PRODUCT", 98, 108], ["monocytes", "CELL", 129, 138], ["mitogen-activated protein kinase extracellular signal-regulated kinase-1/2", "GENE_OR_GENE_PRODUCT", 231, 305], ["MAPK-ERK1/2", "GENE_OR_GENE_PRODUCT", 307, 318], ["cystatin C", "PROTEIN", 54, 64], ["cystatin C", "PROTEIN", 98, 108], ["monocytes", "CELL_TYPE", 129, 138], ["mitogen-activated protein kinase", "PROTEIN", 231, 263], ["MAPK", "PROTEIN", 307, 311], ["ERK1", "PROTEIN", 312, 316], ["molecular events", "PROBLEM", 10, 26], ["cystatin C", "PROBLEM", 54, 64], ["cystatin C", "PROBLEM", 98, 108], ["monocytes", "TEST", 129, 138], ["an active endocytic process", "PROBLEM", 143, 170], ["decreased phosphorylation", "PROBLEM", 183, 208], ["the mitogen", "TEST", 227, 238], ["activated protein kinase", "TEST", 239, 263], ["extracellular signal", "TEST", 264, 284], ["kinase", "TEST", 295, 301], ["MAPK", "TEST", 307, 311], ["ERK1", "TEST", 312, 316], ["signaling pathway", "TEST", 320, 337], ["active endocytic process", "OBSERVATION", 146, 170], ["decreased phosphorylation", "OBSERVATION", 183, 208]]], ["Consistent with the mouse data, a recent study also reported that cystatin C down-regulated phosphorylation of the ERK1/2 pathway in human samples [83].Cystatin C and T cells ::: Cystatin C regulates immunity at cellular levelsT lymphocytes are important mediators of adaptive immunity against both foreign antigens and self-tissues.", [["samples", "ANATOMY", 139, 146], ["T cells", "ANATOMY", 167, 174], ["cellular levelsT lymphocytes", "ANATOMY", 212, 240], ["tissues", "ANATOMY", 325, 332], ["mouse", "ORGANISM", 20, 25], ["cystatin C", "GENE_OR_GENE_PRODUCT", 66, 76], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 115, 121], ["human", "ORGANISM", 133, 138], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 152, 162], ["T cells", "CELL", 167, 174], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 179, 189], ["cellular levelsT lymphocytes", "CELL", 212, 240], ["tissues", "TISSUE", 325, 332], ["cystatin C", "PROTEIN", 66, 76], ["ERK1/2", "PROTEIN", 115, 121], ["Cystatin C", "PROTEIN", 152, 162], ["T cells", "CELL_TYPE", 167, 174], ["Cystatin C", "PROTEIN", 179, 189], ["cellular levelsT lymphocytes", "CELL_TYPE", 212, 240], ["mouse", "SPECIES", 20, 25], ["human", "SPECIES", 133, 138], ["mouse", "SPECIES", 20, 25], ["human", "SPECIES", 133, 138], ["a recent study", "TEST", 32, 46], ["cystatin C", "TEST", 66, 76], ["the ERK1", "TEST", 111, 119], ["human samples", "TEST", 133, 146], ["Cystatin C and T cells", "TEST", 152, 174], ["Cystatin C regulates immunity at cellular levelsT lymphocytes", "PROBLEM", 179, 240], ["adaptive immunity", "TREATMENT", 268, 285], ["levelsT lymphocytes", "OBSERVATION", 221, 240]]], ["Cystatin C can regulate the proliferation, differentiation, and co-stimulatory molecule expression of T cells either directly or indirectly via various cytokines [12,84].Cystatin C and T cells ::: Cystatin C regulates immunity at cellular levelsThe differentiation of functional effectors such as Th1 and Th2 cells from T cells are subjected to the regulation of cytokines.", [["T cells", "ANATOMY", 102, 109], ["T cells", "ANATOMY", 185, 192], ["cellular", "ANATOMY", 230, 238], ["Th2 cells", "ANATOMY", 305, 314], ["T cells", "ANATOMY", 320, 327], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 0, 10], ["T cells", "CELL", 102, 109], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 170, 180], ["T cells", "CELL", 185, 192], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 197, 207], ["cellular", "CELL", 230, 238], ["Th1", "GENE_OR_GENE_PRODUCT", 297, 300], ["Th2 cells", "CELL", 305, 314], ["T cells", "CELL", 320, 327], ["Cystatin C", "PROTEIN", 0, 10], ["T cells", "CELL_TYPE", 102, 109], ["cytokines", "PROTEIN", 152, 161], ["Cystatin C", "PROTEIN", 170, 180], ["T cells", "CELL_TYPE", 185, 192], ["Cystatin C", "PROTEIN", 197, 207], ["Th1 and Th2 cells", "CELL_TYPE", 297, 314], ["T cells", "CELL_TYPE", 320, 327], ["cytokines", "PROTEIN", 363, 372], ["Cystatin C", "PROBLEM", 0, 10], ["the proliferation", "PROBLEM", 24, 41], ["T cells", "PROBLEM", 102, 109], ["Cystatin C and T cells", "TEST", 170, 192], ["Cystatin C regulates immunity at cellular levels", "PROBLEM", 197, 245], ["functional effectors", "PROBLEM", 268, 288], ["Th1 and Th2 cells", "PROBLEM", 297, 314], ["T cells", "PROBLEM", 320, 327], ["proliferation", "OBSERVATION_MODIFIER", 28, 41], ["functional effectors", "OBSERVATION", 268, 288], ["Th2 cells", "OBSERVATION", 305, 314]]], ["For example, IL-12 promotes the differentiation of Th1 cells that secrete Th1 cytokine IFN-\u03b3, whereas IL-4 drives the differentiation of Th2 cells that secrete Th2 cytokine IL-4.", [["Th1 cells", "ANATOMY", 51, 60], ["Th2 cells", "ANATOMY", 137, 146], ["IL-12", "GENE_OR_GENE_PRODUCT", 13, 18], ["Th1 cells", "CELL", 51, 60], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 87, 92], ["IL-4", "GENE_OR_GENE_PRODUCT", 102, 106], ["Th2 cells", "CELL", 137, 146], ["IL-4", "GENE_OR_GENE_PRODUCT", 173, 177], ["IL-12", "PROTEIN", 13, 18], ["Th1 cells", "CELL_TYPE", 51, 60], ["Th1 cytokine IFN-\u03b3", "PROTEIN", 74, 92], ["IL-4", "PROTEIN", 102, 106], ["Th2 cells", "CELL_TYPE", 137, 146], ["Th2 cytokine IL-4", "PROTEIN", 160, 177], ["IL", "TEST", 13, 15], ["Th1 cells", "PROBLEM", 51, 60], ["Th1 cytokine IFN", "TEST", 74, 90], ["IL", "TEST", 102, 104], ["Th2 cells", "PROBLEM", 137, 146], ["Th2 cytokine IL", "TEST", 160, 175], ["Th1 cells", "OBSERVATION", 51, 60], ["Th2 cells", "OBSERVATION", 137, 146]]], ["When BALB/c mice susceptible to infection with Leishmania major were treated with cystatin C, those mice acquired resistance against infection with the parasites and showed the shift of immune responses from disease-promoting Th2 to protective Th1 type.", [["infection", "DISEASE", 32, 41], ["infection", "DISEASE", 133, 142], ["BALB/c mice", "ORGANISM", 5, 16], ["Leishmania major", "ORGANISM", 47, 63], ["cystatin C", "GENE_OR_GENE_PRODUCT", 82, 92], ["mice", "ORGANISM", 100, 104], ["cystatin C", "PROTEIN", 82, 92], ["Th2 to protective Th1 type", "CELL_TYPE", 226, 252], ["mice", "SPECIES", 12, 16], ["mice", "SPECIES", 100, 104], ["mice", "SPECIES", 12, 16], ["Leishmania major", "SPECIES", 47, 63], ["mice", "SPECIES", 100, 104], ["infection", "PROBLEM", 32, 41], ["Leishmania", "PROBLEM", 47, 57], ["cystatin C", "TREATMENT", 82, 92], ["infection", "PROBLEM", 133, 142], ["the parasites", "TEST", 148, 161], ["immune responses", "PROBLEM", 186, 202], ["disease", "PROBLEM", 208, 215], ["infection", "OBSERVATION", 32, 41], ["infection", "OBSERVATION", 133, 142]]], ["These mice produce specific immunoglobulin G 2 (IgG2) antibody and generated IFN-\u03b3 in contrast to the untreated but infected mice that produced IgG1 and IgE and generated IL-4 [79].", [["mice", "ORGANISM", 6, 10], ["immunoglobulin G 2", "GENE_OR_GENE_PRODUCT", 28, 46], ["IgG2", "GENE_OR_GENE_PRODUCT", 48, 52], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 77, 82], ["mice", "ORGANISM", 125, 129], ["IgG1", "GENE_OR_GENE_PRODUCT", 144, 148], ["IgE", "GENE_OR_GENE_PRODUCT", 153, 156], ["IL-4", "GENE_OR_GENE_PRODUCT", 171, 175], ["immunoglobulin G 2 (IgG2) antibody", "PROTEIN", 28, 62], ["IFN", "PROTEIN", 77, 80], ["\u03b3", "PROTEIN", 81, 82], ["IgG1", "PROTEIN", 144, 148], ["IgE", "PROTEIN", 153, 156], ["IL", "PROTEIN", 171, 173], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 125, 129], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 125, 129], ["These mice", "TEST", 0, 10], ["specific immunoglobulin G", "TEST", 19, 44], ["IgG2", "TEST", 48, 52], ["antibody", "TEST", 54, 62], ["IFN", "TEST", 77, 80], ["IgG1", "TEST", 144, 148], ["IL", "TEST", 171, 173], ["infected", "OBSERVATION", 116, 124]]], ["Overall, these data suggested that cystatin C must have induced Th1 polorizing cytokine production in vivo to affect T cells differentiation.", [["T cells", "ANATOMY", 117, 124], ["cystatin C", "GENE_OR_GENE_PRODUCT", 35, 45], ["Th1", "GENE_OR_GENE_PRODUCT", 64, 67], ["T cells", "CELL", 117, 124], ["cystatin C", "PROTEIN", 35, 45], ["cytokine", "PROTEIN", 79, 87], ["T cells", "CELL_TYPE", 117, 124], ["cystatin C", "PROBLEM", 35, 45], ["Th1 polorizing cytokine production", "TREATMENT", 64, 98]]], ["However, since the in vivo system is complicated with many cells involved, whether this effect of T cell differentiation by cystatin C was directly imparted to the na\u00efve T cells or mediated through other cells need to be further characterized in vitro.Cystatin C and T cells ::: Cystatin C regulates immunity at cellular levelsApart from regulation of T cell differentiation, cystatin C may also exert direct effect on T cell proliferation.", [["cells", "ANATOMY", 59, 64], ["T cell", "ANATOMY", 98, 104], ["T cells", "ANATOMY", 170, 177], ["cells", "ANATOMY", 204, 209], ["T cells", "ANATOMY", 267, 274], ["cellular", "ANATOMY", 312, 320], ["T cell", "ANATOMY", 352, 358], ["T cell", "ANATOMY", 419, 425], ["cells", "CELL", 59, 64], ["T cell", "CELL", 98, 104], ["cystatin C", "GENE_OR_GENE_PRODUCT", 124, 134], ["T cells", "CELL", 170, 177], ["cells", "CELL", 204, 209], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 252, 262], ["T cells", "CELL", 267, 274], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 279, 289], ["cellular", "CELL", 312, 320], ["T cell", "CELL", 352, 358], ["cystatin C", "GENE_OR_GENE_PRODUCT", 376, 386], ["T cell", "CELL", 419, 425], ["cystatin C", "PROTEIN", 124, 134], ["na\u00efve T cells", "CELL_TYPE", 164, 177], ["Cystatin C", "PROTEIN", 252, 262], ["T cells", "CELL_TYPE", 267, 274], ["Cystatin C", "PROTEIN", 279, 289], ["cystatin C", "PROTEIN", 376, 386], ["many cells", "PROBLEM", 54, 64], ["T cell differentiation", "PROBLEM", 98, 120], ["cystatin C", "PROBLEM", 124, 134], ["Cystatin C and T cells", "TEST", 252, 274], ["Cystatin C regulates immunity at cellular levels", "PROBLEM", 279, 327], ["T cell differentiation", "TREATMENT", 352, 374], ["cystatin C", "PROBLEM", 376, 386], ["T cell proliferation", "PROBLEM", 419, 439], ["T cell differentiation", "OBSERVATION", 352, 374], ["cell proliferation", "OBSERVATION", 421, 439]]], ["A 17-kDa antigen (Av17) of the rodent filarial parasite Acanthocheilonema viteae, which shows amino acid homologies to cystatin C, was found to markedly suppress mitogen-induced T cell proliferation in mice [85].", [["T cell", "ANATOMY", 178, 184], ["amino acid", "CHEMICAL", 94, 104], ["amino acid", "CHEMICAL", 94, 104], ["kDa antigen", "GENE_OR_GENE_PRODUCT", 5, 16], ["Av17", "GENE_OR_GENE_PRODUCT", 18, 22], ["rodent", "ORGANISM", 31, 37], ["filarial parasite", "ORGANISM", 38, 55], ["Acanthocheilonema viteae", "ORGANISM", 56, 80], ["amino acid", "AMINO_ACID", 94, 104], ["cystatin C", "GENE_OR_GENE_PRODUCT", 119, 129], ["T cell", "CELL", 178, 184], ["mice", "ORGANISM", 202, 206], ["17-kDa antigen", "PROTEIN", 2, 16], ["Av17", "PROTEIN", 18, 22], ["cystatin C", "PROTEIN", 119, 129], ["mitogen", "PROTEIN", 162, 169], ["rodent", "SPECIES", 31, 37], ["Acanthocheilonema viteae", "SPECIES", 56, 80], ["mice", "SPECIES", 202, 206], ["Acanthocheilonema viteae", "SPECIES", 56, 80], ["mice", "SPECIES", 202, 206], ["A 17-kDa antigen", "TEST", 0, 16], ["the rodent filarial parasite Acanthocheilonema viteae", "PROBLEM", 27, 80], ["amino acid homologies", "PROBLEM", 94, 115], ["cystatin C", "TEST", 119, 129], ["mitogen", "TEST", 162, 169], ["filarial parasite", "OBSERVATION", 38, 55], ["cell proliferation", "OBSERVATION", 180, 198]]], ["Consistent with its nature counterpart produced from the parasites, recombinant Av17 (rAv17), expressed in Escherichia coli, with biological activity as a cysteine protease inhibitor, also demonstrated the same inhibitive effect on T cell proliferation.", [["T cell", "ANATOMY", 232, 238], ["cysteine", "CHEMICAL", 155, 163], ["Av17", "GENE_OR_GENE_PRODUCT", 80, 84], ["rAv17", "GENE_OR_GENE_PRODUCT", 86, 91], ["Escherichia coli", "ORGANISM", 107, 123], ["T cell", "CELL", 232, 238], ["recombinant Av17", "PROTEIN", 68, 84], ["rAv17", "PROTEIN", 86, 91], ["Escherichia coli", "SPECIES", 107, 123], ["Escherichia coli", "SPECIES", 107, 123], ["the parasites", "PROBLEM", 53, 66], ["Escherichia coli", "PROBLEM", 107, 123], ["a cysteine protease inhibitor", "TREATMENT", 153, 182], ["T cell proliferation", "PROBLEM", 232, 252], ["parasites", "OBSERVATION", 57, 66], ["Escherichia coli", "OBSERVATION", 107, 123], ["cell proliferation", "OBSERVATION", 234, 252]]], ["In the presence of rAvl7, T cell receptor (TCR)-induced proliferation in purified T cells was severely impaired in comparison to the control protein, whereas the B cell receptor (BCR)-induced proliferation of murine B cell hybridomas was unaffected, indicating T cell specific inhibition rather than a more fundamental block of cellular proliferation [85].Cystatin C and T cells ::: Cystatin C regulates immunity at cellular levelsMechanistically, T cell activation requires two signals, with one being transmitted by the TCR complex and the other by its co-receptors.", [["T cell", "ANATOMY", 26, 32], ["T cells", "ANATOMY", 82, 89], ["B cell", "ANATOMY", 162, 168], ["B cell hybridomas", "ANATOMY", 216, 233], ["T cell", "ANATOMY", 261, 267], ["cellular", "ANATOMY", 328, 336], ["T cells", "ANATOMY", 371, 378], ["cellular", "ANATOMY", 416, 424], ["T cell", "ANATOMY", 448, 454], ["TCR", "CHEMICAL", 43, 46], ["rAvl7", "GENE_OR_GENE_PRODUCT", 19, 24], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 26, 41], ["TCR", "GENE_OR_GENE_PRODUCT", 43, 46], ["T cells", "CELL", 82, 89], ["B cell receptor", "GENE_OR_GENE_PRODUCT", 162, 177], ["BCR", "GENE_OR_GENE_PRODUCT", 179, 182], ["murine", "ORGANISM", 209, 215], ["B cell hybridomas", "CELL", 216, 233], ["T cell", "CELL", 261, 267], ["cellular", "CELL", 328, 336], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 356, 366], ["T cells", "CELL", 371, 378], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 383, 393], ["cellular", "CELL", 416, 424], ["T cell", "CELL", 448, 454], ["TCR", "GENE_OR_GENE_PRODUCT", 522, 525], ["rAvl7", "PROTEIN", 19, 24], ["T cell receptor", "PROTEIN", 26, 41], ["TCR", "PROTEIN", 43, 46], ["purified T cells", "CELL_TYPE", 73, 89], ["B cell receptor", "PROTEIN", 162, 177], ["BCR", "PROTEIN", 179, 182], ["murine B cell hybridomas", "CELL_LINE", 209, 233], ["Cystatin C", "PROTEIN", 356, 366], ["T cells", "CELL_TYPE", 371, 378], ["Cystatin C", "PROTEIN", 383, 393], ["TCR complex", "PROTEIN", 522, 533], ["co-receptors", "PROTEIN", 555, 567], ["murine", "SPECIES", 209, 215], ["rAvl7", "TEST", 19, 24], ["T cell receptor", "TEST", 26, 41], ["induced proliferation in purified T cells", "PROBLEM", 48, 89], ["severely impaired", "PROBLEM", 94, 111], ["the control protein", "TEST", 129, 148], ["the B cell receptor", "TEST", 158, 177], ["BCR", "TEST", 179, 182], ["murine B cell hybridomas", "PROBLEM", 209, 233], ["T cell specific inhibition", "PROBLEM", 261, 287], ["cellular proliferation", "PROBLEM", 328, 350], ["Cystatin C and T cells", "TEST", 356, 378], ["Cystatin C regulates immunity at cellular levels", "PROBLEM", 383, 431], ["cell hybridomas", "OBSERVATION", 218, 233], ["cellular proliferation", "OBSERVATION", 328, 350], ["cell activation", "OBSERVATION", 450, 465]]], ["For full T cell activation, co-stimulatory signals are required for IL-2 production, proliferation and differentiation to effectors function [86].", [["T cell", "ANATOMY", 9, 15], ["T cell", "CELL", 9, 15], ["IL-2", "GENE_OR_GENE_PRODUCT", 68, 72], ["IL", "PROTEIN", 68, 70], ["co-stimulatory signals", "TEST", 28, 50], ["IL-2 production", "TREATMENT", 68, 83], ["proliferation", "PROBLEM", 85, 98]]], ["At present, it is unclear which signal molecule is affected by the filarial cystatin when it inhibit T cell proliferation.", [["T cell", "ANATOMY", 101, 107], ["filarial", "ORGANISM", 67, 75], ["cystatin", "GENE_OR_GENE_PRODUCT", 76, 84], ["T cell", "CELL", 101, 107], ["filarial cystatin", "PROTEIN", 67, 84], ["the filarial cystatin", "TREATMENT", 63, 84], ["T cell proliferation", "PROBLEM", 101, 121], ["cell proliferation", "OBSERVATION", 103, 121]]], ["Of note, it was reported that rAvl7 changed the production pattern from the T cell cultures of NO, a potent T cell inhibitive compound for proliferation, as other cystatins did [32], however, whether this effect affected co-stimulatory signaling and contributed to the hypo-responsiveness of T cells remain to be further defined.Cystatin C and other immune cells ::: Cystatin C regulates immunity at cellular levelsCystatin C was reported to inhibit the activation of cathepsins to mediate the natural killer (NK) cells killing [87].", [["T cell cultures", "ANATOMY", 76, 91], ["T cell", "ANATOMY", 108, 114], ["T cells", "ANATOMY", 292, 299], ["immune cells", "ANATOMY", 350, 362], ["cellular", "ANATOMY", 400, 408], ["natural killer (NK) cells", "ANATOMY", 494, 519], ["NO", "CHEMICAL", 95, 97], ["NO", "CHEMICAL", 95, 97], ["rAvl7", "GENE_OR_GENE_PRODUCT", 30, 35], ["T cell cultures", "CELL", 76, 91], ["NO", "SIMPLE_CHEMICAL", 95, 97], ["T cell", "CELL", 108, 114], ["T cells", "CELL", 292, 299], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 329, 339], ["immune cells", "CELL", 350, 362], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 367, 377], ["cellular", "CELL", 400, 408], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 415, 425], ["cathepsins", "GENE_OR_GENE_PRODUCT", 468, 478], ["natural killer (NK) cells", "CELL", 494, 519], ["rAvl7", "PROTEIN", 30, 35], ["T cell cultures", "CELL_LINE", 76, 91], ["T cells", "CELL_TYPE", 292, 299], ["Cystatin C", "PROTEIN", 329, 339], ["immune cells", "CELL_TYPE", 350, 362], ["Cystatin C", "PROTEIN", 367, 377], ["Cystatin C", "PROTEIN", 415, 425], ["cathepsins", "PROTEIN", 468, 478], ["natural killer (NK) cells", "CELL_TYPE", 494, 519], ["the T cell cultures", "TEST", 72, 91], ["a potent T cell inhibitive compound", "PROBLEM", 99, 134], ["proliferation", "PROBLEM", 139, 152], ["other cystatins", "TEST", 157, 172], ["this effect affected co-stimulatory signaling", "PROBLEM", 200, 245], ["the hypo-responsiveness of T cells", "PROBLEM", 265, 299], ["Cystatin C", "TEST", 329, 339], ["Cystatin C regulates immunity at cellular levels", "PROBLEM", 367, 415], ["Cystatin C", "PROBLEM", 415, 425], ["cathepsins", "TREATMENT", 468, 478], ["immune cells", "OBSERVATION", 350, 362]]], ["In addition, cystatin C from Onchocerca volvulus could also significantly inhibit the peripheral blood mononuclear cell proliferation and antigen presentation in response to tuberculin purified protein derivative, and suppress the expression of co-stimulate molecule CD86 on monocyte (but had no effect on the expression of CD40, CD80) [88].", [["peripheral blood mononuclear cell", "ANATOMY", 86, 119], ["monocyte", "ANATOMY", 275, 283], ["Onchocerca volvulus", "DISEASE", 29, 48], ["cystatin C", "GENE_OR_GENE_PRODUCT", 13, 23], ["Onchocerca volvulus", "ORGANISM", 29, 48], ["peripheral blood mononuclear cell", "CELL", 86, 119], ["CD86", "GENE_OR_GENE_PRODUCT", 267, 271], ["monocyte", "CELL", 275, 283], ["CD40", "GENE_OR_GENE_PRODUCT", 324, 328], ["CD80", "GENE_OR_GENE_PRODUCT", 330, 334], ["cystatin C", "PROTEIN", 13, 23], ["peripheral blood mononuclear cell", "CELL_TYPE", 86, 119], ["tuberculin purified protein derivative", "PROTEIN", 174, 212], ["co-stimulate molecule", "PROTEIN", 245, 266], ["CD86", "PROTEIN", 267, 271], ["monocyte", "CELL_TYPE", 275, 283], ["CD40", "PROTEIN", 324, 328], ["CD80", "PROTEIN", 330, 334], ["Onchocerca volvulus", "SPECIES", 29, 48], ["Onchocerca volvulus", "SPECIES", 29, 48], ["cystatin C", "PROBLEM", 13, 23], ["Onchocerca volvulus", "PROBLEM", 29, 48], ["the peripheral blood mononuclear cell proliferation", "PROBLEM", 82, 133], ["antigen presentation", "TEST", 138, 158], ["tuberculin purified protein derivative", "TREATMENT", 174, 212], ["monocyte", "TEST", 275, 283], ["Onchocerca volvulus", "OBSERVATION", 29, 48], ["peripheral", "ANATOMY_MODIFIER", 86, 96], ["blood", "ANATOMY", 97, 102], ["mononuclear cell proliferation", "OBSERVATION", 103, 133]]], ["Collectively, these data highlight the important impact of cystatin C on other immune system cells for effective immune regulation under inflammatory conditions.IFN-\u03b3 ::: Cystatin C regulate immunity at molecular levelsAs a dimerized soluble cytokine produced predominantly by NK and active T cells, IFN-\u03b3 is an important activator of macrophages and inducer of MHC-II molecule expression critical for antiviral and anti-tumor immunity [89].", [["immune system cells", "ANATOMY", 79, 98], ["NK", "ANATOMY", 277, 279], ["T cells", "ANATOMY", 291, 298], ["macrophages", "ANATOMY", 335, 346], ["cystatin C", "GENE_OR_GENE_PRODUCT", 59, 69], ["immune system cells", "CELL", 79, 98], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 171, 181], ["NK", "CELL", 277, 279], ["T cells", "CELL", 291, 298], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 300, 305], ["macrophages", "CELL", 335, 346], ["MHC-II molecule", "GENE_OR_GENE_PRODUCT", 362, 377], ["anti-tumor", "CANCER", 416, 426], ["cystatin C", "PROTEIN", 59, 69], ["immune system cells", "CELL_TYPE", 79, 98], ["IFN", "PROTEIN", 161, 164], ["Cystatin C", "PROTEIN", 171, 181], ["dimerized soluble cytokine", "PROTEIN", 224, 250], ["NK and active T cells", "CELL_TYPE", 277, 298], ["IFN-\u03b3", "PROTEIN", 300, 305], ["macrophages", "CELL_TYPE", 335, 346], ["MHC-II molecule", "PROTEIN", 362, 377], ["cystatin C", "TREATMENT", 59, 69], ["other immune system cells", "TREATMENT", 73, 98], ["effective immune regulation", "TREATMENT", 103, 130], ["inflammatory conditions", "PROBLEM", 137, 160], ["Cystatin C regulate immunity at molecular levels", "PROBLEM", 171, 219], ["a dimerized soluble cytokine", "TREATMENT", 222, 250], ["active T cells", "PROBLEM", 284, 298], ["IFN", "TEST", 300, 303], ["antiviral and anti-tumor immunity", "TREATMENT", 402, 435], ["inflammatory", "OBSERVATION_MODIFIER", 137, 149]]], ["Aberrant IFN-\u03b3 expression is associated with a number of auto-inflammatory and auto-immune diseases.", [["auto-immune diseases", "DISEASE", 79, 99], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 9, 14], ["IFN", "PROTEIN", 9, 12], ["\u03b3", "PROTEIN", 13, 14], ["Aberrant IFN", "PROBLEM", 0, 12], ["auto-inflammatory and auto-immune diseases", "PROBLEM", 57, 99], ["IFN", "OBSERVATION", 9, 12], ["inflammatory", "OBSERVATION_MODIFIER", 62, 74], ["auto-immune diseases", "OBSERVATION", 79, 99]]], ["It has been documented that cystatin C is involved in the IFN-\u03b3 signal transduction pathway.Previously it has been shown that in vitro treatment of murine peritoneal macrophages with IFN-\u03b3 causes a down-regulation of cystatin C secretion [89].", [["peritoneal macrophages", "ANATOMY", 155, 177], ["IFN-\u03b3", "CHEMICAL", 183, 188], ["cystatin C", "GENE_OR_GENE_PRODUCT", 28, 38], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 58, 63], ["murine", "ORGANISM", 148, 154], ["peritoneal macrophages", "CELL", 155, 177], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 183, 188], ["cystatin C", "GENE_OR_GENE_PRODUCT", 217, 227], ["cystatin C", "PROTEIN", 28, 38], ["IFN", "PROTEIN", 58, 61], ["\u03b3", "PROTEIN", 62, 63], ["murine peritoneal macrophages", "CELL_TYPE", 148, 177], ["IFN-\u03b3", "PROTEIN", 183, 188], ["cystatin C", "PROTEIN", 217, 227], ["murine", "SPECIES", 148, 154], ["cystatin C", "PROBLEM", 28, 38], ["murine peritoneal macrophages", "TREATMENT", 148, 177], ["IFN", "TREATMENT", 183, 186], ["cystatin C secretion", "PROBLEM", 217, 237], ["peritoneal", "ANATOMY", 155, 165], ["macrophages", "OBSERVATION", 166, 177]]], ["Conversely, it is curious to know whether cystatin C in turn can affect inflammatory responses mediated by IFN-\u03b3 in macrophages.", [["macrophages", "ANATOMY", 116, 127], ["cystatin C", "GENE_OR_GENE_PRODUCT", 42, 52], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 107, 112], ["macrophages", "CELL", 116, 127], ["cystatin C", "PROTEIN", 42, 52], ["IFN-\u03b3", "PROTEIN", 107, 112], ["macrophages", "CELL_TYPE", 116, 127], ["cystatin C", "PROBLEM", 42, 52], ["inflammatory responses", "PROBLEM", 72, 94], ["macrophages", "ANATOMY", 116, 127]]], ["To this end, the effects of IFN-\u03b3 on macrophages isolated from cystatin C knockout (cystatin C\u2212/\u2212) and wild-type (cystatin C+/+) mice were compared.", [["macrophages", "ANATOMY", 37, 48], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 28, 33], ["macrophages", "CELL", 37, 48], ["cystatin C", "GENE_OR_GENE_PRODUCT", 63, 73], ["cystatin", "GENE_OR_GENE_PRODUCT", 84, 92], ["cystatin C", "GENE_OR_GENE_PRODUCT", 114, 124], ["mice", "ORGANISM", 129, 133], ["IFN-\u03b3", "PROTEIN", 28, 33], ["macrophages", "CELL_TYPE", 37, 48], ["cystatin C", "PROTEIN", 63, 73], ["cystatin", "PROTEIN", 84, 92], ["cystatin C", "PROTEIN", 114, 124], ["mice", "SPECIES", 129, 133], ["mice", "SPECIES", 129, 133], ["IFN", "TEST", 28, 31], ["macrophages", "PROBLEM", 37, 48], ["cystatin C knockout", "TEST", 63, 82], ["cystatin C\u2212", "TEST", 84, 95], ["cystatin C", "TEST", 114, 124]]], ["It was shown that, in cystatin C\u2212/\u2212 macrophages, IFN-\u03b3 induced higher IL-10, but lower TNF-\u03b1 expression, compared to the similarly primed cystatin C+/+ cells [90], indicating an indispensable role of cystatin C in regulating the IFN-\u03b3 induced inflammatory cytokine production in macrophages.IFN-\u03b3 ::: Cystatin C regulate immunity at molecular levelsConsistently, the following evidences indicate that cystatin C is involved in the IFN-\u03b3 signaling pathway.", [["C\u2212/\u2212 macrophages", "ANATOMY", 31, 47], ["cystatin C+/+ cells", "ANATOMY", 138, 157], ["macrophages", "ANATOMY", 279, 290], ["cystatin", "GENE_OR_GENE_PRODUCT", 22, 30], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 49, 54], ["IL-10", "GENE_OR_GENE_PRODUCT", 70, 75], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 87, 92], ["cystatin C", "GENE_OR_GENE_PRODUCT", 138, 148], ["cystatin C", "GENE_OR_GENE_PRODUCT", 200, 210], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 229, 234], ["macrophages", "CELL", 279, 290], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 301, 311], ["cystatin C", "GENE_OR_GENE_PRODUCT", 401, 411], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 431, 436], ["cystatin C\u2212/\u2212 macrophages", "CELL_LINE", 22, 47], ["IFN-\u03b3", "PROTEIN", 49, 54], ["IL-10", "PROTEIN", 70, 75], ["TNF", "PROTEIN", 87, 90], ["cystatin C", "PROTEIN", 138, 148], ["cystatin C", "PROTEIN", 200, 210], ["IFN-\u03b3", "PROTEIN", 229, 234], ["inflammatory cytokine", "PROTEIN", 243, 264], ["macrophages", "CELL_TYPE", 279, 290], ["IFN", "PROTEIN", 291, 294], ["Cystatin C", "PROTEIN", 301, 311], ["cystatin C", "PROTEIN", 401, 411], ["IFN", "PROTEIN", 431, 434], ["\u03b3", "PROTEIN", 435, 436], ["cystatin", "TEST", 22, 30], ["IFN", "TEST", 49, 52], ["cystatin C", "TEST", 138, 148], ["cystatin C", "PROBLEM", 200, 210], ["the IFN", "TEST", 225, 232], ["inflammatory cytokine production in macrophages", "PROBLEM", 243, 290], ["Cystatin C regulate immunity at molecular levels", "PROBLEM", 301, 349], ["cystatin C", "PROBLEM", 401, 411], ["macrophages", "ANATOMY", 36, 47], ["inflammatory cytokine production", "OBSERVATION", 243, 275], ["macrophages", "ANATOMY", 279, 290]]], ["First, exogenously added cystatin C to cystatin C\u2212/\u2212 macrophages enhanced IFN-\u03b3 induced activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-\u03baB) p65, which is known to regulate the expression of pro-inflammatory cytokines and co-stimulatory molecules such as TNF-\u03b1 and NO [91].", [["C\u2212/\u2212 macrophages", "ANATOMY", 48, 64], ["B cells", "ANATOMY", 157, 164], ["NO", "CHEMICAL", 297, 299], ["NO", "CHEMICAL", 297, 299], ["cystatin C", "GENE_OR_GENE_PRODUCT", 25, 35], ["cystatin", "GENE_OR_GENE_PRODUCT", 39, 47], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 74, 79], ["kappa-light-chain-enhancer of activated B cells", "GENE_OR_GENE_PRODUCT", 117, 164], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 166, 171], ["p65", "GENE_OR_GENE_PRODUCT", 173, 176], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 287, 292], ["NO [91]", "SIMPLE_CHEMICAL", 297, 304], ["cystatin C", "PROTEIN", 25, 35], ["cystatin C\u2212/\u2212 macrophages", "CELL_LINE", 39, 64], ["IFN-\u03b3", "PROTEIN", 74, 79], ["nuclear factor kappa-light-chain-enhancer of activated B cells (NF-\u03baB", "PROTEIN", 102, 171], ["p65", "PROTEIN", 173, 176], ["pro-inflammatory cytokines", "PROTEIN", 223, 249], ["co-stimulatory molecules", "PROTEIN", 254, 278], ["TNF", "PROTEIN", 287, 290], ["cystatin C", "TREATMENT", 25, 35], ["cystatin C\u2212", "TEST", 39, 50], ["macrophages", "PROBLEM", 53, 64], ["IFN", "TEST", 74, 77], ["nuclear factor kappa-light", "TEST", 102, 128], ["activated B cells", "PROBLEM", 147, 164], ["NF", "TEST", 166, 168], ["pro-inflammatory cytokines", "PROBLEM", 223, 249], ["co-stimulatory molecules", "TEST", 254, 278], ["TNF", "TEST", 287, 290], ["macrophages", "ANATOMY", 53, 64], ["pro-inflammatory cytokines", "OBSERVATION", 223, 249]]], ["Furthermore, cystatin C was found to be able to synergize with IFN-\u03b3 to induce ERK1/2 phosphorylation and NF-\u03baB DNA-binding activity, as pretreatment of cells with specific inhibitors of NF-\u03baB or ERK1/2 pathway blocked the cystatin plus IFN-\u03b3-inducible NF-\u03baB activity [82].", [["cells", "ANATOMY", 153, 158], ["cystatin C", "GENE_OR_GENE_PRODUCT", 13, 23], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 63, 68], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 79, 85], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 106, 111], ["DNA", "CELLULAR_COMPONENT", 112, 115], ["cells", "CELL", 153, 158], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 187, 192], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 196, 202], ["cystatin", "GENE_OR_GENE_PRODUCT", 223, 231], ["IFN-\u03b3-", "GENE_OR_GENE_PRODUCT", 237, 243], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 253, 258], ["cystatin C", "PROTEIN", 13, 23], ["IFN", "PROTEIN", 63, 66], ["ERK1", "PROTEIN", 79, 83], ["NF-\u03baB", "PROTEIN", 187, 192], ["ERK1/2", "PROTEIN", 196, 202], ["cystatin", "PROTEIN", 223, 231], ["IFN", "PROTEIN", 237, 240], ["NF-\u03baB", "PROTEIN", 253, 258], ["cystatin C", "PROBLEM", 13, 23], ["IFN", "TEST", 63, 66], ["ERK1", "TEST", 79, 83], ["phosphorylation", "TEST", 86, 101], ["NF", "TEST", 106, 108], ["B DNA", "PROBLEM", 110, 115], ["specific inhibitors", "TREATMENT", 164, 183], ["NF", "TEST", 187, 189], ["the cystatin", "TREATMENT", 219, 231], ["inducible NF", "PROBLEM", 243, 255]]], ["Moreover, increased mRNA levels of inducible NO synthase (iNOS), as well as the levels of NO and TNF-\u03b1 were found in the cell culture medium of IFN-\u03b3 and cystatin C treated macrophages [92].Cystatin C was also reported to affect T cell polarizing cytokine production in response to IFN-\u03b3 signaling.", [["cell", "ANATOMY", 121, 125], ["macrophages", "ANATOMY", 173, 184], ["T cell", "ANATOMY", 229, 235], ["NO", "CHEMICAL", 45, 47], ["NO", "CHEMICAL", 90, 92], ["NO", "CHEMICAL", 45, 47], ["NO", "CHEMICAL", 90, 92], ["inducible NO synthase", "GENE_OR_GENE_PRODUCT", 35, 56], ["iNOS", "GENE_OR_GENE_PRODUCT", 58, 62], ["NO", "GENE_OR_GENE_PRODUCT", 90, 92], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 97, 102], ["cell", "CELL", 121, 125], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 144, 149], ["cystatin C", "SIMPLE_CHEMICAL", 154, 164], ["macrophages", "CELL", 173, 184], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 190, 200], ["T cell", "CELL", 229, 235], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 282, 287], ["NO synthase", "PROTEIN", 45, 56], ["iNOS", "PROTEIN", 58, 62], ["TNF-\u03b1", "PROTEIN", 97, 102], ["IFN-\u03b3 and cystatin C treated macrophages", "CELL_LINE", 144, 184], ["Cystatin C", "PROTEIN", 190, 200], ["cytokine", "PROTEIN", 247, 255], ["IFN", "PROTEIN", 282, 285], ["increased mRNA levels", "PROBLEM", 10, 31], ["the levels", "TEST", 76, 86], ["TNF", "TEST", 97, 100], ["the cell culture", "TEST", 117, 133], ["IFN", "TEST", 144, 147], ["cystatin C treated macrophages", "PROBLEM", 154, 184], ["Cystatin C", "PROBLEM", 190, 200], ["IFN", "TEST", 282, 285], ["NO", "UNCERTAINTY", 45, 47], ["cell polarizing", "OBSERVATION", 231, 246], ["cytokine production", "OBSERVATION", 247, 266]]], ["Transcript levels of IL-4 were found to be reduced in the mice given combined therapy of IFN-\u03b3 and cystatin C, whereas IL-12 was significantly elevated [93], indicating that cystatin C has the potential to facilitate the IFN-\u03b3-induced switch of T cell differentiation from Th2 to Th1 in favor of eliminating pathogen infection.", [["T cell", "ANATOMY", 245, 251], ["pathogen infection", "DISEASE", 308, 326], ["IL-4", "GENE_OR_GENE_PRODUCT", 21, 25], ["mice", "ORGANISM", 58, 62], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 89, 94], ["cystatin C", "GENE_OR_GENE_PRODUCT", 99, 109], ["IL-12", "GENE_OR_GENE_PRODUCT", 119, 124], ["cystatin C", "GENE_OR_GENE_PRODUCT", 174, 184], ["IFN-\u03b3-", "GENE_OR_GENE_PRODUCT", 221, 227], ["T cell", "CELL", 245, 251], ["Th2", "GENE_OR_GENE_PRODUCT", 273, 276], ["IL-4", "PROTEIN", 21, 25], ["IFN", "PROTEIN", 89, 92], ["cystatin C", "PROTEIN", 99, 109], ["IL-12", "PROTEIN", 119, 124], ["cystatin C", "PROTEIN", 174, 184], ["IFN", "PROTEIN", 221, 224], ["Th1", "CELL_TYPE", 280, 283], ["mice", "SPECIES", 58, 62], ["mice", "SPECIES", 58, 62], ["Transcript levels", "TEST", 0, 17], ["IL", "TEST", 21, 23], ["combined therapy", "TREATMENT", 69, 85], ["IFN", "TREATMENT", 89, 92], ["cystatin C", "TEST", 99, 109], ["IL", "TEST", 119, 121], ["significantly elevated", "PROBLEM", 129, 151], ["cystatin C", "PROBLEM", 174, 184], ["the IFN", "TREATMENT", 217, 224], ["T cell differentiation", "TREATMENT", 245, 267], ["pathogen infection", "PROBLEM", 308, 326], ["reduced", "OBSERVATION_MODIFIER", 43, 50], ["pathogen", "OBSERVATION_MODIFIER", 308, 316], ["infection", "OBSERVATION", 317, 326]]], ["Collectively, these data suggested that as an immunomodulatory molecule, cystatin C alters the responses of immune cells to IFN-\u03b3 [92].NO ::: Cystatin C regulate immunity at molecular levelsNO is a molecular and chemical compound containing free radical with a wide range of biological functions, ranging from regulating platelet aggregation, neural signal transduction, enzyme activity, and leukocyte homeostasis [94].", [["immune cells", "ANATOMY", 108, 120], ["platelet", "ANATOMY", 321, 329], ["neural", "ANATOMY", 343, 349], ["leukocyte", "ANATOMY", 392, 401], ["NO", "CHEMICAL", 135, 137], ["NO", "CHEMICAL", 190, 192], ["platelet aggregation", "DISEASE", 321, 341], ["NO", "CHEMICAL", 135, 137], ["NO", "CHEMICAL", 190, 192], ["cystatin C", "GENE_OR_GENE_PRODUCT", 73, 83], ["immune cells", "CELL", 108, 120], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 124, 129], ["NO", "SIMPLE_CHEMICAL", 135, 137], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 142, 152], ["NO", "SIMPLE_CHEMICAL", 190, 192], ["free radical", "SIMPLE_CHEMICAL", 241, 253], ["platelet", "CELL", 321, 329], ["leukocyte", "CELL", 392, 401], ["cystatin C", "PROTEIN", 73, 83], ["immune cells", "CELL_TYPE", 108, 120], ["IFN", "PROTEIN", 124, 127], ["Cystatin C", "PROTEIN", 142, 152], ["an immunomodulatory molecule", "PROBLEM", 43, 71], ["cystatin C alters", "TREATMENT", 73, 90], ["immune cells", "PROBLEM", 108, 120], ["IFN", "TEST", 124, 127], ["Cystatin C regulate immunity", "PROBLEM", 142, 170], ["a molecular and chemical compound containing free radical", "PROBLEM", 196, 253], ["platelet aggregation", "TEST", 321, 341], ["neural signal transduction", "TEST", 343, 369], ["enzyme activity", "TEST", 371, 386], ["leukocyte homeostasis", "TEST", 392, 413], ["immune cells", "OBSERVATION", 108, 120], ["free radical", "OBSERVATION", 241, 253], ["platelet aggregation", "OBSERVATION", 321, 341]]], ["NO produced by the cytokine-activated macrophage during parasite infection is known to play a central role in the control of parasite killing and cell apoptosis [95].NO ::: Cystatin C regulate immunity at molecular levelsThe studies on Angiostrongylus cantonensis confirmed cystatin C can significantly induce NO generation from macrophages [96,97].", [["macrophage", "ANATOMY", 38, 48], ["cell", "ANATOMY", 146, 150], ["macrophages", "ANATOMY", 329, 340], ["NO", "CHEMICAL", 0, 2], ["parasite infection", "DISEASE", 56, 74], ["NO", "CHEMICAL", 166, 168], ["Angiostrongylus cantonensis", "DISEASE", 236, 263], ["cystatin C", "CHEMICAL", 274, 284], ["NO", "CHEMICAL", 310, 312], ["NO", "CHEMICAL", 0, 2], ["NO", "CHEMICAL", 166, 168], ["NO", "CHEMICAL", 310, 312], ["NO", "SIMPLE_CHEMICAL", 0, 2], ["macrophage", "CELL", 38, 48], ["cell", "CELL", 146, 150], ["NO", "SIMPLE_CHEMICAL", 166, 168], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 173, 183], ["Angiostrongylus cantonensis", "ORGANISM", 236, 263], ["cystatin C", "GENE_OR_GENE_PRODUCT", 274, 284], ["NO", "SIMPLE_CHEMICAL", 310, 312], ["macrophages", "CELL", 329, 340], ["cytokine", "PROTEIN", 19, 27], ["Cystatin C", "PROTEIN", 173, 183], ["cystatin C", "PROTEIN", 274, 284], ["macrophages", "CELL_TYPE", 329, 340], ["Angiostrongylus cantonensis", "SPECIES", 236, 263], ["Angiostrongylus cantonensis", "SPECIES", 236, 263], ["parasite infection", "PROBLEM", 56, 74], ["parasite killing", "PROBLEM", 125, 141], ["cell apoptosis", "PROBLEM", 146, 160], ["Cystatin C regulate immunity", "TREATMENT", 173, 201], ["The studies", "TEST", 221, 232], ["Angiostrongylus cantonensis", "TEST", 236, 263], ["cystatin C", "PROBLEM", 274, 284], ["macrophages", "PROBLEM", 329, 340], ["infection", "OBSERVATION", 65, 74], ["macrophages", "OBSERVATION", 329, 340]]], ["More recently, cystatin C from parasites such as Onchocerca volvulus and Dipetalonema perstans also has the potential to induce NO production from other cells [84,98,99].NO ::: Cystatin C regulate immunity at molecular levelsFurther study of the mechanism revealed that cystatin C induce the production of NO independent of its inhibitor\u2019s activity, because an irreversible and structurally unrelated cysteine protease inhibitor E64 did not induce any increase in nitrite levels [32].", [["cells", "ANATOMY", 153, 158], ["Onchocerca volvulus", "DISEASE", 49, 68], ["NO", "CHEMICAL", 128, 130], ["NO", "CHEMICAL", 170, 172], ["NO", "CHEMICAL", 306, 308], ["E64", "CHEMICAL", 429, 432], ["nitrite", "CHEMICAL", 464, 471], ["NO", "CHEMICAL", 128, 130], ["NO", "CHEMICAL", 170, 172], ["NO", "CHEMICAL", 306, 308], ["cysteine", "CHEMICAL", 401, 409], ["E64", "CHEMICAL", 429, 432], ["nitrite", "CHEMICAL", 464, 471], ["cystatin C", "GENE_OR_GENE_PRODUCT", 15, 25], ["Onchocerca volvulus", "ORGANISM", 49, 68], ["Dipetalonema perstans", "ORGANISM", 73, 94], ["NO", "SIMPLE_CHEMICAL", 128, 130], ["cells", "CELL", 153, 158], ["NO", "SIMPLE_CHEMICAL", 170, 172], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 177, 187], ["cystatin C", "GENE_OR_GENE_PRODUCT", 270, 280], ["NO", "SIMPLE_CHEMICAL", 306, 308], ["nitrite", "SIMPLE_CHEMICAL", 464, 471], ["cystatin C", "PROTEIN", 15, 25], ["Cystatin C", "PROTEIN", 177, 187], ["cystatin C", "PROTEIN", 270, 280], ["Onchocerca volvulus", "SPECIES", 49, 68], ["Dipetalonema perstans", "SPECIES", 73, 94], ["Onchocerca volvulus", "SPECIES", 49, 68], ["Dipetalonema perstans", "SPECIES", 73, 94], ["cystatin C", "PROBLEM", 15, 25], ["parasites", "PROBLEM", 31, 40], ["Onchocerca volvulus", "PROBLEM", 49, 68], ["Dipetalonema perstans", "PROBLEM", 73, 94], ["production from other cells", "PROBLEM", 131, 158], ["Cystatin C regulate immunity", "PROBLEM", 177, 205], ["Further study", "TEST", 225, 238], ["cystatin C", "PROBLEM", 270, 280], ["an irreversible and structurally unrelated cysteine protease inhibitor", "TREATMENT", 358, 428], ["any increase in nitrite levels", "PROBLEM", 448, 478], ["Onchocerca volvulus", "OBSERVATION", 49, 68]]], ["The role of cystatin C on the NO production relies on the activation of iNOS pathway as it was almost completely abrogated in the presence of L-NMMA, a specific iNOS inhibitor.", [["NO", "CHEMICAL", 30, 32], ["L-NMMA", "CHEMICAL", 142, 148], ["NO", "CHEMICAL", 30, 32], ["L-NMMA", "CHEMICAL", 142, 148], ["cystatin C", "GENE_OR_GENE_PRODUCT", 12, 22], ["NO", "SIMPLE_CHEMICAL", 30, 32], ["iNOS", "GENE_OR_GENE_PRODUCT", 72, 76], ["L-NMMA", "SIMPLE_CHEMICAL", 142, 148], ["iNOS", "GENE_OR_GENE_PRODUCT", 161, 165], ["cystatin C", "PROTEIN", 12, 22], ["iNOS", "PROTEIN", 72, 76], ["iNOS", "PROTEIN", 161, 165], ["cystatin C", "TREATMENT", 12, 22], ["iNOS pathway", "TREATMENT", 72, 84], ["L-NMMA", "TREATMENT", 142, 148], ["a specific iNOS inhibitor", "TREATMENT", 150, 175], ["NMMA", "OBSERVATION", 144, 148]]], ["Further study revealed that the cystatin C involved iNOS expression is mostly controlled by two regulatory regions present in the iNOS promoter, which contains binding sequences for two transcription factors, NF-\u03baB and IFN regulatory factor 1 (IRF-1) [100].", [["cystatin C", "GENE_OR_GENE_PRODUCT", 32, 42], ["iNOS", "GENE_OR_GENE_PRODUCT", 52, 56], ["iNOS", "GENE_OR_GENE_PRODUCT", 130, 134], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 209, 214], ["IFN regulatory factor 1", "GENE_OR_GENE_PRODUCT", 219, 242], ["IRF-1", "GENE_OR_GENE_PRODUCT", 244, 249], ["cystatin C", "PROTEIN", 32, 42], ["iNOS", "PROTEIN", 52, 56], ["regulatory regions", "DNA", 96, 114], ["iNOS promoter", "DNA", 130, 143], ["transcription factors", "PROTEIN", 186, 207], ["NF-\u03baB", "PROTEIN", 209, 214], ["IFN regulatory factor 1 (IRF-1", "PROTEIN", 219, 249], ["Further study", "TEST", 0, 13], ["the cystatin C involved iNOS expression", "PROBLEM", 28, 67], ["the iNOS promoter", "TREATMENT", 126, 143], ["two transcription factors", "TEST", 182, 207], ["NF", "TEST", 209, 211], ["IFN regulatory factor", "TEST", 219, 240], ["IRF", "TEST", 244, 247], ["iNOS expression", "OBSERVATION", 52, 67], ["iNOS promoter", "OBSERVATION", 130, 143]]], ["Later on, a number of studies demonstrated a direct correlation between ERK1/2 activation and up-regulation of both NF-\u03baB activity and NO production through the participation of mitogen- and stress-activated protein kinase 1 (MSK1) [82,101].NO ::: Cystatin C regulate immunity at molecular levelsAlthough detailed signaling pathways still remain to be defined, a better knowledge of the mechanism by which cystatin C triggers the production of microbicidal NO, could permit the development of immune modulators useful not only for non-healing leishmaniasis but also for other chronic infectious diseases [82].TGF-\u03b2 ::: Cystatin C regulate immunity at molecular levelsTransforming growth factor \u03b2 (TGF-\u03b2) is a strong immunosuppressant, which plays an important role in tumor development by affecting immune cell mediated immune surveillance [102].", [["tumor", "ANATOMY", 768, 773], ["immune cell", "ANATOMY", 799, 810], ["NO", "CHEMICAL", 135, 137], ["NO", "CHEMICAL", 241, 243], ["NO", "CHEMICAL", 457, 459], ["leishmaniasis", "DISEASE", 543, 556], ["chronic infectious diseases", "DISEASE", 576, 603], ["tumor", "DISEASE", 768, 773], ["NO", "CHEMICAL", 135, 137], ["NO", "CHEMICAL", 241, 243], ["NO", "CHEMICAL", 457, 459], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 72, 78], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 116, 121], ["NO", "SIMPLE_CHEMICAL", 135, 137], ["mitogen- and stress-activated protein kinase 1", "GENE_OR_GENE_PRODUCT", 178, 224], ["MSK1", "GENE_OR_GENE_PRODUCT", 226, 230], ["NO", "SIMPLE_CHEMICAL", 241, 243], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 248, 258], ["cystatin C", "GENE_OR_GENE_PRODUCT", 406, 416], ["NO", "SIMPLE_CHEMICAL", 457, 459], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 609, 614], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 619, 629], ["Transforming growth factor \u03b2", "GENE_OR_GENE_PRODUCT", 667, 695], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 697, 702], ["tumor", "CANCER", 768, 773], ["immune cell", "CELL", 799, 810], ["ERK1", "PROTEIN", 72, 76], ["NF-\u03baB", "PROTEIN", 116, 121], ["mitogen- and stress-activated protein kinase 1", "PROTEIN", 178, 224], ["MSK1", "PROTEIN", 226, 230], ["Cystatin C", "PROTEIN", 248, 258], ["cystatin C", "PROTEIN", 406, 416], ["TGF", "PROTEIN", 609, 612], ["Cystatin C", "PROTEIN", 619, 629], ["Transforming growth factor \u03b2", "PROTEIN", 667, 695], ["TGF-\u03b2", "PROTEIN", 697, 702], ["studies", "TEST", 22, 29], ["ERK1", "TEST", 72, 76], ["both NF", "TEST", 111, 118], ["mitogen", "TEST", 178, 185], ["stress-activated protein kinase", "TEST", 191, 222], ["Cystatin C regulate immunity", "TREATMENT", 248, 276], ["cystatin C", "PROBLEM", 406, 416], ["immune modulators", "PROBLEM", 493, 510], ["non-healing leishmaniasis", "PROBLEM", 531, 556], ["other chronic infectious diseases", "PROBLEM", 570, 603], ["Cystatin C regulate immunity at molecular levels", "PROBLEM", 619, 667], ["Transforming growth factor", "TEST", 667, 693], ["TGF", "TEST", 697, 700], ["a strong immunosuppressant", "TREATMENT", 707, 733], ["leishmaniasis", "OBSERVATION", 543, 556], ["chronic", "OBSERVATION_MODIFIER", 576, 583], ["infectious", "OBSERVATION", 584, 594], ["tumor", "OBSERVATION", 768, 773]]], ["For example, TGF-\u03b2 can inhibit the maturation of DCs, that make T cells unable to differentiate into cytotoxic T lymphocytes (CTLs) or Ths, thus promoting tumorigenesis [103].", [["DCs", "ANATOMY", 49, 52], ["T cells", "ANATOMY", 64, 71], ["cytotoxic T lymphocytes", "ANATOMY", 101, 124], ["CTLs", "ANATOMY", 126, 130], ["Ths", "ANATOMY", 135, 138], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 13, 18], ["DCs", "CELL", 49, 52], ["T cells", "CELL", 64, 71], ["cytotoxic T lymphocytes", "CELL", 101, 124], ["CTLs", "CELL", 126, 130], ["Ths", "GENE_OR_GENE_PRODUCT", 135, 138], ["TGF-\u03b2", "PROTEIN", 13, 18], ["DCs", "CELL_TYPE", 49, 52], ["T cells", "CELL_TYPE", 64, 71], ["cytotoxic T lymphocytes", "CELL_TYPE", 101, 124], ["CTLs", "CELL_TYPE", 126, 130], ["Ths", "CELL_TYPE", 135, 138], ["TGF", "TEST", 13, 16], ["T cells", "PROBLEM", 64, 71]]], ["In addition, TGF-\u03b2 was also found to promote the proliferation of Tregs in vitro and increase the expression of HLA-DR in Tregs to enhance the immunosuppressive function [104].", [["Tregs", "ANATOMY", 66, 71], ["Tregs", "ANATOMY", 122, 127], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 13, 18], ["Tregs", "CELL", 66, 71], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 112, 118], ["Tregs", "CELL", 122, 127], ["TGF-\u03b2", "PROTEIN", 13, 18], ["Tregs", "CELL_TYPE", 66, 71], ["HLA-DR", "PROTEIN", 112, 118], ["Tregs", "CELL_TYPE", 122, 127], ["TGF", "TEST", 13, 16], ["Tregs in vitro", "TREATMENT", 66, 80], ["the immunosuppressive function", "TEST", 139, 169]]], ["Moreover, there were also evidences to suggest a negative regulatory roles of TGF-\u03b2 in NK cells and monocytes [103].", [["NK cells", "ANATOMY", 87, 95], ["monocytes", "ANATOMY", 100, 109], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 78, 83], ["NK cells", "CELL", 87, 95], ["monocytes [103]", "CELL", 100, 115], ["TGF-\u03b2", "PROTEIN", 78, 83], ["NK cells", "CELL_TYPE", 87, 95], ["monocytes", "CELL_TYPE", 100, 109], ["TGF", "TEST", 78, 81], ["monocytes", "TEST", 100, 109], ["negative", "OBSERVATION", 49, 57]]], ["Based on existing research findings, it has been well established that cystatin C can antagonize the suppressive functions of TGF-\u03b2 via physically interacting with its receptor or its signaling molecules.TGF-\u03b2 mediates its biological activities via binding to cell surface receptors with high affinity [105].", [["cell surface", "ANATOMY", 260, 272], ["cystatin C", "GENE_OR_GENE_PRODUCT", 71, 81], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 126, 131], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 204, 209], ["cell", "CELL", 260, 264], ["cystatin C", "PROTEIN", 71, 81], ["TGF-\u03b2", "PROTEIN", 126, 131], ["signaling molecules", "PROTEIN", 184, 203], ["TGF-\u03b2", "PROTEIN", 204, 209], ["cell surface receptors", "PROTEIN", 260, 282], ["cystatin C", "TREATMENT", 71, 81], ["TGF", "TEST", 204, 207], ["high affinity", "PROBLEM", 288, 301]]], ["The inhibitory effect of \u039414Cst C, a cystatin C mutant that lacks the cysteine protease inhibitor signature sequences, on TGF-\u03b2 signaling suggested that cystatin C may inhibit TGF-\u03b2 signaling by antagonizing the interaction between TGF-\u03b2 and its receptors [106].", [["\u039414Cst C", "CHEMICAL", 25, 33], ["cysteine", "CHEMICAL", 70, 78], ["\u039414Cst C", "SIMPLE_CHEMICAL", 25, 33], ["cystatin C", "GENE_OR_GENE_PRODUCT", 37, 47], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 122, 127], ["cystatin C", "GENE_OR_GENE_PRODUCT", 153, 163], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 176, 181], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 232, 237], ["\u039414Cst C", "PROTEIN", 25, 33], ["cystatin C mutant", "PROTEIN", 37, 54], ["cysteine protease", "PROTEIN", 70, 87], ["TGF-\u03b2", "PROTEIN", 122, 127], ["cystatin C", "PROTEIN", 153, 163], ["TGF-\u03b2", "PROTEIN", 176, 181], ["TGF-\u03b2", "PROTEIN", 232, 237], ["\u039414Cst C", "TREATMENT", 25, 33], ["a cystatin C mutant", "TREATMENT", 35, 54], ["the cysteine protease inhibitor", "TREATMENT", 66, 97], ["TGF", "TEST", 122, 125], ["cystatin C", "PROBLEM", 153, 163], ["TGF", "TEST", 176, 179], ["TGF", "TEST", 232, 235]]], ["This hypothesis seemed especially attractive given the fact that the type III cystatin family member, fetuin (also known as \u03b12-HSglycoprotein), inhibits TGF-\u03b2 signaling by physically interacting with and preventing the binding of TGF-\u03b2 to its receptors [107].", [["type III cystatin", "GENE_OR_GENE_PRODUCT", 69, 86], ["fetuin", "GENE_OR_GENE_PRODUCT", 102, 108], ["\u03b12-HSglycoprotein", "GENE_OR_GENE_PRODUCT", 124, 141], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 153, 158], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 230, 235], ["type III cystatin family member", "PROTEIN", 69, 100], ["fetuin", "PROTEIN", 102, 108], ["\u03b12", "PROTEIN", 124, 126], ["HSglycoprotein", "PROTEIN", 127, 141], ["TGF-\u03b2", "PROTEIN", 153, 158], ["TGF-\u03b2", "PROTEIN", 230, 235]]], ["Consistently, down-regulation of tumor development through a similar mechanism has also been shown for a cystatin that inhibits colon carcinogenesis by blocking the interaction of TGF-\u03b2 with cell surface receptors to suppress its signal transduction [108].", [["tumor", "ANATOMY", 33, 38], ["colon", "ANATOMY", 128, 133], ["cell surface", "ANATOMY", 191, 203], ["tumor", "DISEASE", 33, 38], ["colon carcinogenesis", "DISEASE", 128, 148], ["tumor", "CANCER", 33, 38], ["cystatin", "GENE_OR_GENE_PRODUCT", 105, 113], ["colon", "ORGAN", 128, 133], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 180, 185], ["cell", "CELL", 191, 195], ["cystatin", "PROTEIN", 105, 113], ["TGF-\u03b2", "PROTEIN", 180, 185], ["cell surface receptors", "PROTEIN", 191, 213], ["tumor development", "PROBLEM", 33, 50], ["a cystatin", "TREATMENT", 103, 113], ["colon carcinogenesis", "PROBLEM", 128, 148], ["TGF", "TEST", 180, 183], ["cell surface receptors", "TREATMENT", 191, 213], ["tumor", "OBSERVATION", 33, 38], ["colon", "ANATOMY", 128, 133]]], ["In agreement with these in vitro findings, the growth, weight, and proliferative index of 4T1 tumors in BALB/c mice were inhibited significantly by their expression of either cystatin C or \u039414Cst C in vivo via antagonizing the efficacy of TGF-\u03b2 [109].TGF-\u03b2 ::: Cystatin C regulate immunity at molecular levelsIn addition to directly blocking of its receptor, cystatin C may also prevent TGF-\u03b2 signaling by affecting its downstream molecules.", [["4T1 tumors", "ANATOMY", 90, 100], ["tumors", "DISEASE", 94, 100], ["4T1 tumors", "CANCER", 90, 100], ["BALB/c mice", "ORGANISM", 104, 115], ["cystatin C", "GENE_OR_GENE_PRODUCT", 175, 185], ["\u039414Cst C", "GENE_OR_GENE_PRODUCT", 189, 197], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 239, 244], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 251, 256], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 261, 271], ["cystatin C", "GENE_OR_GENE_PRODUCT", 359, 369], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 387, 392], ["cystatin C", "PROTEIN", 175, 185], ["\u039414Cst C", "PROTEIN", 189, 197], ["TGF", "PROTEIN", 239, 242], ["TGF", "PROTEIN", 251, 254], ["Cystatin C", "PROTEIN", 261, 271], ["cystatin C", "PROTEIN", 359, 369], ["TGF-\u03b2", "PROTEIN", 387, 392], ["mice", "SPECIES", 111, 115], ["mice", "SPECIES", 111, 115], ["the growth", "TEST", 43, 53], ["weight", "TEST", 55, 61], ["proliferative index", "TEST", 67, 86], ["cystatin C", "TREATMENT", 175, 185], ["TGF", "TEST", 239, 242], ["Cystatin C regulate immunity at molecular levels", "PROBLEM", 261, 309], ["its receptor", "TREATMENT", 345, 357], ["cystatin C", "TREATMENT", 359, 369], ["TGF", "TEST", 387, 390]]], ["Immunohistochemistry studies were conducted to monitor the activation status of all three TGF-\u03b2 effectors, drosophila mothers against decapentaplegic protein (Smad), p38 MAPKs and ERK1/2, by staining with phospho-specific antibodies [109].", [["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 90, 95], ["drosophila", "ORGANISM", 107, 117], ["decapentaplegic protein", "GENE_OR_GENE_PRODUCT", 134, 157], ["Smad", "GENE_OR_GENE_PRODUCT", 159, 163], ["p38 MAPKs", "GENE_OR_GENE_PRODUCT", 166, 175], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 180, 186], ["TGF-\u03b2 effectors", "PROTEIN", 90, 105], ["drosophila mothers", "PROTEIN", 107, 125], ["decapentaplegic protein", "PROTEIN", 134, 157], ["Smad", "PROTEIN", 159, 163], ["p38 MAPKs", "PROTEIN", 166, 175], ["ERK1/2", "PROTEIN", 180, 186], ["phospho-specific antibodies", "PROTEIN", 205, 232], ["Immunohistochemistry studies", "TEST", 0, 28], ["decapentaplegic protein (Smad)", "TEST", 134, 164], ["p38 MAPKs", "TEST", 166, 175], ["ERK1/2", "TEST", 180, 186], ["phospho-specific antibodies", "TEST", 205, 232]]], ["The result shows that the phosphorylation and activation of these effectors were inhibited significantly in cells expressing cystatin C compared with their control samples [109], suggesting that cystatin C can block the TGF-\u03b2 signaling pathway partly by decreasing the phosphorylation of Smad2, p38 MAPK, and ERK1/2, although the physical evidence for the direct interaction between cystatin C and these signaling effectors remain to be identified.Other cytokines ::: Cystatin C regulate immunity at molecular levelsAs a very common and important basic pathological process, inflammation is a protective response involving numerous immune cells against invading pathogens, during which many inflammatory cytokines and mediators are released.", [["cells", "ANATOMY", 108, 113], ["samples", "ANATOMY", 164, 171], ["immune cells", "ANATOMY", 632, 644], ["inflammation", "DISEASE", 575, 587], ["cells", "CELL", 108, 113], ["cystatin C", "GENE_OR_GENE_PRODUCT", 125, 135], ["cystatin C", "GENE_OR_GENE_PRODUCT", 195, 205], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 220, 225], ["Smad2", "GENE_OR_GENE_PRODUCT", 288, 293], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 295, 303], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 309, 315], ["cystatin C", "GENE_OR_GENE_PRODUCT", 383, 393], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 468, 478], ["immune cells", "CELL", 632, 644], ["cystatin C", "PROTEIN", 125, 135], ["cystatin C", "PROTEIN", 195, 205], ["TGF-\u03b2", "PROTEIN", 220, 225], ["Smad2", "PROTEIN", 288, 293], ["p38 MAPK", "PROTEIN", 295, 303], ["ERK1/2", "PROTEIN", 309, 315], ["cystatin C", "PROTEIN", 383, 393], ["signaling effectors", "PROTEIN", 404, 423], ["cytokines", "PROTEIN", 454, 463], ["Cystatin C", "PROTEIN", 468, 478], ["immune cells", "CELL_TYPE", 632, 644], ["inflammatory cytokines", "PROTEIN", 691, 713], ["the phosphorylation", "PROBLEM", 22, 41], ["these effectors", "PROBLEM", 60, 75], ["cystatin C", "TEST", 125, 135], ["cystatin C", "PROBLEM", 195, 205], ["the TGF", "TEST", 216, 223], ["p38 MAPK", "TEST", 295, 303], ["ERK1", "TEST", 309, 313], ["cystatin C", "TREATMENT", 383, 393], ["these signaling effectors", "PROBLEM", 398, 423], ["Cystatin C regulate immunity at molecular levels", "PROBLEM", 468, 516], ["a very common and important basic pathological process", "PROBLEM", 519, 573], ["inflammation", "PROBLEM", 575, 587], ["numerous immune cells", "PROBLEM", 623, 644], ["invading pathogens", "PROBLEM", 653, 671], ["inflammation", "OBSERVATION", 575, 587], ["numerous", "OBSERVATION_MODIFIER", 623, 631], ["immune cells", "OBSERVATION", 632, 644], ["inflammatory", "OBSERVATION_MODIFIER", 691, 703]]], ["In addition to the factors mentioned above, other inflammatory factors have also been reported to interact with cystatin C or its analogues.Other cytokines ::: Cystatin C regulate immunity at molecular levelsIt was found that filarial cystatin rAvl7was associated with a marked increase in IL-10 production.", [["cystatin C", "GENE_OR_GENE_PRODUCT", 112, 122], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 160, 170], ["cystatin", "GENE_OR_GENE_PRODUCT", 235, 243], ["IL-10", "GENE_OR_GENE_PRODUCT", 290, 295], ["inflammatory factors", "PROTEIN", 50, 70], ["cystatin C", "PROTEIN", 112, 122], ["cytokines", "PROTEIN", 146, 155], ["Cystatin C", "PROTEIN", 160, 170], ["filarial cystatin rAvl7was", "PROTEIN", 226, 252], ["IL", "PROTEIN", 290, 292], ["other inflammatory factors", "PROBLEM", 44, 70], ["cystatin C", "TREATMENT", 112, 122], ["Cystatin C regulate immunity at molecular levels", "PROBLEM", 160, 208], ["filarial cystatin rAvl7was", "PROBLEM", 226, 252], ["a marked increase in IL", "PROBLEM", 269, 292], ["inflammatory", "OBSERVATION", 50, 62], ["filarial cystatin", "OBSERVATION", 226, 243], ["marked", "OBSERVATION_MODIFIER", 271, 277], ["increase", "OBSERVATION_MODIFIER", 278, 286], ["IL", "OBSERVATION_MODIFIER", 290, 292]]], ["In contrast, there was a trend towards a decreased production of IL-4 by mitogen-stimulated spleen cells in the presence of rAvl7 [85].", [["spleen cells", "ANATOMY", 92, 104], ["IL-4", "GENE_OR_GENE_PRODUCT", 65, 69], ["spleen cells", "CELL", 92, 104], ["rAvl7", "GENE_OR_GENE_PRODUCT", 124, 129], ["IL-4", "PROTEIN", 65, 69], ["mitogen", "PROTEIN", 73, 80], ["spleen cells", "CELL_TYPE", 92, 104], ["a decreased production of IL", "PROBLEM", 39, 67], ["decreased", "OBSERVATION_MODIFIER", 41, 50], ["spleen", "ANATOMY", 92, 98]]], ["It is possible that the lower IL-4 quantities in the presence of rAvl7 resulted from the increased IL-10 levels, as IL-10 and IL-4 were described to be inversely correlated [110].", [["IL-4", "GENE_OR_GENE_PRODUCT", 30, 34], ["rAvl7", "GENE_OR_GENE_PRODUCT", 65, 70], ["IL-10", "GENE_OR_GENE_PRODUCT", 99, 104], ["IL-10", "GENE_OR_GENE_PRODUCT", 116, 121], ["IL-4", "GENE_OR_GENE_PRODUCT", 126, 130], ["IL-4", "PROTEIN", 30, 34], ["rAvl7", "PROTEIN", 65, 70], ["IL", "PROTEIN", 99, 101], ["IL", "PROTEIN", 126, 128], ["the increased IL", "TREATMENT", 85, 101], ["IL", "TEST", 116, 118], ["lower", "OBSERVATION_MODIFIER", 24, 29], ["increased", "OBSERVATION_MODIFIER", 89, 98], ["IL", "OBSERVATION_MODIFIER", 99, 101]]], ["Although the cellular target of cystatin and the mechanisms of IL-10 secretion await further investigation, this filarial cystatin is a likely effector molecule of immune-modulation and a potential target for anti-filarial intervention.Cystatin C and apoptosisApoptosis is one of the important forms of immune regulation, which not only controls the numbers but also implements the effects of immune cells.", [["cellular", "ANATOMY", 13, 21], ["anti-filarial", "ANATOMY", 209, 222], ["immune cells", "ANATOMY", 393, 405], ["apoptosisApoptosis", "DISEASE", 251, 269], ["cellular", "CELL", 13, 21], ["cystatin", "GENE_OR_GENE_PRODUCT", 32, 40], ["IL-10", "GENE_OR_GENE_PRODUCT", 63, 68], ["filarial", "ORGANISM", 113, 121], ["cystatin", "GENE_OR_GENE_PRODUCT", 122, 130], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 236, 246], ["immune cells", "CELL", 393, 405], ["cystatin", "PROTEIN", 32, 40], ["filarial cystatin", "PROTEIN", 113, 130], ["Cystatin C", "PROTEIN", 236, 246], ["immune cells", "CELL_TYPE", 393, 405], ["cystatin", "TREATMENT", 32, 40], ["IL", "TEST", 63, 65], ["further investigation", "TEST", 85, 106], ["this filarial cystatin", "PROBLEM", 108, 130], ["anti-filarial intervention", "TREATMENT", 209, 235], ["Cystatin C and apoptosisApoptosis", "PROBLEM", 236, 269], ["immune regulation", "PROBLEM", 303, 320], ["immune cells", "PROBLEM", 393, 405], ["immune regulation", "OBSERVATION", 303, 320], ["immune cells", "OBSERVATION", 393, 405]]], ["When target cells suffer from the external insults elicited from immune effector cells, or immune cells themselves experience environmental changes, the lysosomes inside the cells will release cysteine proteases to promote cell apoptosis in order to maintain the immune homeostasis [111,112].", [["cells", "ANATOMY", 12, 17], ["immune effector cells", "ANATOMY", 65, 86], ["immune cells", "ANATOMY", 91, 103], ["lysosomes", "ANATOMY", 153, 162], ["cells", "ANATOMY", 174, 179], ["cell", "ANATOMY", 223, 227], ["cysteine", "CHEMICAL", 193, 201], ["cells", "CELL", 12, 17], ["immune effector cells", "CELL", 65, 86], ["immune cells", "CELL", 91, 103], ["lysosomes", "CELLULAR_COMPONENT", 153, 162], ["cells", "CELL", 174, 179], ["cell", "CELL", 223, 227], ["target cells", "CELL_TYPE", 5, 17], ["immune effector cells", "CELL_TYPE", 65, 86], ["immune cells", "CELL_TYPE", 91, 103], ["cysteine proteases", "PROTEIN", 193, 211], ["target cells", "PROBLEM", 5, 17], ["the external insults", "PROBLEM", 30, 50], ["immune effector cells", "PROBLEM", 65, 86], ["immune cells", "PROBLEM", 91, 103], ["environmental changes", "PROBLEM", 126, 147], ["cysteine proteases", "TREATMENT", 193, 211], ["promote cell apoptosis", "PROBLEM", 215, 237], ["cell apoptosis", "OBSERVATION", 223, 237]]], ["Cystatin C, as a powerful endogenous cysteine protease inhibitor, must have been involved in these processes, although its specific roles vary or are even opposite among cells (Fig. 2).Cystatin C and apoptosisSince typical characteristics of apoptosis are cell shrinkage, membrane blebbing and DNA condensation as a result of catabolic actions inside cells caused by hydrolytic enzymes [113], cathepsins led out from digitonin-permeabilized lysosomes have the potentials to cause apoptosis directly or indirectly by destroying cytoskeletal proteins, nuclear proteins, DNA repair enzymes or DNA via activating caspases [114].", [["cells", "ANATOMY", 170, 175], ["cell", "ANATOMY", 256, 260], ["membrane", "ANATOMY", 272, 280], ["cells", "ANATOMY", 351, 356], ["lysosomes", "ANATOMY", 441, 450], ["cytoskeletal", "ANATOMY", 527, 539], ["nuclear", "ANATOMY", 550, 557], ["digitonin", "CHEMICAL", 417, 426], ["cysteine", "CHEMICAL", 37, 45], ["digitonin", "CHEMICAL", 417, 426], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 0, 10], ["cells", "CELL", 170, 175], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 185, 195], ["cell", "CELL", 256, 260], ["membrane", "CELLULAR_COMPONENT", 272, 280], ["DNA", "CELLULAR_COMPONENT", 294, 297], ["cells", "CELL", 351, 356], ["cathepsins", "GENE_OR_GENE_PRODUCT", 393, 403], ["digitonin", "SIMPLE_CHEMICAL", 417, 426], ["lysosomes", "CELLULAR_COMPONENT", 441, 450], ["nuclear", "CELLULAR_COMPONENT", 550, 557], ["DNA", "CELLULAR_COMPONENT", 568, 571], ["DNA", "CELLULAR_COMPONENT", 590, 593], ["Cystatin C", "PROTEIN", 0, 10], ["Cystatin C", "PROTEIN", 185, 195], ["hydrolytic enzymes", "PROTEIN", 367, 385], ["cathepsins", "PROTEIN", 393, 403], ["cytoskeletal proteins", "PROTEIN", 527, 548], ["nuclear proteins", "PROTEIN", 550, 566], ["DNA repair enzymes", "PROTEIN", 568, 586], ["caspases", "PROTEIN", 609, 617], ["Cystatin C", "PROBLEM", 0, 10], ["a powerful endogenous cysteine protease inhibitor", "TREATMENT", 15, 64], ["Cystatin C", "PROBLEM", 185, 195], ["apoptosis", "PROBLEM", 242, 251], ["cell shrinkage", "PROBLEM", 256, 270], ["membrane blebbing", "PROBLEM", 272, 289], ["DNA condensation", "PROBLEM", 294, 310], ["catabolic actions inside cells", "PROBLEM", 326, 356], ["hydrolytic enzymes", "TEST", 367, 385], ["cathepsins", "TREATMENT", 393, 403], ["digitonin", "TREATMENT", 417, 426], ["permeabilized lysosomes", "PROBLEM", 427, 450], ["apoptosis", "PROBLEM", 480, 489], ["nuclear proteins", "TEST", 550, 566], ["DNA repair enzymes", "TEST", 568, 586], ["DNA", "PROBLEM", 590, 593], ["activating caspases", "TEST", 598, 617], ["apoptosis", "OBSERVATION", 242, 251], ["cell shrinkage", "OBSERVATION", 256, 270], ["membrane blebbing", "OBSERVATION", 272, 289]]], ["Indeed, the roles of cysteine proteinases and cystatin C in apoptosis occurred in, or induced by immune cells like B cells, T cells, NK cells, neutrophils and monocytes have now increasingly been appreciated.Cystatin C and apoptosisCystatin C plays an important role in the apoptosis of lymphocytes to maintain their high potency by inhibiting cathepsin-induced endonuclease activation for DNA fragmentation.", [["immune cells", "ANATOMY", 97, 109], ["B cells", "ANATOMY", 115, 122], ["T cells", "ANATOMY", 124, 131], ["NK cells", "ANATOMY", 133, 141], ["neutrophils", "ANATOMY", 143, 154], ["monocytes", "ANATOMY", 159, 168], ["lymphocytes", "ANATOMY", 287, 298], ["cysteine", "CHEMICAL", 21, 29], ["apoptosisCystatin C", "CHEMICAL", 223, 242], ["cysteine proteinases", "GENE_OR_GENE_PRODUCT", 21, 41], ["cystatin C", "GENE_OR_GENE_PRODUCT", 46, 56], ["immune cells", "CELL", 97, 109], ["B cells", "CELL", 115, 122], ["T cells", "CELL", 124, 131], ["NK cells", "CELL", 133, 141], ["neutrophils", "CELL", 143, 154], ["monocytes", "CELL", 159, 168], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 208, 218], ["apoptosisCystatin C", "GENE_OR_GENE_PRODUCT", 223, 242], ["lymphocytes", "CELL", 287, 298], ["cathepsin", "GENE_OR_GENE_PRODUCT", 344, 353], ["DNA", "CELLULAR_COMPONENT", 390, 393], ["cysteine proteinases", "PROTEIN", 21, 41], ["cystatin C", "PROTEIN", 46, 56], ["immune cells", "CELL_TYPE", 97, 109], ["B cells", "CELL_TYPE", 115, 122], ["T cells", "CELL_TYPE", 124, 131], ["NK cells", "CELL_TYPE", 133, 141], ["neutrophils", "CELL_TYPE", 143, 154], ["monocytes", "CELL_TYPE", 159, 168], ["Cystatin C", "PROTEIN", 208, 218], ["apoptosisCystatin C", "PROTEIN", 223, 242], ["lymphocytes", "CELL_TYPE", 287, 298], ["cathepsin", "PROTEIN", 344, 353], ["endonuclease", "PROTEIN", 362, 374], ["cysteine proteinases", "TREATMENT", 21, 41], ["cystatin C in apoptosis", "PROBLEM", 46, 69], ["immune cells", "PROBLEM", 97, 109], ["T cells", "TEST", 124, 131], ["NK cells", "TEST", 133, 141], ["neutrophils", "TEST", 143, 154], ["monocytes", "TEST", 159, 168], ["Cystatin C and apoptosisCystatin C", "TREATMENT", 208, 242], ["lymphocytes", "PROBLEM", 287, 298], ["cathepsin-induced endonuclease activation", "TREATMENT", 344, 385], ["DNA fragmentation", "PROBLEM", 390, 407], ["immune cells", "OBSERVATION", 97, 109], ["B cells", "OBSERVATION", 115, 122], ["NK cells", "OBSERVATION", 133, 141], ["high potency", "OBSERVATION_MODIFIER", 317, 329]]], ["During their life span, both B and T lymphocytes encounter various episodes of selection.", [["B", "ANATOMY", 29, 30], ["T lymphocytes", "ANATOMY", 35, 48], ["B", "CELL", 29, 30], ["T lymphocytes", "CELL", 35, 48], ["B and T lymphocytes", "CELL_TYPE", 29, 48], ["lymphocytes", "ANATOMY", 37, 48]]], ["The basic selection mechanism is the survival of highly specific B or T cells with strong affinity to the antigens at the cost of their non-specific counterparts with lower affinity, which die by apoptosis.", [["B", "ANATOMY", 65, 66], ["T cells", "ANATOMY", 70, 77], ["B", "CELL", 65, 66], ["T cells", "CELL", 70, 77], ["B or T cells", "CELL_TYPE", 65, 77], ["antigens", "PROTEIN", 106, 114], ["highly specific B or T cells", "PROBLEM", 49, 77], ["strong affinity", "PROBLEM", 83, 98], ["lower affinity", "PROBLEM", 167, 181], ["apoptosis", "PROBLEM", 196, 205], ["lower affinity", "OBSERVATION_MODIFIER", 167, 181], ["apoptosis", "OBSERVATION", 196, 205]]], ["B cell apoptosis can be induced at several stages and requires the activities of both caspases and cathepsins, because triggering of the BCR causes a cathepsin-like proteinase to leak out of the lysosomal compartment and activate the downstream caspases to regulate the activity of endonuclease for DNA fragmentation [115].", [["B cell", "ANATOMY", 0, 6], ["lysosomal compartment", "ANATOMY", 195, 216], ["B cell", "CELL", 0, 6], ["caspases", "GENE_OR_GENE_PRODUCT", 86, 94], ["cathepsins", "GENE_OR_GENE_PRODUCT", 99, 109], ["BCR", "GENE_OR_GENE_PRODUCT", 137, 140], ["cathepsin-like proteinase", "GENE_OR_GENE_PRODUCT", 150, 175], ["lysosomal compartment", "CELLULAR_COMPONENT", 195, 216], ["caspases", "GENE_OR_GENE_PRODUCT", 245, 253], ["DNA", "CELLULAR_COMPONENT", 299, 302], ["caspases", "PROTEIN", 86, 94], ["cathepsins", "PROTEIN", 99, 109], ["BCR", "PROTEIN", 137, 140], ["cathepsin-like proteinase", "PROTEIN", 150, 175], ["downstream caspases", "PROTEIN", 234, 253], ["endonuclease", "PROTEIN", 282, 294], ["B cell apoptosis", "PROBLEM", 0, 16], ["both caspases", "TREATMENT", 81, 94], ["cathepsins", "TREATMENT", 99, 109], ["the BCR", "PROBLEM", 133, 140], ["a cathepsin-like proteinase", "PROBLEM", 148, 175], ["leak", "PROBLEM", 179, 183], ["the lysosomal compartment", "PROBLEM", 191, 216], ["the downstream caspases", "TREATMENT", 230, 253], ["DNA fragmentation", "PROBLEM", 299, 316], ["cell apoptosis", "OBSERVATION", 2, 16], ["lysosomal compartment", "ANATOMY", 195, 216]]], ["Interestingly, the occurrence of DNA strand breaks in B and T cells could be prevented by addition of analogue of cystatin C to inhibit cysteine proteinase activity [116].", [["B", "ANATOMY", 54, 55], ["T cells", "ANATOMY", 60, 67], ["cysteine", "CHEMICAL", 136, 144], ["DNA", "CELLULAR_COMPONENT", 33, 36], ["B", "CELL", 54, 55], ["T cells", "CELL", 60, 67], ["cystatin C", "GENE_OR_GENE_PRODUCT", 114, 124], ["cysteine proteinase", "GENE_OR_GENE_PRODUCT", 136, 155], ["B and T cells", "CELL_TYPE", 54, 67], ["cystatin C", "PROTEIN", 114, 124], ["cysteine proteinase", "PROTEIN", 136, 155], ["DNA strand breaks in B and T cells", "PROBLEM", 33, 67], ["analogue of cystatin C", "TREATMENT", 102, 124], ["cysteine proteinase activity", "TEST", 136, 164], ["strand breaks", "OBSERVATION", 37, 50]]], ["In addition, a comparable mechanism was found when apoptosis was induced with bile salts or virus in cell lines, where cystatin was capable of inhibiting cathepsin B downstream of caspases to protect cells from death [117,118].", [["bile", "ANATOMY", 78, 82], ["cell lines", "ANATOMY", 101, 111], ["cells", "ANATOMY", 200, 205], ["bile salts", "CHEMICAL", 78, 88], ["death", "DISEASE", 211, 216], ["bile salts", "CHEMICAL", 78, 88], ["bile salts", "SIMPLE_CHEMICAL", 78, 88], ["cell lines", "CELL", 101, 111], ["cystatin", "GENE_OR_GENE_PRODUCT", 119, 127], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 154, 165], ["caspases", "GENE_OR_GENE_PRODUCT", 180, 188], ["cells", "CELL", 200, 205], ["cell lines", "CELL_LINE", 101, 111], ["cystatin", "PROTEIN", 119, 127], ["cathepsin B", "PROTEIN", 154, 165], ["caspases", "PROTEIN", 180, 188], ["apoptosis", "PROBLEM", 51, 60], ["bile salts", "PROBLEM", 78, 88], ["virus in cell lines", "TREATMENT", 92, 111], ["cystatin", "TREATMENT", 119, 127], ["cathepsin B downstream of caspases", "TREATMENT", 154, 188], ["death", "PROBLEM", 211, 216], ["bile", "ANATOMY", 78, 82], ["cell lines", "OBSERVATION", 101, 111]]], ["Consistently, large amounts of cystatins exist in- or out-side cells to inhibit the endonuclease activity via cathepsins [21].", [["cells", "ANATOMY", 63, 68], ["cystatins", "GENE_OR_GENE_PRODUCT", 31, 40], ["cells", "CELL", 63, 68], ["cathepsins [21]", "GENE_OR_GENE_PRODUCT", 110, 125], ["cystatins", "PROTEIN", 31, 40], ["endonuclease", "PROTEIN", 84, 96], ["cathepsins", "PROTEIN", 110, 120], ["cystatins exist", "PROBLEM", 31, 46], ["side cells", "PROBLEM", 58, 68], ["large", "OBSERVATION_MODIFIER", 14, 19], ["amounts", "OBSERVATION_MODIFIER", 20, 27]]], ["In addition, cystatin C can also inhibit cathapsin C-mediated cathapsin G leakage to control apoptosis.", [["cystatin C", "GENE_OR_GENE_PRODUCT", 13, 23], ["cathapsin C", "GENE_OR_GENE_PRODUCT", 41, 52], ["cathapsin G", "GENE_OR_GENE_PRODUCT", 62, 73], ["cystatin C", "PROTEIN", 13, 23], ["cathapsin C", "PROTEIN", 41, 52], ["cathapsin G", "PROTEIN", 62, 73], ["cystatin C", "TREATMENT", 13, 23], ["cathapsin C-mediated cathapsin G leakage", "TREATMENT", 41, 81], ["leakage", "OBSERVATION", 74, 81]]], ["Neutrophils are short-lived cells and their life span forms a crucial mechanism for maintaining immune system homeostasis, as extended survival of neutrophils may lead to chronic inflammation, but reduced number of living neutrophils may enhance susceptibility to infections [119].", [["Neutrophils", "ANATOMY", 0, 11], ["cells", "ANATOMY", 28, 33], ["immune system", "ANATOMY", 96, 109], ["neutrophils", "ANATOMY", 147, 158], ["neutrophils", "ANATOMY", 222, 233], ["inflammation", "DISEASE", 179, 191], ["infections", "DISEASE", 264, 274], ["Neutrophils", "CELL", 0, 11], ["cells", "CELL", 28, 33], ["immune system", "ANATOMICAL_SYSTEM", 96, 109], ["neutrophils", "CELL", 147, 158], ["neutrophils", "CELL", 222, 233], ["Neutrophils", "CELL_TYPE", 0, 11], ["neutrophils", "CELL_TYPE", 147, 158], ["living neutrophils", "CELL_TYPE", 215, 233], ["Neutrophils", "TEST", 0, 11], ["neutrophils", "PROBLEM", 147, 158], ["chronic inflammation", "PROBLEM", 171, 191], ["susceptibility to infections", "PROBLEM", 246, 274], ["may lead to", "UNCERTAINTY", 159, 170], ["chronic", "OBSERVATION_MODIFIER", 171, 178], ["inflammation", "OBSERVATION", 179, 191], ["reduced", "OBSERVATION_MODIFIER", 197, 204], ["number", "OBSERVATION_MODIFIER", 205, 211]]], ["Of note, neutrophil cultured in the presence of cystatin C resulted in a significant drop in apoptotic cell percentage compared to the controls, and this hampering effects on neutrophil apoptosis was attributed to its inhibitory influence on cathepsin activity [120].", [["neutrophil", "ANATOMY", 9, 19], ["cell", "ANATOMY", 103, 107], ["neutrophil", "ANATOMY", 175, 185], ["cystatin C", "CHEMICAL", 48, 58], ["neutrophil", "CELL", 9, 19], ["cystatin C", "SIMPLE_CHEMICAL", 48, 58], ["cell", "CELL", 103, 107], ["neutrophil", "CELL", 175, 185], ["cathepsin", "GENE_OR_GENE_PRODUCT", 242, 251], ["neutrophil", "CELL_TYPE", 9, 19], ["cystatin C", "PROTEIN", 48, 58], ["neutrophil", "CELL_TYPE", 175, 185], ["cathepsin", "PROTEIN", 242, 251], ["neutrophil cultured", "TEST", 9, 28], ["cystatin C", "PROBLEM", 48, 58], ["a significant drop in apoptotic cell percentage", "PROBLEM", 71, 118], ["neutrophil apoptosis", "PROBLEM", 175, 195], ["cathepsin activity", "TEST", 242, 260], ["significant", "OBSERVATION_MODIFIER", 73, 84], ["drop", "OBSERVATION_MODIFIER", 85, 89], ["apoptotic cell percentage", "OBSERVATION", 93, 118], ["neutrophil apoptosis", "OBSERVATION", 175, 195]]], ["Consistently, it was found that cathepsin G was involved in apoptosis by activating recombinant procaspase-7 [121].", [["cathepsin G", "GENE_OR_GENE_PRODUCT", 32, 43], ["procaspase-7", "GENE_OR_GENE_PRODUCT", 96, 108], ["cathepsin G", "PROTEIN", 32, 43], ["procaspase", "PROTEIN", 96, 106], ["cathepsin G", "TREATMENT", 32, 43], ["activating recombinant procaspase", "TREATMENT", 73, 106]]], ["Furthermore, it was demonstrated that when errors occur in packaging, de-granulation or phagocytosis, cathepsin G was introduced into the cytoplasm and induced morphological changes that are characteristic for apoptosis [122].", [["cytoplasm", "ANATOMY", 138, 147], ["cathepsin G", "GENE_OR_GENE_PRODUCT", 102, 113], ["cytoplasm", "ORGANISM_SUBSTANCE", 138, 147], ["cathepsin G", "PROTEIN", 102, 113], ["packaging", "TREATMENT", 59, 68], ["de-granulation", "PROBLEM", 70, 84], ["phagocytosis", "PROBLEM", 88, 100], ["cathepsin G", "TREATMENT", 102, 113], ["apoptosis", "PROBLEM", 210, 219]]], ["Since cathepsin C is involved in post-translational processing and activation of cathepsin G [123], the inhibition of cathepsin C by cystatin could impair the cathepsin G-induced apoptosis in neutrophils.Cystatin C and apoptosisMoreover, cystatin C was found to suppress pro-granzyme cleavage/activation to protect cytotoxic lymphocytes from apoptosis.", [["neutrophils", "ANATOMY", 192, 203], ["lymphocytes", "ANATOMY", 325, 336], ["cathepsin C", "GENE_OR_GENE_PRODUCT", 6, 17], ["cathepsin G [123]", "GENE_OR_GENE_PRODUCT", 81, 98], ["cathepsin C", "GENE_OR_GENE_PRODUCT", 118, 129], ["cystatin", "GENE_OR_GENE_PRODUCT", 133, 141], ["cathepsin G", "GENE_OR_GENE_PRODUCT", 159, 170], ["neutrophils", "CELL", 192, 203], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 204, 214], ["cystatin C", "GENE_OR_GENE_PRODUCT", 238, 248], ["pro-granzyme", "GENE_OR_GENE_PRODUCT", 271, 283], ["cytotoxic lymphocytes", "CELL", 315, 336], ["cathepsin C", "PROTEIN", 6, 17], ["cathepsin G", "PROTEIN", 81, 92], ["cathepsin C", "PROTEIN", 118, 129], ["cystatin", "PROTEIN", 133, 141], ["cathepsin G", "PROTEIN", 159, 170], ["neutrophils", "CELL_TYPE", 192, 203], ["Cystatin C", "PROTEIN", 204, 214], ["cystatin C", "PROTEIN", 238, 248], ["cytotoxic lymphocytes", "CELL_TYPE", 315, 336], ["cathepsin G", "TREATMENT", 81, 92], ["cathepsin C", "TREATMENT", 118, 129], ["cystatin", "TREATMENT", 133, 141], ["the cathepsin G", "TEST", 155, 170], ["apoptosis in neutrophils", "PROBLEM", 179, 203], ["Cystatin C", "PROBLEM", 204, 214], ["apoptosisMoreover", "PROBLEM", 219, 236], ["cystatin C", "PROBLEM", 238, 248], ["pro-granzyme cleavage", "TREATMENT", 271, 292], ["cytotoxic lymphocytes", "PROBLEM", 315, 336], ["apoptosis", "PROBLEM", 342, 351], ["neutrophils", "ANATOMY", 192, 203], ["cytotoxic lymphocytes", "OBSERVATION", 315, 336], ["apoptosis", "OBSERVATION_MODIFIER", 342, 351]]], ["CTLs and NK cells can kill target cells by contact-dependent mechanisms that involve cysteine proteinases.", [["CTLs", "ANATOMY", 0, 4], ["NK cells", "ANATOMY", 9, 17], ["cells", "ANATOMY", 34, 39], ["cysteine", "CHEMICAL", 85, 93], ["CTLs", "CELL", 0, 4], ["NK cells", "CELL", 9, 17], ["cells", "CELL", 34, 39], ["cysteine proteinases", "GENE_OR_GENE_PRODUCT", 85, 105], ["CTLs", "CELL_TYPE", 0, 4], ["NK cells", "CELL_TYPE", 9, 17], ["target cells", "CELL_TYPE", 27, 39], ["cysteine proteinases", "PROTEIN", 85, 105], ["CTLs", "TEST", 0, 4], ["cysteine proteinases", "PROBLEM", 85, 105], ["NK cells", "OBSERVATION", 9, 17]]], ["This killing of CTL and NK cells depends on exocytosis of granules, perforin, in combination with secretion of granzymes, which are stored in lysosomes [124].", [["CTL", "ANATOMY", 16, 19], ["NK cells", "ANATOMY", 24, 32], ["granules", "ANATOMY", 58, 66], ["lysosomes", "ANATOMY", 142, 151], ["CTL", "CELL", 16, 19], ["NK cells", "CELL", 24, 32], ["granules", "ORGANISM_SUBSTANCE", 58, 66], ["perforin", "GENE_OR_GENE_PRODUCT", 68, 76], ["granzymes", "GENE_OR_GENE_PRODUCT", 111, 120], ["lysosomes", "CELLULAR_COMPONENT", 142, 151], ["CTL", "CELL_TYPE", 16, 19], ["NK cells", "CELL_TYPE", 24, 32], ["perforin", "PROTEIN", 68, 76], ["granzymes", "PROTEIN", 111, 120], ["CTL", "PROBLEM", 16, 19], ["NK cells", "PROBLEM", 24, 32], ["exocytosis of granules", "PROBLEM", 44, 66], ["perforin", "TREATMENT", 68, 76], ["secretion of granzymes", "PROBLEM", 98, 120], ["NK cells", "OBSERVATION", 24, 32]]], ["Cathepsin C has the ability to activate granzyme through removing dipeptides from its amino terminus [125,126].", [["dipeptides", "CHEMICAL", 66, 76], ["amino", "CHEMICAL", 86, 91], ["Cathepsin C", "GENE_OR_GENE_PRODUCT", 0, 11], ["granzyme", "GENE_OR_GENE_PRODUCT", 40, 48], ["amino", "AMINO_ACID", 86, 91], ["Cathepsin C", "PROTEIN", 0, 11], ["granzyme", "PROTEIN", 40, 48], ["Cathepsin C", "TREATMENT", 0, 11], ["dipeptides", "TREATMENT", 66, 76], ["its amino terminus", "TREATMENT", 82, 100]]], ["It has recently been demonstrated that although cathepsin knockout mice contain normal levels of granzymes, all granzymes were not active, indicating that cathepsin is required for the activation of granzyme- and granule-mediated apoptosis [127,128].", [["granule", "ANATOMY", 213, 220], ["cathepsin", "GENE_OR_GENE_PRODUCT", 48, 57], ["mice", "ORGANISM", 67, 71], ["granzymes", "GENE_OR_GENE_PRODUCT", 97, 106], ["granzymes", "GENE_OR_GENE_PRODUCT", 112, 121], ["cathepsin", "GENE_OR_GENE_PRODUCT", 155, 164], ["granzyme", "GENE_OR_GENE_PRODUCT", 199, 207], ["granule", "CELLULAR_COMPONENT", 213, 220], ["cathepsin", "PROTEIN", 48, 57], ["granzymes", "PROTEIN", 97, 106], ["granzymes", "PROTEIN", 112, 121], ["cathepsin", "PROTEIN", 155, 164], ["granzyme", "PROTEIN", 199, 207], ["mice", "SPECIES", 67, 71], ["mice", "SPECIES", 67, 71], ["cathepsin knockout mice", "TREATMENT", 48, 71], ["all granzymes", "TEST", 108, 121], ["cathepsin", "TREATMENT", 155, 164], ["granzyme", "TEST", 199, 207]]], ["Interestingly, high levels of cystatin C could reverse this effect by inhibiting the conversion of inactive granzymes into active granzymes via cathepsin C to protect cells from apoptosis [129].Cystatin C and apoptosisThere are always two sides to everything.", [["cells", "ANATOMY", 167, 172], ["cystatin C", "GENE_OR_GENE_PRODUCT", 30, 40], ["granzymes", "GENE_OR_GENE_PRODUCT", 108, 117], ["granzymes", "GENE_OR_GENE_PRODUCT", 130, 139], ["cathepsin C", "GENE_OR_GENE_PRODUCT", 144, 155], ["cells", "CELL", 167, 172], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 194, 204], ["cystatin C", "PROTEIN", 30, 40], ["inactive granzymes", "PROTEIN", 99, 117], ["granzymes", "PROTEIN", 130, 139], ["cathepsin C", "PROTEIN", 144, 155], ["Cystatin C", "PROTEIN", 194, 204], ["cystatin C", "TREATMENT", 30, 40], ["inactive granzymes", "TREATMENT", 99, 117], ["cathepsin C", "TREATMENT", 144, 155], ["apoptosis", "PROBLEM", 178, 187], ["Cystatin C and apoptosis", "PROBLEM", 194, 218], ["apoptosis", "OBSERVATION", 209, 218]]], ["Although inhibiting apoptosis in most cases, cystatin C, in some cases, was capable of promoting apoptosis by regulating the expression of B-cell lymphoma-2 (Bcl-2) family members.", [["cystatin C", "GENE_OR_GENE_PRODUCT", 45, 55], ["B-cell lymphoma-2", "GENE_OR_GENE_PRODUCT", 139, 156], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 158, 163], ["cystatin C", "PROTEIN", 45, 55], ["B-cell lymphoma-2 (Bcl-2) family members", "PROTEIN", 139, 179], ["apoptosis", "PROBLEM", 20, 29], ["cystatin C", "PROBLEM", 45, 55], ["promoting apoptosis", "PROBLEM", 87, 106], ["B-cell lymphoma", "PROBLEM", 139, 154], ["apoptosis", "OBSERVATION", 97, 106], ["B-cell lymphoma", "OBSERVATION", 139, 154]]], ["High concentration of cystatin C was found to up-regulate the expression of Bid [130], a pro-apoptotic protein of Bcl-2 family, whose activation can induce mitochondrion release of cytochrome c (cyt c), resulting in the activation of caspase-9.", [["mitochondrion", "ANATOMY", 156, 169], ["cystatin C", "CHEMICAL", 22, 32], ["cystatin C", "GENE_OR_GENE_PRODUCT", 22, 32], ["Bid", "GENE_OR_GENE_PRODUCT", 76, 79], ["130", "GENE_OR_GENE_PRODUCT", 81, 84], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 114, 119], ["mitochondrion", "CELLULAR_COMPONENT", 156, 169], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 181, 193], ["cyt c", "GENE_OR_GENE_PRODUCT", 195, 200], ["caspase-9", "GENE_OR_GENE_PRODUCT", 234, 243], ["cystatin C", "PROTEIN", 22, 32], ["Bid [130", "PROTEIN", 76, 84], ["pro-apoptotic protein", "PROTEIN", 89, 110], ["Bcl-2 family", "PROTEIN", 114, 126], ["cytochrome c", "PROTEIN", 181, 193], ["cyt c", "PROTEIN", 195, 200], ["caspase-9", "PROTEIN", 234, 243], ["High concentration of cystatin C", "PROBLEM", 0, 32], ["a pro-apoptotic protein", "TEST", 87, 110], ["cytochrome c (cyt c)", "TREATMENT", 181, 201], ["caspase", "TEST", 234, 241]]], ["Consistently, recent studies also indicated that the induction of cystatin C decreased an anti-apoptotic Bcl-2 protein expression at both mRNA and protein levels to eliminate its anti-apoptotic effects on preventing cell death [131].Cystatin C and apoptosisAlong the same line, another evidence to indicate the pro-apoptotic role of cystatin C comes from extrinsic pathway where lymphocytes kills their target cells via cell\u2013cell contacts.", [["cell", "ANATOMY", 216, 220], ["lymphocytes", "ANATOMY", 379, 390], ["cells", "ANATOMY", 410, 415], ["cell\u2013cell contacts", "ANATOMY", 420, 438], ["death", "DISEASE", 221, 226], ["cystatin C", "GENE_OR_GENE_PRODUCT", 66, 76], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 105, 110], ["cell", "CELL", 216, 220], ["Cystatin C", "GENE_OR_GENE_PRODUCT", 233, 243], ["cystatin C", "GENE_OR_GENE_PRODUCT", 333, 343], ["lymphocytes", "CELL", 379, 390], ["cells", "CELL", 410, 415], ["cell\u2013cell contacts", "CELLULAR_COMPONENT", 420, 438], ["cystatin C", "PROTEIN", 66, 76], ["Bcl", "PROTEIN", 105, 108], ["Cystatin C", "PROTEIN", 233, 243], ["cystatin C", "PROTEIN", 333, 343], ["lymphocytes", "CELL_TYPE", 379, 390], ["target cells", "CELL_TYPE", 403, 415], ["recent studies", "TEST", 14, 28], ["cystatin C", "TREATMENT", 66, 76], ["an anti-apoptotic Bcl", "TEST", 87, 108], ["protein levels", "TEST", 147, 161], ["its anti-apoptotic effects", "PROBLEM", 175, 201], ["cell death", "PROBLEM", 216, 226], ["Cystatin C", "PROBLEM", 233, 243], ["apoptosis", "PROBLEM", 248, 257], ["cystatin C", "TREATMENT", 333, 343], ["lymphocytes", "PROBLEM", 379, 390], ["apoptosis", "OBSERVATION", 248, 257]]], ["For example, cystatin C was reported to cause rapid de-granulation and granzyme activation in CTL for apoptosis via a perforin-dependent process [132].", [["CTL", "ANATOMY", 94, 97], ["cystatin C", "GENE_OR_GENE_PRODUCT", 13, 23], ["granzyme", "GENE_OR_GENE_PRODUCT", 71, 79], ["CTL", "CELL", 94, 97], ["perforin", "GENE_OR_GENE_PRODUCT", 118, 126], ["cystatin C", "PROTEIN", 13, 23], ["granzyme", "PROTEIN", 71, 79], ["CTL", "CELL_TYPE", 94, 97], ["perforin", "PROTEIN", 118, 126], ["cystatin C", "PROBLEM", 13, 23], ["rapid de-granulation", "PROBLEM", 46, 66], ["granzyme activation", "PROBLEM", 71, 90], ["apoptosis", "PROBLEM", 102, 111], ["a perforin-dependent process", "TREATMENT", 116, 144]]], ["It has been demonstrated that CTL and NK cells die within a few hours if they were triggered to de-granulate in the presence of nontoxic thiol cathepsin inhibitors, indicating that the suicide of CTLs in the presence of cystatin C requires the granule exocytosis cytotoxicity pathway [132].Involved in immune associated apoptosis via various mechanisms including both anti- and pro- apoptosis in different cell types under different conditions, cystatin C could be a promising target molecule for the treatment of inflammatory autoimmune diseases by altering its roles in the apoptosis of immune cells or their target cells.", [["CTL", "ANATOMY", 30, 33], ["NK cells", "ANATOMY", 38, 46], ["granule", "ANATOMY", 244, 251], ["cell", "ANATOMY", 406, 410], ["immune cells", "ANATOMY", 589, 601], ["cells", "ANATOMY", 618, 623], ["thiol", "CHEMICAL", 137, 142], ["autoimmune diseases", "DISEASE", 527, 546], ["thiol", "CHEMICAL", 137, 142], ["CTL", "CELL", 30, 33], ["NK cells", "CELL", 38, 46], ["cathepsin", "GENE_OR_GENE_PRODUCT", 143, 152], ["CTLs", "CELL", 196, 200], ["cystatin C", "GENE_OR_GENE_PRODUCT", 220, 230], ["granule", "CELLULAR_COMPONENT", 244, 251], ["cell", "CELL", 406, 410], ["cystatin C", "GENE_OR_GENE_PRODUCT", 445, 455], ["immune cells", "CELL", 589, 601], ["cells", "CELL", 618, 623], ["CTL", "CELL_TYPE", 30, 33], ["NK cells", "CELL_TYPE", 38, 46], ["CTLs", "CELL_TYPE", 196, 200], ["cystatin C", "PROTEIN", 220, 230], ["cystatin C", "PROTEIN", 445, 455], ["immune cells", "CELL_TYPE", 589, 601], ["target cells", "CELL_TYPE", 611, 623], ["CTL and NK cells", "TREATMENT", 30, 46], ["nontoxic thiol cathepsin inhibitors", "TREATMENT", 128, 163], ["the suicide of CTLs", "PROBLEM", 181, 200], ["cystatin C", "PROBLEM", 220, 230], ["the granule exocytosis cytotoxicity pathway", "PROBLEM", 240, 283], ["immune associated apoptosis", "PROBLEM", 302, 329], ["both anti", "TREATMENT", 363, 372], ["pro- apoptosis", "PROBLEM", 378, 392], ["cystatin C", "TREATMENT", 445, 455], ["inflammatory autoimmune diseases", "PROBLEM", 514, 546], ["immune cells", "PROBLEM", 589, 601], ["different cell", "OBSERVATION_MODIFIER", 396, 410], ["inflammatory", "OBSERVATION_MODIFIER", 514, 526], ["autoimmune", "OBSERVATION", 527, 537], ["immune cells", "OBSERVATION", 589, 601], ["target cells", "OBSERVATION", 611, 623]]], ["Further studies are needed to define the upstream molecules in the cystatin C-involved apoptotic pathways so that effective regulation of this powerful inhibitor could be achieved for therapeutic gains.Conclusion and future directionOverall, as an abundantly expressed protein, cystatin C is involved in numerous biological activities under both physiological and pathological conditions.", [["cystatin C", "GENE_OR_GENE_PRODUCT", 67, 77], ["cystatin C", "GENE_OR_GENE_PRODUCT", 278, 288], ["upstream molecules", "PROTEIN", 41, 59], ["cystatin C", "PROTEIN", 67, 77], ["cystatin C", "PROTEIN", 278, 288], ["Further studies", "TEST", 0, 15], ["the upstream molecules", "PROBLEM", 37, 59], ["the cystatin C", "TREATMENT", 63, 77], ["apoptotic pathways", "TREATMENT", 87, 105], ["this powerful inhibitor", "TREATMENT", 138, 161], ["cystatin C", "TREATMENT", 278, 288]]], ["At steady state, cystatin C is mainly used as an index of kidney function due to its relatively small molecular weight and easy detection, whereas under pathological conditions, it serves as an important biomarker for the diseases because of its participation in the immune responses against pathogen invasion directly or indirectly.", [["kidney", "ANATOMY", 58, 64], ["cystatin C", "GENE_OR_GENE_PRODUCT", 17, 27], ["kidney", "ORGAN", 58, 64], ["cystatin C", "PROTEIN", 17, 27], ["cystatin C", "TREATMENT", 17, 27], ["kidney function", "TEST", 58, 73], ["the diseases", "PROBLEM", 218, 230], ["pathogen invasion", "PROBLEM", 292, 309], ["kidney", "ANATOMY", 58, 64]]], ["The involvement of cystatin C in host immunity is multifaceted and tridimensional, covering every stage of immune responses in both innate and adaptive immunity, and interfering with various immunological abnormalities during inflammation, autoimmune diseases and tumor development in compromised immune surveillance.", [["tumor", "ANATOMY", 264, 269], ["inflammation", "DISEASE", 226, 238], ["autoimmune diseases", "DISEASE", 240, 259], ["tumor", "DISEASE", 264, 269], ["cystatin C", "GENE_OR_GENE_PRODUCT", 19, 29], ["tumor", "CANCER", 264, 269], ["cystatin C", "PROTEIN", 19, 29], ["cystatin C in host immunity", "TREATMENT", 19, 46], ["immune responses", "PROBLEM", 107, 123], ["various immunological abnormalities", "PROBLEM", 183, 218], ["inflammation", "PROBLEM", 226, 238], ["autoimmune diseases", "PROBLEM", 240, 259], ["tumor development", "PROBLEM", 264, 281], ["tumor", "OBSERVATION", 264, 269]]], ["It has become evident that disturbances in the expression and localization of cystatin C may be either the casual or effector factor of the pathological processes.", [["cystatin C", "GENE_OR_GENE_PRODUCT", 78, 88], ["cystatin C", "PROTEIN", 78, 88], ["effector factor", "PROTEIN", 117, 132], ["cystatin C", "PROBLEM", 78, 88], ["disturbances", "OBSERVATION", 27, 39]]], ["To support this notion, growing evidences demonstrated that cystatin C could interact with numerous inflammatory factors and mediators to regulate the inflammation process at molecular levels.", [["inflammation", "DISEASE", 151, 163], ["cystatin C", "GENE_OR_GENE_PRODUCT", 60, 70], ["cystatin C", "PROTEIN", 60, 70], ["inflammatory factors", "PROTEIN", 100, 120], ["cystatin C", "PROBLEM", 60, 70], ["numerous inflammatory factors", "PROBLEM", 91, 120], ["the inflammation process", "PROBLEM", 147, 171], ["numerous", "OBSERVATION_MODIFIER", 91, 99], ["inflammatory", "OBSERVATION", 100, 112], ["inflammation", "OBSERVATION", 151, 163]]], ["Moreover, the influences of cystatin C on the immune cells are not only limited to their functions, but also extended to their survivals, causing tumor development or autoimmunity.Conclusion and future directionSince cystatin C has many clinical implications with the increasingly discovered roles in various immunological disorders, characterization of the mechanisms that control cystatin C expression could provide valuable clues for the treatment of pathologies associated with this protease inhibitor.", [["immune cells", "ANATOMY", 46, 58], ["tumor", "ANATOMY", 146, 151], ["tumor", "DISEASE", 146, 151], ["autoimmunity", "DISEASE", 167, 179], ["immunological disorders", "DISEASE", 309, 332], ["cystatin C", "GENE_OR_GENE_PRODUCT", 28, 38], ["immune cells", "CELL", 46, 58], ["tumor", "CANCER", 146, 151], ["cystatin C", "GENE_OR_GENE_PRODUCT", 217, 227], ["cystatin C", "GENE_OR_GENE_PRODUCT", 382, 392], ["cystatin C", "PROTEIN", 28, 38], ["immune cells", "CELL_TYPE", 46, 58], ["cystatin C", "PROTEIN", 217, 227], ["cystatin C", "PROTEIN", 382, 392], ["cystatin C", "PROBLEM", 28, 38], ["the immune cells", "TREATMENT", 42, 58], ["tumor development", "PROBLEM", 146, 163], ["autoimmunity", "PROBLEM", 167, 179], ["cystatin C", "PROBLEM", 217, 227], ["various immunological disorders", "PROBLEM", 301, 332], ["cystatin C expression", "TREATMENT", 382, 403], ["pathologies", "PROBLEM", 454, 465], ["this protease inhibitor", "TREATMENT", 482, 505], ["tumor", "OBSERVATION", 146, 151]]], ["For example, signaling molecules that up-regulate cystatin C expression could be used to promote cystatin C secretion in the case that requires slightly higher cystatin C concentration at the sites of inflammation where excessive protease activity causes tissue damage, as has been suggested to occur in atherosclerosis and aortic aneurysm [39].", [["sites", "ANATOMY", 192, 197], ["tissue", "ANATOMY", 255, 261], ["aortic aneurysm", "ANATOMY", 324, 339], ["inflammation", "DISEASE", 201, 213], ["tissue damage", "DISEASE", 255, 268], ["atherosclerosis", "DISEASE", 304, 319], ["aortic aneurysm", "DISEASE", 324, 339], ["cystatin C", "GENE_OR_GENE_PRODUCT", 50, 60], ["cystatin C", "GENE_OR_GENE_PRODUCT", 97, 107], ["cystatin C", "GENE_OR_GENE_PRODUCT", 160, 170], ["tissue", "TISSUE", 255, 261], ["aortic", "ORGAN", 324, 330], ["signaling molecules", "PROTEIN", 13, 32], ["cystatin C", "PROTEIN", 50, 60], ["cystatin C", "PROTEIN", 97, 107], ["cystatin C", "PROTEIN", 160, 170], ["protease", "PROTEIN", 230, 238], ["signaling molecules", "PROBLEM", 13, 32], ["cystatin C expression", "TREATMENT", 50, 71], ["cystatin C secretion", "PROBLEM", 97, 117], ["slightly higher cystatin C concentration", "TREATMENT", 144, 184], ["inflammation", "PROBLEM", 201, 213], ["excessive protease activity", "PROBLEM", 220, 247], ["tissue damage", "PROBLEM", 255, 268], ["atherosclerosis", "PROBLEM", 304, 319], ["aortic aneurysm", "PROBLEM", 324, 339], ["inflammation", "OBSERVATION", 201, 213], ["atherosclerosis", "OBSERVATION", 304, 319], ["aortic", "ANATOMY", 324, 330], ["aneurysm", "OBSERVATION", 331, 339]]], ["On the other hand, the cytokines that repress cystatin C expression, such as IL-10, could be developed for the treatment of diseases associated with too much cystatin C in apoptosis or formation of cystatin C amyloid like Icelandic type of Hereditary Cerebral Amyloid Angiopathy.", [["Hereditary", "DISEASE", 240, 250], ["Cerebral Amyloid Angiopathy", "DISEASE", 251, 278], ["cystatin C", "GENE_OR_GENE_PRODUCT", 46, 56], ["IL-10", "GENE_OR_GENE_PRODUCT", 77, 82], ["cystatin C", "GENE_OR_GENE_PRODUCT", 158, 168], ["cystatin C amyloid", "SIMPLE_CHEMICAL", 198, 216], ["cytokines", "PROTEIN", 23, 32], ["cystatin C", "PROTEIN", 46, 56], ["IL", "PROTEIN", 77, 79], ["cystatin C", "PROTEIN", 158, 168], ["the cytokines", "TREATMENT", 19, 32], ["cystatin C expression", "PROBLEM", 46, 67], ["diseases", "PROBLEM", 124, 132], ["too much cystatin C in apoptosis", "PROBLEM", 149, 181], ["cystatin C amyloid", "PROBLEM", 198, 216], ["Hereditary Cerebral Amyloid Angiopathy", "PROBLEM", 240, 278], ["diseases", "OBSERVATION", 124, 132], ["Icelandic type", "OBSERVATION_MODIFIER", 222, 236], ["Hereditary Cerebral", "OBSERVATION", 240, 259], ["Amyloid Angiopathy", "OBSERVATION", 260, 278]]], ["Moreover, since cystatin C itself has been proven successful in switching the inefficient Th2 cytokine response to an effective Th1 response that cleared the parasite infection in an animal model, it is tempting to speculate that the recombinant product would work in clinical trials.", [["cystatin C", "CHEMICAL", 16, 26], ["parasite infection", "DISEASE", 158, 176], ["cystatin C", "GENE_OR_GENE_PRODUCT", 16, 26], ["cystatin C", "PROTEIN", 16, 26], ["Th2 cytokine", "PROTEIN", 90, 102], ["cystatin C", "TREATMENT", 16, 26], ["the parasite infection", "PROBLEM", 154, 176], ["parasite", "OBSERVATION_MODIFIER", 158, 166], ["infection", "OBSERVATION", 167, 176]]], ["Furthermore, identification of the receptors or signaling pathways that initiate the cystatin C uptake on the cell surface could be translated to target this potent inhibitor to intracellular cancer-promoting proteolysis via the cystatin C internalization.Conclusion and future directionFinally, identification of transplantable cellular sources for major cystatin C production will also be of great clinical value.", [["cell surface", "ANATOMY", 110, 122], ["intracellular cancer", "ANATOMY", 178, 198], ["cellular", "ANATOMY", 329, 337], ["cancer", "DISEASE", 192, 198], ["cystatin C", "GENE_OR_GENE_PRODUCT", 85, 95], ["cell surface", "CELLULAR_COMPONENT", 110, 122], ["intracellular cancer", "CANCER", 178, 198], ["cystatin C", "GENE_OR_GENE_PRODUCT", 229, 239], ["cellular", "CELL", 329, 337], ["cystatin C", "GENE_OR_GENE_PRODUCT", 356, 366], ["cystatin C", "PROTEIN", 85, 95], ["cystatin C", "PROTEIN", 229, 239], ["cystatin C", "PROTEIN", 356, 366], ["signaling pathways", "PROBLEM", 48, 66], ["the cystatin C uptake", "PROBLEM", 81, 102], ["the cell surface", "TREATMENT", 106, 122], ["intracellular cancer", "PROBLEM", 178, 198], ["promoting proteolysis", "PROBLEM", 199, 220], ["the cystatin C internalization", "TREATMENT", 225, 255], ["transplantable cellular sources", "PROBLEM", 314, 345], ["major cystatin C production", "PROBLEM", 350, 377], ["cancer", "OBSERVATION", 192, 198]]], ["Since cystatin C is involved in inflammatory autoimmune diseases, in which immune cells accumulated and played important roles, bone marrow-derived cells are an important cellular source for cystatin C manipulation.", [["immune cells", "ANATOMY", 75, 87], ["bone marrow-derived cells", "ANATOMY", 128, 153], ["cellular", "ANATOMY", 171, 179], ["autoimmune diseases", "DISEASE", 45, 64], ["cystatin C", "GENE_OR_GENE_PRODUCT", 6, 16], ["immune cells", "CELL", 75, 87], ["bone marrow-derived cells", "CELL", 128, 153], ["cellular", "CELL", 171, 179], ["cystatin C", "GENE_OR_GENE_PRODUCT", 191, 201], ["cystatin C", "PROTEIN", 6, 16], ["immune cells", "CELL_TYPE", 75, 87], ["bone marrow-derived cells", "CELL_TYPE", 128, 153], ["cystatin C", "PROTEIN", 191, 201], ["cystatin C", "PROBLEM", 6, 16], ["inflammatory autoimmune diseases", "PROBLEM", 32, 64], ["immune cells", "PROBLEM", 75, 87], ["cystatin C manipulation", "TREATMENT", 191, 214], ["inflammatory", "OBSERVATION_MODIFIER", 32, 44], ["autoimmune", "OBSERVATION", 45, 55], ["immune cells", "OBSERVATION", 75, 87], ["bone", "ANATOMY", 128, 132]]], ["Along this line, we found that hematopoietic cells contribute significantly to the systematic pools of cystatin C [43].", [["hematopoietic cells", "ANATOMY", 31, 50], ["hematopoietic cells", "CELL", 31, 50], ["cystatin C", "GENE_OR_GENE_PRODUCT", 103, 113], ["hematopoietic cells", "CELL_TYPE", 31, 50], ["cystatin C", "PROTEIN", 103, 113], ["hematopoietic cells", "PROBLEM", 31, 50], ["cystatin C", "TEST", 103, 113], ["hematopoietic cells", "OBSERVATION", 31, 50]]], ["Therefore, bone marrow transplantation would be an applicable approach in clinic to treat patients with cystatin C angiopathy or reduction.", [["bone marrow", "ANATOMY", 11, 22], ["angiopathy", "DISEASE", 115, 125], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 11, 22], ["patients", "ORGANISM", 90, 98], ["cystatin C", "GENE_OR_GENE_PRODUCT", 104, 114], ["patients", "SPECIES", 90, 98], ["bone marrow transplantation", "TREATMENT", 11, 38], ["cystatin C angiopathy", "PROBLEM", 104, 125], ["reduction", "TREATMENT", 129, 138], ["bone", "ANATOMY", 11, 15]]], ["It is not difficult to speculate that many agents or cystatin C derivatives as an immune regulator would be developed in near future for the treatment of diseases associated with cystatin C related inflammation or autoimmunity.Declaration of interestThe authors declare no financial or commercial conflict of interest.", [["inflammation", "DISEASE", 198, 210], ["autoimmunity", "DISEASE", 214, 226], ["cystatin C derivatives", "SIMPLE_CHEMICAL", 53, 75], ["cystatin C", "GENE_OR_GENE_PRODUCT", 179, 189], ["cystatin C", "PROTEIN", 179, 189], ["cystatin C derivatives", "TREATMENT", 53, 75], ["an immune regulator", "TREATMENT", 79, 98], ["diseases", "PROBLEM", 154, 162], ["cystatin C related inflammation", "PROBLEM", 179, 210], ["autoimmunity", "PROBLEM", 214, 226], ["diseases", "OBSERVATION", 154, 162], ["inflammation", "OBSERVATION", 198, 210]]]], "PMC7326510": [["USE TELEHEALTH FOR COUNSELING AND SCREENINGUse various communication methods that do not require in-person contact (SMS, WhatsApp, video calls, or telephone calls) to:Counsel new clients requesting contraception and to screen for medical eligibility.4\u20136Issue new prescriptions and refills for clients who desire user-controlled contraceptives (e.g., combined oral contraceptives, progestin-only pills, contraceptive patches, or vaginal contraceptive rings) if no contraindications are evident.", [["oral", "ANATOMY", 359, 363], ["vaginal", "ANATOMY", 428, 435], ["contraceptives", "CHEMICAL", 328, 342], ["oral contraceptives", "CHEMICAL", 359, 378], ["progestin-only pills, contraceptive", "CHEMICAL", 380, 415], ["vaginal contraceptive", "CHEMICAL", 428, 449], ["progestin", "CHEMICAL", 380, 389], ["oral", "ORGANISM_SUBDIVISION", 359, 363], ["progestin", "SIMPLE_CHEMICAL", 380, 389], ["vaginal", "ORGANISM_SUBDIVISION", 428, 435], ["contraception", "TREATMENT", 198, 211], ["user-controlled contraceptives", "TREATMENT", 312, 342], ["combined oral contraceptives", "TREATMENT", 350, 378], ["progestin", "TREATMENT", 380, 389], ["pills", "TREATMENT", 395, 400], ["contraceptive patches", "TREATMENT", 402, 423], ["vaginal contraceptive rings", "TREATMENT", 428, 455], ["vaginal", "ANATOMY", 428, 435]]], ["Send all prescriptions directly to the pharmacy or clinic to limit contacts.Inform clients who desire long-acting reversible contraceptives (LARCs) of service locations where LARCs are being provided.Manage and treat contraceptive side effects, if possible.PROVIDE ADDITIONAL COUNSELING AND INFORMATION", [["reversible contraceptives", "CHEMICAL", 114, 139], ["long-acting reversible contraceptives", "TREATMENT", 102, 139], ["LARCs", "TREATMENT", 175, 180], ["contraceptive side effects", "TREATMENT", 217, 243]]]], "PMC7498513": [["LBB pacing technique ::: IntroductionPreparing the system in the surgical table requires to insert the lead in the delivery catheter and then to extend the retractable helix in order for it to be exposed for the subsequent mapping and screwing.", [["the lead in the delivery catheter", "TREATMENT", 99, 132], ["the retractable helix", "TREATMENT", 152, 173], ["the subsequent mapping", "TEST", 208, 230], ["catheter", "OBSERVATION", 124, 132]]], ["After cannulation of the axillary vein, electrophysiological mapping of the Hisian area was performed in unipolar fashion (red alligator clip on the skin and black clip to the tip of the lead) with the pacing lead supported by the delivery catheter (Figure 1) and connected to both the electrophysiology recording system (Bard Labsystem Pro EP V2.4a; C.R. Bard Inc, Lowell, MA) and the pacing system analyzer (Renamic; Biotronik).", [["axillary vein", "ANATOMY", 25, 38], ["Hisian area", "ANATOMY", 76, 87], ["skin", "ANATOMY", 149, 153], ["axillary vein", "MULTI-TISSUE_STRUCTURE", 25, 38], ["alligator", "ORGANISM_SUBDIVISION", 127, 136], ["skin", "ORGAN", 149, 153], ["cannulation of the axillary vein", "TREATMENT", 6, 38], ["electrophysiological mapping", "TEST", 40, 68], ["the Hisian area", "TREATMENT", 72, 87], ["red alligator clip", "TREATMENT", 123, 141], ["black clip", "TREATMENT", 158, 168], ["the pacing lead", "TREATMENT", 198, 213], ["the delivery catheter", "TREATMENT", 227, 248], ["C.R. Bard Inc", "TREATMENT", 351, 364], ["the pacing system analyzer", "TREATMENT", 382, 408], ["cannulation", "OBSERVATION", 6, 17], ["axillary vein", "ANATOMY", 25, 38], ["skin", "ANATOMY", 149, 153], ["tip", "OBSERVATION_MODIFIER", 176, 179], ["pacing lead", "OBSERVATION", 202, 213], ["catheter", "OBSERVATION", 240, 248]]], ["The His bundle electrogram was initially recorded for fluoroscopic reference in anteroposterior projection.", [["His", "CHEMICAL", 4, 7], ["The His bundle electrogram", "TEST", 0, 26], ["fluoroscopic reference in anteroposterior projection", "TEST", 54, 106]]], ["The whole system, composed of the delivery catheter and the lead inside, was then rotated counterclockwise toward the apex 1\u20132 cm along the virtual line between the His bundle site and RV apex in right anterior oblique fluoroscopic view.", [["His bundle site", "ANATOMY", 165, 180], ["His", "CHEMICAL", 165, 168], ["the delivery catheter", "TREATMENT", 30, 51], ["right anterior oblique fluoroscopic view", "TEST", 196, 236], ["catheter", "OBSERVATION", 43, 51], ["apex", "ANATOMY_MODIFIER", 118, 122], ["virtual line", "OBSERVATION", 140, 152], ["bundle", "ANATOMY_MODIFIER", 169, 175], ["RV", "ANATOMY", 185, 187], ["apex", "ANATOMY_MODIFIER", 188, 192], ["right", "ANATOMY_MODIFIER", 196, 201], ["anterior", "ANATOMY_MODIFIER", 202, 210], ["oblique", "ANATOMY_MODIFIER", 211, 218]]], ["Afterward, in left anterior oblique projection, we confirm the catheter position to be perpendicular to the septum, toward the spinal column as much as possible.", [["septum", "ANATOMY", 108, 114], ["spinal column", "ANATOMY", 127, 140], ["septum", "MULTI-TISSUE_STRUCTURE", 108, 114], ["the catheter position", "TREATMENT", 59, 80], ["left", "ANATOMY_MODIFIER", 14, 18], ["anterior", "ANATOMY_MODIFIER", 19, 27], ["catheter", "OBSERVATION", 63, 71], ["perpendicular", "OBSERVATION_MODIFIER", 87, 100], ["septum", "ANATOMY_MODIFIER", 108, 114], ["spinal column", "ANATOMY", 127, 140]]], ["While pacing, in left anterior oblique projection, the lead body was manually rotated to engage the previously extended and exposed helix into the septal wall.", [["left anterior oblique projection", "ANATOMY", 17, 49], ["body", "ANATOMY", 60, 64], ["septal wall", "ANATOMY", 147, 158], ["body", "ORGANISM_SUBDIVISION", 60, 64], ["septal wall", "TISSUE", 147, 158], ["pacing", "TREATMENT", 6, 12], ["pacing", "OBSERVATION", 6, 12], ["left", "ANATOMY_MODIFIER", 17, 21], ["anterior", "ANATOMY_MODIFIER", 22, 30], ["helix", "ANATOMY_MODIFIER", 132, 137], ["septal", "ANATOMY_MODIFIER", 147, 153], ["wall", "ANATOMY_MODIFIER", 154, 158]]], ["This maneuver into the septal wall resulted in partial helix retraction, which required further helix-lead screwing from the tip of the lead using normal helix extension.", [["septal wall", "ANATOMY", 23, 34], ["septal wall", "MULTI-TISSUE_STRUCTURE", 23, 34], ["partial helix retraction", "PROBLEM", 47, 71], ["further helix-lead screwing", "TREATMENT", 88, 115], ["septal", "ANATOMY_MODIFIER", 23, 29], ["wall", "ANATOMY_MODIFIER", 30, 34], ["partial", "OBSERVATION_MODIFIER", 47, 54], ["helix retraction", "OBSERVATION", 55, 71], ["helix", "OBSERVATION_MODIFIER", 96, 101], ["lead screwing", "OBSERVATION", 102, 115], ["tip", "OBSERVATION_MODIFIER", 125, 128], ["normal", "OBSERVATION", 147, 153], ["helix", "OBSERVATION_MODIFIER", 154, 159], ["extension", "OBSERVATION_MODIFIER", 160, 169]]], ["These alternating maneuvers of rotating the body of the lead and the extension of the helix were performed 2\u20133 times to fully penetrate the ventricular septum under fluoro control.", [["body", "ANATOMY", 44, 48], ["ventricular septum", "ANATOMY", 140, 158], ["body", "ORGANISM_SUBDIVISION", 44, 48], ["ventricular septum", "MULTI-TISSUE_STRUCTURE", 140, 158], ["fluoro control", "TREATMENT", 165, 179], ["helix", "ANATOMY", 86, 91], ["ventricular septum", "ANATOMY", 140, 158], ["fluoro control", "OBSERVATION", 165, 179]]], ["While rotating the lead we focus on paced QRS morphology on electrocardiogram (ECG) and lead impedance changes as described by Chen and colleagues.5 Lead V1 moves from a wide \u201cW\u201d shape with a notch at the nadir of the QRS to a right bundle block morphology.", [["right bundle", "ANATOMY", 227, 239], ["QRS", "PROTEIN", 218, 221], ["electrocardiogram", "TEST", 60, 77], ["ECG", "TEST", 79, 82], ["lead impedance changes", "PROBLEM", 88, 110], ["a notch", "PROBLEM", 190, 197], ["shape", "OBSERVATION_MODIFIER", 179, 184], ["notch", "OBSERVATION_MODIFIER", 192, 197], ["right", "ANATOMY_MODIFIER", 227, 232], ["bundle", "ANATOMY_MODIFIER", 233, 239]]], ["In lateral precordial leads V4\u2013V6 the left ventricular (LV) activation time, defined as the stimulus to the peak of the R wave, progressively shortens.", [["lateral precordial", "ANATOMY", 3, 21], ["left ventricular", "ANATOMY", 38, 54], ["LV", "ANATOMY", 56, 58], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 38, 54], ["LV", "MULTI-TISSUE_STRUCTURE", 56, 58], ["progressively shortens", "PROBLEM", 128, 150], ["lateral", "ANATOMY_MODIFIER", 3, 10], ["precordial", "ANATOMY_MODIFIER", 11, 21], ["leads", "ANATOMY_MODIFIER", 22, 27], ["V4", "ANATOMY_MODIFIER", 28, 30], ["left ventricular", "ANATOMY", 38, 54], ["LV", "ANATOMY", 56, 58], ["progressively", "OBSERVATION_MODIFIER", 128, 141], ["shortens", "OBSERVATION_MODIFIER", 142, 150]]], ["Selective LBB pacing was defined as only capturing the LBB without myocardial capture, with ECG pattern depicting the stimulus artefact followed by a small isoelectric line and a typical morphology of right bundle branch block in V1.", [["LBB", "ANATOMY", 55, 58], ["myocardial", "ANATOMY", 67, 77], ["right bundle branch", "ANATOMY", 201, 220], ["LBB", "MULTI-TISSUE_STRUCTURE", 10, 13], ["myocardial", "MULTI-TISSUE_STRUCTURE", 67, 77], ["Selective LBB pacing", "TREATMENT", 0, 20], ["myocardial capture", "PROBLEM", 67, 85], ["ECG pattern", "TEST", 92, 103], ["the stimulus artefact", "PROBLEM", 114, 135], ["a small isoelectric line", "PROBLEM", 148, 172], ["right bundle branch block", "PROBLEM", 201, 226], ["pacing", "OBSERVATION", 14, 20], ["without", "UNCERTAINTY", 59, 66], ["myocardial", "ANATOMY", 67, 77], ["capture", "OBSERVATION", 78, 85], ["stimulus artefact", "OBSERVATION", 118, 135], ["small", "OBSERVATION_MODIFIER", 150, 155], ["isoelectric line", "OBSERVATION", 156, 172], ["right", "ANATOMY_MODIFIER", 201, 206], ["bundle", "ANATOMY_MODIFIER", 207, 213], ["branch", "ANATOMY_MODIFIER", 214, 220], ["block", "OBSERVATION", 221, 226], ["V1", "ANATOMY_MODIFIER", 230, 232]]], ["Moreover, a discrete local component separate from the stimulus artifact on the unipolar electrogram (EGM) from the LBB pacing lead is observed.", [["LBB", "ANATOMY", 116, 119], ["a discrete local component", "PROBLEM", 10, 36], ["the stimulus artifact", "PROBLEM", 51, 72], ["the unipolar electrogram", "TEST", 76, 100], ["the LBB pacing lead", "TREATMENT", 112, 131], ["discrete", "OBSERVATION_MODIFIER", 12, 20], ["local", "OBSERVATION_MODIFIER", 21, 26], ["component", "OBSERVATION_MODIFIER", 27, 36], ["stimulus artifact", "OBSERVATION", 55, 72], ["pacing lead", "OBSERVATION", 120, 131]]], ["Nonselective LBB pacing is defined as capturing both the LBB and the local myocardium, with ECG pattern characterized by a small pre-excitation following the artefact stimulus; EGM does not record a discrete potential.6 Sensing and pacing thresholds were recorded in a unipolar and bipolar manner.", [["LBB", "ANATOMY", 57, 60], ["myocardium", "ANATOMY", 75, 85], ["bipolar", "DISEASE", 282, 289], ["LBB", "MULTI-TISSUE_STRUCTURE", 13, 16], ["LBB", "CANCER", 57, 60], ["myocardium", "ORGAN", 75, 85], ["Nonselective LBB pacing", "TREATMENT", 0, 23], ["ECG pattern", "TEST", 92, 103], ["a small pre-excitation", "PROBLEM", 121, 143], ["the artefact stimulus", "TEST", 154, 175], ["Sensing and pacing thresholds", "TREATMENT", 220, 249], ["LBB pacing", "OBSERVATION", 13, 23], ["LBB", "ANATOMY_MODIFIER", 57, 60], ["local myocardium", "ANATOMY", 69, 85], ["small", "OBSERVATION_MODIFIER", 123, 128], ["pre-excitation", "OBSERVATION", 129, 143], ["pacing", "OBSERVATION", 232, 238]]], ["Before cutting of the sheath, a small amount of contrast dye (5 mL) was injected through the delivery catheter to confirm the location of the lead.Case 1 ::: Case reportAn 86-year-old woman with atrial fibrillation and high ventricular response was referred to our clinic in February 2020 owing to heart failure symptoms.", [["sheath", "ANATOMY", 22, 28], ["atrial", "ANATOMY", 195, 201], ["ventricular", "ANATOMY", 224, 235], ["heart", "ANATOMY", 298, 303], ["contrast dye", "CHEMICAL", 48, 60], ["atrial fibrillation", "DISEASE", 195, 214], ["heart failure", "DISEASE", 298, 311], ["sheath", "TISSUE", 22, 28], ["woman", "ORGANISM", 184, 189], ["ventricular", "MULTI-TISSUE_STRUCTURE", 224, 235], ["heart", "ORGAN", 298, 303], ["woman", "SPECIES", 184, 189], ["the sheath", "TREATMENT", 18, 28], ["a small amount of contrast dye", "TREATMENT", 30, 60], ["the delivery catheter", "TREATMENT", 89, 110], ["atrial fibrillation", "PROBLEM", 195, 214], ["high ventricular response", "PROBLEM", 219, 244], ["heart failure symptoms", "PROBLEM", 298, 320], ["sheath", "ANATOMY", 22, 28], ["small", "OBSERVATION_MODIFIER", 32, 37], ["catheter", "OBSERVATION", 102, 110], ["lead", "OBSERVATION", 142, 146], ["atrial", "ANATOMY", 195, 201], ["fibrillation", "OBSERVATION", 202, 214], ["high ventricular response", "OBSERVATION", 219, 244], ["heart", "ANATOMY", 298, 303], ["failure", "OBSERVATION", 304, 311]]], ["The 12-lead ECG showed atrial fibrillation with 145 beats/min ventricular rate, left axis deviation, and QRS duration 88 ms.", [["atrial", "ANATOMY", 23, 29], ["ventricular", "ANATOMY", 62, 73], ["left axis", "ANATOMY", 80, 89], ["atrial fibrillation", "DISEASE", 23, 42], ["atrial", "MULTI-TISSUE_STRUCTURE", 23, 29], ["ventricular", "MULTI-TISSUE_STRUCTURE", 62, 73], ["The 12-lead ECG", "TEST", 0, 15], ["atrial fibrillation", "PROBLEM", 23, 42], ["145 beats/min ventricular rate", "PROBLEM", 48, 78], ["left axis deviation", "PROBLEM", 80, 99], ["QRS duration", "TEST", 105, 117], ["atrial", "ANATOMY", 23, 29], ["fibrillation", "OBSERVATION", 30, 42], ["left axis", "ANATOMY", 80, 89]]], ["Transthoracic echocardiography showed LV ejection fraction 46% and mild mitral regurgitation.", [["LV", "ANATOMY", 38, 40], ["mitral", "ANATOMY", 72, 78], ["mitral regurgitation", "DISEASE", 72, 92], ["mitral", "PATHOLOGICAL_FORMATION", 72, 78], ["Transthoracic echocardiography", "TEST", 0, 30], ["LV ejection fraction", "TEST", 38, 58], ["mild mitral regurgitation", "PROBLEM", 67, 92], ["LV", "ANATOMY", 38, 40], ["ejection fraction", "OBSERVATION", 41, 58], ["mild", "OBSERVATION_MODIFIER", 67, 71], ["mitral regurgitation", "OBSERVATION", 72, 92]]], ["Multiple and different pharmacological strategies were attempted that aimed to reduce the ventricular response (verapamil, metoprolol, amiodarone, digitalis), but without beneficial effects.", [["ventricular", "ANATOMY", 90, 101], ["verapamil", "CHEMICAL", 112, 121], ["metoprolol", "CHEMICAL", 123, 133], ["amiodarone", "CHEMICAL", 135, 145], ["digitalis", "CHEMICAL", 147, 156], ["verapamil", "CHEMICAL", 112, 121], ["metoprolol", "CHEMICAL", 123, 133], ["amiodarone", "CHEMICAL", 135, 145], ["digitalis", "CHEMICAL", 147, 156], ["ventricular", "MULTI-TISSUE_STRUCTURE", 90, 101], ["verapamil", "SIMPLE_CHEMICAL", 112, 121], ["metoprolol", "SIMPLE_CHEMICAL", 123, 133], ["amiodarone", "SIMPLE_CHEMICAL", 135, 145], ["digitalis", "SIMPLE_CHEMICAL", 147, 156], ["verapamil", "TREATMENT", 112, 121], ["metoprolol", "TREATMENT", 123, 133], ["amiodarone", "TREATMENT", 135, 145], ["digitalis", "TREATMENT", 147, 156], ["ventricular", "ANATOMY", 90, 101]]], ["After 20 days, despite slight clinical improvement, ventricular rate persisted high and consequently the \u201cablate and pace\u201d strategy was planned.", [["ventricular", "ANATOMY", 52, 63], ["ventricular", "MULTI-TISSUE_STRUCTURE", 52, 63], ["ventricular rate", "TEST", 52, 68], ["pace\u201d strategy", "TREATMENT", 117, 131], ["slight", "OBSERVATION_MODIFIER", 23, 29]]], ["The patient\u2019s informed consent was collected.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["The new Selectra 3D 55-M curve (Biotronik) was utilized to support the Solia S 60 lead (Biotronik) during mapping of the Hisian area.", [["M curve (Biotronik)", "TREATMENT", 23, 42], ["the Solia S 60 lead (Biotronik", "TREATMENT", 67, 97], ["new", "OBSERVATION_MODIFIER", 4, 7], ["Hisian", "ANATOMY", 121, 127], ["area", "ANATOMY_MODIFIER", 128, 132]]], ["Owing to high pacing threshold with His pacing, intraseptal LBB pacing was planned.", [["intraseptal", "ANATOMY", 48, 59], ["His", "CHEMICAL", 36, 39], ["high pacing threshold", "TREATMENT", 9, 30], ["His pacing", "TREATMENT", 36, 46], ["intraseptal LBB pacing", "TREATMENT", 48, 70], ["high pacing", "OBSERVATION", 9, 20], ["pacing", "OBSERVATION", 40, 46], ["LBB pacing", "OBSERVATION", 60, 70]]], ["A sharp LB potential was recorded with the LBB-V interval of 16 ms (Figure 2C).", [["A sharp LB potential", "PROBLEM", 0, 20], ["the LBB", "TEST", 39, 46], ["sharp", "OBSERVATION_MODIFIER", 2, 7]]], ["The right bundle branch block pattern appeared in lead V1 when the screw reached the left bundle (Figure 2B).", [["right bundle branch", "ANATOMY", 4, 23], ["left bundle", "ANATOMY", 85, 96], ["The right bundle branch block pattern", "PROBLEM", 0, 37], ["the screw", "TREATMENT", 63, 72], ["right", "ANATOMY_MODIFIER", 4, 9], ["bundle", "ANATOMY_MODIFIER", 10, 16], ["branch", "ANATOMY_MODIFIER", 17, 23], ["block", "OBSERVATION", 24, 29], ["lead V1", "OBSERVATION", 50, 57], ["screw", "OBSERVATION", 67, 72], ["left", "ANATOMY_MODIFIER", 85, 89], ["bundle", "ANATOMY_MODIFIER", 90, 96]]], ["A small injection of iodine contrast (5 mL) confirmed the complete penetration of the tip into the septum with the anode in correspondence of the right aspect of the interventricular septum (Figure 2D).", [["septum", "ANATOMY", 99, 105], ["right aspect", "ANATOMY", 146, 158], ["interventricular septum", "ANATOMY", 166, 189], ["iodine", "CHEMICAL", 21, 27], ["iodine", "CHEMICAL", 21, 27], ["iodine", "SIMPLE_CHEMICAL", 21, 27], ["septum", "MULTI-TISSUE_STRUCTURE", 99, 105], ["interventricular septum", "MULTI-TISSUE_STRUCTURE", 166, 189], ["A small injection of iodine contrast", "TREATMENT", 0, 36], ["small", "OBSERVATION_MODIFIER", 2, 7], ["penetration", "OBSERVATION_MODIFIER", 67, 78], ["tip", "OBSERVATION_MODIFIER", 86, 89], ["septum", "ANATOMY_MODIFIER", 99, 105], ["anode", "OBSERVATION_MODIFIER", 115, 120], ["right", "ANATOMY_MODIFIER", 146, 151], ["interventricular septum", "ANATOMY", 166, 189]]], ["The electrical parameters were as follows: sensing 13 mV, threshold 0.5 V @ 0.4 ms, impedance 554 ohms.", [["The electrical parameters", "TEST", 0, 25], ["threshold", "TEST", 58, 67]]], ["However, considering the novelty of the technology, a second lead in the RV apex was implanted as back-up lead (Figure 2E).", [["RV apex", "ANATOMY", 73, 80], ["RV apex", "MULTI-TISSUE_STRUCTURE", 73, 80], ["a second lead in the RV apex", "TREATMENT", 52, 80], ["RV", "ANATOMY", 73, 75], ["apex", "ANATOMY_MODIFIER", 76, 80]]], ["The LBB lead was connected to the atrial port and the apical lead in the RV port of a dual-chamber pacemaker settled in a DVI mode.", [["LBB", "ANATOMY", 4, 7], ["atrial port", "ANATOMY", 34, 45], ["apical", "ANATOMY", 54, 60], ["RV", "ANATOMY", 73, 75], ["LBB", "SIMPLE_CHEMICAL", 4, 7], ["atrial port", "MULTI-TISSUE_STRUCTURE", 34, 45], ["The LBB lead", "TREATMENT", 0, 12], ["the atrial port", "TREATMENT", 30, 45], ["a dual-chamber pacemaker", "TREATMENT", 84, 108], ["a DVI mode", "TREATMENT", 120, 130], ["atrial", "ANATOMY", 34, 40], ["port", "ANATOMY_MODIFIER", 41, 45], ["apical", "ANATOMY_MODIFIER", 54, 60], ["lead", "OBSERVATION", 61, 65], ["RV", "ANATOMY", 73, 75], ["port", "ANATOMY_MODIFIER", 76, 80], ["chamber pacemaker", "OBSERVATION", 91, 108]]], ["After 5 days atrioventricular node ablation was performed, obtaining 100% of ventricular pacing.", [["atrioventricular node", "ANATOMY", 13, 34], ["ventricular", "ANATOMY", 77, 88], ["atrioventricular node", "MULTI-TISSUE_STRUCTURE", 13, 34], ["ventricular", "MULTI-TISSUE_STRUCTURE", 77, 88], ["atrioventricular node ablation", "TREATMENT", 13, 43], ["ventricular pacing", "TREATMENT", 77, 95], ["node ablation", "OBSERVATION", 30, 43], ["ventricular pacing", "OBSERVATION", 77, 95]]], ["Paced QRS measured 120 ms (Figure 2B).", [["QRS", "PROTEIN", 6, 9], ["Paced QRS", "TEST", 0, 9]]], ["The 2 procedures were successfully completed without complications.", [["The 2 procedures", "TREATMENT", 0, 16], ["complications", "PROBLEM", 53, 66]]], ["The patient was discharged a few days later, being in good clinical status.Case 2 ::: Case reportAn 81-year-old woman with previous history of hypertension and radiotherapy for breast cancer presented with dyspnea and fatigue after 3 episodes of syncope.", [["breast cancer", "ANATOMY", 177, 190], ["hypertension", "DISEASE", 143, 155], ["breast cancer", "DISEASE", 177, 190], ["dyspnea", "DISEASE", 206, 213], ["fatigue", "DISEASE", 218, 225], ["syncope", "DISEASE", 246, 253], ["patient", "ORGANISM", 4, 11], ["woman", "ORGANISM", 112, 117], ["breast cancer", "CANCER", 177, 190], ["patient", "SPECIES", 4, 11], ["woman", "SPECIES", 112, 117], ["hypertension", "PROBLEM", 143, 155], ["radiotherapy", "TREATMENT", 160, 172], ["breast cancer", "PROBLEM", 177, 190], ["dyspnea", "PROBLEM", 206, 213], ["fatigue", "PROBLEM", 218, 225], ["syncope", "PROBLEM", 246, 253], ["hypertension", "OBSERVATION", 143, 155], ["breast", "ANATOMY", 177, 183], ["cancer", "OBSERVATION", 184, 190], ["dyspnea", "OBSERVATION", 206, 213], ["syncope", "OBSERVATION", 246, 253]]], ["Symptoms started 1 month before but owing to the coronavirus disease 2019 (COVID-19) emergency, she initially decided to stay at home, avoiding hospital access.", [["coronavirus disease", "DISEASE", 49, 68], ["Symptoms", "PROBLEM", 0, 8], ["the coronavirus disease", "PROBLEM", 45, 68]]], ["ECG on presentation revealed intermittent episodes of 2:1 atrioventricular block, left fascicular anterior block, and QRS duration of 110 ms.", [["atrioventricular", "ANATOMY", 58, 74], ["left fascicular anterior", "ANATOMY", 82, 106], ["atrioventricular block", "DISEASE", 58, 80], ["ECG", "TEST", 0, 3], ["2:1 atrioventricular block", "PROBLEM", 54, 80], ["left fascicular anterior block", "PROBLEM", 82, 112], ["QRS duration", "TEST", 118, 130], ["intermittent", "OBSERVATION_MODIFIER", 29, 41], ["atrioventricular block", "OBSERVATION", 58, 80], ["left", "ANATOMY_MODIFIER", 82, 86], ["fascicular", "ANATOMY_MODIFIER", 87, 97], ["anterior", "ANATOMY_MODIFIER", 98, 106], ["block", "OBSERVATION", 107, 112]]], ["Echocardiogram showed LV ejection fraction of 65% and normal values in blood sample.", [["LV", "ANATOMY", 22, 24], ["blood sample", "ANATOMY", 71, 83], ["LV", "MULTI-TISSUE_STRUCTURE", 22, 24], ["blood", "ORGANISM_SUBSTANCE", 71, 76], ["Echocardiogram", "TEST", 0, 14], ["LV ejection fraction", "TEST", 22, 42], ["blood sample", "TEST", 71, 83], ["LV", "ANATOMY", 22, 24], ["ejection fraction", "OBSERVATION", 25, 42]]], ["Permanent pacemaker implantation with HBP was attempted.", [["Permanent pacemaker implantation", "TREATMENT", 0, 32], ["HBP", "TREATMENT", 38, 41], ["pacemaker implantation", "OBSERVATION", 10, 32]]], ["The Selectra 3D 55-M curve (Biotronik) was utilized to support the Solia S 60 lead (Biotronik) during mapping of the Hisian area.", [["The Selectra 3D 55-M curve (Biotronik)", "TREATMENT", 0, 38], ["the Solia S 60 lead (Biotronik", "TREATMENT", 63, 93], ["Hisian", "ANATOMY", 117, 123], ["area", "ANATOMY_MODIFIER", 124, 128]]], ["HV interval was measured as 100 ms.", [["HV interval", "TEST", 0, 11]]], ["Both selective and nonselective HBP were obtained but >3 V output was required to capture the His bundle.", [["His", "CHEMICAL", 94, 97], ["HBP", "SIMPLE_CHEMICAL", 32, 35], ["His bundle", "PROTEIN", 94, 104], ["nonselective HBP", "TEST", 19, 35], ["selective", "OBSERVATION_MODIFIER", 5, 14]]], ["Finally, after 3 suboptimal attempts, LBB pacing was planned.", [["LBB pacing", "TREATMENT", 38, 48]]], ["The lead was successfully screwed into the interventricular septum.", [["interventricular septum", "ANATOMY", 43, 66], ["interventricular septum", "MULTI-TISSUE_STRUCTURE", 43, 66], ["The lead", "TREATMENT", 0, 8], ["successfully screwed", "OBSERVATION", 13, 33], ["interventricular septum", "ANATOMY", 43, 66]]], ["R-wave amplitude was 11 mV.", [["R-wave amplitude", "TEST", 0, 16], ["wave amplitude", "OBSERVATION", 2, 16]]], ["Fluoroscopic view of the LBB pacing lead and fulcrum sign6 are shown in Figure 3.DiscussionHBP has emerged as a physiological mode of pacing avoiding the detrimental effect of RV apical pacing.", [["LBB", "ANATOMY", 25, 28], ["RV apical", "ANATOMY", 176, 185], ["RV apical", "MULTI-TISSUE_STRUCTURE", 176, 185], ["Fluoroscopic view", "TEST", 0, 17], ["the LBB pacing lead", "TREATMENT", 21, 40], ["fulcrum sign6", "TEST", 45, 58], ["pacing", "TREATMENT", 134, 140], ["RV apical pacing", "TREATMENT", 176, 192], ["apical", "ANATOMY_MODIFIER", 179, 185], ["pacing", "OBSERVATION", 186, 192]]], ["Implant success rate with HBP is high, reaching more than 80%7; however, some possible drawbacks have emerged from this established technique.", [["Implant success rate", "TREATMENT", 0, 20], ["HBP", "TEST", 26, 29], ["high", "OBSERVATION_MODIFIER", 33, 37]]], ["Pacing thresholds can be higher and sensing slightly lower compared to standard RV pacing, possibly affecting the longevity of devices.", [["Pacing thresholds", "TREATMENT", 0, 17], ["standard RV pacing", "TREATMENT", 71, 89], ["RV pacing", "OBSERVATION", 80, 89]]], ["LBB pacing is a new and promising technique that, together with HBP, merges in the so-called His-Purkinje conduction system pacing.", [["LBB pacing", "TREATMENT", 0, 10], ["HBP", "TEST", 64, 67], ["Purkinje conduction system pacing", "TREATMENT", 97, 130], ["pacing", "OBSERVATION", 4, 10], ["new", "OBSERVATION_MODIFIER", 16, 19], ["Purkinje conduction", "OBSERVATION", 97, 116], ["system pacing", "OBSERVATION", 117, 130]]], ["Although no direct comparison between the 2 pacing sites has been published, LBB pacing seems to have better electrical parameters with high ventricular sensing and low threshold.6,8 All the published experiences of LBB pacing, until now, have been performed with the Medtronic system, composed of a 3830 4F lead with fixed helix and the fixed-curve sheath (C315 SelectSite).", [["ventricular", "ANATOMY", 141, 152], ["ventricular", "MULTI-TISSUE_STRUCTURE", 141, 152], ["the 2 pacing sites", "TREATMENT", 38, 56], ["LBB pacing", "TREATMENT", 77, 87], ["LBB pacing", "TREATMENT", 216, 226], ["the Medtronic system", "TREATMENT", 264, 284], ["fixed helix", "TREATMENT", 318, 329], ["the fixed-curve sheath", "TREATMENT", 334, 356], ["LBB pacing", "OBSERVATION", 77, 87], ["low threshold", "OBSERVATION_MODIFIER", 165, 178], ["LBB pacing", "OBSERVATION", 216, 226]]], ["This lead is supposed to have the advantage of the isodiametric shape between the lead body and the helix, facilitating ease of screwing into the ventricular septum.", [["body", "ANATOMY", 87, 91], ["ventricular septum", "ANATOMY", 146, 164], ["ventricular septum", "MULTI-TISSUE_STRUCTURE", 146, 164], ["isodiametric shape", "OBSERVATION", 51, 69], ["lead body", "OBSERVATION", 82, 91], ["helix", "ANATOMY_MODIFIER", 100, 105], ["ventricular septum", "ANATOMY", 146, 164]]], ["The newly available Selectra 3D delivery sheath (Biotronik) has been designed for positioning the active-fixation Solia S lead (Biotronik) at the His bundle location, and preliminary experiences are ongoing worldwide.", [["The newly available Selectra 3D delivery sheath (Biotronik)", "TREATMENT", 0, 59], ["the active-fixation Solia S lead (Biotronik", "TREATMENT", 94, 137], ["active", "OBSERVATION_MODIFIER", 98, 104], ["fixation Solia", "OBSERVATION", 105, 119]]], ["The system, composed of the stylet inside the screw lead and a firm delivery catheter, has good stability and support for screwing the lead into the septum.", [["septum", "ANATOMY", 149, 155], ["septum", "MULTI-TISSUE_STRUCTURE", 149, 155], ["the stylet inside the screw lead", "TREATMENT", 24, 56], ["a firm delivery catheter", "TREATMENT", 61, 85], ["screw lead", "OBSERVATION", 46, 56], ["firm", "OBSERVATION_MODIFIER", 63, 67], ["delivery", "OBSERVATION_MODIFIER", 68, 76], ["catheter", "OBSERVATION", 77, 85], ["good", "OBSERVATION_MODIFIER", 91, 95], ["stability", "OBSERVATION_MODIFIER", 96, 105], ["septum", "ANATOMY", 149, 155]]], ["Conversely, the 6F diameter could represent a limit if multiple attempts are required.", [["6F diameter", "OBSERVATION_MODIFIER", 16, 27]]], ["A possible limitation is represented by the fact that the operator has a very large experience in His pacing.", [["His", "CHEMICAL", 98, 101], ["His pacing", "TREATMENT", 98, 108], ["possible", "UNCERTAINTY", 2, 10], ["very", "OBSERVATION_MODIFIER", 73, 77], ["large", "OBSERVATION_MODIFIER", 78, 83], ["pacing", "OBSERVATION", 102, 108]]], ["Whereas HBP is a established therapy and many patients have already been implanted all over the world, LBB pacing is a relatively new practice and could not be immediately reproducible on a large scale; but it is a starting point, and future studies are needed to understand the full applicability of this approach with those new tools.", [["HBP", "SIMPLE_CHEMICAL", 8, 11], ["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["a established therapy", "TREATMENT", 15, 36], ["LBB pacing", "TREATMENT", 103, 113], ["a large scale", "TREATMENT", 188, 201], ["future studies", "TEST", 235, 249], ["this approach", "TREATMENT", 301, 314], ["pacing", "OBSERVATION", 107, 113]]], ["In conclusion, the novelty of these 2 case reports is represented by the possibility of pacing the LBB also with a standard stylet-driven lead with a retractable helix coupled with the Selectra 3D introducer.Key Teaching Points\u2022Left bundle branch (LBB) pacing together with His bundle pacing (HBP) merges in the so-called His-Purkinje conduction system pacing.", [["Left bundle branch", "ANATOMY", 228, 246], ["LBB", "ANATOMY", 248, 251], ["His", "CHEMICAL", 274, 277], ["LBB", "CANCER", 99, 102], ["LBB", "MULTI-TISSUE_STRUCTURE", 248, 251], ["pacing the LBB", "PROBLEM", 88, 102], ["a standard stylet", "TREATMENT", 113, 130], ["a retractable helix", "TREATMENT", 148, 167], ["the Selectra 3D introducer", "TREATMENT", 181, 207], ["LBB) pacing", "TREATMENT", 248, 259], ["His bundle pacing", "TREATMENT", 274, 291], ["Purkinje conduction system pacing", "TREATMENT", 326, 359], ["pacing", "OBSERVATION", 88, 94], ["Left bundle", "ANATOMY", 228, 239], ["branch", "ANATOMY_MODIFIER", 240, 246], ["pacing", "OBSERVATION", 253, 259], ["bundle pacing", "OBSERVATION", 278, 291], ["Purkinje conduction", "OBSERVATION", 326, 345], ["system pacing", "OBSERVATION", 346, 359]]], ["LBB pacing seems to have better electrical parameters with high ventricular sensing and low threshold.\u2022All the published experiences of LBB pacing, until now, have been performed with the Medtronic system (Medtronic, Minneapolis, MN), composed of a 3830 4F lead with fixed helix and a fixed-curve sheath (C315 SelectSite).", [["ventricular", "ANATOMY", 64, 75], ["LBB", "SIMPLE_CHEMICAL", 0, 3], ["ventricular", "MULTI-TISSUE_STRUCTURE", 64, 75], ["LBB pacing", "TREATMENT", 0, 10], ["LBB pacing", "TREATMENT", 136, 146], ["the Medtronic system", "TREATMENT", 184, 204], ["a 3830 4F lead", "TREATMENT", 247, 261], ["fixed helix", "TREATMENT", 267, 278], ["a fixed-curve sheath", "TREATMENT", 283, 303], ["pacing", "OBSERVATION", 4, 10], ["LBB pacing", "OBSERVATION", 136, 146]]], ["The isodiametric shape between lead body and the helix facilitates ease of screwing into the ventricular septum.\u2022Our preliminary experience of LBB pacing using a standard stylet-driven lead delivered through a specific designed introducer (Biotronik Selectra 3D, Biotronik SE & Co. KG, Berlin, Germany) opens the possibility of pacing the LBB also with a standard stylet-driven lead with a retractable helix coupled with the Selectra 3D introducer.", [["body", "ANATOMY", 36, 40], ["ventricular septum", "ANATOMY", 93, 111], ["ventricular septum", "MULTI-TISSUE_STRUCTURE", 93, 111], ["LBB", "CANCER", 339, 342], ["The isodiametric shape between lead body and the helix", "PROBLEM", 0, 54], ["LBB pacing", "TREATMENT", 143, 153], ["a standard stylet", "TREATMENT", 160, 177], ["a specific designed introducer (Biotronik Selectra 3D", "TREATMENT", 208, 261], ["Biotronik SE & Co", "TREATMENT", 263, 280], ["pacing the LBB", "TREATMENT", 328, 342], ["a standard stylet", "TREATMENT", 353, 370], ["a retractable helix", "TREATMENT", 388, 407], ["the Selectra 3D introducer", "TREATMENT", 421, 447], ["isodiametric", "OBSERVATION_MODIFIER", 4, 16], ["shape", "OBSERVATION_MODIFIER", 17, 22], ["lead body", "OBSERVATION", 31, 40], ["helix", "ANATOMY_MODIFIER", 49, 54], ["ventricular septum", "ANATOMY", 93, 111], ["pacing", "OBSERVATION", 328, 334]]]], "5c5d81d718b0fceb6fcee96a4c01b5b98eb84da8": [["IntroductionCoronaviruses (CoVs) are enveloped viruses with positive singlestranded RNA genomes infecting both animals and human (Fung & Liu, 2019) .", [["IntroductionCoronaviruses", "GENE_OR_GENE_PRODUCT", 0, 25], ["CoVs", "GENE_OR_GENE_PRODUCT", 27, 31], ["human", "ORGANISM", 123, 128], ["CoVs", "PROTEIN", 27, 31], ["positive singlestranded RNA genomes", "DNA", 60, 95], ["human", "SPECIES", 123, 128], ["human", "SPECIES", 123, 128], ["IntroductionCoronaviruses (CoVs)", "PROBLEM", 0, 32], ["enveloped viruses", "PROBLEM", 37, 54]]], ["CoVs are caused of several diseases from common cold to more severe highly pathogenic ones such as SARS (Severe acute respiratory syndrome), MERS (Middle-east respiratory syndrome) and Coronavirus disease 2019 with higher mortalities (Cui et al., 2019) .", [["SARS", "DISEASE", 99, 103], ["acute respiratory syndrome", "DISEASE", 112, 138], ["MERS", "DISEASE", 141, 145], ["Middle-east respiratory syndrome", "DISEASE", 147, 179], ["Coronavirus disease", "DISEASE", 185, 204], ["CoVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["CoVs", "PROBLEM", 0, 4], ["several diseases", "PROBLEM", 19, 35], ["common cold to more severe highly pathogenic ones", "PROBLEM", 41, 90], ["SARS (Severe acute respiratory syndrome", "PROBLEM", 99, 138], ["MERS (Middle-east respiratory syndrome", "PROBLEM", 141, 179], ["Coronavirus disease", "PROBLEM", 185, 204], ["higher mortalities", "PROBLEM", 215, 233], ["caused of", "UNCERTAINTY", 9, 18], ["several", "OBSERVATION_MODIFIER", 19, 26], ["diseases", "OBSERVATION", 27, 35], ["more severe", "OBSERVATION_MODIFIER", 56, 67], ["highly", "OBSERVATION_MODIFIER", 68, 74], ["pathogenic", "OBSERVATION", 75, 85], ["Severe", "OBSERVATION_MODIFIER", 105, 111], ["acute", "OBSERVATION_MODIFIER", 112, 117], ["respiratory syndrome", "OBSERVATION", 118, 138], ["Middle", "ANATOMY_MODIFIER", 147, 153], ["respiratory syndrome", "OBSERVATION", 159, 179], ["Coronavirus disease", "OBSERVATION", 185, 204]]], ["A novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is responsible for Covid-19 that first appeared in Wuhan region of China within December 2019 .", [["acute respiratory syndrome coronavirus", "DISEASE", 39, 77], ["coronavirus SARS-CoV-2", "ORGANISM", 8, 30], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 32, 77], ["coronavirus SARS-CoV", "SPECIES", 8, 28], ["coronavirus", "SPECIES", 66, 77], ["SARS-CoV-2 (severe acute respiratory syndrome coronavirus", "SPECIES", 20, 77], ["A novel coronavirus SARS", "TEST", 0, 24], ["CoV", "TEST", 25, 28], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 32, 77], ["Covid", "TEST", 100, 105], ["coronavirus SARS", "OBSERVATION", 8, 24], ["severe", "OBSERVATION_MODIFIER", 32, 38], ["acute", "OBSERVATION_MODIFIER", 39, 44], ["respiratory syndrome", "OBSERVATION", 45, 65]]], ["Due to high transmission rate, SARS-CoV-2 spread quickly in multiple countries and the WHO declared an outbreak of COVID-19 a pandemic on March 2020 (https://www.who.int/emergencies/ diseases/novel-coronavirus-2019; Gorbalenya et al., 2020) .", [["SARS", "DISEASE", 31, 35], ["COVID", "DISEASE", 115, 120], ["SARS-CoV", "SPECIES", 31, 39], ["high transmission rate", "PROBLEM", 7, 29], ["SARS", "PROBLEM", 31, 35], ["CoV", "TEST", 36, 39], ["diseases", "PROBLEM", 183, 191]]], ["At the time of writing present manuscript, more than 200 countries were affected with more than 2600000 confirmed cases and about 180000 deaths making it a serious threat to global public health (https://www.who.int/emergencies/diseases/novel-coronavirus-2019).IntroductionSimilar to other members of beta-coronaviruses (SARS-CoV and MERS-CoV), SARS-CoV-2 cause viral pneumonia by attacking lower respiratory system, entry into alveolar epithelial cells, rapid replication and triggering a strong immune response leading to pulmonary tissue damage (Villar et al., 2019) .", [["respiratory system", "ANATOMY", 397, 415], ["alveolar epithelial cells", "ANATOMY", 428, 453], ["pulmonary tissue", "ANATOMY", 524, 540], ["deaths", "DISEASE", 137, 143], ["pneumonia", "DISEASE", 368, 377], ["pulmonary tissue damage", "DISEASE", 524, 547], ["beta-coronaviruses", "ORGANISM", 301, 319], ["SARS-CoV", "ORGANISM", 321, 329], ["MERS-CoV", "ORGANISM", 334, 342], ["SARS-CoV-2", "ORGANISM", 345, 355], ["alveolar epithelial cells", "CELL", 428, 453], ["pulmonary tissue", "TISSUE", 524, 540], ["alveolar epithelial cells", "CELL_TYPE", 428, 453], ["SARS-CoV", "SPECIES", 321, 329], ["MERS-CoV", "SPECIES", 334, 342], ["SARS-CoV", "SPECIES", 345, 353], ["beta-coronaviruses", "PROBLEM", 301, 319], ["SARS", "PROBLEM", 321, 325], ["SARS", "PROBLEM", 345, 349], ["viral pneumonia", "PROBLEM", 362, 377], ["attacking lower respiratory system", "PROBLEM", 381, 415], ["entry into alveolar epithelial cells", "PROBLEM", 417, 453], ["rapid replication", "TREATMENT", 455, 472], ["a strong immune response", "PROBLEM", 488, 512], ["pulmonary tissue damage", "PROBLEM", 524, 547], ["viral", "OBSERVATION_MODIFIER", 362, 367], ["pneumonia", "OBSERVATION", 368, 377], ["lower", "ANATOMY_MODIFIER", 391, 396], ["respiratory system", "ANATOMY", 397, 415], ["alveolar epithelial cells", "OBSERVATION", 428, 453], ["pulmonary tissue", "ANATOMY", 524, 540], ["damage", "OBSERVATION", 541, 547]]], ["More vulnerable population that must be majorly managed on prevention of SARS-CoV2 infection, are the people with decreased immune function such as the elderly and individuals suffering from basic diseases .IntroductionGiven the urgency of highly contagious SARS-CoV2 and considering the lack of validated therapeutic drugs or vaccines against this pathogen, several research groups rely on repurposing FDA approved drugs with proven effectiveness against similar infectious diseases (Boopathi et al., 2020; Liu et al., 2020) .", [["SARS-CoV2 infection", "DISEASE", 73, 92], ["SARS", "DISEASE", 258, 262], ["infectious diseases", "DISEASE", 464, 483], ["SARS-CoV2", "ORGANISM", 73, 82], ["people", "ORGANISM", 102, 108], ["people", "SPECIES", 102, 108], ["SARS", "PROBLEM", 73, 77], ["CoV2 infection", "PROBLEM", 78, 92], ["decreased immune function", "PROBLEM", 114, 139], ["basic diseases", "PROBLEM", 191, 205], ["validated therapeutic drugs", "TREATMENT", 296, 323], ["vaccines", "TREATMENT", 327, 335], ["this pathogen", "PROBLEM", 344, 357], ["repurposing FDA", "TREATMENT", 391, 406], ["drugs", "TREATMENT", 416, 421], ["similar infectious diseases", "PROBLEM", 456, 483], ["vulnerable", "OBSERVATION_MODIFIER", 5, 15], ["population", "OBSERVATION", 16, 26], ["SARS", "OBSERVATION", 73, 77], ["infection", "OBSERVATION", 83, 92], ["highly", "OBSERVATION_MODIFIER", 240, 246], ["contagious", "OBSERVATION_MODIFIER", 247, 257]]], ["Numerous drugs, such as ribavirin, lopinavir and interferon have been tried against SARS or MERS, although the efficacies of some drugs remained controversial (Zumla et al., 2016) .", [["ribavirin", "CHEMICAL", 24, 33], ["lopinavir", "CHEMICAL", 35, 44], ["interferon", "CHEMICAL", 49, 59], ["SARS", "DISEASE", 84, 88], ["ribavirin", "CHEMICAL", 24, 33], ["lopinavir", "CHEMICAL", 35, 44], ["ribavirin", "SIMPLE_CHEMICAL", 24, 33], ["lopinavir", "SIMPLE_CHEMICAL", 35, 44], ["interferon", "GENE_OR_GENE_PRODUCT", 49, 59], ["interferon", "PROTEIN", 49, 59], ["Numerous drugs", "TREATMENT", 0, 14], ["ribavirin", "TREATMENT", 24, 33], ["lopinavir", "TREATMENT", 35, 44], ["interferon", "TREATMENT", 49, 59], ["SARS", "PROBLEM", 84, 88], ["drugs", "OBSERVATION", 9, 14]]], ["A few reports indicated that broad-spectrum antiviral drug arbidol that has been used against influenza outbreaks, could enter the clinical trials (Li & De Clercq, 2020) .", [["arbidol", "CHEMICAL", 59, 66], ["influenza outbreaks", "DISEASE", 94, 113], ["arbidol", "CHEMICAL", 59, 66], ["arbidol", "SIMPLE_CHEMICAL", 59, 66], ["broad-spectrum antiviral drug arbidol", "TREATMENT", 29, 66], ["influenza outbreaks", "PROBLEM", 94, 113]]], ["Optimistic results on the application of chloroquine and remdesivir against clinical isolate of 2019-nCoV have been attained and remdesivir is also currently under clinical investigations against Ebola virus infection (Mulangu et al., 2019) .", [["chloroquine", "CHEMICAL", 41, 52], ["remdesivir", "CHEMICAL", 57, 67], ["remdesivir", "CHEMICAL", 129, 139], ["Ebola virus infection", "DISEASE", 196, 217], ["chloroquine", "CHEMICAL", 41, 52], ["remdesivir", "CHEMICAL", 57, 67], ["remdesivir", "CHEMICAL", 129, 139], ["chloroquine", "SIMPLE_CHEMICAL", 41, 52], ["remdesivir", "SIMPLE_CHEMICAL", 57, 67], ["2019-nCoV", "ORGANISM", 96, 105], ["remdesivir", "SIMPLE_CHEMICAL", 129, 139], ["Ebola virus", "ORGANISM", 196, 207], ["Ebola virus", "SPECIES", 196, 207], ["Ebola virus", "SPECIES", 196, 207], ["chloroquine", "TREATMENT", 41, 52], ["remdesivir", "TREATMENT", 57, 67], ["clinical investigations", "TEST", 164, 187], ["Ebola virus infection", "PROBLEM", 196, 217]]], ["Barcitinib was proposed as a potential anti-Covid-19 agents on the basis of its anti-inflammatory effect and possibly reducing viral entry (Richardson et al., 2020) .", [["Barcitinib", "CHEMICAL", 0, 10], ["Barcitinib", "CHEMICAL", 0, 10], ["anti-Covid-19", "CHEMICAL", 39, 52], ["Barcitinib", "SIMPLE_CHEMICAL", 0, 10], ["anti-Covid-19 agents", "SIMPLE_CHEMICAL", 39, 59], ["Barcitinib", "TREATMENT", 0, 10], ["a potential anti-Covid-19 agents", "TREATMENT", 27, 59], ["its anti-inflammatory effect", "TREATMENT", 76, 104], ["anti-inflammatory effect", "OBSERVATION", 80, 104]]], ["In an open-label control study, Cai et al. demonstrated that favipiravir could control Covid-19 progression and viral clearance (Cai et al., 2020) .", [["favipiravir", "CHEMICAL", 61, 72], ["favipiravir", "CHEMICAL", 61, 72], ["favipiravir", "SIMPLE_CHEMICAL", 61, 72], ["label control study", "TEST", 11, 30], ["favipiravir", "TREATMENT", 61, 72], ["Covid", "TEST", 87, 92]]], ["Another open-label non-randomized clinical trial survey indicated that viral load reduction/disappearance in hydroxychloroquine administered Covid-19 patients were reinforced by azithromycin (Gautret et al., 2020) .", [["hydroxychloroquine", "CHEMICAL", 109, 127], ["azithromycin", "CHEMICAL", 178, 190], ["hydroxychloroquine", "CHEMICAL", 109, 127], ["azithromycin", "CHEMICAL", 178, 190], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 109, 127], ["patients", "ORGANISM", 150, 158], ["azithromycin", "SIMPLE_CHEMICAL", 178, 190], ["patients", "SPECIES", 150, 158], ["clinical trial survey", "TEST", 34, 55], ["viral load reduction", "TREATMENT", 71, 91], ["hydroxychloroquine", "TREATMENT", 109, 127], ["azithromycin", "TREATMENT", 178, 190], ["viral load", "OBSERVATION", 71, 81]]], ["In addition to synthetic drugs (Adeoye et al., 2020; Lobo-Galo et al., 2020) , traditional Chinese medicines (Ren et al., 2020; Tahir et al., 2019) and other medicinal plants (Aanouz et al., 2020; Enmozhi et al., 2020; Islam et al., 2020; Umesh et al., 2020) also draw attention in treatment of Covid-19.IntroductionElucidation of SARS-CoV2 pathogenic mechanisms with the aim of identifying potential drug targets, contribute significantly to successful drug repurposing purposes and also design and development of novel therapeutic agents with probably less side effects (Al-Khafaji et al., 2020) .", [["SARS", "DISEASE", 331, 335], ["traditional Chinese medicines", "TREATMENT", 79, 108], ["Covid", "TEST", 295, 300], ["SARS", "PROBLEM", 331, 335], ["successful drug repurposing purposes", "TREATMENT", 443, 479], ["novel therapeutic agents", "TREATMENT", 515, 539], ["SARS", "OBSERVATION", 331, 335]]], ["Human CoVs are characterized by structural proteins such as spike protein (Protein S) and also nonstructural proteins including 3-chymotrypsin-like cysteine protease (3CLpro), papain-like protease (PLpro) and RNA dependent RNA polymerase (RdRp) (Ibrahim et al., 2019) .", [["CoVs", "ANATOMY", 6, 10], ["cysteine", "CHEMICAL", 148, 156], ["Human", "ORGANISM", 0, 5], ["CoVs", "GENE_OR_GENE_PRODUCT", 6, 10], ["spike protein", "GENE_OR_GENE_PRODUCT", 60, 73], ["Protein S", "GENE_OR_GENE_PRODUCT", 75, 84], ["3-chymotrypsin-like cysteine protease", "GENE_OR_GENE_PRODUCT", 128, 165], ["3CLpro", "GENE_OR_GENE_PRODUCT", 167, 173], ["papain-like protease", "GENE_OR_GENE_PRODUCT", 176, 196], ["PLpro", "GENE_OR_GENE_PRODUCT", 198, 203], ["Human CoVs", "PROTEIN", 0, 10], ["structural proteins", "PROTEIN", 32, 51], ["spike protein", "PROTEIN", 60, 73], ["Protein S", "PROTEIN", 75, 84], ["nonstructural proteins", "PROTEIN", 95, 117], ["chymotrypsin", "PROTEIN", 130, 142], ["cysteine protease", "PROTEIN", 148, 165], ["3CLpro", "PROTEIN", 167, 173], ["papain-like protease", "PROTEIN", 176, 196], ["PLpro", "PROTEIN", 198, 203], ["RNA dependent RNA polymerase", "PROTEIN", 209, 237], ["RdRp", "PROTEIN", 239, 243], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human CoVs", "PROBLEM", 0, 10], ["structural proteins", "PROBLEM", 32, 51], ["spike protein", "TEST", 60, 73], ["Protein S", "TEST", 75, 84], ["nonstructural proteins", "TEST", 95, 117], ["chymotrypsin", "TREATMENT", 130, 142], ["cysteine protease (3CLpro)", "TREATMENT", 148, 174], ["papain", "TREATMENT", 176, 182], ["protease (PLpro)", "TREATMENT", 188, 204], ["RNA dependent RNA polymerase", "PROBLEM", 209, 237]]], ["During viral infection progression, both structural and nonstructural proteins play a key part, proposing that targeting them could be a promising strategy for controlling COVID-19 infection (Duan et al., 2020) .", [["viral infection", "DISEASE", 7, 22], ["infection", "DISEASE", 181, 190], ["COVID-19", "ORGANISM", 172, 180], ["nonstructural proteins", "PROTEIN", 56, 78], ["COVID-19", "SPECIES", 172, 180], ["viral infection progression", "PROBLEM", 7, 34], ["infection", "PROBLEM", 181, 190], ["viral", "OBSERVATION_MODIFIER", 7, 12], ["infection", "OBSERVATION", 13, 22], ["nonstructural proteins", "OBSERVATION", 56, 78]]], ["It should be noted that some of the considered proteins were previously proven to be drug discovery targets in the case of SARS-CoV and MERS-CoV (ul Qamar et al., 2020) and may be looked upon as druggable targets in the case of SARS-CoV2 due to the sequence similarity with SARS-CoV (ul Qamar et al., 2020) and also similar binding sites (Joshi et al., 2020; Liu et al., 2020) .", [["SARS", "DISEASE", 123, 127], ["SARS", "DISEASE", 228, 232], ["SARS", "DISEASE", 274, 278], ["SARS-CoV", "ORGANISM", 123, 131], ["MERS-CoV", "ORGANISM", 136, 144], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 228, 237], ["SARS-CoV", "SPECIES", 123, 131], ["MERS-CoV", "SPECIES", 136, 144], ["SARS-CoV", "SPECIES", 274, 282], ["SARS", "PROBLEM", 123, 127], ["CoV", "TEST", 128, 131], ["SARS", "PROBLEM", 228, 232], ["the sequence similarity", "TEST", 245, 268], ["SARS", "PROBLEM", 274, 278]]], ["Hoffmann et al. conducted an interesting research on TMPRSS2 (host-cell produced transmembrane protease serine 2) that facilitates binding of spike protein to angiotensin-converting enzyme 2 (ACE2) on the host cell surface membrane.", [["cell", "ANATOMY", 67, 71], ["cell surface membrane", "ANATOMY", 210, 231], ["angiotensin", "CHEMICAL", 159, 170], ["serine", "CHEMICAL", 104, 110], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 53, 60], ["host-cell", "CELL", 62, 71], ["transmembrane protease serine 2", "GENE_OR_GENE_PRODUCT", 81, 112], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 159, 190], ["ACE2", "GENE_OR_GENE_PRODUCT", 192, 196], ["cell surface membrane", "CELLULAR_COMPONENT", 210, 231], ["TMPRSS2", "PROTEIN", 53, 60], ["host-cell produced transmembrane protease serine 2", "PROTEIN", 62, 112], ["spike protein", "PROTEIN", 142, 155], ["angiotensin-converting enzyme 2", "PROTEIN", 159, 190], ["ACE2", "PROTEIN", 192, 196], ["TMPRSS2 (host-cell", "TREATMENT", 53, 71], ["transmembrane protease serine", "TREATMENT", 81, 110], ["spike protein", "PROBLEM", 142, 155], ["angiotensin", "TEST", 159, 170], ["converting enzyme", "TEST", 171, 188], ["host cell", "OBSERVATION", 205, 214], ["surface membrane", "OBSERVATION", 215, 231]]], ["It was demonstrated that SARS-CoV-2 uses the SARS-CoV ACE2 and TMPRSS2 for host cell entry and clinically proven TMPRSS2 inhibitor camostat mesylate could block SARS-CoV-2 entry (Hoffmann et al., 2020) .IntroductionAlong with conducting in vitro and clinical assessments with the aim of successful drug repurposing, few evaluations were also dedicated to in silico development or computational molecular modeling of new phytochemicals or synthetic compounds (Elfiky, 2020d; Elfiky & Azzam, 2020; Gyebi et al., 2020; Wahedi et al., 2020) or FDA approved drugs against different SARS-CoV2 targets such as RdRp (Elfiky, 2020a (Elfiky, , 2020b (Elfiky, , 2020c , 3CLpro (Khan, Jha, et al. 2020a; Khan, Zia, et al. 2020b; Muralidharan et al., 2020; Pant et al., 2020) , helicase (Beck et al., 2020) , hydrolase (Elmezayen et al., 2020) , nucleocapsid protein (Sarma et al., 2020) , envelope protein (Gupta et al., 2020) , cell-surface Heat Shock Protein A5, ACE2 and spike protein (Abdelli et al., 2020; Ibrahim et al., 2020; Sinha et al., 2020) .", [["cell", "ANATOMY", 80, 84], ["cell", "ANATOMY", 917, 921], ["camostat mesylate", "CHEMICAL", 131, 148], ["SARS", "DISEASE", 577, 581], ["camostat mesylate", "CHEMICAL", 131, 148], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 25, 35], ["SARS-CoV ACE2", "GENE_OR_GENE_PRODUCT", 45, 58], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 63, 70], ["host cell", "CELL", 75, 84], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 113, 120], ["camostat mesylate", "SIMPLE_CHEMICAL", 131, 148], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 161, 171], ["nucleocapsid protein", "GENE_OR_GENE_PRODUCT", 833, 853], ["cell-surface Heat Shock Protein A5", "GENE_OR_GENE_PRODUCT", 917, 951], ["ACE2", "GENE_OR_GENE_PRODUCT", 953, 957], ["SARS-CoV ACE2", "PROTEIN", 45, 58], ["TMPRSS2", "PROTEIN", 63, 70], ["SARS-CoV2 targets", "DNA", 577, 594], ["hydrolase", "PROTEIN", 796, 805], ["nucleocapsid protein", "PROTEIN", 833, 853], ["envelope protein", "PROTEIN", 877, 893], ["cell-surface Heat Shock Protein A5", "PROTEIN", 917, 951], ["ACE2", "PROTEIN", 953, 957], ["spike protein", "PROTEIN", 962, 975], ["SARS-CoV", "SPECIES", 45, 53], ["SARS", "TEST", 25, 29], ["CoV", "TEST", 30, 33], ["the SARS", "TEST", 41, 49], ["CoV ACE2", "TREATMENT", 50, 58], ["TMPRSS2", "TREATMENT", 63, 70], ["host cell entry", "TREATMENT", 75, 90], ["TMPRSS2 inhibitor camostat mesylate", "TREATMENT", 113, 148], ["clinical assessments", "TEST", 250, 270], ["successful drug repurposing", "TREATMENT", 287, 314], ["few evaluations", "TEST", 316, 331], ["drugs", "TREATMENT", 553, 558], ["hydrolase", "TEST", 796, 805], ["nucleocapsid protein", "TEST", 833, 853], ["Sarma et al.", "TEST", 855, 867], ["envelope protein", "TEST", 877, 893], ["cell", "TEST", 917, 921], ["Protein A5", "TEST", 941, 951], ["ACE2", "TEST", 953, 957], ["spike protein", "TEST", 962, 975]]], ["Moreover, some studies focused on the design of a vaccine and a preventative peptidomimetic SARS-CoV2 antagonist (Enayatkhani et al., 2020; Hasan et al., 2020; Robson, 2020) .", [["SARS", "DISEASE", 92, 96], ["some studies", "TEST", 10, 22], ["a vaccine", "TREATMENT", 48, 57], ["a preventative peptidomimetic SARS-CoV2 antagonist", "TREATMENT", 62, 112]]], ["SARS-CoV2 protease enzymes are of significant interest in targeting and modeling studies since they have determinant role in cleaving viral polyproteins into effector proteins, deubiquitinating certain host cell proteins and immune suppression (Baez-Santos et al., 2015; Liu et al., 2020) .IntroductionGiven the vital role of SARS-CoV2 protease in viral infection, current study focused on the identification of in silico hit compounds as potential SARS-CoV2 inhibitors via multistep modeling strategy comprising docking, molecular dynamics (MD) simulations and ab initio based amino acid decomposition analysis of a ZINC retrieved chemical entities (Sterling & Irwin, 2015) .", [["cell", "ANATOMY", 207, 211], ["SARS", "DISEASE", 0, 4], ["viral infection", "DISEASE", 348, 363], ["amino acid", "CHEMICAL", 578, 588], ["amino acid", "CHEMICAL", 578, 588], ["SARS-CoV2 protease", "GENE_OR_GENE_PRODUCT", 0, 18], ["cell", "CELL", 207, 211], ["SARS-CoV2 protease", "GENE_OR_GENE_PRODUCT", 326, 344], ["SARS-CoV2 protease enzymes", "PROTEIN", 0, 26], ["viral polyproteins", "PROTEIN", 134, 152], ["effector proteins", "PROTEIN", 158, 175], ["deubiquitinating certain host cell proteins", "PROTEIN", 177, 220], ["SARS-CoV2 protease", "PROTEIN", 326, 344], ["SARS", "PROBLEM", 0, 4], ["CoV2 protease enzymes", "TEST", 5, 26], ["modeling studies", "TEST", 72, 88], ["cleaving viral polyproteins into effector proteins", "PROBLEM", 125, 175], ["SARS", "PROBLEM", 326, 330], ["CoV2 protease", "TREATMENT", 331, 344], ["viral infection", "PROBLEM", 348, 363], ["current study", "TEST", 365, 378], ["potential SARS", "PROBLEM", 439, 453], ["CoV2 inhibitors", "TREATMENT", 454, 469], ["multistep modeling strategy", "TREATMENT", 474, 501], ["ab initio based amino acid decomposition", "TREATMENT", 562, 602], ["host cell proteins", "OBSERVATION", 202, 220], ["viral infection", "OBSERVATION", 348, 363]]], ["Our structure based simulations run on high-resolution 3D structures of SARS-CoV2 main protease (Mpro) in complex with several fragment ligands (PDB IDs 5R7Y, 5R7Z, 5R80, 5R81, 5R82, 5R83 and 5R84) which were recently unveiled by Fearon et al. (Fearon et al., 2020) .", [["Mpro", "GENE_OR_GENE_PRODUCT", 97, 101], ["SARS-CoV2 main protease", "PROTEIN", 72, 95], ["Mpro", "PROTEIN", 97, 101], ["SARS", "PROBLEM", 72, 76], ["several fragment ligands", "PROBLEM", 119, 143], ["PDB IDs", "TEST", 145, 152], ["5R7Z", "TEST", 159, 163], ["several", "OBSERVATION_MODIFIER", 119, 126], ["fragment ligands", "OBSERVATION", 127, 143]]], ["To get more information, hierarchical view of the multi-step simulations is depicted in Figure 1 .Target dataset3D structures of SARS-CoV2 Mpro in complex with several fragment ligands (5R7Y, 5R7Z, 5R80, 5R81, 5R82, 5R83 and 5R84) were retrieved from the Protein Data Bank (www.rcsb. org) (Fearon et al., 2020) .", [["SARS-CoV2 Mpro", "GENE_OR_GENE_PRODUCT", 129, 143], ["5R84", "GENE_OR_GENE_PRODUCT", 225, 229], ["SARS-CoV2 Mpro", "DNA", 129, 143], ["5R84", "PROTEIN", 225, 229], ["SARS", "PROBLEM", 129, 133], ["several fragment ligands", "PROBLEM", 160, 184], ["5R7Z", "TEST", 192, 196], ["SARS", "OBSERVATION", 129, 133], ["several", "OBSERVATION_MODIFIER", 160, 167], ["fragment ligands", "OBSERVATION", 168, 184]]], ["Co-crystallographic dimethyl sulfoxide and water molecules were all removed from the original PDB files and non-polar hydrogens merged.", [["dimethyl sulfoxide", "CHEMICAL", 20, 38], ["dimethyl sulfoxide", "CHEMICAL", 20, 38], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 20, 38], ["water molecules", "SIMPLE_CHEMICAL", 43, 58], ["non-polar hydrogens", "SIMPLE_CHEMICAL", 108, 127], ["Co-crystallographic dimethyl sulfoxide", "TREATMENT", 0, 38], ["water molecules", "TREATMENT", 43, 58], ["PDB", "ANATOMY", 94, 97], ["non-polar hydrogens", "OBSERVATION", 108, 127]]], ["Acquired files were converted to pdbqt format after assigning Kollman charges and solvation parameters via AutoDock Tools program (ADT) (Morris et al., 2009; Sanner, 1999) .Ligand datasetInternal validation of AutoDock4.2 software was done by seven co-crystallographic ligands (5R7Y, 5R7Z, 5R80, 5R81, 5R82, 5R83 and 5R84) using their interacted conformations as starting point.", [["5R84", "PROTEIN", 317, 321], ["Kollman charges and solvation parameters", "TREATMENT", 62, 102], ["AutoDock", "TEST", 210, 218]]], ["Detailed characteristics of cognate ligands are summarized in internal validation section.", [["internal validation section", "TEST", 62, 89], ["cognate ligands", "OBSERVATION", 28, 43]]], ["All archived ligands that were retrieved in MOL format from Zinc15 database (Sterling & Irwin, 2015) were finally converted to pdbqt using ADT subsequent to the assignment of Gasteiger charges and solvation parameters (Morris et al., 2009; Sanner, 1999) .", [["MOL", "PROTEIN", 44, 47], ["pdbqt", "PROTEIN", 127, 132], ["All archived ligands", "PROBLEM", 0, 20], ["pdbqt", "TREATMENT", 127, 132], ["ADT", "TREATMENT", 139, 142], ["Gasteiger charges", "TREATMENT", 175, 192]]], ["Physicochemical descriptors and ADME parameters were computed by web-based SwissADME program (Daina et al., 2017) .Molecular dockingLamarckian genetic algorithm (LGA) incorporated into AutoDock4.2 package was used to run ligand flexible docking simulations on Zinc driven small molecules (Morris et al., 2009; Sanner, 1999) .", [["Zinc", "CHEMICAL", 260, 264], ["Zinc", "CHEMICAL", 260, 264], ["Zinc", "SIMPLE_CHEMICAL", 260, 264], ["ADME parameters", "TEST", 32, 47], ["AutoDock4.2 package", "TREATMENT", 185, 204]]], ["All the processing steps and docking parameters were arranged according to previous protocols (Alikhani et al., 2018) .", [["docking parameters", "TEST", 29, 47]]], ["Post-docking representation and analysis of ligand-enzyme interactions were performed by the aid of the protein-ligand interaction profiler (PLIP) web server (Salentin et al., 2015) .", [["analysis of ligand-enzyme interactions", "TEST", 32, 70]]], ["Besides protein-ligand interaction profiler (PLIP) package, discovery studio visualizer (ViewerLite) 3.5 was also used to graphically represent the molecules.MD Simulation studyThe all-atom MD simulations were performed using GROMACS 4.6.5 simulation package (Hess et al., 2008) with standard AMBER99SB-ILDN force fields (Lindorff-Larsen et al., 2010) .", [["PLIP", "PROTEIN", 45, 49], ["MD Simulation study", "TEST", 158, 177], ["molecules", "OBSERVATION", 148, 157]]], ["The compatible topologies of the ligands were prepared using the General Amber Force Field (GAFF) (Wang et al., 2004) and ANTECHAMBER suite of programs (Case et al, 2005) , applying the semiempirical AM1BCC charges (Jakalian et al., 2002) .", [["the semiempirical AM1BCC charges", "TREATMENT", 182, 214]]], ["MD simulations were performed according to previous studies (Ebadi et al., 2013; Razzaghi-Asl et al., 2018) .", [["MD simulations", "TEST", 0, 14], ["previous studies", "TEST", 43, 59]]], ["Briefly, two 10000 and 5000 steps steepest descent and conjugated gradient minimizations were performed to remove potential clashes between water, ions, and ligand-enzyme in the simulation box.", [["water", "SIMPLE_CHEMICAL", 140, 145], ["ions", "SIMPLE_CHEMICAL", 147, 151], ["enzyme", "PROTEIN", 164, 170], ["conjugated gradient minimizations", "TREATMENT", 55, 88]]], ["Following initial optimization, the system was equilibrated at 300 K during 500 ps NVT and 1000 ps NPT ensembles.", [["500 ps NVT", "TREATMENT", 76, 86]]], ["50 ns MD production was performed in NPT ensemble without any restraint.", [["any restraint", "TREATMENT", 58, 71]]], ["The temperature and pressure were Figure 1 .", [["The temperature", "TEST", 0, 15], ["pressure", "OBSERVATION_MODIFIER", 20, 28]]], ["Hierarchical view of the multi-step simulations to identify hit compounds as potential SARS-CoV2 inhibitors; Covid-19 related 3 D Mpro structures were screened and subjected to AutoDock4.2 validation step to afford three holo structures with PDB IDs 5R80, 5R81 & 5R84 (Fearon et al., 2020) .", [["Covid-19", "CHEMICAL", 109, 117], ["SARS-CoV2", "SIMPLE_CHEMICAL", 87, 96], ["Covid-19 related 3 D Mpro structures", "DNA", 109, 145], ["hit compounds", "PROBLEM", 60, 73], ["potential SARS", "PROBLEM", 77, 91], ["CoV2 inhibitors", "TREATMENT", 92, 107], ["Covid", "TEST", 109, 114], ["AutoDock", "TEST", 177, 185], ["PDB IDs", "TEST", 242, 249]]], ["Corresponding co-crystallographic fragment ligands were subjected to substructure query in Zinc15 database with the criteria set on all subsets including purchasable compounds (Sterling & Irwin, 2015) .", [["Corresponding co-crystallographic fragment ligands", "PROBLEM", 0, 50], ["fragment ligands", "OBSERVATION", 34, 50]]], ["295 compounds were selected and entered into molecular docking study to attain three top-ranked analogues with highest binding affinities to related protease targets.", [["protease targets", "PROTEIN", 149, 165], ["molecular docking study", "TEST", 45, 68], ["highest binding affinities", "PROBLEM", 111, 137], ["protease targets", "TREATMENT", 149, 165]]], ["Time dependent stability of top-ranked ligand-protease complexes were checked by MD simulations within 50 ns and the cycle might be repeated for next top-ranked candidates if non-desirable results were achieved.", [["protease complexes", "PROTEIN", 46, 64], ["protease complexes", "TEST", 46, 64]]], ["Subsequent amino acid decomposition analysis was performed on in silico hit compounds to acquire ligand-residue intermolecular binding energies by functional B3LYP in association with split valence basis set using polarization functions (Def2-TZVPP).", [["amino acid", "CHEMICAL", 11, 21], ["amino acid", "CHEMICAL", 11, 21], ["amino acid", "AMINO_ACID", 11, 21], ["Def2", "PROTEIN", 238, 242], ["TZVPP", "PROTEIN", 243, 248], ["Subsequent amino acid decomposition analysis", "TEST", 0, 44], ["residue intermolecular binding energies", "PROBLEM", 104, 143], ["functional B3LYP", "TREATMENT", 147, 163], ["split valence basis", "TREATMENT", 184, 203]]], ["Schematic 3 D representation of fragment-enzyme complexes were generated by NGL which is a WebGL based 3 D viewer incorporated into PDB (Rose et al., 2018) .MD Simulation studycontrolled using the modified V-rescale thermostat from Berendsen (Berendsen et al., 1984) with 0.1 ps time constant and Parrinello-Rahman barostat (Parrinello & Rahman, 1981) with 2 ps time constant for coupling respectively.Amino acid decomposition analysisAnalyzing of intermolecular binding energy components was performed via constructing a chemical environment including key interacted SARS-CoV2 residues around a docked molecule.", [["Amino acid", "CHEMICAL", 402, 412], ["Amino acid", "CHEMICAL", 402, 412], ["Amino acid", "AMINO_ACID", 402, 412], ["enzyme complexes", "PROTEIN", 41, 57], ["NGL", "PROTEIN", 76, 79], ["SARS-CoV2 residues", "PROTEIN", 568, 586], ["docked molecule", "PROTEIN", 596, 611], ["fragment-enzyme complexes", "PROBLEM", 32, 57], ["NGL", "TEST", 76, 79], ["Parrinello", "TREATMENT", 297, 307], ["Amino acid decomposition analysis", "TEST", 402, 435], ["intermolecular binding energy components", "PROBLEM", 448, 488], ["fragment", "OBSERVATION", 32, 40], ["PDB", "ANATOMY", 132, 135], ["intermolecular binding", "OBSERVATION", 448, 470]]], ["N-terminals of interacted amino acids were acetylated while C-terminals were methyl amidated without disturbing original conformational and configurational features.", [["amino acids", "CHEMICAL", 26, 37], ["methyl amidated", "CHEMICAL", 77, 92], ["N", "CHEMICAL", 0, 1], ["amino acids", "CHEMICAL", 26, 37], ["C", "CHEMICAL", 60, 61], ["methyl", "CHEMICAL", 77, 83], ["amino acids", "AMINO_ACID", 26, 37], ["methyl amidated", "SIMPLE_CHEMICAL", 77, 92], ["N-terminals", "PROTEIN", 0, 11], ["C-terminals", "PROTEIN", 60, 71], ["interacted amino acids", "TREATMENT", 15, 37], ["configurational features", "OBSERVATION", 140, 164]]], ["Polar hydrogen bonds were optimized using B3LYP/Def2-TZVPP method through heavy atom fixing (HAF) approximation (constrained optimizations) (Fogarasi et al., 1992) .", [["hydrogen", "CHEMICAL", 6, 14], ["Polar hydrogen bonds", "SIMPLE_CHEMICAL", 0, 20], ["Def2", "PROTEIN", 48, 52], ["TZVPP", "PROTEIN", 53, 58], ["Polar hydrogen bonds", "TREATMENT", 0, 20], ["B3LYP/Def2", "TREATMENT", 42, 52], ["TZVPP method", "TREATMENT", 53, 65], ["heavy atom fixing (HAF) approximation", "TREATMENT", 74, 111]]], ["All the ligand-residue binding energies were estimated by the same method and basis set.", [["residue binding energies", "PROBLEM", 15, 39], ["binding energies", "OBSERVATION", 23, 39]]], ["The whole calculations were performed with the ORCA ab initio quantum chemistry package (Neese, 2012) .Molecular dockingTo check the validity of LGA in predicting binding modes within SARS-CoV2 Mpro binding site, candidate co-crystalized ligands were extracted from original complex structures and subjected to re-docking into the corresponding induced fit models (5R7Y, 5R7Z, 5R80, 5R81, 5R82, 5R83 and 5R84).", [["SARS-CoV2 Mpro binding site", "DNA", 184, 211], ["The whole calculations", "TEST", 0, 22], ["SARS", "PROBLEM", 184, 188], ["co-crystalized ligands", "PROBLEM", 223, 245]]], ["For this purpose, root-mean-square deviation (RMSD) of the Cartesian coordinates of re-docked co-crystallographic ligand atoms were used as validation criteria (Vyas et al., 2008) .", [["root", "ANATOMY", 18, 22], ["root", "TEST", 18, 22], ["re-docked co-crystallographic ligand atoms", "TREATMENT", 84, 126], ["root", "ANATOMY", 18, 22]]], ["On the basis of re-docking results, adaptable predictability levels ( 2 \u00c5) could be achieved with 100 independent GA runs and 2.5 \u00c2 10 7 maximum number of evaluations for complexes 5R80, 5R81 and 5R84 (Table 1) .Molecular dockingDrug-enzyme inhibition constants (K i ) were estimated via calculation of free binding energies (equation 1) which was incorporated into the force-field of AutoDock4 as a dependent variable (equation 2):Molecular dockingIn equation 1, DG b is indicative of free binding energy (kcal/ mol), R is the gas constant (Cal.K \u00c01 .mol \u00c01 ) and T represents temperature in kelvin (298.15 K).", [["AutoDock4", "SIMPLE_CHEMICAL", 385, 394], ["DG b", "SIMPLE_CHEMICAL", 464, 468], ["5R80", "PROTEIN", 181, 185], ["5R81", "PROTEIN", 187, 191], ["5R84", "PROTEIN", 196, 200], ["AutoDock4", "PROTEIN", 385, 394], ["adaptable predictability levels", "TEST", 36, 67], ["evaluations", "TEST", 155, 166], ["complexes", "TEST", 171, 180], ["Molecular dockingDrug-enzyme inhibition constants", "PROBLEM", 212, 261], ["K i", "TEST", 263, 266], ["the gas", "TEST", 524, 531], ["K", "TEST", 546, 547], ["indicative of", "UNCERTAINTY", 472, 485]]], ["A number 2.71828 is indicates Napier's constant.", [["Napier's constant", "PROBLEM", 30, 47]]], ["In equation 2, DG Torsional is a term which shows loss of torsional free energy upon binding to enzyme binding site.", [["DG", "SIMPLE_CHEMICAL", 15, 17], ["enzyme binding site", "PROTEIN", 96, 115], ["loss of torsional free energy", "PROBLEM", 50, 79], ["enzyme binding site", "PROBLEM", 96, 115], ["torsional", "OBSERVATION_MODIFIER", 58, 67], ["free energy", "OBSERVATION", 68, 79]]], ["E vdW and E H-bond and E Electrostatic define hydrophobic interaction energy (van der Waals energy), hydrogen bond interaction energy and electrostatic interaction energies.", [["hydrogen", "CHEMICAL", 101, 109], ["H", "CHEMICAL", 12, 13], ["hydrogen", "CHEMICAL", 101, 109], ["E vdW and E H", "TEST", 0, 13], ["hydrophobic interaction energy", "PROBLEM", 46, 76], ["hydrogen bond interaction energy", "PROBLEM", 101, 133], ["electrostatic interaction energies", "PROBLEM", 138, 172]]], ["E Desolvation represents desolvation energy or 'hydrophobicity' for drug target interaction.", [["desolvation energy", "OBSERVATION", 25, 43]]], ["Achieved docked poses were ranked to attain best and worst conformations associated with their binding affinities (Table 2) .Molecular dockingTo characterize binding modes of screened compounds inside the active site of SARS-CoV2 Mpro, all intermolecular interactions of ZINC_170619726, ZINC_108126011 and ZINC_252512772 with key residues, schematic representation of ligand binding poses are depicted in Figure 2 .", [["ZINC_170619726", "CHEMICAL", 271, 285], ["ZINC_108126011", "CHEMICAL", 287, 301], ["ZINC_252512772", "CHEMICAL", 306, 320], ["screened compounds", "PROBLEM", 175, 193]]], ["It should be noted that for salt bridge interactions, the distance is reported between charge centers.MD SimulationsAll systems reached steady-state after a few ps from the beginning of MD simulation.", [["salt bridge interactions", "TREATMENT", 28, 52], ["a few ps", "TREATMENT", 155, 163]]], ["The temperature of the holo 5R84, ZINC_170619726, ZINC_108126011 and ZINC_252512772 systems were stable at 300 K (300.0 (RSD: 0.38) in four systems).", [["ZINC_170619726", "CHEMICAL", 34, 48], ["ZINC_252512772", "CHEMICAL", 69, 83], ["The temperature", "TEST", 0, 15], ["the holo", "TEST", 19, 27], ["ZINC_", "TEST", 34, 39], ["ZINC", "TEST", 69, 73], ["K", "TEST", 111, 112], ["RSD", "TEST", 121, 124]]], ["The energy of holo 5R84, Zinc_170619726, ZINC_108126011, and ZINC_252512772 systems reached \u00c0173007 (RSD: 0.16%), \u00c0168959 (RSD: 0.16), \u00c0170846 (0.16) and \u00c0173011 (0.16) kcal/mol, respectively and were stable during 50 ns MD simulation.MD SimulationsThe stability of SARS-CoV2 Mpro during MD simulation was evaluated through monitoring the RMSD matrix, the radius of gyration, and intra-enzyme hydrogen bonds.", [["SARS", "DISEASE", 266, 270], ["Zinc_170619726", "CHEMICAL", 25, 39], ["ZINC_108126011", "CHEMICAL", 41, 55], ["ZINC_252512772", "CHEMICAL", 61, 75], ["hydrogen", "CHEMICAL", 393, 401], ["holo 5R84", "SIMPLE_CHEMICAL", 14, 23], ["matrix", "CELLULAR_COMPONENT", 344, 350], ["Zinc_", "TEST", 25, 30], ["ZINC_", "TEST", 41, 46], ["ZINC", "TEST", 61, 65], ["RSD", "TEST", 101, 104], ["RSD", "TEST", 123, 126], ["kcal/mol", "TEST", 169, 177], ["SARS", "PROBLEM", 266, 270], ["intra-enzyme hydrogen bonds", "PROBLEM", 380, 407], ["stable", "OBSERVATION_MODIFIER", 201, 207], ["stability", "OBSERVATION_MODIFIER", 253, 262], ["radius", "ANATOMY", 356, 362], ["hydrogen bonds", "OBSERVATION", 393, 407]]], ["The 3 D structure of SARS-CoV2 Mpro was stable during the 50 ns MD simulation.", [["SARS", "DISEASE", 21, 25], ["SARS-CoV2 Mpro", "DNA", 21, 35], ["SARS", "PROBLEM", 21, 25], ["stable", "OBSERVATION_MODIFIER", 40, 46]]], ["The RMSD of protein in crystallographic structure (5R84) increased to 0.12 nm in 20 ps at the beginning of production run.", [["crystallographic structure", "TEST", 23, 49], ["RMSD", "OBSERVATION_MODIFIER", 4, 8], ["protein", "OBSERVATION", 12, 19], ["0.12 nm", "OBSERVATION_MODIFIER", 70, 77], ["20 ps", "OBSERVATION_MODIFIER", 81, 86]]], ["The RMSD was stable during 50 ns MD simulation (0.19 \u00b1 0.014 nm (RSD: 7.7%)).", [["RSD", "TEST", 65, 68], ["stable", "OBSERVATION_MODIFIER", 13, 19]]], ["The radius of gyration (Rg) was constant during 50 ns MD simulation (2.21 \u00b1 0.009 nm).", [["radius", "OBSERVATION_MODIFIER", 4, 10], ["gyration", "OBSERVATION_MODIFIER", 14, 22]]], ["The mean number of intra-hydrogen bonds in SARS-CoV2 Mpro for crystallographic structure (5R84) was calculated 231.7 \u00b1 7.3.", [["SARS", "DISEASE", 43, 47], ["intra-hydrogen", "CHEMICAL", 19, 33], ["SARS", "TEST", 43, 47], ["crystallographic structure", "TEST", 62, 88], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["number", "OBSERVATION_MODIFIER", 9, 15], ["intra-hydrogen bonds", "OBSERVATION", 19, 39]]], ["Figure 3 shows the RMSD matrix and radius of gyration of three potential inhibitors of SARS-CoV2 Mpro found via virtual screening.", [["SARS", "DISEASE", 87, 91], ["the RMSD matrix", "PROBLEM", 15, 30], ["SARS", "PROBLEM", 87, 91], ["virtual screening", "TEST", 112, 129], ["RMSD matrix", "OBSERVATION", 19, 30], ["radius", "OBSERVATION_MODIFIER", 35, 41]]], ["The maximum RMSD changes in the RMSD matrix of three systems were less than 0.3 nm indicating the convergence of SARS-CoV2 Mpro to equilibrium structure.MD SimulationsThe mean number of intra-hydrogen bonds in SARS-CoV2 Mpro for Zinc_170619726, ZINC_108126011, and ZINC_252512772 systems were calculated as 227.3 \u00b1 6.9, 226.0 \u00b1 7.2 and 225.6 \u00b1 6.9 in each frame of trajectories, respectively.MD SimulationsMD simulation of holo structure of SARS-CoV2 Mpro revealed that the Mpro formed stable complex with Z31792168 ( Figure 4) .", [["SARS", "DISEASE", 113, 117], ["SARS", "DISEASE", 210, 214], ["SARS", "DISEASE", 441, 445], ["intra-hydrogen", "CHEMICAL", 186, 200], ["Zinc_170619726", "CHEMICAL", 229, 243], ["ZINC_108126011", "CHEMICAL", 245, 259], ["ZINC_252512772", "CHEMICAL", 265, 279], ["Z31792168", "CHEMICAL", 506, 515], ["Mpro", "SIMPLE_CHEMICAL", 474, 478], ["Mpro", "PROTEIN", 474, 478], ["The maximum RMSD changes", "PROBLEM", 0, 24], ["SARS", "PROBLEM", 113, 117], ["Zinc_", "TEST", 229, 234], ["SARS", "PROBLEM", 441, 445], ["CoV2 Mpro", "TEST", 446, 455], ["maximum", "OBSERVATION_MODIFIER", 4, 11], ["RMSD", "OBSERVATION", 12, 16], ["RMSD", "ANATOMY_MODIFIER", 32, 36], ["SARS", "OBSERVATION", 113, 117], ["equilibrium structure", "OBSERVATION", 131, 152], ["stable", "OBSERVATION_MODIFIER", 486, 492]]], ["Z31792168 was stable in the active site of SARS-CoV2 Mpro.", [["Z31792168", "CHEMICAL", 0, 9], ["Z31792168", "CHEMICAL", 0, 9], ["Z31792168", "SIMPLE_CHEMICAL", 0, 9], ["SARS-CoV2 Mpro", "DNA", 43, 57], ["CoV2 Mpro", "TREATMENT", 48, 57], ["stable", "OBSERVATION_MODIFIER", 14, 20], ["active", "OBSERVATION_MODIFIER", 28, 34], ["site", "OBSERVATION_MODIFIER", 35, 39], ["SARS", "OBSERVATION", 43, 47]]], ["Main conformational changes about 9 ns (red line in the RMSD matrix) was due to the rotation of cyclohexane ring and did not change the orientation of Z31792168 in the active site.MD SimulationsThe stability of Zinc_170619726 in complex with SARS-CoV2 Mpro was evaluated in terms of RMSD matrix and clustering analysis.", [["cyclohexane", "CHEMICAL", 96, 107], ["Z31792168", "CHEMICAL", 151, 160], ["Zinc_170619726", "CHEMICAL", 211, 225], ["SARS", "DISEASE", 242, 246], ["cyclohexane", "CHEMICAL", 96, 107], ["Z31792168", "CHEMICAL", 151, 160], ["Zinc_170619726", "CHEMICAL", 211, 225], ["cyclohexane ring", "SIMPLE_CHEMICAL", 96, 112], ["Z31792168", "SIMPLE_CHEMICAL", 151, 160], ["Zinc_170619726", "SIMPLE_CHEMICAL", 211, 225], ["Zinc_170619726", "PROTEIN", 211, 225], ["SARS-CoV2 Mpro", "DNA", 242, 256], ["Main conformational changes", "PROBLEM", 0, 27], ["9 ns (red line in the RMSD matrix", "TREATMENT", 34, 67], ["the rotation of cyclohexane ring", "TREATMENT", 80, 112], ["SARS", "TEST", 242, 246], ["clustering analysis", "TEST", 299, 318], ["active site", "OBSERVATION", 168, 179], ["stability", "OBSERVATION_MODIFIER", 198, 207]]], ["The conformational changes in Zinc_170619726 during the 50 ns MD simulation led to 14 clusters by considering 2 nm cutoff and using gromos method.", [["Zinc_170619726", "CHEMICAL", 30, 44], ["Zinc_170619726", "CHEMICAL", 30, 44], ["The conformational changes", "PROBLEM", 0, 26], ["gromos method", "TREATMENT", 132, 145]]], ["The size of the top three clusters was obtained as 83.8, 6.5, and 4.8% of the total population, respectively.", [["size", "OBSERVATION_MODIFIER", 4, 8], ["top", "OBSERVATION_MODIFIER", 16, 19]]], ["Conformational changes of Zinc_170619726 in the active site of SARS-CoV2 Mpro are depicted in Figure 5 .", [["Zinc_170619726", "CHEMICAL", 26, 40], ["SARS", "DISEASE", 63, 67], ["Zinc_170619726", "CHEMICAL", 26, 40], ["Zinc_170619726", "GENE_OR_GENE_PRODUCT", 26, 40], ["SARS-CoV2 Mpro", "GENE_OR_GENE_PRODUCT", 63, 77], ["Zinc_170619726", "PROTEIN", 26, 40], ["SARS-CoV2 Mpro", "DNA", 63, 77], ["Conformational changes of Zinc_", "PROBLEM", 0, 31]]], ["The red color in the margin of the RMSD matrix before 7 ns indicated the Figure 6 shows that ZINC_108126011 experienced a high level of conformational variation.", [["ZINC_108126011", "CHEMICAL", 93, 107], ["ZINC_108126011", "CHEMICAL", 93, 107], ["The red color", "TEST", 0, 13], ["ZINC", "TEST", 93, 97], ["red", "OBSERVATION_MODIFIER", 4, 7], ["color", "OBSERVATION_MODIFIER", 8, 13], ["margin", "OBSERVATION_MODIFIER", 21, 27], ["conformational variation", "OBSERVATION", 136, 160]]], ["The amine group of ZINC_108126011 formed a salt bridge with Glu166 in 31.9% of trajectories.", [["amine", "CHEMICAL", 4, 9], ["ZINC_108126011", "CHEMICAL", 19, 33], ["Glu166", "CHEMICAL", 60, 66], ["amine", "CHEMICAL", 4, 9], ["ZINC_108126011", "CHEMICAL", 19, 33], ["Glu166", "CHEMICAL", 60, 66], ["amine", "SIMPLE_CHEMICAL", 4, 9], ["ZINC_108126011", "SIMPLE_CHEMICAL", 19, 33], ["Glu166", "SIMPLE_CHEMICAL", 60, 66], ["a salt bridge", "TREATMENT", 41, 54], ["Glu166", "TEST", 60, 66]]], ["During this time, ZINC_108126011 formed a stable hydrogen bond with Asn142 indicating a different induced fit in the structure of SARS-CoV2 Mpro.", [["ZINC_108126011", "CHEMICAL", 18, 32], ["Asn142", "CHEMICAL", 68, 74], ["SARS", "DISEASE", 130, 134], ["ZINC_108126011", "CHEMICAL", 18, 32], ["hydrogen", "CHEMICAL", 49, 57], ["Asn142", "CHEMICAL", 68, 74], ["Asn142", "SIMPLE_CHEMICAL", 68, 74], ["SARS-CoV2 Mpro", "GENE_OR_GENE_PRODUCT", 130, 144], ["SARS-CoV2 Mpro", "PROTEIN", 130, 144], ["ZINC_", "TEST", 18, 23], ["CoV2 Mpro", "TREATMENT", 135, 144], ["stable", "OBSERVATION_MODIFIER", 42, 48], ["different", "OBSERVATION_MODIFIER", 88, 97], ["induced fit", "OBSERVATION", 98, 109]]], ["In the last 10 ns of MD simulation, the amino moiety was only exposed to the bulk water.MD SimulationsConformational changes of ZINC_252512772 in the initial predicted binding mode were less than Zinc_170619726 and ZINC_108126011 (Figure 7) .", [["amino moiety", "CHEMICAL", 40, 52], ["amino", "CHEMICAL", 40, 45], ["ZINC_252512772", "CHEMICAL", 128, 142], ["Zinc_170619726", "CHEMICAL", 196, 210], ["ZINC_108126011", "CHEMICAL", 215, 229], ["amino moiety", "AMINO_ACID", 40, 52], ["MD simulation", "TREATMENT", 21, 34], ["the amino moiety", "TREATMENT", 36, 52], ["ZINC_", "TEST", 215, 220]]], ["The maximum change of the RMSD matrix was 0.34 nm.", [["maximum", "OBSERVATION_MODIFIER", 4, 11], ["change", "OBSERVATION_MODIFIER", 12, 18], ["RMSD", "OBSERVATION_MODIFIER", 26, 30]]], ["ZINC_252512772 formed a permanent hydrogen bond with Glu166 during 98% of MD simulations time.MD SimulationsThe short range electrostatic and vdW interactions between studied ligands and the active site of SARS-CoV2 Mpro is reported in Table 3 .Intermolecular binding energy componentsOn the basis of molecular docking and MD simulations results, ZINC_252512772 exhibited superior binding features and less conformational variations during 50 ns inside active site of SARS-CoV2 Mpro.", [["ZINC_252512772", "CHEMICAL", 0, 14], ["Glu166", "CHEMICAL", 53, 59], ["SARS", "DISEASE", 206, 210], ["ZINC_252512772", "CHEMICAL", 347, 361], ["ZINC_252512772", "CHEMICAL", 0, 14], ["hydrogen", "CHEMICAL", 34, 42], ["Glu166", "CHEMICAL", 53, 59], ["ZINC_252512772", "CHEMICAL", 347, 361], ["ZINC_252512772", "SIMPLE_CHEMICAL", 0, 14], ["Glu166", "SIMPLE_CHEMICAL", 53, 59], ["ZINC_252512772", "SIMPLE_CHEMICAL", 347, 361], ["SARS-CoV2 Mpro", "PROTEIN", 468, 482], ["The short range electrostatic and vdW interactions between studied ligands", "PROBLEM", 108, 182], ["SARS", "PROBLEM", 206, 210], ["Intermolecular binding energy components", "PROBLEM", 245, 285], ["superior binding features", "PROBLEM", 372, 397], ["less conformational variations", "PROBLEM", 402, 432], ["CoV2 Mpro", "TREATMENT", 473, 482], ["active", "OBSERVATION_MODIFIER", 191, 197], ["binding energy", "OBSERVATION", 260, 274], ["components", "OBSERVATION_MODIFIER", 275, 285]]], ["In order to determine the relative contribution of each interacted Mpro residue in binding to ZINC_252512772, we were convinced to estimate the binding energies of the most probable binding pose of ZINC_252512772 with key residues surrounding active site in B3LYP level of theory with Def2-TZVPP split basis set (Table 4 ).", [["ZINC_252512772", "CHEMICAL", 198, 212], ["Mpro", "CHEMICAL", 67, 71], ["ZINC_252512772", "CHEMICAL", 94, 108], ["ZINC_252512772", "CHEMICAL", 198, 212], ["Mpro residue", "PROTEIN", 67, 79], ["Def2", "PROTEIN", 285, 289], ["TZVPP", "PROTEIN", 290, 295], ["each interacted Mpro residue", "PROBLEM", 51, 79], ["ZINC_", "TREATMENT", 198, 203], ["key residues", "PROBLEM", 218, 230], ["Def2", "TREATMENT", 285, 289], ["active", "OBSERVATION_MODIFIER", 243, 249], ["site", "OBSERVATION_MODIFIER", 250, 254]]], ["It should be noted that Cys145 and Thr190 were also taken into consideration as the interacted environment due to MD outputs.", [["Cys145", "CHEMICAL", 24, 30], ["Thr", "CHEMICAL", 35, 38], ["Cys145", "GENE_OR_GENE_PRODUCT", 24, 30], ["Thr190", "AMINO_ACID", 35, 41]]], ["All the ligand-residue binding interaction energies (DE b ) were calculated through equation 3:Intermolecular binding energy componentsE LR is indicative of residue ligand interaction energy while ER and EL stand for electronic energies for residues and ligand, respectively.Pharmacokinetics predictionIn silico prediction of pharmacokinetics profile was performed through SwissADME calculator (Table 5 ).Analysis of binding affinity/modeGrowing fragments into drug-like structures via adding layers of rings, substituents and linkers has been regarded as a key approach for drug design (Jacquemard & Kellenberger, 2019) .", [["fragments", "ANATOMY", 446, 455], ["ER", "GENE_OR_GENE_PRODUCT", 197, 199], ["ER", "PROTEIN", 197, 199], ["EL", "PROTEIN", 204, 206], ["residue ligand interaction energy", "PROBLEM", 157, 190], ["Pharmacokinetics", "TREATMENT", 275, 291], ["pharmacokinetics profile", "TEST", 326, 350], ["binding affinity", "TEST", 417, 433], ["Growing fragments into drug-like structures", "PROBLEM", 438, 481], ["substituents and linkers", "TREATMENT", 510, 534], ["indicative of", "UNCERTAINTY", 143, 156], ["residue ligand", "OBSERVATION", 157, 171], ["fragments", "OBSERVATION", 446, 455], ["drug", "OBSERVATION_MODIFIER", 461, 465]]], ["Desirable fragment libraries are appropriate starting points for developing privileged medicinal structures provided that further interactions to hotspots inside a target binding region can be reached upon molecular extension.", [["target binding region", "DNA", 164, 185], ["Desirable fragment libraries", "PROBLEM", 0, 28], ["fragment", "OBSERVATION_MODIFIER", 10, 18], ["libraries", "OBSERVATION", 19, 28]]], ["Analysis of docked poses exhibited that ZINC_170619726, ZINC_108126011 and ZINC_252512772 were located in the binding site of SARS-CoV2 protease (Figure 8) .Analysis of binding affinity/modeAssessed compounds participated in H-bond interaction and hydrophobic contacts with 13 hydrophilic and hydrophobic residues of SARS-CoV2 protease.", [["H", "CHEMICAL", 225, 226], ["ZINC_170619726", "CHEMICAL", 40, 54], ["H", "CHEMICAL", 225, 226], ["SARS-CoV2 protease", "GENE_OR_GENE_PRODUCT", 126, 144], ["H-bond", "SIMPLE_CHEMICAL", 225, 231], ["SARS-CoV2 protease", "GENE_OR_GENE_PRODUCT", 317, 335], ["SARS-CoV2 protease", "PROTEIN", 126, 144], ["Figure 8", "PROTEIN", 146, 154], ["SARS-CoV2 protease", "PROTEIN", 317, 335], ["ZINC_", "TEST", 40, 45], ["SARS-CoV2 protease", "TREATMENT", 126, 144], ["binding affinity", "PROBLEM", 169, 185], ["modeAssessed compounds", "PROBLEM", 186, 208], ["SARS", "PROBLEM", 317, 321], ["CoV2 protease", "TREATMENT", 322, 335]]], ["In addition to Hbond interactions and hydrophobic contacts, Zinc_170619726 built salt bridge via carboxylate moiety with His41 imidazole nitrogens (depicted with yellow spheres as charge centers in Figure 2 and the reported distance is between charge centers).", [["Zinc_170619726", "CHEMICAL", 60, 74], ["carboxylate", "CHEMICAL", 97, 108], ["His41 imidazole", "CHEMICAL", 121, 136], ["Zinc_170619726", "CHEMICAL", 60, 74], ["carboxylate", "CHEMICAL", 97, 108], ["His41 imidazole nitrogens", "CHEMICAL", 121, 146], ["Hbond", "SIMPLE_CHEMICAL", 15, 20], ["Zinc_170619726", "SIMPLE_CHEMICAL", 60, 74], ["salt bridge", "SIMPLE_CHEMICAL", 81, 92], ["carboxylate moiety", "SIMPLE_CHEMICAL", 97, 115], ["His41 imidazole nitrogens", "SIMPLE_CHEMICAL", 121, 146], ["Zinc_", "TREATMENT", 60, 65], ["salt bridge via carboxylate moiety", "TREATMENT", 81, 115], ["His41 imidazole nitrogens", "TREATMENT", 121, 146], ["yellow spheres", "TREATMENT", 162, 176]]], ["His41 is one of the catalytic dyad residues building an active site of the enzyme (Das et al., 2020; Yang et al., 2003) .", [["His41", "GENE_OR_GENE_PRODUCT", 0, 5], ["His41", "PROTEIN", 0, 5], ["catalytic dyad residues", "PROTEIN", 20, 43], ["the catalytic dyad residues", "PROBLEM", 16, 43], ["active", "OBSERVATION_MODIFIER", 56, 62]]], ["Comparison of interaction models indicated that Zinc_170619726 tended to made more hydrophilic bonds (Table 6 ) while hydrophobic contacts were dominant for ZINC_252512772 through involvement of cyclic carbon atoms (Table 7) .", [["Zinc_170619726", "CHEMICAL", 48, 62], ["ZINC_252512772", "CHEMICAL", 157, 171], ["cyclic carbon", "CHEMICAL", 195, 208], ["Zinc_170619726", "CHEMICAL", 48, 62], ["ZINC_252512772", "CHEMICAL", 157, 171], ["cyclic carbon", "CHEMICAL", 195, 208], ["Zinc_170619726", "SIMPLE_CHEMICAL", 48, 62], ["ZINC_252512772", "SIMPLE_CHEMICAL", 157, 171], ["cyclic carbon atoms", "SIMPLE_CHEMICAL", 195, 214], ["interaction models", "TEST", 14, 32], ["ZINC", "TREATMENT", 157, 161], ["cyclic carbon atoms", "TREATMENT", 195, 214]]], ["Although more diverse residues were interacted, Zinc_170619726 was associated with lower free binding energy with regard to other three molecules.Analysis of binding affinity/modeMet165 and Glu166 were found to form H-bond and hydrophobic interactions with all of the three molecules (Tables 6-8 ) and hence may be regarded as key residues in maintaining relevant complexes .", [["Zinc_170619726", "CHEMICAL", 48, 62], ["Zinc_170619726", "CHEMICAL", 48, 62], ["Glu166", "CHEMICAL", 190, 196], ["H", "CHEMICAL", 216, 217], ["modeMet165", "GENE_OR_GENE_PRODUCT", 175, 185], ["Glu166", "GENE_OR_GENE_PRODUCT", 190, 196], ["Tables 6-8", "PROTEIN", 285, 295], ["lower free binding energy", "PROBLEM", 83, 108], ["binding affinity", "TEST", 158, 174], ["modeMet165", "TEST", 175, 185], ["Glu166", "TEST", 190, 196], ["hydrophobic interactions", "PROBLEM", 227, 251], ["diverse", "OBSERVATION_MODIFIER", 14, 21], ["residues", "OBSERVATION", 22, 30]]], ["Perpendicular orientation of pyridyl ring and piperidinyl ring of ZINC_252512772 in the active site of SARS-CoV2 protease provided two hydrogen bonds with side chain carboxylate oxygen and backbone NH of Glu166 (Figure 2c) .", [["pyridyl", "CHEMICAL", 29, 36], ["piperidinyl", "CHEMICAL", 46, 57], ["ZINC_252512772", "CHEMICAL", 66, 80], ["oxygen", "CHEMICAL", 178, 184], ["pyridyl", "CHEMICAL", 29, 36], ["piperidinyl", "CHEMICAL", 46, 57], ["ZINC_252512772", "CHEMICAL", 66, 80], ["hydrogen", "CHEMICAL", 135, 143], ["carboxylate", "CHEMICAL", 166, 177], ["oxygen", "CHEMICAL", 178, 184], ["NH", "CHEMICAL", 198, 200], ["Glu166", "CHEMICAL", 204, 210], ["pyridyl ring", "SIMPLE_CHEMICAL", 29, 41], ["piperidinyl ring", "SIMPLE_CHEMICAL", 46, 62], ["ZINC_252512772", "SIMPLE_CHEMICAL", 66, 80], ["side chain carboxylate oxygen", "SIMPLE_CHEMICAL", 155, 184], ["Glu166", "SIMPLE_CHEMICAL", 204, 210], ["SARS-CoV2 protease", "PROTEIN", 103, 121], ["Perpendicular orientation of pyridyl ring", "TREATMENT", 0, 41], ["piperidinyl ring of ZINC_", "TREATMENT", 46, 71], ["SARS", "PROBLEM", 103, 107], ["CoV2 protease", "TREATMENT", 108, 121], ["two hydrogen bonds", "TREATMENT", 131, 149], ["side chain carboxylate oxygen", "TREATMENT", 155, 184], ["pyridyl ring", "OBSERVATION", 29, 41]]], ["Similar Hbond pattern could be detected for ZINC_170619726 between ester carbonyl oxygen and Glu166 backbone NH (Figure 2a) .", [["ZINC_170619726", "CHEMICAL", 44, 58], ["ester carbonyl", "CHEMICAL", 67, 81], ["oxygen", "CHEMICAL", 82, 88], ["Glu166", "CHEMICAL", 93, 99], ["ZINC_170619726", "CHEMICAL", 44, 58], ["ester carbonyl oxygen", "CHEMICAL", 67, 88], ["Glu", "CHEMICAL", 93, 96], ["NH", "CHEMICAL", 109, 111], ["ZINC_170619726", "SIMPLE_CHEMICAL", 44, 58], ["ester carbonyl oxygen", "SIMPLE_CHEMICAL", 67, 88], ["Glu166", "SIMPLE_CHEMICAL", 93, 99], ["ZINC", "TEST", 44, 48], ["ester carbonyl oxygen", "TREATMENT", 67, 88], ["Glu", "TEST", 93, 96]]], ["Comparable hydrogen bond interaction was recorded between Glu166 carboxylate and amino methyl substituent of ZINC_108126011.Analysis of binding affinity/modeDocking results proposed that N-aryl amide derivative (ZINC_252512772) could bind to SARS-CoV2 protease with high binding energy (DG b \u00c09.18 kcal/mol) and hence might be a good anti-coronavirus candidate for further development strategies.", [["Glu166 carboxylate", "CHEMICAL", 58, 76], ["amino methyl substituent", "CHEMICAL", 81, 105], ["ZINC_108126011", "CHEMICAL", 109, 123], ["N-aryl amide", "CHEMICAL", 187, 199], ["ZINC_252512772", "CHEMICAL", 212, 226], ["hydrogen", "CHEMICAL", 11, 19], ["Glu166 carboxylate", "CHEMICAL", 58, 76], ["amino methyl", "CHEMICAL", 81, 93], ["ZINC_108126011", "CHEMICAL", 109, 123], ["N-aryl amide", "CHEMICAL", 187, 199], ["ZINC_252512772", "CHEMICAL", 212, 226], ["Glu166 carboxylate", "SIMPLE_CHEMICAL", 58, 76], ["amino methyl substituent", "SIMPLE_CHEMICAL", 81, 105], ["ZINC_108126011", "SIMPLE_CHEMICAL", 109, 123], ["N-aryl amide derivative", "SIMPLE_CHEMICAL", 187, 210], ["ZINC_252512772", "SIMPLE_CHEMICAL", 212, 226], ["SARS-CoV2 protease", "GENE_OR_GENE_PRODUCT", 242, 260], ["anti-coronavirus", "CANCER", 334, 350], ["SARS-CoV2 protease", "PROTEIN", 242, 260], ["carboxylate and amino methyl substituent of ZINC", "TREATMENT", 65, 113], ["binding affinity", "TEST", 136, 152], ["N-aryl amide derivative (ZINC_", "TREATMENT", 187, 217], ["SARS", "PROBLEM", 242, 246], ["CoV2 protease", "TREATMENT", 247, 260], ["high binding energy", "PROBLEM", 266, 285], ["further development strategies", "TREATMENT", 365, 395], ["hydrogen bond", "OBSERVATION", 11, 24]]], ["Most of the established interactions were hydrophobic in nature (Table 7) and probably Glu166 was the most significant residue that participated in three key interactions with C19, pyridyl nitrogen and terminal amide nitrogen of ZINC_252512772.", [["Glu166", "CHEMICAL", 87, 93], ["C19, pyridyl nitrogen", "CHEMICAL", 176, 197], ["terminal amide nitrogen", "CHEMICAL", 202, 225], ["ZINC_252512772", "CHEMICAL", 229, 243], ["Glu166", "CHEMICAL", 87, 93], ["C19", "CHEMICAL", 176, 179], ["pyridyl", "CHEMICAL", 181, 188], ["nitrogen", "CHEMICAL", 189, 197], ["amide", "CHEMICAL", 211, 216], ["nitrogen", "CHEMICAL", 217, 225], ["ZINC_252512772", "CHEMICAL", 229, 243], ["Glu166", "GENE_OR_GENE_PRODUCT", 87, 93], ["C19", "SIMPLE_CHEMICAL", 176, 179], ["pyridyl nitrogen", "SIMPLE_CHEMICAL", 181, 197], ["terminal amide nitrogen", "SIMPLE_CHEMICAL", 202, 225], ["significant residue", "PROBLEM", 107, 126], ["C19, pyridyl nitrogen", "TREATMENT", 176, 197], ["terminal amide nitrogen of ZINC_", "TREATMENT", 202, 234], ["most significant", "OBSERVATION_MODIFIER", 102, 118], ["residue", "OBSERVATION", 119, 126]]], ["Similar results could be found on drug repurposing studies of an anti-asthmatic drug montelukast which showed highly binding affinity to SARS-CoV2 Mpro through hydrophobic contacts with Thr24, Leu27, His41, Phe140, Cys145, His163, Met165, Pro168 and His172 (Wu et al., 2020) .Analysis of binding affinity/modeIn the case of sulfonamide derivatives (ZINC_170619726 and ZINC_108126011), it seemed that non-rigidified sulfonamide (ZINC_108126011) could bind more tightly to the SARS-CoV2 binding site.", [["montelukast", "CHEMICAL", 85, 96], ["Phe140", "CHEMICAL", 207, 213], ["sulfonamide", "CHEMICAL", 324, 335], ["ZINC_170619726", "CHEMICAL", 349, 363], ["ZINC_108126011", "CHEMICAL", 368, 382], ["sulfonamide", "CHEMICAL", 415, 426], ["ZINC_108126011", "CHEMICAL", 428, 442], ["montelukast", "CHEMICAL", 85, 96], ["Thr24", "CHEMICAL", 186, 191], ["Leu27", "CHEMICAL", 193, 198], ["His41", "CHEMICAL", 200, 205], ["Phe", "CHEMICAL", 207, 210], ["Cys", "CHEMICAL", 215, 218], ["His", "CHEMICAL", 223, 226], ["Met", "CHEMICAL", 231, 234], ["Pro168", "CHEMICAL", 239, 245], ["His", "CHEMICAL", 250, 253], ["sulfonamide", "CHEMICAL", 324, 335], ["ZINC_170619726", "CHEMICAL", 349, 363], ["ZINC_108126011", "CHEMICAL", 368, 382], ["sulfonamide", "CHEMICAL", 415, 426], ["ZINC_108126011", "CHEMICAL", 428, 442], ["montelukast", "SIMPLE_CHEMICAL", 85, 96], ["SARS-CoV2 Mpro", "GENE_OR_GENE_PRODUCT", 137, 151], ["Thr24", "GENE_OR_GENE_PRODUCT", 186, 191], ["Leu27", "GENE_OR_GENE_PRODUCT", 193, 198], ["His41", "GENE_OR_GENE_PRODUCT", 200, 205], ["Phe140", "AMINO_ACID", 207, 213], ["Cys145", "AMINO_ACID", 215, 221], ["Met165", "GENE_OR_GENE_PRODUCT", 231, 237], ["Pro168", "GENE_OR_GENE_PRODUCT", 239, 245], ["sulfonamide derivatives", "SIMPLE_CHEMICAL", 324, 347], ["non-rigidified sulfonamide", "SIMPLE_CHEMICAL", 400, 426], ["ZINC_108126011", "SIMPLE_CHEMICAL", 428, 442], ["SARS-CoV2 binding site", "DNA", 475, 497], ["an anti-asthmatic drug montelukast", "TREATMENT", 62, 96], ["highly binding affinity", "PROBLEM", 110, 133], ["SARS", "TEST", 137, 141], ["Leu27", "TEST", 193, 198], ["His41", "TEST", 200, 205], ["Phe", "TEST", 207, 210], ["Cys", "TEST", 215, 218], ["His", "TEST", 223, 226], ["Met", "TEST", 231, 234], ["Pro168", "TEST", 239, 245], ["His", "TEST", 250, 253], ["binding affinity", "TEST", 288, 304], ["sulfonamide derivatives", "TREATMENT", 324, 347], ["ZINC_", "TREATMENT", 349, 354], ["non-rigidified sulfonamide (ZINC_", "TREATMENT", 400, 433], ["SARS", "OBSERVATION", 475, 479]]], ["Attachment of a primary amine into cyclopentyl ring of ZINC_108126011 provided a good HBD (hydrogen bond donor) and at the same time HBA (hydrogen bond acceptor) site to interact through H-bonding with Glu166 and Leu167.", [["amine", "CHEMICAL", 24, 29], ["cyclopentyl", "CHEMICAL", 35, 46], ["ZINC_108126011", "CHEMICAL", 55, 69], ["primary amine", "CHEMICAL", 16, 29], ["cyclopentyl", "CHEMICAL", 35, 46], ["ZINC_108126011", "CHEMICAL", 55, 69], ["hydrogen", "CHEMICAL", 91, 99], ["HBA", "CHEMICAL", 133, 136], ["hydrogen", "CHEMICAL", 138, 146], ["H-", "CHEMICAL", 187, 189], ["Glu166", "CHEMICAL", 202, 208], ["Leu167", "CHEMICAL", 213, 219], ["amine", "SIMPLE_CHEMICAL", 24, 29], ["cyclopentyl ring", "SIMPLE_CHEMICAL", 35, 51], ["ZINC_108126011", "SIMPLE_CHEMICAL", 55, 69], ["HBD", "GENE_OR_GENE_PRODUCT", 86, 89], ["HBA", "SIMPLE_CHEMICAL", 133, 136], ["H-bonding", "SIMPLE_CHEMICAL", 187, 196], ["Glu166", "SIMPLE_CHEMICAL", 202, 208], ["Leu167", "SIMPLE_CHEMICAL", 213, 219], ["HBD", "PROTEIN", 86, 89], ["hydrogen bond acceptor) site", "PROTEIN", 138, 166], ["a primary amine into cyclopentyl ring of ZINC", "TREATMENT", 14, 59], ["a good HBD (hydrogen bond donor", "TREATMENT", 79, 110], ["HBA (hydrogen bond acceptor", "TREATMENT", 133, 160], ["Glu166", "TEST", 202, 208]]], ["Similar H-bond interaction could not be recorded for ZINC_170619726 due to the lack of hydrogen on sulfonamide nitrogen and also its non-protruding orientation.", [["H", "CHEMICAL", 8, 9], ["ZINC_170619726", "CHEMICAL", 53, 67], ["hydrogen", "CHEMICAL", 87, 95], ["sulfonamide nitrogen", "CHEMICAL", 99, 119], ["H", "CHEMICAL", 8, 9], ["ZINC_170619726", "CHEMICAL", 53, 67], ["hydrogen", "CHEMICAL", 87, 95], ["sulfonamide", "CHEMICAL", 99, 110], ["nitrogen", "CHEMICAL", 111, 119], ["hydrogen", "SIMPLE_CHEMICAL", 87, 95], ["sulfonamide nitrogen", "SIMPLE_CHEMICAL", 99, 119], ["ZINC", "TEST", 53, 57], ["sulfonamide nitrogen", "TREATMENT", 99, 119]]], ["Moreover, none of the sulfonamide oxygens formed Hbonds with SARS-CoV2 residues.MD AnalysisEnzymes are flexible macromolecules that can adopt a limited induced-fit models in order to achieve probably best steric and electronic complementary with their ligands.", [["sulfonamide", "CHEMICAL", 22, 33], ["SARS", "DISEASE", 61, 65], ["sulfonamide oxygens", "CHEMICAL", 22, 41], ["sulfonamide oxygens", "SIMPLE_CHEMICAL", 22, 41], ["Hbonds", "SIMPLE_CHEMICAL", 49, 55], ["SARS-CoV2", "SIMPLE_CHEMICAL", 61, 70], ["the sulfonamide oxygens", "TREATMENT", 18, 41], ["SARS", "PROBLEM", 61, 65], ["CoV2 residues", "PROBLEM", 66, 79], ["MD AnalysisEnzymes", "TEST", 80, 98], ["flexible macromolecules", "PROBLEM", 103, 126], ["CoV2 residues", "OBSERVATION", 66, 79]]], ["To evaluate the stability of predicted SARS-CoV2 Mpro complexes with regard to the dynamic characteristics of the enzyme, 50 ns MD simulations of three systems (ZINC_170619726, ZINC_108126011 and ZINC_252512772) were conducted in explicit water.", [["SARS", "DISEASE", 39, 43], ["ZINC_252512772", "CHEMICAL", 196, 210], ["ZINC_170619726", "CHEMICAL", 161, 175], ["ZINC_108126011", "CHEMICAL", 177, 191], ["ZINC_252512772", "CHEMICAL", 196, 210], ["SARS-CoV2 Mpro complexes", "PROTEIN", 39, 63], ["predicted SARS", "PROBLEM", 29, 43], ["the enzyme", "TEST", 110, 120]]], ["The obtained results of three studied systems were compared to the result of 50 ns MD simulation of crystallographic holo structure (PDB ID: 5R84).MD AnalysisThe evaluation of temperature and energy during MD simulations indicated that the systems reached to the steady-state and conservation of energy law was satisfied within four systems.MD AnalysisA comparison of MD results indicated that density of polar surface area in the structure of SARS-CoV2 Mpro inhibitor is the dominant factor in stability of ligand-enzyme complex.", [["surface area", "ANATOMY", 411, 423], ["SARS", "DISEASE", 444, 448], ["SARS-CoV2 Mpro", "SIMPLE_CHEMICAL", 444, 458], ["ligand-enzyme complex", "GENE_OR_GENE_PRODUCT", 508, 529], ["crystallographic holo structure", "PROTEIN", 100, 131], ["ligand-enzyme complex", "PROTEIN", 508, 529], ["three studied systems", "TEST", 24, 45], ["The evaluation", "TEST", 158, 172], ["MD simulations", "TEST", 206, 220], ["density of polar surface area", "PROBLEM", 394, 423], ["SARS", "PROBLEM", 444, 448], ["CoV2 Mpro inhibitor", "TREATMENT", 449, 468], ["density", "OBSERVATION", 394, 401], ["polar", "OBSERVATION_MODIFIER", 405, 410], ["surface", "OBSERVATION_MODIFIER", 411, 418], ["SARS", "OBSERVATION", 444, 448], ["dominant", "OBSERVATION_MODIFIER", 476, 484]]], ["Distribution of polar surfaces (O and N atoms) in the structure of ZINC_252512772 is more than ZINC_170619726 and ZINC_108126011.", [["O", "CHEMICAL", 32, 33], ["N", "CHEMICAL", 38, 39], ["ZINC_252512772", "CHEMICAL", 67, 81], ["ZINC_170619726", "CHEMICAL", 95, 109], ["ZINC_108126011", "CHEMICAL", 114, 128], ["polar", "OBSERVATION_MODIFIER", 16, 21], ["surfaces", "OBSERVATION_MODIFIER", 22, 30]]], ["The active site of SARS-CoV2 Mpro is exposed to the surface of enzyme and polar hydroxyl and quaternary amine in the structures of ZINC_170619726 and ZINC_108126011 tended to be more exposed to the bulk water than interacting with enzyme active site.", [["surface", "ANATOMY", 52, 59], ["SARS", "DISEASE", 19, 23], ["Mpro", "CHEMICAL", 29, 33], ["hydroxyl", "CHEMICAL", 80, 88], ["amine", "CHEMICAL", 104, 109], ["ZINC_170619726", "CHEMICAL", 131, 145], ["ZINC_108126011", "CHEMICAL", 150, 164], ["hydroxyl", "CHEMICAL", 80, 88], ["quaternary amine", "CHEMICAL", 93, 109], ["ZINC_170619726", "CHEMICAL", 131, 145], ["ZINC_108126011", "CHEMICAL", 150, 164], ["SARS-CoV2 Mpro", "GENE_OR_GENE_PRODUCT", 19, 33], ["surface", "CELLULAR_COMPONENT", 52, 59], ["polar hydroxyl", "SIMPLE_CHEMICAL", 74, 88], ["quaternary amine", "SIMPLE_CHEMICAL", 93, 109], ["SARS-CoV2 Mpro", "DNA", 19, 33], ["enzyme active site", "PROTEIN", 231, 249], ["SARS", "PROBLEM", 19, 23], ["enzyme", "TEST", 63, 69], ["polar hydroxyl", "TREATMENT", 74, 88], ["quaternary amine", "TREATMENT", 93, 109], ["active", "OBSERVATION_MODIFIER", 4, 10], ["site", "OBSERVATION_MODIFIER", 11, 15], ["SARS", "OBSERVATION", 19, 23]]], ["This structural feature has been seen in the structure of other known protease inhibitors especially in -navir and -previr classes (Lv et al., 2015) .", [["-navir", "SIMPLE_CHEMICAL", 104, 110], ["other known protease inhibitors", "TREATMENT", 58, 89], ["protease inhibitors", "OBSERVATION", 70, 89]]], ["Appropriate but not the most potent interaction with ionized carboxylate of Glu166 eased the binding and also increased the stability of the ligand-enzyme complex.", [["ionized carboxylate", "CHEMICAL", 53, 72], ["Glu166", "CHEMICAL", 76, 82], ["carboxylate", "CHEMICAL", 61, 72], ["Glu166", "CHEMICAL", 76, 82], ["ionized carboxylate", "SIMPLE_CHEMICAL", 53, 72], ["Glu166", "SIMPLE_CHEMICAL", 76, 82], ["enzyme complex", "PROTEIN", 148, 162], ["ionized carboxylate of Glu166", "TEST", 53, 82], ["stability", "OBSERVATION_MODIFIER", 124, 133]]], ["MD estimated van der Waals and electrostatic energies of 5r80 (Zinc_170619726), 5r81 (ZINC_108126011) and 5r84 (ZINC_252512772).CompoundElectrostatic (kcal/mol) vdW (kcal/mol) 5r84 (holo structure) \u00c011.3 (\u00b13.7) \u00c032.2 (\u00b13.2) 5r80 \u00c011.7 (\u00b15.0) \u00c032.0 (\u00b12.4) 5r81Compound\u00c06.6 (\u00b13.6) 32.6 (\u00b13.6) 5r84Compound\u00c016.9 (\u00b13.8) \u00c041.4 (\u00b12.4) Comparing the RMSF of three systems during the 50 ns MD simulations showed that ZINC_252512772 formed tight binding with SARS-CoV2 Mpro.", [["ZINC_252512772", "CHEMICAL", 409, 423], ["5r81", "CHEMICAL", 80, 84], ["5r84", "CHEMICAL", 106, 110], ["ZINC_252512772", "CHEMICAL", 112, 126], ["ZINC_252512772", "CHEMICAL", 409, 423], ["ZINC_252512772", "SIMPLE_CHEMICAL", 409, 423], ["SARS-CoV2 Mpro", "PROTEIN", 450, 464], ["CompoundElectrostatic (kcal/mol) vdW (kcal/mol)", "TREATMENT", 128, 175], ["holo structure", "TEST", 182, 196], ["ZINC_", "TEST", 409, 414]]], ["The RMSF in residue Glu166 indicated a significant change among three systems.", [["Glu166", "AMINO_ACID", 20, 26], ["RMSF", "PROTEIN", 4, 8], ["The RMSF in residue Glu166", "TEST", 0, 26], ["a significant change among three systems", "PROBLEM", 37, 77], ["RMSF", "OBSERVATION", 4, 8], ["significant", "OBSERVATION_MODIFIER", 39, 50], ["change", "OBSERVATION", 51, 57]]], ["The RMSF of Glu166 in ZINC_252512772, ZINC_108126011 and Zinc_170619726 was 0.08, 0.13 and 0.12 nm respectively.", [["ZINC_252512772", "CHEMICAL", 22, 36], ["Zinc_170619726", "CHEMICAL", 57, 71], ["Glu166", "CHEMICAL", 12, 18], ["ZINC_252512772", "CHEMICAL", 22, 36], ["ZINC_108126011", "CHEMICAL", 38, 52], ["Zinc_170619726", "CHEMICAL", 57, 71], ["The RMSF", "TEST", 0, 8], ["ZINC_", "TEST", 22, 27], ["Zinc_", "TEST", 57, 62], ["RMSF", "OBSERVATION", 4, 8]]], ["ZINC_108126011 with quaternary amine formed less favorable interactions with Glu166.", [["ZINC_108126011", "CHEMICAL", 0, 14], ["quaternary amine", "CHEMICAL", 20, 36], ["Glu166", "CHEMICAL", 77, 83], ["ZINC_108126011", "CHEMICAL", 0, 14], ["quaternary amine", "CHEMICAL", 20, 36], ["Glu", "CHEMICAL", 77, 80], ["ZINC_108126011", "SIMPLE_CHEMICAL", 0, 14], ["quaternary amine", "SIMPLE_CHEMICAL", 20, 36], ["Glu166", "SIMPLE_CHEMICAL", 77, 83], ["Glu", "TEST", 77, 80]]], ["In comparison, ZINC_252512772, which interacted with Glu166 via its primary amid moiety, had the most binding energy.", [["ZINC_252512772", "CHEMICAL", 15, 29], ["Glu166", "CHEMICAL", 53, 59], ["ZINC_252512772", "CHEMICAL", 15, 29], ["Glu166", "CHEMICAL", 53, 59], ["ZINC_252512772", "SIMPLE_CHEMICAL", 15, 29], ["Glu166", "SIMPLE_CHEMICAL", 53, 59], ["Glu166", "PROTEIN", 53, 59]]], ["Interestingly, ZINC_108126011 and Zinc_170619726 had more constructive interactions with hydrophobic residues (His41, Pro52, and Phe140).", [["ZINC_108126011", "CHEMICAL", 15, 29], ["Zinc_170619726", "CHEMICAL", 34, 48], ["Phe140", "CHEMICAL", 129, 135], ["ZINC_108126011", "CHEMICAL", 15, 29], ["Zinc_170619726", "CHEMICAL", 34, 48], ["His41", "CHEMICAL", 111, 116], ["Pro52", "CHEMICAL", 118, 123], ["Phe", "CHEMICAL", 129, 132], ["Zinc_", "TREATMENT", 34, 39], ["hydrophobic residues", "PROBLEM", 89, 109], ["His41", "TEST", 111, 116], ["Pro52", "TEST", 118, 123]]], ["In this regard, the most noticeable change in the binding pose of Zinc_170619726 was the protruding of methyl benzoate moiety into the SARS-CoV2 Mpro active site (Figure 4 ).", [["Zinc_170619726", "CHEMICAL", 66, 80], ["methyl benzoate", "CHEMICAL", 103, 118], ["Zinc_170619726", "CHEMICAL", 66, 80], ["methyl benzoate", "CHEMICAL", 103, 118], ["Zinc_170619726", "SIMPLE_CHEMICAL", 66, 80], ["methyl benzoate moiety", "SIMPLE_CHEMICAL", 103, 125], ["SARS-CoV2 Mpro active site", "PROTEIN", 135, 161], ["methyl benzoate moiety", "TREATMENT", 103, 125], ["the SARS", "PROBLEM", 131, 139], ["noticeable", "OBSERVATION_MODIFIER", 25, 35], ["change", "OBSERVATION", 36, 42]]], ["Similar shift in binding pose could be detected for ZINC_108126011 in a way that tetrahydroquinoline ring permeated into the hydrophobic pocket and made the sulfonamide and quaternary amine more water exposable ( Figure 5) .CompoundThe electrostatic interaction decreased in the following order: 5r84 > 5r80 $ 5r84 (holo structure) > 5r81.", [["ZINC_108126011", "CHEMICAL", 52, 66], ["tetrahydroquinoline", "CHEMICAL", 81, 100], ["sulfonamide", "CHEMICAL", 157, 168], ["ZINC_108126011", "CHEMICAL", 52, 66], ["tetrahydroquinoline", "CHEMICAL", 81, 100], ["sulfonamide", "CHEMICAL", 157, 168], ["quaternary amine", "CHEMICAL", 173, 189], ["tetrahydroquinoline ring", "SIMPLE_CHEMICAL", 81, 105], ["sulfonamide", "SIMPLE_CHEMICAL", 157, 168], ["quaternary amine", "SIMPLE_CHEMICAL", 173, 189], ["holo structure", "PROTEIN", 316, 330], ["5r81", "PROTEIN", 334, 338], ["Similar shift in binding pose", "PROBLEM", 0, 29], ["ZINC_", "TREATMENT", 52, 57], ["tetrahydroquinoline ring", "TREATMENT", 81, 105], ["the hydrophobic pocket", "PROBLEM", 121, 143], ["the sulfonamide and quaternary amine", "TREATMENT", 153, 189], ["shift", "OBSERVATION", 8, 13], ["hydrophobic pocket", "OBSERVATION", 125, 143], ["electrostatic interaction", "OBSERVATION", 236, 261], ["decreased", "OBSERVATION_MODIFIER", 262, 271]]], ["The vdW interaction of 5r84 with the active site of SARS-CoV2 Mpro was more than 5r81, 5r84 (holo structure) and 5r80.CompoundAccording to obtained results, ZINC_252512772 showed better steric and electronic complementary fitness with the SARS-CoV2 Mpro active site in comparison to ZINC_108126011 and Zinc_170619726.Amino acid decomposition analysisMD results confirmed that within 50 ns simulations, less conformational changes were met in binding of ZINC_252512772 with regard to ZINC_170619726 and ZINC_108126011.", [["ZINC_252512772", "CHEMICAL", 157, 171], ["Amino acid", "CHEMICAL", 317, 327], ["ZINC_252512772", "CHEMICAL", 453, 467], ["Zinc_170619726", "CHEMICAL", 302, 316], ["Amino acid", "CHEMICAL", 317, 327], ["ZINC_252512772", "CHEMICAL", 453, 467], ["ZINC_170619726", "CHEMICAL", 483, 497], ["ZINC_108126011", "CHEMICAL", 502, 516], ["5r84", "GENE_OR_GENE_PRODUCT", 23, 27], ["SARS-CoV2 Mpro", "GENE_OR_GENE_PRODUCT", 52, 66], ["Amino acid", "AMINO_ACID", 317, 327], ["5r84", "PROTEIN", 23, 27], ["SARS-CoV2 Mpro", "DNA", 52, 66], ["5r84", "PROTEIN", 87, 91], ["holo structure", "PROTEIN", 93, 107], ["5r80", "PROTEIN", 113, 117], ["SARS-CoV2 Mpro active site", "DNA", 239, 265], ["SARS", "PROBLEM", 52, 56], ["CoV2 Mpro", "TEST", 57, 66], ["the SARS", "TEST", 235, 243], ["Zinc_", "TEST", 302, 307], ["Amino acid decomposition analysisMD", "TEST", 317, 352], ["less conformational changes", "PROBLEM", 402, 429]]], ["More stable ZINC_252512772-Mpro complex convinced us to determine relative contribution of each interacted Mpro residue in binding to the most probable conformation of the corresponding ligand.", [["Mpro", "CHEMICAL", 107, 111], ["ZINC_252512772-Mpro complex", "GENE_OR_GENE_PRODUCT", 12, 39], ["Mpro", "GENE_OR_GENE_PRODUCT", 107, 111], ["ZINC_252512772", "PROTEIN", 12, 26], ["Mpro complex", "PROTEIN", 27, 39], ["Mpro residue", "PROTEIN", 107, 119], ["each interacted Mpro residue in binding", "PROBLEM", 91, 130], ["stable", "OBSERVATION_MODIFIER", 5, 11], ["Mpro residue", "OBSERVATION", 107, 119]]], ["On the basis of achieved results (Table 4) , five residues (Phe140, Asn142, Cys145, Glu166 & Thr190) were associated with attractive binding forces while His41, Pro52, Met165, Arg188 and Gln189 were associated with repulsive binding forces.Amino acid decomposition analysisProbably the most favorable result could be achieved in the case of Glu166 which is one of the catalytic dyad residues.", [["Amino acid", "CHEMICAL", 240, 250], ["Glu166", "CHEMICAL", 341, 347], ["Phe140", "CHEMICAL", 60, 66], ["Asn142", "CHEMICAL", 68, 74], ["Cys", "CHEMICAL", 76, 79], ["Glu", "CHEMICAL", 84, 87], ["Thr", "CHEMICAL", 93, 96], ["His41", "CHEMICAL", 154, 159], ["Pro52", "CHEMICAL", 161, 166], ["Met", "CHEMICAL", 168, 171], ["Arg", "CHEMICAL", 176, 179], ["Gln189", "CHEMICAL", 187, 193], ["Amino acid", "CHEMICAL", 240, 250], ["Glu166", "CHEMICAL", 341, 347], ["Cys145", "AMINO_ACID", 76, 82], ["Glu", "AMINO_ACID", 84, 87], ["Thr190", "AMINO_ACID", 93, 99], ["His41", "GENE_OR_GENE_PRODUCT", 154, 159], ["Pro52", "GENE_OR_GENE_PRODUCT", 161, 166], ["Met165", "GENE_OR_GENE_PRODUCT", 168, 174], ["Arg188", "AMINO_ACID", 176, 182], ["Gln189", "GENE_OR_GENE_PRODUCT", 187, 193], ["Amino acid", "AMINO_ACID", 240, 250], ["Glu166", "SIMPLE_CHEMICAL", 341, 347], ["catalytic dyad residues", "PROTEIN", 368, 391], ["Phe140", "TEST", 60, 66], ["Cys", "TEST", 76, 79], ["Glu", "TEST", 84, 87], ["Thr", "TEST", 93, 96], ["attractive binding forces", "PROBLEM", 122, 147], ["His41", "TEST", 154, 159], ["Pro52", "TEST", 161, 166], ["Met", "TEST", 168, 171], ["Arg", "TEST", 176, 179], ["repulsive binding forces", "PROBLEM", 215, 239], ["Amino acid decomposition", "TREATMENT", 240, 264], ["the catalytic dyad residues", "PROBLEM", 364, 391], ["repulsive binding", "OBSERVATION", 215, 232]]], ["Quantum chemical calculations confirmed MD results and indicated pivotal role of Glu166 in making permanent hydrogen bond (98% of MD simulations time) with ZINC_252512772 (DE b \u00c031.66 kcal/mol).", [["Glu166", "CHEMICAL", 81, 87], ["Glu166", "CHEMICAL", 81, 87], ["hydrogen", "CHEMICAL", 108, 116], ["ZINC_252512772", "CHEMICAL", 156, 170], ["Glu166", "SIMPLE_CHEMICAL", 81, 87], ["Quantum chemical calculations", "TEST", 0, 29], ["permanent hydrogen bond", "TREATMENT", 98, 121], ["ZINC_", "TREATMENT", 156, 161]]], ["Our calculations showed that Glu166 was responsible for tight binding of ZINC_252512772 into the Mpro active site.", [["Glu166", "CHEMICAL", 29, 35], ["ZINC_252512772", "CHEMICAL", 73, 87], ["Glu166", "CHEMICAL", 29, 35], ["ZINC_252512772", "CHEMICAL", 73, 87], ["Glu166", "SIMPLE_CHEMICAL", 29, 35], ["Mpro active site", "DNA", 97, 113], ["Our calculations", "TEST", 0, 16], ["Glu166", "TEST", 29, 35], ["tight binding of ZINC", "PROBLEM", 56, 77], ["active site", "OBSERVATION", 102, 113]]], ["Interaction of Glu166 with a few synthetic and phytochemical agents were previously reported (ul Qamar et al., 2020) and moreover functional role of conserved residue Glu166 within substratebinding site of SARS-CoV was pointed before (Lin et al., 2004) .Amino acid decomposition analysisSome hydrophobic contacts were associated with lower binding energies (Phe140 \u00c0 0.08 kcal/mol) in B3LYP/Def2-TZVPP level of calculation.", [["Glu166", "CHEMICAL", 15, 21], ["Glu166", "CHEMICAL", 167, 173], ["SARS", "DISEASE", 206, 210], ["Amino acid", "CHEMICAL", 254, 264], ["Glu166", "CHEMICAL", 15, 21], ["Glu166", "CHEMICAL", 167, 173], ["Amino acid", "CHEMICAL", 254, 264], ["Glu166", "GENE_OR_GENE_PRODUCT", 15, 21], ["Glu166", "AMINO_ACID", 167, 173], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 206, 214], ["Amino acid", "AMINO_ACID", 254, 264], ["substratebinding site", "DNA", 181, 202], ["Def2", "PROTEIN", 391, 395], ["TZVPP", "PROTEIN", 396, 401], ["SARS-CoV", "SPECIES", 206, 214], ["conserved residue Glu166", "PROBLEM", 149, 173], ["SARS", "PROBLEM", 206, 210], ["CoV", "PROBLEM", 211, 214], ["Amino acid decomposition analysisSome", "TREATMENT", 254, 291], ["hydrophobic contacts", "PROBLEM", 292, 312], ["lower binding energies", "PROBLEM", 334, 356], ["Def2", "TREATMENT", 391, 395]]], ["Second-ranked interacting residues were found to be Asn142 with \u00c03.16 kcal/mol supported binding energy.", [["Asn142", "CHEMICAL", 52, 58], ["Asn142", "SIMPLE_CHEMICAL", 52, 58]]], ["Modeling studies showed a hydrogen bond between Asn142 backbone NH and terminal amide oxygen of ZINC_252512772 and estimated binding energy for MD simulated complex might be attributed to the stability of this key interaction.", [["Asn142", "CHEMICAL", 48, 54], ["oxygen", "CHEMICAL", 86, 92], ["ZINC_252512772", "CHEMICAL", 96, 110], ["hydrogen", "CHEMICAL", 26, 34], ["Asn142", "CHEMICAL", 48, 54], ["NH", "CHEMICAL", 64, 66], ["amide", "CHEMICAL", 80, 85], ["oxygen", "CHEMICAL", 86, 92], ["ZINC_252512772", "CHEMICAL", 96, 110], ["Asn142 backbone NH", "SIMPLE_CHEMICAL", 48, 66], ["terminal amide oxygen", "SIMPLE_CHEMICAL", 71, 92], ["ZINC_252512772", "SIMPLE_CHEMICAL", 96, 110], ["Modeling studies", "TEST", 0, 16], ["a hydrogen bond", "PROBLEM", 24, 39], ["Asn142 backbone NH", "TREATMENT", 48, 66], ["terminal amide oxygen", "TREATMENT", 71, 92], ["ZINC_", "TREATMENT", 96, 101], ["hydrogen bond", "OBSERVATION", 26, 39], ["terminal", "OBSERVATION_MODIFIER", 71, 79], ["amide", "OBSERVATION_MODIFIER", 80, 85]]], ["Despite prediction of H-bond interaction between Arg188 backbone oxygen and internal amide His163 Salt bridge 5.10 -Carboxylate Imidazole Ns a For hydrophobic interactions distance is reported between interacting carbon atoms; For H-bonds distance is reported between hydrogen and acceptor atom; For salt bridges distance is reported between charge centers. b For Hydrogen bonds donor angle is reported as the angle between donor, acceptor and hydrogen atoms.", [["H", "CHEMICAL", 22, 23], ["Arg188", "CHEMICAL", 49, 55], ["oxygen", "CHEMICAL", 65, 71], ["Salt", "CHEMICAL", 98, 102], ["5.10 -Carboxylate Imidazole", "CHEMICAL", 110, 137], ["H", "CHEMICAL", 231, 232], ["Hydrogen", "CHEMICAL", 364, 372], ["H", "CHEMICAL", 22, 23], ["Arg188", "CHEMICAL", 49, 55], ["oxygen", "CHEMICAL", 65, 71], ["amide", "CHEMICAL", 85, 90], ["His", "CHEMICAL", 91, 94], ["5.10 -Carboxylate Imidazole Ns", "CHEMICAL", 110, 140], ["carbon", "CHEMICAL", 213, 219], ["H", "CHEMICAL", 231, 232], ["hydrogen", "CHEMICAL", 268, 276], ["Hydrogen", "CHEMICAL", 364, 372], ["hydrogen", "CHEMICAL", 444, 452], ["Arg188 backbone", "SIMPLE_CHEMICAL", 49, 64], ["oxygen", "SIMPLE_CHEMICAL", 65, 71], ["carbon atoms", "SIMPLE_CHEMICAL", 213, 225], ["hydrogen", "SIMPLE_CHEMICAL", 268, 276], ["acceptor atom", "SIMPLE_CHEMICAL", 281, 294], ["Hydrogen", "SIMPLE_CHEMICAL", 364, 372], ["hydrogen atoms", "SIMPLE_CHEMICAL", 444, 458], ["Arg188 backbone oxygen", "TREATMENT", 49, 71], ["internal amide", "TREATMENT", 76, 90], ["Salt bridge", "TREATMENT", 98, 109], ["Carboxylate Imidazole Ns", "TREATMENT", 116, 140], ["hydrophobic interactions distance", "PROBLEM", 147, 180], ["hydrogen and acceptor atom", "TREATMENT", 268, 294], ["salt bridges distance", "PROBLEM", 300, 321], ["Hydrogen bonds donor angle", "TREATMENT", 364, 390], ["donor, acceptor and hydrogen atoms", "TREATMENT", 424, 458]]], ["NH of ZINC_252512772 by molecular docking, QM calculations did not dedicate attractive binding force to the corresponding interaction (1.98 kcal/mol).", [["ZINC_252512772", "CHEMICAL", 6, 20], ["NH", "CHEMICAL", 0, 2], ["ZINC_252512772", "CHEMICAL", 6, 20], ["ZINC_", "TREATMENT", 6, 11]]], ["According to this, we were prompted to estimate the binding energy to Arg188 in docked pose of ZINC_252512772 which was found to be \u00c00.98 kcal/mol.", [["Arg188", "CHEMICAL", 70, 76], ["ZINC_252512772", "CHEMICAL", 95, 109], ["Arg188", "CHEMICAL", 70, 76], ["ZINC_252512772", "CHEMICAL", 95, 109]]], ["Different binding energies confirmed MD results and indicated that predicted hydrogen bond between Arg188 backbone oxygen and internal amide NH of ZINC_252512772 might not be a stable interaction since considerable torsional deviation occurred within the most probable binding pose of the ligand during MD time.In silico ADMET predictionPhysiochemical properties have substantial effects on the behavior of compounds within a living system and therefore it is significant to predict ADMET properties through hit identification.", [["Arg188", "CHEMICAL", 99, 105], ["oxygen", "CHEMICAL", 115, 121], ["amide NH", "CHEMICAL", 135, 143], ["ZINC_252512772", "CHEMICAL", 147, 161], ["hydrogen", "CHEMICAL", 77, 85], ["Arg188", "CHEMICAL", 99, 105], ["oxygen", "CHEMICAL", 115, 121], ["amide", "CHEMICAL", 135, 140], ["NH", "CHEMICAL", 141, 143], ["ZINC_252512772", "CHEMICAL", 147, 161], ["Arg188 backbone", "SIMPLE_CHEMICAL", 99, 114], ["oxygen", "SIMPLE_CHEMICAL", 115, 121], ["ZINC_252512772", "SIMPLE_CHEMICAL", 147, 161], ["Arg188 backbone oxygen", "TREATMENT", 99, 121], ["internal amide NH", "TREATMENT", 126, 143], ["considerable torsional deviation", "PROBLEM", 202, 234], ["substantial effects", "PROBLEM", 368, 387], ["hit identification", "TEST", 508, 526], ["stable", "OBSERVATION", 177, 183], ["torsional deviation", "OBSERVATION", 215, 234], ["substantial", "OBSERVATION_MODIFIER", 368, 379]]], ["Results of estimated parameters indicated that ZINC_170619726, ZINC_108126011 and ZINC_252512772 met the criteria for drug-likeness and followed Lipinski's rule of five.ConclusionA new pathogen (SARS-CoV2) that first emerged in Wuhan region of China in December 2019 spread quickly into all countries of the world.", [["ZINC_252512772", "CHEMICAL", 82, 96], ["SARS-CoV2", "ORGANISM", 195, 204], ["estimated parameters", "TEST", 11, 31], ["ZINC_", "TEST", 47, 52], ["ZINC", "TEST", 82, 86], ["drug-likeness", "PROBLEM", 118, 131], ["Lipinski", "TEST", 145, 153], ["ConclusionA new pathogen", "PROBLEM", 169, 193]]], ["Given an urgent need toward therapeutic drugs or vaccines against the pathogen, seeking for new privileged anti-SARS-CoV2 molecules with good synthetic accessibility or commercial availability is now an important attitude for structure-based hit/lead generation.", [["anti-SARS-CoV2 molecules", "PROTEIN", 107, 131], ["therapeutic drugs", "TREATMENT", 28, 45], ["vaccines", "TREATMENT", 49, 57], ["the pathogen", "PROBLEM", 66, 78], ["hit/lead generation", "TREATMENT", 242, 261]]], ["In the current study potential SARS-CoV2 inhibitors were proposed through in silico analysis of ZINC15 driven commercially available compounds against Mpro as the specific enzyme of pathogen with determinant role in maturation of viral nonstructural proteins (Nsps) and hence viral life cycle.", [["Mpro", "CHEMICAL", 151, 155], ["CoV2", "GENE_OR_GENE_PRODUCT", 36, 40], ["ZINC15", "SIMPLE_CHEMICAL", 96, 102], ["Mpro", "GENE_OR_GENE_PRODUCT", 151, 155], ["viral nonstructural proteins", "GENE_OR_GENE_PRODUCT", 230, 258], ["Nsps", "GENE_OR_GENE_PRODUCT", 260, 264], ["Mpro", "PROTEIN", 151, 155], ["viral nonstructural proteins", "PROTEIN", 230, 258], ["Nsps", "PROTEIN", 260, 264], ["SARS-CoV2 inhibitors", "TREATMENT", 31, 51], ["silico analysis", "TEST", 77, 92], ["ZINC15", "TREATMENT", 96, 102], ["Mpro", "TREATMENT", 151, 155], ["viral nonstructural proteins", "PROBLEM", 230, 258]]], ["For this purpose, a few co-crystallographic ligands of SARS-CoV2 Mpro with N-aryl amide and aryl sulfonamide based fragments were used to identify new and potential enzyme inhibitors via screening ZINC driven commercially available developed structures.", [["SARS", "DISEASE", 55, 59], ["N-aryl amide", "CHEMICAL", 75, 87], ["aryl sulfonamide", "CHEMICAL", 92, 108], ["N-aryl amide", "CHEMICAL", 75, 87], ["aryl sulfonamide", "CHEMICAL", 92, 108], ["SARS-CoV2 Mpro", "SIMPLE_CHEMICAL", 55, 69], ["N-aryl amide", "SIMPLE_CHEMICAL", 75, 87], ["aryl sulfonamide", "SIMPLE_CHEMICAL", 92, 108], ["ZINC", "SIMPLE_CHEMICAL", 197, 201], ["ZINC", "PROTEIN", 197, 201], ["SARS", "TEST", 55, 59], ["CoV2 Mpro", "TREATMENT", 60, 69], ["N-aryl amide", "TREATMENT", 75, 87], ["aryl sulfonamide based fragments", "TREATMENT", 92, 124], ["potential enzyme inhibitors", "TREATMENT", 155, 182], ["screening ZINC", "TEST", 187, 201]]], ["Molecular docking simulations proposed ZINC_108126011 and ZINC_252512772 as superior Mpro binders with free binding energies comparable to a few re-purposed drugs.", [["ZINC_108126011", "CHEMICAL", 39, 53], ["ZINC_252512772", "CHEMICAL", 58, 72], ["ZINC_108126011", "SIMPLE_CHEMICAL", 39, 53], ["ZINC_252512772", "SIMPLE_CHEMICAL", 58, 72], ["ZINC_252512772", "TREATMENT", 58, 72], ["superior Mpro binders", "TREATMENT", 76, 97], ["free binding energies", "PROBLEM", 103, 124], ["a few re-purposed drugs", "TREATMENT", 139, 162]]], ["H-bond interactions and hydrophobic contacts were dominant attractive forces in binding to target.", [["H", "CHEMICAL", 0, 1], ["H", "CHEMICAL", 0, 1]]], ["MD simulations on top-ranked docked poses demonstrated less conformational changes (more stable binding mode) for ZINC_252512772 within Mpro active site during 50 ns trajectory.", [["ZINC_252512772", "CHEMICAL", 114, 128], ["ZINC_252512772", "SIMPLE_CHEMICAL", 114, 128], ["ZINC_252512772", "PROTEIN", 114, 128], ["Mpro active site", "DNA", 136, 152], ["less conformational changes", "PROBLEM", 55, 82]]], ["Per-residue binding energy analysis of ZINC_252512772-Mpro complex determined relative contribution of individual interacted residues in binding to the selected hit.", [["ZINC_252512772-Mpro", "GENE_OR_GENE_PRODUCT", 39, 58], ["ZINC_252512772", "PROTEIN", 39, 53], ["Mpro complex", "PROTEIN", 54, 66], ["Per-residue binding energy analysis", "TEST", 0, 35], ["ZINC_252512772", "TEST", 39, 53], ["individual interacted residues", "PROBLEM", 103, 133], ["interacted residues", "OBSERVATION", 114, 133]]], ["Quantum chemical calculations confirmed MD results and proved the pivotal role of Glu166 in making permanent hydrogen bond (98% of MD simulations time) with ZINC_252512772.", [["Glu166", "CHEMICAL", 82, 88], ["Glu166", "CHEMICAL", 82, 88], ["hydrogen", "CHEMICAL", 109, 117], ["ZINC_252512772", "CHEMICAL", 157, 171], ["Glu166", "SIMPLE_CHEMICAL", 82, 88], ["Quantum chemical calculations", "TEST", 0, 29], ["permanent hydrogen bond", "TREATMENT", 99, 122]]], ["Obtained results showed that ZINC_252512772 might be a desirable in silico hit for further development of potent SARS-CoV2 inhibitors.", [["ZINC_252512772", "CHEMICAL", 29, 43], ["ZINC_252512772", "CHEMICAL", 29, 43], ["ZINC_252512772", "SIMPLE_CHEMICAL", 29, 43], ["SARS-CoV2", "SIMPLE_CHEMICAL", 113, 122], ["potent SARS-CoV2 inhibitors", "TREATMENT", 106, 133]]], ["Although additional effort remains to be made for in vitro, in vivo and clinical validations, it is hoped that proposed compound could serve as appropriate hit molecules for further development of anti-Covid-19 agents.Disclosure statementNo potential conflict of interest was reported by the author(s).", [["anti-Covid-19", "CHEMICAL", 197, 210], ["anti-Covid-19 agents", "SIMPLE_CHEMICAL", 197, 217], ["anti-Covid-19 agents", "TREATMENT", 197, 217]]], ["O (Backbone) a For hydrophobic interactions distance is reported between interacting carbon atoms; For H-bonds distance is reported between hydrogen and acceptor atom; For salt bridges distance is reported between charge centers. b For Hydrogen bonds donor angle is reported as the angle between donor, acceptor and hydrogen atoms.", [["H", "CHEMICAL", 103, 104], ["Hydrogen", "CHEMICAL", 236, 244], ["O", "CHEMICAL", 0, 1], ["carbon", "CHEMICAL", 85, 91], ["H", "CHEMICAL", 103, 104], ["hydrogen", "CHEMICAL", 140, 148], ["Hydrogen", "CHEMICAL", 236, 244], ["hydrogen", "CHEMICAL", 316, 324], ["carbon atoms", "SIMPLE_CHEMICAL", 85, 97], ["hydrogen", "SIMPLE_CHEMICAL", 140, 148], ["acceptor atom", "SIMPLE_CHEMICAL", 153, 166], ["Hydrogen", "SIMPLE_CHEMICAL", 236, 244], ["hydrogen atoms", "SIMPLE_CHEMICAL", 316, 330], ["hydrogen and acceptor atom", "TREATMENT", 140, 166], ["salt bridges distance", "PROBLEM", 172, 193], ["Hydrogen bonds donor angle", "TREATMENT", 236, 262], ["donor, acceptor and hydrogen atoms", "TREATMENT", 296, 330]]]], "PMC7482922": [["IntroductionThe SARS-CoV-2 virus that has spread throughout the globe has created societal disruption and had a massive impact on global health [1].", [["SARS-CoV-2 virus", "ORGANISM", 16, 32], ["CoV-2 virus", "SPECIES", 21, 32], ["SARS-CoV-2 virus", "SPECIES", 16, 32], ["The SARS-CoV-2 virus", "PROBLEM", 12, 32], ["created societal disruption", "PROBLEM", 74, 101], ["globe", "ANATOMY", 64, 69], ["societal disruption", "OBSERVATION", 82, 101], ["massive", "OBSERVATION_MODIFIER", 112, 119]]], ["With no known treatment, public policy and human behavior are currently the only tools that are available to mitigate the spread [2].", [["human", "ORGANISM", 43, 48], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 43, 48], ["known treatment", "TREATMENT", 8, 23]]], ["A fundamental characteristic of SARS-CoV-2 is that after an individual is exposed, that individual passes through an extended presymptomatic stage followed by either an asymptomatic or symptomatic stage [3].", [["SARS", "DISEASE", 32, 36], ["SARS-CoV", "SPECIES", 32, 40], ["an extended presymptomatic stage", "PROBLEM", 114, 146], ["an asymptomatic or symptomatic stage", "PROBLEM", 166, 202], ["SARS", "OBSERVATION", 32, 36], ["symptomatic", "OBSERVATION_MODIFIER", 185, 196]]], ["Our goal in this work is to construct a theoretical network disease model with these qualities and investigate phase transitions associated with three types of control measures.", [["phase transitions", "PROBLEM", 111, 128], ["control measures", "TREATMENT", 160, 176]]], ["While many models related to SARS-CoV-2 are designed to be forecasting tools, our study is intended as a contribution to the theoretical literature regarding qualitative aspects of control measures for viruses with these pathways of disease progression.IntroductionIn the specific case of SARS-CoV-2, one control measure that has been used is government-mandated social distancing.", [["SARS", "DISEASE", 29, 33], ["SARS", "DISEASE", 289, 293], ["SARS-CoV-2", "ORGANISM", 29, 39], ["SARS-CoV", "SPECIES", 29, 37], ["SARS-CoV", "SPECIES", 289, 297], ["SARS", "PROBLEM", 29, 33], ["our study", "TEST", 78, 87], ["control measures", "TREATMENT", 181, 197], ["viruses", "PROBLEM", 202, 209], ["disease progression", "PROBLEM", 233, 252], ["SARS", "PROBLEM", 289, 293], ["disease", "OBSERVATION", 233, 240]]], ["A second control method involves individually-determined changes to social behavior, which work in concert with mandated social distancing to mitigate viral transmission [5, 6].", [["A second control method", "TREATMENT", 0, 23]]], ["One question is whether these individual responses of behavioral modification are sufficient to moderate epidemic spread and whether there are additive or non-additive effects when implemented with top-down government policy on social distancing [5].", [["behavioral modification", "PROBLEM", 54, 77], ["moderate epidemic spread", "PROBLEM", 96, 120]]], ["A third type of control measure involves use of personal protective equipment to reduce the rate of viral transmission.", [["personal protective equipment", "TREATMENT", 48, 77], ["viral transmission", "OBSERVATION", 100, 118]]], ["For example, mask usage has been found to be effective in this regard for SARS-CoV-2 [8\u201310].IntroductionThese real-world aspects of SARS-CoV-2 highlight the need for a more thorough understanding of the general behavior of viruses exhibiting multiple progressions of disease development.", [["SARS", "DISEASE", 74, 78], ["SARS", "DISEASE", 132, 136], ["SARS-CoV-2", "ORGANISM", 132, 142], ["SARS-CoV", "SPECIES", 74, 82], ["mask usage", "TREATMENT", 13, 23], ["SARS", "PROBLEM", 132, 136], ["disease development", "PROBLEM", 267, 286], ["disease", "OBSERVATION", 267, 274]]], ["With this as motivation, we develop a theoretical model in which we investigate how three types of control measures are associated with sharp phase transitions for the total number of infected individuals.", [["control measures", "TREATMENT", 99, 115], ["sharp phase transitions", "PROBLEM", 136, 159], ["infected individuals", "PROBLEM", 184, 204], ["infected", "OBSERVATION", 184, 192]]], ["While modeling contacts can be done in mean-field, statistical, and metapopulation SIR models [1, 11\u201314], we use an agent-based model (ABM) on Watts-Strogatz small world networks [15\u201317].", [["an agent", "TREATMENT", 113, 121]]], ["Small world networks have connectedness properties that are found in real-world social networks and have been previously considered in epidemiological contexts [18, 19].IntroductionThe first control measure in our ABM is social distancing imposed on the network at a global scale.", [["social networks", "MULTI-TISSUE_STRUCTURE", 80, 95], ["The first control measure", "TREATMENT", 181, 206]]], ["Our model encodes this global social distancing as complete isolation of an agent from other agents.", [["an agent", "TREATMENT", 73, 81], ["other agents", "TREATMENT", 87, 99]]], ["The likelihood of social distancing is applied uniformly to all agents.", [["social distancing", "OBSERVATION", 18, 35]]], ["The second control measure arises when agents have social connections that are infected and symptomatic [2, 8].", [["symptomatic", "PROBLEM", 92, 103], ["infected", "OBSERVATION", 79, 87]]], ["In this case, agents temporarily isolate from their contacts in the network if they are in contact with a sufficient number of symptomatic agents.", [["agents", "TREATMENT", 14, 20], ["symptomatic agents", "TREATMENT", 127, 145]]], ["The third type of control measure is to alter the rate of viral spread, which reflects behavior such as use of personal protective equipment, e.g., masks [8, 10].", [["viral spread", "PROBLEM", 58, 70], ["personal protective equipment", "TREATMENT", 111, 140], ["viral spread", "OBSERVATION", 58, 70]]], ["We examine how each of these measures alone and in concert with each other influence the viral outbreak.IntroductionFor each of these control measures, we ask the following questions:Agent-based model ::: Model and parametersWe develop an SIR, network-based, agent-based model where agents pass through various infection states (Fig 1).", [["infection", "DISEASE", 311, 320], ["these measures", "TREATMENT", 23, 37], ["the viral outbreak", "PROBLEM", 85, 103], ["these control measures", "TREATMENT", 128, 150], ["agent-based model where agents", "TREATMENT", 259, 289], ["various infection states", "PROBLEM", 303, 327], ["viral outbreak", "OBSERVATION", 89, 103], ["infection", "OBSERVATION", 311, 320]]], ["Agents pass through a presymptomatic infection state followed by either an asymptomatic infected stage or a symptomatic infected stage.", [["infection", "DISEASE", 37, 46], ["Agents", "TREATMENT", 0, 6], ["a presymptomatic infection state", "PROBLEM", 20, 52], ["an asymptomatic infected stage", "PROBLEM", 72, 102], ["a symptomatic infected stage", "PROBLEM", 106, 134], ["presymptomatic", "OBSERVATION_MODIFIER", 22, 36], ["infection", "OBSERVATION", 37, 46], ["asymptomatic", "OBSERVATION_MODIFIER", 75, 87], ["infected", "OBSERVATION", 88, 96], ["symptomatic", "OBSERVATION_MODIFIER", 108, 119], ["infected", "OBSERVATION", 120, 128]]], ["In our model, each agent carries an individual pathogen level that changes in response to contact with infected agents.", [["an individual pathogen level", "PROBLEM", 33, 61], ["infected agents", "TREATMENT", 103, 118]]], ["Initially, this level is set to 0 pathogen units for susceptible agents.", [["susceptible agents", "TREATMENT", 53, 71]]], ["At each time step (conceived as a day), if a susceptible agent has no infected contacts then their pathogen level does not change.", [["a susceptible agent", "PROBLEM", 43, 62], ["infected contacts", "PROBLEM", 70, 87]]], ["For each day that a susceptible agent has one or more infected neighbors, their pathogen level increases by a fixed fraction of the pathogen levels of their infected neighbors.", [["a susceptible agent", "TREATMENT", 18, 37], ["their pathogen level", "PROBLEM", 74, 94], ["infected", "OBSERVATION", 157, 165]]], ["There is a global infection threshold that applies to all agents, which we fix at 25 pathogen units; in other words, the day after the pathogen level for an individual agent exceeds 25 units, that agent enters the presymptomatic infected state.", [["infection", "DISEASE", 18, 27], ["a global infection threshold", "PROBLEM", 9, 37], ["all agents", "TREATMENT", 54, 64], ["the pathogen level", "TEST", 131, 149], ["an individual agent", "TREATMENT", 154, 173], ["the presymptomatic infected state", "PROBLEM", 210, 243], ["global", "OBSERVATION_MODIFIER", 11, 17], ["infection", "OBSERVATION", 18, 27], ["presymptomatic", "OBSERVATION_MODIFIER", 214, 228], ["infected", "OBSERVATION", 229, 237]]], ["Once an agent enters the infected state, their pathogen level stays constant until they have reached the resistant/removed state, at which point it is reset to 0 units.", [["their pathogen level", "PROBLEM", 41, 61], ["infected", "OBSERVATION", 25, 33]]], ["Model runs are initiated with a small number of infected agents, whose pathogen levels are initially set at 35 pathogen units, and the remainder of the agents are initially deemed susceptible.Agent-based model ::: Model and parametersThese initial and threshold values for the pathogen levels in our model are not based on real-world data, but rather were selected for simplicity to investigate general behavior of phase transitions under a mechanism of viral shedding with individualized pathogen levels.", [["Model runs", "PROBLEM", 0, 10], ["infected agents", "TREATMENT", 48, 63], ["whose pathogen levels", "TEST", 65, 86], ["the agents", "TREATMENT", 148, 158], ["threshold values", "TEST", 252, 268], ["the pathogen levels", "TEST", 273, 292], ["phase transitions", "PROBLEM", 415, 432], ["viral shedding", "PROBLEM", 454, 468], ["individualized pathogen levels", "PROBLEM", 474, 504], ["small", "OBSERVATION_MODIFIER", 32, 37], ["infected agents", "OBSERVATION", 48, 63], ["viral", "OBSERVATION", 454, 459]]], ["Because our model does not use a transmission probability for each contact, but rather a viral shedding rate where each individual agent has varying levels of pathogen load, this model is well-suited to ABM simulations and less amenable to ODE-based deterministic analysis.Agent-based model ::: Model and parametersOnce the individual pathogen level for an agent exceeds 25 units, that agent enters a presymptomatic infection stage, followed by either a symptomatic or asymptomatic stage (Fig 1).", [["infection", "DISEASE", 416, 425], ["a viral shedding rate", "PROBLEM", 87, 108], ["pathogen load", "PROBLEM", 159, 172], ["ABM simulations", "TEST", 203, 218], ["deterministic analysis", "TEST", 250, 272], ["the individual pathogen level", "TEST", 320, 349], ["an agent", "TREATMENT", 354, 362], ["a presymptomatic infection stage", "PROBLEM", 399, 431], ["a symptomatic or asymptomatic stage (Fig", "PROBLEM", 452, 492], ["presymptomatic", "OBSERVATION_MODIFIER", 401, 415], ["infection", "OBSERVATION", 416, 425]]], ["The length of the presymptomatic stage is the same for all agents, and can be set to last one or more days.", [["length", "OBSERVATION_MODIFIER", 4, 10]]], ["The lengths of the two possible main infection stages are set independently from each other, but are the same for all agents.", [["infection", "DISEASE", 37, 46], ["main infection stages", "PROBLEM", 32, 53], ["all agents", "TREATMENT", 114, 124], ["lengths", "OBSERVATION_MODIFIER", 4, 11], ["possible", "UNCERTAINTY", 23, 31], ["main", "OBSERVATION_MODIFIER", 32, 36], ["infection", "OBSERVATION", 37, 46]]], ["Following the main infection stage, the agent is either resistant or removed.Agent-based model ::: Model and parametersIn addition to the infection stages, each agent is in one of two daily behavior states: socially distanced or not socially distanced.", [["infection", "DISEASE", 19, 28], ["infection", "DISEASE", 138, 147], ["the main infection stage", "PROBLEM", 10, 34], ["the agent", "TREATMENT", 36, 45], ["the infection stages", "PROBLEM", 134, 154], ["main", "OBSERVATION_MODIFIER", 14, 18], ["infection", "OBSERVATION", 19, 28], ["infection", "OBSERVATION", 138, 147]]], ["If an agent is not socially distanced on a given day, then that agent can interact with any neighboring agent.", [["any neighboring agent", "TREATMENT", 88, 109]]], ["A global social distance probability is set, which determines the chance that an agent will socially distance on a given day.", [["A global social distance probability", "PROBLEM", 0, 36], ["global", "OBSERVATION_MODIFIER", 2, 8], ["social", "OBSERVATION", 9, 15]]], ["If the number of infected symptomatic neighbors of an agent equals or exceeds this threshold, the agent will social distance independently of the global parameter.", [["an agent equals", "TREATMENT", 51, 66], ["infected", "OBSERVATION_MODIFIER", 17, 25], ["symptomatic", "OBSERVATION_MODIFIER", 26, 37]]], ["This local threshold is the same for all agents.Model parameters and simulations ::: Model and parametersWe implement our agent-based model on Watts-Strogatz (WS) networks.", [["all agents", "TREATMENT", 37, 47], ["our agent", "TREATMENT", 118, 127], ["Watts-Strogatz (WS) networks", "TREATMENT", 143, 171]]], ["The WS networks can simultaneously demonstrate both high clustering and short average path length, and thus serve as effective approximations of social networks that are neither completely random nor regular [15].", [["WS networks", "MULTI-TISSUE_STRUCTURE", 4, 15], ["both high clustering and short average path length", "PROBLEM", 47, 97], ["both", "OBSERVATION_MODIFIER", 47, 51], ["high", "OBSERVATION_MODIFIER", 52, 56]]], ["High clustering and short average path length allow for local interactions and more distant interactions to be incorporated [16, 17, 20], which are properties often found in real-world networks.", [["High clustering and short average path length", "PROBLEM", 0, 45], ["short average", "OBSERVATION_MODIFIER", 20, 33]]], ["The WS small world network in our model is characterized by three parameters: number of nodes N, average node degree K and rewiring probability.", [["node", "ANATOMY", 105, 109], ["The WS small world network", "PROBLEM", 0, 26], ["average node degree K", "PROBLEM", 97, 118], ["rewiring probability", "PROBLEM", 123, 143], ["small", "OBSERVATION_MODIFIER", 7, 12], ["nodes", "OBSERVATION", 88, 93], ["rewiring probability", "OBSERVATION", 123, 143]]], ["The rewiring parameter is used to determine the likelihood of rewiring each edge starting from a regular ring lattice.", [["The rewiring parameter", "TREATMENT", 0, 22], ["rewiring each edge", "PROBLEM", 62, 80], ["a regular ring lattice", "TREATMENT", 95, 117], ["rewiring", "OBSERVATION", 4, 12], ["rewiring", "OBSERVATION", 62, 70], ["ring lattice", "OBSERVATION", 105, 117]]], ["A rewiring parameter of 0 preserves the original ring lattice; a rewiring parameter of 1 simulates a random network.", [["A rewiring parameter", "TEST", 0, 20], ["the original ring lattice", "TREATMENT", 36, 61], ["a rewiring parameter", "TEST", 63, 83], ["rewiring", "OBSERVATION", 2, 10], ["ring lattice", "OBSERVATION", 49, 61]]], ["We fix the number of nodes N = 500 and the average degree K = 20, which allows ln(N) \u226a K \u226a N. We then vary the rewiring probability among the values {0.05, 0.10, 0.25, 0.50}.", [["K", "CHEMICAL", 87, 88], ["nodes N", "TEST", 21, 28], ["the average degree K", "TEST", 39, 59], ["the values", "TEST", 138, 148], ["nodes", "OBSERVATION", 21, 26]]], ["Based on the results of this primary simulation, we ran a secondary set of simulations over the refined parameter space given in Table 2 to provide a more detailed analysis of the phase transition behavior observed in the primary simulations.", [["the refined parameter space", "TREATMENT", 92, 119]]], ["The parameters for the secondary simulation were selected based on our analysis of the primary data using regression trees to identify critical variables and on the observed ranges where phase transitions were observed.Regression tree ::: ResultsWe used a regression tree to partition the variation in final number of infected nodes across model parameters and runs in our primary simulation [21].", [["nodes", "ANATOMY", 327, 332], ["nodes", "MULTI-TISSUE_STRUCTURE", 327, 332], ["the secondary simulation", "TEST", 19, 43], ["our analysis", "TEST", 67, 79], ["the primary data", "TEST", 83, 99], ["phase transitions", "PROBLEM", 187, 204], ["a regression tree", "TREATMENT", 254, 271], ["infected nodes", "PROBLEM", 318, 332], ["infected nodes", "OBSERVATION", 318, 332]]], ["Reductions in viral shedding were associated with the primary partition in the regression tree in Fig 2.", [["viral shedding", "PROBLEM", 14, 28], ["viral shedding", "OBSERVATION", 14, 28]]], ["Viral shedding below 15% compared to a value of 25% were associated with a mean number of infections of 46 out of 500 agents.", [["infections", "DISEASE", 90, 100], ["Viral", "ORGANISM", 0, 5], ["Viral shedding", "TEST", 0, 14], ["a value", "TEST", 37, 44], ["infections", "PROBLEM", 90, 100], ["infections", "OBSERVATION", 90, 100]]], ["Reduced viral shedding with social distancing probability over 25% led to overall infection of approximately 2% of the agents.", [["infection", "DISEASE", 82, 91], ["Reduced viral shedding", "PROBLEM", 0, 22], ["overall infection", "PROBLEM", 74, 91], ["the agents", "TREATMENT", 115, 125], ["viral", "OBSERVATION", 8, 13], ["infection", "OBSERVATION", 82, 91]]], ["If the overall viral shedding is reduced dramatically to 5%, even without additional social distancing of any type, less than 1% of the population becomes infected.Regression tree ::: ResultsAchieving low levels of infections in populations without reducing viral shedding requires significantly higher levels of global social distancing, where each agent has at least a 75% chance of social distancing each day; this results in an approximately 1% infection rate among agents.", [["infections", "DISEASE", 215, 225], ["infection", "DISEASE", 449, 458], ["the overall viral shedding", "PROBLEM", 3, 29], ["infected", "PROBLEM", 155, 163], ["infections in populations", "PROBLEM", 215, 240], ["reducing viral shedding", "PROBLEM", 249, 272], ["overall", "OBSERVATION_MODIFIER", 7, 14], ["viral", "OBSERVATION", 15, 20], ["reduced", "OBSERVATION_MODIFIER", 33, 40], ["dramatically", "OBSERVATION_MODIFIER", 41, 53], ["infected", "OBSERVATION", 155, 163], ["low levels", "OBSERVATION_MODIFIER", 201, 211], ["infections", "OBSERVATION", 215, 225]]], ["If each agent has less than a 75% chance of social distancing each day, the total infection rates for the populations are much higher; these range from a low of 21% (if individuals self-isolate in response to one infected social contact) all the way up to 97% with low levels of any type of social distancing.Regression tree ::: ResultsThus, with a higher level of viral shedding, it becomes important to have agents self-isolate when a contact becomes symptomatic.", [["infection", "DISEASE", 82, 91], ["the total infection rates", "PROBLEM", 72, 97], ["viral shedding", "PROBLEM", 365, 379], ["agents self-isolate", "TREATMENT", 410, 429], ["symptomatic", "PROBLEM", 453, 464]]], ["Even if this occurs, the infection rate in the population is an order of magnitude higher (10% vs. 1%) than if the viral shedding is reduced.", [["infection", "DISEASE", 25, 34], ["the infection rate", "PROBLEM", 21, 39], ["the viral shedding", "PROBLEM", 111, 129], ["infection", "OBSERVATION", 25, 34], ["viral", "OBSERVATION", 115, 120], ["reduced", "OBSERVATION_MODIFIER", 133, 140]]], ["Failure to achieve this strict social distancing in response to an infected social contact results in a wide-spread outbreak with approximately 62% of the agents infected.Phase transitions ::: ResultsBecause our goal is to understand the behavior of phase transitions regarding total number of infections in our model, we conducted secondary simulations on a refined parameter space based on the results of our regression tree analysis.", [["infections", "DISEASE", 294, 304], ["Failure", "PROBLEM", 0, 7], ["infections", "PROBLEM", 294, 304], ["a refined parameter space", "TREATMENT", 357, 382], ["our regression tree analysis", "TEST", 407, 435], ["infections", "OBSERVATION", 294, 304]]], ["In these simulations, we observed sharp phase transitions in the total number of infections as a function of all three control methods.", [["infections", "DISEASE", 81, 91], ["sharp phase transitions", "PROBLEM", 34, 57], ["infections", "PROBLEM", 81, 91], ["sharp", "OBSERVATION_MODIFIER", 34, 39], ["phase", "OBSERVATION_MODIFIER", 40, 45], ["transitions", "OBSERVATION_MODIFIER", 46, 57], ["total number", "OBSERVATION_MODIFIER", 65, 77], ["infections", "OBSERVATION", 81, 91]]], ["In these figures, the maximum number of possible infections is 500, as there are 500 nodes in our networks.Phase transitions ::: ResultsIn Fig 3, a phase transition exists between viral shedding of 5% and 10%, across all levels of social distance thresholds and social distance probabilities.", [["infections", "DISEASE", 49, 59], ["infections", "PROBLEM", 49, 59], ["a phase transition", "TEST", 146, 164], ["viral shedding", "TEST", 180, 194], ["maximum", "OBSERVATION_MODIFIER", 22, 29], ["number", "OBSERVATION_MODIFIER", 30, 36], ["possible", "UNCERTAINTY", 40, 48], ["infections", "OBSERVATION", 49, 59], ["nodes", "OBSERVATION", 85, 90]]], ["In Fig 4, a phase transition exists at a social distance threshold of 1, across all levels of social distance probabilities and viral shedding.", [["viral shedding", "PROBLEM", 128, 142], ["viral shedding", "OBSERVATION", 128, 142]]], ["If the social distance threshold parameter is 2 or more, then it is possible to have epidemics that infect the entire population.", [["epidemics", "PROBLEM", 85, 94]]], ["In Fig 5, a phase transition exists around a social distance probability of 73-74%, across all levels of social distance threshold and viral shedding.", [["viral shedding", "PROBLEM", 135, 149]]], ["If the social distance probability is 74% or more, then our simulations end with a small number of infected agents.Number of infections and length of epidemic ::: ResultsGiven the regression tree analysis of our primary simulations, it is clear that viral shedding and social distance probability play key roles.", [["infections", "DISEASE", 125, 135], ["infected agents", "TREATMENT", 99, 114], ["infections", "PROBLEM", 125, 135], ["viral shedding", "PROBLEM", 250, 264], ["small", "OBSERVATION_MODIFIER", 83, 88], ["infected", "OBSERVATION", 99, 107], ["infections", "OBSERVATION", 125, 135], ["tree", "OBSERVATION_MODIFIER", 191, 195], ["viral", "OBSERVATION_MODIFIER", 250, 255]]], ["In our secondary simulations over a refined parameter space, this becomes more clear.", [["a refined parameter space", "TREATMENT", 34, 59], ["more", "OBSERVATION_MODIFIER", 74, 78], ["clear", "OBSERVATION", 79, 84]]], ["In Fig 6, we observe additional confirmation of the regression tree findings that the main driver of total number of infections is the viral shedding rate, with social distance probability being the next critical factor.", [["infections", "DISEASE", 117, 127], ["infections", "PROBLEM", 117, 127], ["the viral shedding rate", "PROBLEM", 131, 154], ["main", "OBSERVATION_MODIFIER", 86, 90], ["total", "OBSERVATION_MODIFIER", 101, 106], ["number", "OBSERVATION_MODIFIER", 107, 113], ["infections", "OBSERVATION", 117, 127]]], ["Specifically, simulations with large total infections cluster to the upper left of the plot, where viral shedding rates are higher and social distancing is enacted by approximately 60% of agents.Number of infections and length of epidemic ::: ResultsThere is also a clear interaction between the social distance probability and viral shedding parameters and the resulting number of infected agents and the length of the epidemic.", [["infections", "DISEASE", 43, 53], ["infections", "DISEASE", 205, 215], ["large total infections cluster", "PROBLEM", 31, 61], ["viral shedding rates", "PROBLEM", 99, 119], ["infections", "PROBLEM", 205, 215], ["viral shedding parameters", "PROBLEM", 328, 353], ["infected agents", "TREATMENT", 382, 397], ["large", "OBSERVATION_MODIFIER", 31, 36], ["total", "OBSERVATION_MODIFIER", 37, 42], ["infections", "OBSERVATION", 43, 53], ["upper", "ANATOMY_MODIFIER", 69, 74], ["left", "ANATOMY_MODIFIER", 75, 79], ["viral", "OBSERVATION", 99, 104], ["higher", "OBSERVATION_MODIFIER", 124, 130], ["infections", "OBSERVATION", 205, 215], ["clear", "OBSERVATION_MODIFIER", 266, 271], ["interaction", "OBSERVATION", 272, 283], ["viral shedding", "OBSERVATION", 328, 342], ["infected", "OBSERVATION", 382, 390]]], ["In Fig 7, there is clustering of long epidemics when the probability is near 60% and the viral shedding rate is high.", [["long epidemics", "PROBLEM", 33, 47], ["the viral shedding rate", "TEST", 85, 108], ["high", "OBSERVATION_MODIFIER", 112, 116]]], ["As the social distance probability increases to 80% and the viral shedding rate decreases, there is a phase transition where simulations result in outbreaks of short duration.", [["the viral shedding rate", "TEST", 56, 79], ["a phase transition", "PROBLEM", 100, 118], ["increases", "OBSERVATION_MODIFIER", 35, 44], ["short duration", "OBSERVATION_MODIFIER", 160, 174]]], ["In Fig 8, most infections result in either a limited outbreak (less than 125 out of 500 agents) or almost all agents infected.", [["infections", "DISEASE", 15, 25], ["most infections", "PROBLEM", 10, 25]]], ["As the social distance probability is increased from 60% to 80%, the length of the epidemics increase while remaining limited in total number of infections before sharply transitioning to a high number of infections during a return to short epidemic lengths.DiscussionMathematical modeling can provide tools to better understand epidemic dynamics and can vary from purely theoretical to more data driven and predictive [22].", [["infections", "DISEASE", 145, 155], ["infections", "DISEASE", 205, 215], ["the epidemics", "PROBLEM", 79, 92], ["infections", "PROBLEM", 145, 155], ["infections", "PROBLEM", 205, 215], ["increased", "OBSERVATION_MODIFIER", 38, 47], ["epidemics", "OBSERVATION_MODIFIER", 83, 92], ["increase", "OBSERVATION_MODIFIER", 93, 101], ["infections", "OBSERVATION", 145, 155], ["high number", "OBSERVATION_MODIFIER", 190, 201], ["infections", "OBSERVATION", 205, 215]]], ["While a simple model such as this one should not be used to make policy recommendations, it can provide a framework for empirical investigation and specific hypothesis testing related to social networks of smaller size exhibiting small world characteristics, such as those seen in college settings [23].", [["empirical investigation", "TEST", 120, 143], ["specific hypothesis testing", "TEST", 148, 175], ["smaller", "OBSERVATION_MODIFIER", 206, 213], ["size", "OBSERVATION_MODIFIER", 214, 218], ["small", "OBSERVATION_MODIFIER", 230, 235]]], ["Here we use our theoretical model to investigate how different control methods impact the total number of infections in an epidemic on a network caused by a virus with a presymptomatic stage and both asymptomatic and symptomatic pathways.", [["infections", "DISEASE", 106, 116], ["our theoretical model", "TREATMENT", 12, 33], ["infections", "PROBLEM", 106, 116], ["a virus", "PROBLEM", 155, 162], ["a presymptomatic stage", "PROBLEM", 168, 190], ["both asymptomatic and symptomatic pathways", "PROBLEM", 195, 237], ["total number", "OBSERVATION_MODIFIER", 90, 102], ["infections", "OBSERVATION", 106, 116]]], ["We specifically examine three main control measures that can be taken to reduce epidemic spread: 1) Global social distancing with a fixed probability of adherence.", [["Global", "OBSERVATION_MODIFIER", 100, 106], ["social", "OBSERVATION", 107, 113]]], ["2) Individually initiated social isolation when a threshold number of contacts are infected.", [["social isolation", "TREATMENT", 26, 42], ["infected", "OBSERVATION", 83, 91]]], ["3) Reduction of viral shedding.", [["viral shedding", "PROBLEM", 16, 30], ["Reduction", "OBSERVATION_MODIFIER", 3, 12], ["viral shedding", "OBSERVATION", 16, 30]]], ["We observe sharp phase transitions in the total number of infected agents as the strength of each of these control measures are varied.DiscussionTo examine the full potential for global social distancing, we consider a wide range of possible scenarios varying from no social distancing to strong adherence to social distancing (90% of agents).", [["sharp phase transitions", "PROBLEM", 11, 34], ["infected agents", "TREATMENT", 58, 73], ["these control measures", "TREATMENT", 101, 123], ["sharp phase", "OBSERVATION_MODIFIER", 11, 22], ["total number", "OBSERVATION_MODIFIER", 42, 54], ["infected", "OBSERVATION", 58, 66]]], ["Nevertheless, we observe in our small-world models a clear phase transition associated with global social distancing.", [["small", "OBSERVATION_MODIFIER", 32, 37], ["clear phase", "OBSERVATION_MODIFIER", 53, 64], ["social distancing", "OBSERVATION", 99, 116]]], ["In general, a global social distancing probability below 65% results in a wide-spread epidemic, while a global social distancing probability above 75% limits the epidemic to a dramatically lower number of total infections.", [["infections", "DISEASE", 211, 221], ["a wide-spread epidemic", "PROBLEM", 72, 94], ["total infections", "PROBLEM", 205, 221], ["dramatically", "OBSERVATION_MODIFIER", 176, 188], ["lower number", "OBSERVATION_MODIFIER", 189, 201], ["total", "OBSERVATION_MODIFIER", 205, 210], ["infections", "OBSERVATION", 211, 221]]], ["We also found that social distance probabilities that approached the threshold from below resulted in prolonged epidemics while with low overall infection rates.", [["infection", "DISEASE", 145, 154], ["prolonged epidemics", "PROBLEM", 102, 121], ["low overall infection rates", "PROBLEM", 133, 160], ["infection", "OBSERVATION", 145, 154]]], ["For our secondary simulations over a refined parameter space, in the absence of other control measures we observe that there is a phase transition for total infections that occurs as the percentage of agents socially distancing changes from 73% to 74%.DiscussionIndividual behavior taken during a pandemic can greatly affect the dynamics of disease spread.", [["infections", "DISEASE", 157, 167], ["a refined parameter space", "TREATMENT", 35, 60], ["other control measures", "TREATMENT", 80, 102], ["a phase transition", "PROBLEM", 128, 146], ["total infections", "PROBLEM", 151, 167], ["disease spread", "PROBLEM", 341, 355], ["disease", "OBSERVATION", 341, 348]]], ["For example, for SARS-CoV-2, the most commonly recommended guideline after contact with an infected individual is 14 days of self-isolation to avoid exposing other individuals [5, 7, 24].", [["SARS", "DISEASE", 17, 21], ["SARS-CoV", "SPECIES", 17, 25], ["SARS", "TEST", 17, 21], ["self-isolation", "TREATMENT", 125, 139]]], ["In our model, we consider self-imposed social distancing as highly responsive to an agent\u2019s short-term perceptions regarding infection risks within their community.", [["infection", "DISEASE", 125, 134], ["infection risks", "PROBLEM", 125, 140]]], ["Interestingly, for self-isolation to significantly decrease the total number of infections in our model, an extreme level of responsiveness was needed by the agents involved; in our model, it was necessary for self-isolation to occur following exposure to only one infected agent.", [["infections", "DISEASE", 80, 90], ["self-isolation", "TREATMENT", 19, 33], ["infections", "PROBLEM", 80, 90], ["self-isolation", "TREATMENT", 210, 224], ["total", "OBSERVATION_MODIFIER", 64, 69], ["number", "OBSERVATION_MODIFIER", 70, 76], ["infections", "OBSERVATION", 80, 90]]], ["If self-isolation occurred only after contact with two or more symptomatic agents on the same day, the effect on disease spread was minimal.", [["self-isolation", "PROBLEM", 3, 17], ["symptomatic agents", "TREATMENT", 63, 81], ["disease spread", "PROBLEM", 113, 127], ["minimal", "OBSERVATION_MODIFIER", 132, 139]]], ["Our findings also support the well-known fact that real-world contact tracing following an individual\u2019s positive test is critical for limiting the spread of the infection [4].", [["infection", "DISEASE", 161, 170], ["an individual\u2019s positive test", "TEST", 88, 117], ["the infection", "PROBLEM", 157, 170], ["infection", "OBSERVATION", 161, 170]]], ["An important difference between our theoretical model and viruses such as SARS-CoV-2 [13, 25] is that, in the real world, individuals who have come in contact with an infected individual are not aware of their exposure.DiscussionOur theoretical reduction of viral shedding is motivated by behaviors such as mask wearing or other use of personal protective equipment [10].", [["SARS", "DISEASE", 74, 78], ["individuals", "ORGANISM", 122, 133], ["SARS-CoV", "SPECIES", 74, 82], ["viral shedding", "PROBLEM", 258, 272], ["personal protective equipment", "TREATMENT", 336, 365], ["reduction", "OBSERVATION_MODIFIER", 245, 254], ["viral", "OBSERVATION", 258, 263]]], ["While in real-world contexts individual responsiveness to recommended government actions are highly variable [24], a decrease in viral shedding rate can be achieved through use of protective equipment [9].", [["viral shedding rate", "TREATMENT", 129, 148], ["protective equipment", "TREATMENT", 180, 200]]], ["When the viral shedding in our model was set at a high shedding rate of 25%, global social distancing was required to be greater than 80% to control the outbreak, resulting in an approximately 1% infection rate in the population.", [["infection", "DISEASE", 196, 205], ["the viral shedding", "PROBLEM", 5, 23], ["an approximately 1% infection rate in the population", "PROBLEM", 176, 228], ["viral", "OBSERVATION_MODIFIER", 9, 14], ["infection", "OBSERVATION", 196, 205]]], ["Other less stringent social distancing conditions result in a viral infection rate between 25% and 97.5%.", [["viral infection", "DISEASE", 62, 77], ["a viral infection rate", "TEST", 60, 82]]], ["With a moderate rate of viral shedding, the social distance threshold at which someone decides to self-isolate after coming into contact with an infected individual becomes much more important.", [["a moderate rate of viral shedding", "PROBLEM", 5, 38], ["moderate", "OBSERVATION_MODIFIER", 7, 15], ["viral shedding", "OBSERVATION", 24, 38], ["infected", "OBSERVATION", 145, 153]]], ["In our model, if the social distance threshold is set to 1 (agents self-isolate after coming into contact with at least one infected agent), then the final total infection rate in the population is approximately 12%.", [["infection", "DISEASE", 162, 171], ["the social distance threshold", "PROBLEM", 17, 46], ["the final total infection rate", "TEST", 146, 176], ["infection", "OBSERVATION", 162, 171]]], ["However, if the behaviorally induced social distancing does not take place or takes place at a higher threshold, then the total number of infections is much larger with the overall infection rate in the population approximately 62%.", [["infections", "DISEASE", 138, 148], ["infection", "DISEASE", 181, 190], ["infections", "PROBLEM", 138, 148], ["the overall infection rate", "PROBLEM", 169, 195], ["infections", "OBSERVATION", 138, 148], ["much larger", "OBSERVATION_MODIFIER", 152, 163], ["infection", "OBSERVATION", 181, 190]]], ["If the viral shedding rate is very low, then the epidemic does not spread and a low total number of infections is observed.", [["infections", "DISEASE", 100, 110], ["the viral shedding rate", "TEST", 3, 26], ["very low", "PROBLEM", 30, 38], ["a low total number of infections", "PROBLEM", 78, 110], ["low", "OBSERVATION_MODIFIER", 80, 83], ["total", "OBSERVATION_MODIFIER", 84, 89], ["number", "OBSERVATION_MODIFIER", 90, 96], ["infections", "OBSERVATION", 100, 110]]], ["Thus, there is a sharp phase transition as the viral shedding rate moves from 5% to 10%.DiscussionAn important observation regarding these phase transitions is the relatively extreme values at which they occur, e.g., a high social distancing probability, a low social distancing threshold, and a low viral shedding rate.", [["a sharp phase transition", "PROBLEM", 15, 39], ["the viral shedding rate", "TEST", 43, 66], ["a low social distancing threshold", "PROBLEM", 255, 288], ["a low viral shedding rate", "PROBLEM", 294, 319], ["sharp", "OBSERVATION_MODIFIER", 17, 22], ["phase", "OBSERVATION_MODIFIER", 23, 28], ["viral", "OBSERVATION_MODIFIER", 47, 52]]], ["These values are very high and low both within the context of our model and of real-world epidemics that motivate our model.", [["These values", "TEST", 0, 12], ["very high", "PROBLEM", 17, 26], ["very", "OBSERVATION_MODIFIER", 17, 21], ["high", "OBSERVATION", 22, 26], ["low", "OBSERVATION_MODIFIER", 31, 34]]], ["It would be of interest to investigate whether or not, given an arbitrary set of values, a specific network and selection of parameters could be found for which phase transitions occur near these values.", [["phase transitions", "PROBLEM", 161, 178]]], ["Alternatively, if no such network and choice of parameters exist, it would be of interest if a more rigorous theoretical description could be given of the mechanism preventing this occurrence.ConclusionWe develop an agent-based model of epidemic spread on Watts-Strogatz small world networks, where infected agents pass through a presymptomatic stage followed by either an asymptomatic or symptomatic stage.", [["epidemic spread", "PROBLEM", 237, 252], ["infected agents", "TREATMENT", 299, 314], ["a presymptomatic stage", "PROBLEM", 328, 350], ["an asymptomatic or symptomatic stage", "PROBLEM", 370, 406], ["epidemic", "OBSERVATION_MODIFIER", 237, 245], ["spread", "OBSERVATION_MODIFIER", 246, 252], ["symptomatic", "OBSERVATION_MODIFIER", 389, 400]]], ["We consider the impact of three control measures on the total number of infected agents, with regard to both phase transitions and efficacy.", [["three control measures", "TREATMENT", 26, 48], ["infected agents", "TREATMENT", 72, 87], ["infected", "OBSERVATION", 72, 80]]], ["The three control methods we consider all generate sharp phase transitions in the total number of infections as the strength of the method varies.", [["infections", "DISEASE", 98, 108], ["The three control methods", "TREATMENT", 0, 25], ["sharp phase transitions", "PROBLEM", 51, 74], ["infections", "PROBLEM", 98, 108], ["sharp phase", "OBSERVATION_MODIFIER", 51, 62], ["total number", "OBSERVATION_MODIFIER", 82, 94], ["infections", "OBSERVATION", 98, 108]]], ["Social distancing controls in this model exhibit a phase transition regarding total number of infections, either when imposed globally or when based on individual response to infected contacts.", [["infections", "DISEASE", 94, 104], ["infections", "PROBLEM", 94, 104], ["infections", "OBSERVATION", 94, 104]]], ["Individually-enacted social distancing in the form of temporary self-isolation must be immediately enacted if a social contact is known to be infected in order to halt the spread of an epidemic.", [["temporary self-isolation", "TREATMENT", 54, 78]]], ["Reductions in viral shedding lead to significant reductions in the size of the final infected population.", [["viral shedding lead", "PROBLEM", 14, 33], ["significant reductions", "PROBLEM", 37, 59], ["the final infected population", "PROBLEM", 75, 104], ["viral", "OBSERVATION", 14, 19], ["significant", "OBSERVATION_MODIFIER", 37, 48], ["reductions", "OBSERVATION_MODIFIER", 49, 59], ["size", "OBSERVATION_MODIFIER", 67, 71], ["final", "OBSERVATION_MODIFIER", 79, 84], ["infected", "OBSERVATION_MODIFIER", 85, 93], ["population", "OBSERVATION", 94, 104]]]], "de0278e203cc2b6e53eff12900b62c2d43809dc4": [["Three weeks later, a second order was issued, requiring cloth face coverings in public spaces.", [["cloth face coverings", "TREATMENT", 56, 76], ["public spaces", "ANATOMY", 80, 93]]], ["Under mounting pressures to relieve the economic and societal stresses of shelter-in-place orders, the US White House and Centers for Disease Control and Prevention (CDC) issued Opening Up America Again on April 16, 2020, which is a three-phased plan for relaxing such restrictions around the country (3).", [["Disease Control", "TREATMENT", 134, 149], ["pressures", "OBSERVATION_MODIFIER", 15, 24]]]], "36c57bd8ded4b2dc1a5859c15dea5c3800e23413": [["Bats are considered a reservoir of severe emerging infectious diseases.", [["infectious diseases", "DISEASE", 51, 70], ["Bats", "CELL", 0, 4], ["severe emerging infectious diseases", "PROBLEM", 35, 70], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["infectious", "OBSERVATION", 51, 61]]], ["Severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), Nipah virus, Hendra virus, and Ebola virus are all thought to be bat-borne viruses 1, 2 .", [["acute respiratory syndrome coronavirus", "DISEASE", 7, 45], ["SARS-CoV)", "DISEASE", 47, 56], ["Middle East respiratory syndrome coronavirus", "DISEASE", 58, 102], ["Nipah virus", "DISEASE", 115, 126], ["Hendra virus", "DISEASE", 128, 140], ["Ebola virus", "DISEASE", 146, 157], ["Severe acute respiratory syndrome coronavirus", "ORGANISM", 0, 45], ["SARS-CoV", "ORGANISM", 47, 55], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 58, 102], ["MERS-CoV", "ORGANISM", 104, 112], ["Nipah virus", "ORGANISM", 115, 126], ["Hendra virus", "ORGANISM", 128, 140], ["Ebola virus", "ORGANISM", 146, 157], ["Nipah virus", "SPECIES", 115, 126], ["Hendra virus", "SPECIES", 128, 140], ["Ebola virus", "SPECIES", 146, 157], ["Severe acute respiratory syndrome coronavirus", "SPECIES", 0, 45], ["SARS-CoV", "SPECIES", 47, 55], ["Middle East respiratory syndrome coronavirus", "SPECIES", 58, 102], ["MERS-CoV", "SPECIES", 104, 112], ["Nipah virus", "SPECIES", 115, 126], ["Hendra virus", "SPECIES", 128, 140], ["Ebola virus", "SPECIES", 146, 157], ["Severe acute respiratory syndrome coronavirus (SARS-CoV)", "PROBLEM", 0, 56], ["Middle East respiratory syndrome", "PROBLEM", 58, 90], ["coronavirus", "PROBLEM", 91, 102], ["Nipah virus", "PROBLEM", 115, 126], ["Hendra virus", "PROBLEM", 128, 140], ["Ebola virus", "PROBLEM", 146, 157], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory syndrome coronavirus", "OBSERVATION", 13, 45], ["Middle", "ANATOMY_MODIFIER", 58, 64], ["respiratory syndrome", "OBSERVATION", 70, 90], ["Hendra virus", "OBSERVATION", 128, 140], ["Ebola virus", "OBSERVATION", 146, 157]]]], "PMC7118867": [["Sibilances associ\u00e9es aux\u00a0infections respiratoires du\u00a0nourrissonLa bronchite sifflante du nourrisson traduit l'obstruction bronchique secondaire \u00e0 l'agression virale des voies a\u00e9riennes.", [["infections", "DISEASE", 25, 35], ["aux\u00a0infections", "PROBLEM", 21, 35], ["infections", "OBSERVATION", 25, 35]]], ["Sa liaison est intime avec la survenue ult\u00e9rieure d'\u00e9pisodes de sibilance ou wheezing.", [["wheezing", "DISEASE", 77, 85], ["wheezing", "PROBLEM", 77, 85], ["wheezing", "OBSERVATION", 77, 85]]], ["Un suivi prospectif effectu\u00e9 \u00e0 Houston retrouve 70 % des enfants de moins de 1 an infect\u00e9s par le VRS, une affection des voies respiratoires basses se d\u00e9veloppe chez 20 % d'entre eux et seuls 10 % de ces derniers seront hospitalis\u00e9s [4].", [["an infect\u00e9s par le VRS", "PROBLEM", 79, 101], ["une affection des", "PROBLEM", 103, 120], ["respiratoires", "TEST", 127, 140], ["basses", "TEST", 141, 147], ["'entre eux et seuls", "TREATMENT", 172, 191]]], ["On estime que 0,5 \u00e0 2 % des nourrissons seraient hospitalis\u00e9s chaque ann\u00e9e lors de leur primo-infection \u00e0 VRS.", [["VRS", "PROBLEM", 106, 109]]], ["La cohorte de Tucson a permis de pr\u00e9ciser l'\u00e9pid\u00e9miologie virale en population g\u00e9n\u00e9rale des infections respiratoires basses.", [["infections respiratoires basses", "DISEASE", 92, 123], ["a permis de pr\u00e9ciser l'\u00e9pid\u00e9miologie virale", "TREATMENT", 21, 64]]], ["Sur 1246 enfants, 519 ont eu au moins une infection respiratoire basse avant l'\u00e2ge de 3 ans diagnostiqu\u00e9e et prise en charge par un m\u00e9decin [5].", [["infection", "DISEASE", 42, 51], ["ont eu au moins une infection", "TREATMENT", 22, 51], ["infection", "OBSERVATION", 42, 51]]], ["L'\u00e9pid\u00e9miologie pour les enfants ayant b\u00e9n\u00e9fici\u00e9 des investigations virologiques (472 enfants sur les 519) confirme la pr\u00e9dominance virale puisque 43,9 % des pr\u00e9l\u00e8vements retrouvaient le VRS, 14,4 % les VPI, 14,4 % un virus diff\u00e9rent des 2 1rs, chez 27,7 % des enfants aucun virus ne fut identifi\u00e9 lors de l'\u00e9pisode infectieux mais cette recherche virale ignorait les rhinovirus ou d'autres virus plus r\u00e9cemment mis en cause.", [["L'\u00e9pid\u00e9miologie pour les", "TREATMENT", 0, 24], ["virologiques", "TEST", 68, 80], ["la pr\u00e9dominance", "TEST", 116, 131], ["puisque", "TEST", 139, 146], ["le VRS", "TEST", 184, 190], ["VPI", "TEST", 203, 206], ["chez", "TEST", 245, 249], ["ignorait les rhinovirus", "PROBLEM", 355, 378]]], ["Notre \u00e9quipe a montr\u00e9 que cette identification variait selon l'\u00e2ge [1], le ph\u00e9notype clinique et la technique virologique mise en \u0153uvre (Tableau 1, Tableau 2).Virus initiateur de\u00a0l'asthme ou\u00a0de\u00a0l'atopieL'opinion pr\u00e9valente est que les infections virales de la prime enfance n'induisent pas l'asthme atopique, elles ne sont qu'un marqueur d'une population \u00e0 risque par le d\u00e9clenchement pr\u00e9coce d'une 1re exacerbation aigu\u00eb asthmatique [5], [6].", [["infections virales", "DISEASE", 235, 253], ["Virus", "ORGANISM", 159, 164], ["Virus initiateur de\u00a0l'asthme ou\u00a0de\u00a0l'atopieL'opinion pr\u00e9valente est que les infections virales de la prime enfance n'induisent pas l'asthme atopique, elles ne sont qu'un marqueur d'une population \u00e0 risque par le d\u00e9clenchement pr\u00e9coce d'une 1re exacerbation aigu\u00eb", "SPECIES", 159, 421], ["le ph\u00e9notype clinique et la technique", "TREATMENT", 72, 109], ["les infections", "PROBLEM", 231, 245], ["exacerbation aigu\u00eb asthmatique", "PROBLEM", 403, 433]]], ["L'\u00e9pid\u00e9miologie virale d\u00e9pend de la technique utilis\u00e9e (Tableau 3) mais elle diff\u00e8re de celle des bronchiolites aigu\u00ebs virales avec la pr\u00e9sence significativement plus importante des picornavirus (Tableau 2).", [["L'\u00e9pid\u00e9miologie virale", "TREATMENT", 0, 22], ["aigu\u00ebs", "TEST", 112, 118], ["virales", "TEST", 119, 126], ["importante des picornavirus", "PROBLEM", 167, 194]]], ["Cette relation retrouv\u00e9e avec le VRS (OR = 3,0) s'accentue avec le rhinovirus (OR = 6,6) : 63 % des nourrissons de moins de 1 an ayant siffl\u00e9 lors de la saison hivernale continueront \u00e0 le faire \u00e0 3 ans vs 20 % pour ceux qui resteront indemnes [7].", [["le VRS", "TEST", 30, 36], ["le rhinovirus", "PROBLEM", 64, 77], ["ans vs", "TEST", 198, 204], ["rhinovirus", "OBSERVATION", 67, 77]]], ["Une m\u00e9ta-analyse retenant des crit\u00e8res stricts de la bronchiolite \u00e0 VRS, excluant les \u00e9tudes portant sur les enfants \u00e2g\u00e9s de plus de 1 an et celles ne disposant pas de preuve virologique, souligne que les sifflements r\u00e9currents ne sont ni en rapport avec une \u00e9l\u00e9vation ult\u00e9rieure du risque atopique, ni li\u00e9s \u00e0 une fr\u00e9quence plus \u00e9lev\u00e9e des ant\u00e9c\u00e9dents familiaux d'atopie [6].", [["VRS", "TEST", 68, 71]]], ["Cependant une \u00e9tude su\u00e9doise, avec un recul de 13 ans, conclut par une analyse multivari\u00e9e qu'une bronchiolite \u00e0 VRS est le facteur de risque ind\u00e9pendant d'asthme et d'acquisition d'une sensibilisation allerg\u00e9nique [8].", [["multivari\u00e9e", "TEST", 79, 90], ["bronchiolite", "TEST", 98, 110]]], ["Une interpr\u00e9tation diff\u00e9rente peut \u00eatre oppos\u00e9e : les nourrissons non hospitalis\u00e9s lors d'une \u00e9pid\u00e9mie hivernale \u00e0 VRS ont de fait un facteur protecteur non identifi\u00e9 du risque de d\u00e9velopper ult\u00e9rieurement un asthme ou une allergie.Infections respiratoires chez\u00a0l'asthmatiqueLa reconnaissance du r\u00f4le pr\u00e9pond\u00e9rant des virus chez l'asthmatique lors de ces infections est r\u00e9cente.", [["ces infections", "DISEASE", 351, 365], ["Une interpr\u00e9tation", "TEST", 0, 18], ["Infections", "PROBLEM", 232, 242], ["du r\u00f4le", "TEST", 293, 300]]], ["La d\u00e9tection mol\u00e9culaire des virus a permis d'y souligner la 1re place du rhinovirus mais tous les virus capables de produire une infection aigu\u00eb des voies respiratoires peuvent \u00eatre responsables d'une exacerbation asthmatique.", [["infection aigu\u00eb", "DISEASE", 130, 145], ["asthmatique", "DISEASE", 215, 226], ["La d\u00e9tection", "TEST", 0, 12], ["souligner la", "TEST", 48, 60], ["d'une exacerbation asthmatique", "PROBLEM", 196, 226]]], ["Dans le 1er cas, il existe une chute brutale et pr\u00e9coce des d\u00e9bits de pointe puis une r\u00e9cup\u00e9ration lin\u00e9aire sur plusieurs jours, la r\u00e9ponse aux bronchodilatateurs est m\u00e9diocre.", [["Dans le 1er cas", "CHEMICAL", 0, 15]]], ["Nos \u00e9tudes \u00e9pid\u00e9miologiques dans cette pathologie l'ont r\u00e9guli\u00e8rement situ\u00e9e en 3e position avec une pr\u00e9valence oscillant entre 5 et 15 % (Tableau 2, Tableau 3), r\u00e9cemment une \u00e9tude sur les d\u00e9c\u00e8s p\u00e9diatriques li\u00e9s \u00e0 la grippe a retrouv\u00e9 que 20 % d'entre eux pr\u00e9sentaient une pathologie respiratoire chronique dont la moiti\u00e9 un asthme isol\u00e9 [10].ConclusionL'importance des virus respiratoires est maintenant bien \u00e9tablie dans la pathog\u00e9nie de l'asthme, l'int\u00e9r\u00eat demeure dans la poursuite des recherches portant sur l'inflammation g\u00e9n\u00e9r\u00e9e et les m\u00e9canismes pr\u00e9cis sous-jacents.", [["en 3e position avec une pr\u00e9valence oscillant entre", "TREATMENT", 77, 127], ["a retrouv\u00e9 que", "TREATMENT", 226, 240], ["entre eux", "TEST", 248, 257], ["des virus respiratoires", "TEST", 368, 391]]], ["Trois facteurs influencent significativement la survenue de l'asthme : une dysr\u00e9gulation de la s\u00e9cr\u00e9tion de cytokines, les infections virales des voies a\u00e9riennes sup\u00e9rieures et inf\u00e9rieures, les interactions entre g\u00e8nes et l'environnement durant une courte p\u00e9riode critique du d\u00e9veloppement immunitaire et pulmonaire.", [["infections", "DISEASE", 123, 133], ["Trois", "TEST", 0, 5], ["une dysr\u00e9gulation", "PROBLEM", 71, 88], ["les infections virales des", "PROBLEM", 119, 145], ["et inf\u00e9rieures", "PROBLEM", 174, 188]]]], "PMC7531178": [["IntroductionCoronavirus disease 2019 (COVID\u201019), now a worldwide pandemic, has brought various challenges to not only hospitals but also medical schools.1,2,3Continuation of the clinical curriculum has become increasingly difficult due to the pandemic and social distancing rules.4Yet, workforce entry of final\u2010year medical students should not be delayed, especially now as we face this health care crisis.5In addition, medical schools must instill in final\u2010year medical students a professional mindset toward their future encounters with COVID\u201019 in the clinical setting as junior residents.", [["IntroductionCoronavirus disease", "DISEASE", 0, 31], ["COVID\u201019", "CHEMICAL", 38, 46], ["IntroductionCoronavirus disease", "PROBLEM", 0, 31], ["the pandemic and social distancing rules", "PROBLEM", 239, 279]]], ["To this end, there is a need to first understand the thoughts and preparedness of medical students in the present pandemic situation.IntroductionThis study aimed to clarify perceptions among final\u2010year medical students toward the COVID\u201019 pandemic using an essay task and text mining approach.Ethical considerations ::: MethodsThe Institutional Review Board of Osaka Medical College waived approval for this educational study under the condition that anonymity is maintained and that the study does not affect individual student records.", [["This study", "TEST", 145, 155], ["Methods", "TREATMENT", 320, 327], ["this educational study", "TEST", 403, 425], ["the study", "TEST", 484, 493]]], ["Students were informed of the purpose of the survey and explained that their essay can be excluded from analysis if requested within 1 week after the deadline.Medical school structure/curriculum in Japan ::: MethodsThe duration of Japanese medical education is 6 years.", [["Methods", "TREATMENT", 208, 215], ["Japanese medical education", "TREATMENT", 231, 257]]], ["As with other medical schools in Japan, final\u2010year medical students of Osaka Medical College have undergone all basic and clinical medicine lectures and skill training before their clinical clerkships.", [["skill training", "TREATMENT", 153, 167]]], ["In their 6th year, they participate in selective clinical clerkships and take a graduation examination.6Semesters begin in April.Medical school structure/curriculum in Japan ::: MethodsAt our medical school, final\u2010year students participated in clinical clerkships uneventfully until March 2020.", [["a graduation examination", "TEST", 78, 102]]], ["The length of the essay was set to 1500\u20132000 Japanese words.", [["length", "OBSERVATION_MODIFIER", 4, 10]]], ["Students submitted their essays online via Universal Passport (Japan System Technology, Tokyo, Japan) because physical entry into the school was prohibited during the study period.Text mining methodology ::: MethodsText mining can be used to extract information from larger samples of student essays in an efficient and objective manner, and identify patterns between learning situations to create models of the learning experience.7,8We analyzed student essays using KH Coder 3.0 (http://khcoder.net/en/index.html), a free downloadable multilingual text mining program developed by Koichi Higuchi at Ritsumeikan University.7,9", [["7,9", "CHEMICAL", 624, 627], ["Methods", "TREATMENT", 208, 215]]]], "733123de9d0cb0a0d872a541580e15b25f39ff67": [["Gardiner, Geldenhuys, and Gott (2018) identified several effective interventions to reduce loneliness including befriending, development of leisure time skills, health or social care interventions, pet programs, psychotherapy and social facilitation programs.", [["loneliness", "DISEASE", 91, 101], ["several effective interventions", "TREATMENT", 49, 80], ["social care interventions", "TREATMENT", 171, 196], ["pet programs", "TREATMENT", 198, 210], ["psychotherapy", "TREATMENT", 212, 225], ["social facilitation programs", "TREATMENT", 230, 258]]], ["Interestingly, solitary interventions involving video conferencing or providing pets, were also effective, which are feasible solutions even during strict quarantine.", [["solitary interventions", "TREATMENT", 15, 37], ["solitary", "OBSERVATION_MODIFIER", 15, 23]]], ["For example, a study investigated efficacy of an internet training intervention for community-dwelling older people who lived alone, who were housebound through chronic illness or physical disability At the three-year follow-up, intervention group participants reported a significantly greater reduction in overall loneliness in comparison with the control group.", [["chronic illness", "DISEASE", 161, 176], ["physical disability", "DISEASE", 180, 199], ["loneliness", "DISEASE", 315, 325], ["people", "ORGANISM", 109, 115], ["people", "SPECIES", 109, 115], ["participants", "SPECIES", 248, 260], ["a study", "TEST", 13, 20], ["an internet training intervention", "TREATMENT", 46, 79], ["chronic illness", "PROBLEM", 161, 176], ["a significantly greater reduction in overall loneliness", "PROBLEM", 270, 325], ["greater", "OBSERVATION_MODIFIER", 286, 293], ["reduction", "OBSERVATION_MODIFIER", 294, 303], ["overall", "OBSERVATION_MODIFIER", 307, 314], ["loneliness", "OBSERVATION", 315, 325]]], ["This supports the strategy proposed by the Commonwealth Fund, to screen for social isolation and foster digital support by expanding access to telehealth (https://www.commonwealthfund.org/blog/2020/howcovid-19-pandemic-could-increase-social-isolation-and-how-providers-and-policymakers).", [["social isolation", "TREATMENT", 76, 92], ["foster digital support", "TREATMENT", 97, 119]]]]}